<html lang="en-US" class="" data-sd-ui-what-input="mouse"><head>
      <meta property="og:title" content="Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study">
<meta name="dc.identifier" content="10.1016/j.ard.2025.05.023">
<meta property="og:image" content="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-ga1.jpg">
<meta name="citation_pii" content="S0003496725010416">
<meta name="citation_issn" content="0003-4967">
<meta name="citation_volume" content="84">
<meta name="citation_lastpage" content="1674">
<meta name="citation_issue" content="10">
<meta name="citation_doi" content="10.1016/j.ard.2025.05.023">
<meta name="citation_publisher" content="Elsevier">
<meta name="citation_firstpage" content="1660">
<meta name="citation_title" content="Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study">
<meta name="citation_fulltext_world_readable" content="">
<meta name="citation_journal_title" content="Annals of the Rheumatic Diseases">
<meta name="citation_type" content="JOUR">
<meta name="citation_article_type" content="Full-length article">
<meta property="og:description" content="To assess the efficacy, safety, and tolerability of the investigational, oral, allosteric, highly selective, and potent tyrosine kinase 2 inhibitor za¡­">
<meta name="citation_publication_date" content="2025/10/01">
<meta name="citation_online_date" content="2025/07/04">
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOCACHE,NOODP,NOYDIR">
      <title>Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study - ScienceDirect</title>
      <link rel="canonical" href="https://www.sciencedirect.com/science/article/pii/S0003496725010416">
      <meta name="tdm-reservation" content="1">
      <meta name="tdm-policy" content="https://www.elsevier.com/tdm/tdmrep-policy.json">
      <meta property="og:type" content="article">
      <meta name="viewport" content="initial-scale=1">
      <meta name="SDTech" content="Proudly brought to you by the SD Technology team">
      <script async="" src="https://cdn.pendo.io/agent/static/d6c1d995-bc7e-4e53-77f1-2ea4ecbb9565/pendo.js"></script><script data-cfasync="false">(function newRelicBrowserProSPA() {
;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:false},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}};
;NREUM.loader_config={accountID:"2128461",trustKey:"2038175",agentID:"1589087808",licenseKey:"7ac4127487",applicationID:"814814845"};
;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"7ac4127487",applicationID:"814814845",sa:1};
;/*! For license information please see nr-loader-spa-1.290.0.min.js.LICENSE.txt */
(()=>{var e,t,r={8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{if(null===e[a]){r[a]=null;continue}Array.isArray(e[a])&&Array.isArray(t[a])?r[a]=Array.from(new Set([...e[a],...t[a]])):"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>s,f:()=>a});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function a(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const s=e=>(0,i.a)(e,o)},9324:(e,t,r)=>{"use strict";r.d(t,{F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.290.0",i="PROD",o="CDN",a="^2.0.0-alpha.18"},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>s,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>a,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),a=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),s="complete"===a?.document?.readyState,c=Boolean("hidden"===a?.document?.visibilityState),u=""+a?.location,d=/iPad|iPhone|iPod/.test(a.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=a.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>a,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(s(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function a(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,a;i>0?(o=r.substring(0,i),a=r.substring(i)):(o=r,a="");let[s]=o.split(":");n.push({hostname:s,pathname:a})}}function s(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>c,Ze:()=>l,x3:()=>u});var n=r(7836),i=r(3606),o=r(860),a=r(2646);const s={};function c(e,t){const r={staged:!1,priority:o.P3[t]||0};d(e),s[e].get(t)||s[e].set(t,r)}function u(e,t){e&&s[e]&&(s[e].get(t)&&s[e].delete(t),h(e,t,!1),s[e].size&&f(e))}function d(e){if(!e)throw new Error("agentIdentifier required");s[e]||(s[e]=new Map)}function l(e="",t="feature",r=!1){if(d(e),!e||!s[e].get(t)||r)return h(e,t);s[e].get(t).staged=!0,f(e)}function f(e){const t=Array.from(s[e]);t.every((([e,t])=>t.staged))&&(t.sort(((e,t)=>e[1].priority-t[1].priority)),t.forEach((([t])=>{s[e].delete(t),h(e,t)})))}function h(e,t,r=!0){const o=e?n.ee.get(e):n.ee,s=i.i.handlers;if(!o.aborted&&o.backlog&&s){if(r){const e=o.backlog[t],r=s[t];if(r){for(let t=0;e&&t<e.length;++t)p(e[t],r);Object.entries(r).forEach((([e,t])=>{Object.values(t||{}).forEach((t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])}))}))}}o.isolatedBacklog||delete s[t],o.backlog[t]=null,o.emit("drain-"+t,[])}}function p(e,t){var r=e[1];Object.values(t[r]||{}).forEach((t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}}))}},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>s,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),a=r(5607);const s="nr@context:".concat(a.W),c=function e(t,r){var n={},a={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);for(var s=h(n),u=g(e),d=u.length,l=0;l<d;l++)u[l].apply(s,r);var p=v()[a[e]];p&&p.push([f,e,r,s]);return s},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach((([e,n])=>{a[n]=t,t in r||(r[t]=[])}))},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach((e=>{delete f.backlog[e]}))},isBuffering:function(e){return!!v()[a[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,s,(()=>new o.y(s))):new o.y(s)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.d,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>s,ZF:()=>c,bz:()=>a,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map((e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const a=[];for(var s=0;s<e;s++)a.push(o(r,i++).toString(16));return a.join("")}function c(){return s(16)}function u(){return s(32)}},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>a,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>s,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,a=18e5,s={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},944:(e,t,r)=>{"use strict";function n(e,t){"function"==typeof console.debug&&console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t)}r.d(t,{R:()=>n})},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>a});var n=r(3241);const i=new Set,o={};function a(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout((()=>{i=clearTimeout(i)}),t)),n||(clearTimeout(i),i=setTimeout((()=>{e.apply(this,r)}),t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3496:(e,t,r)=>{"use strict";function n(e){return!e||!(!e.licenseKey||!e.applicationID)}function i(e,t){return!e||e.licenseKey===t.info.licenseKey&&e.applicationID===t.info.applicationID}r.d(t,{A:()=>i,I:()=>n})},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,sB:()=>a});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function a(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}},384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>o,US:()=>u,Zm:()=>a,bQ:()=>c,dV:()=>s,pV:()=>d});var n=r(6154),i=r(1863);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function s(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket}),e}function c(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",(function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)}),r,i)}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),a=r(6154);const s={},c=a.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(s[t.debugId]++)return t;s[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(a.RI&&h(document,f),c&&h(c.prototype,f),h(a.gm,f)),t.on(u+"-start",(function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)){var i=(0,o.I)(n,l,(function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n}));this.wrapped=e[1]=i}})),t.on(d+"-start",(function(e){e[1]=this.wrapped||e[1]})),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>c});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W);var a=Object.prototype.hasOwnProperty,s=!1;function c(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const a="-"===n.charAt(0);for(let s=0;s<t.length;s++){const c=t[s],u=e[c];d(u)||(e[c]=r(u,a?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,s,c){return d(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach((function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})})),t}catch(e){u([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,d,l;try{a=this,o=[...arguments],d="function"==typeof n?n(o,a):n||{}}catch(t){u([t,"",[o,a,s],d],e)}i(r+"start",[o,a,s],d,c);try{return l=t.apply(a,o)}catch(e){throw i(r+"err",[o,a,e],d,c),e}finally{i(r+"end",[o,a,l],d,c)}}}function i(r,n,i,o){if(!s||t){var a=s;s=!0;try{e.emit(r,n,i,t,o)}catch(t){u([t,r,n,i],e)}s=a}}}function u(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function d(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>u,TZ:()=>n,Zp:()=>i,kd:()=>c,mq:()=>s,nf:()=>a,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],a=4,s=1e3,c=["PageAction","UserAction","BrowserPerformance"],u={MARKS:"experimental.marks",MEASURES:"experimental.measures",RESOURCES:"experimental.resources"}},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>a,TZ:()=>s,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},a="log",s=n.K7.logging},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),a=r(8154),s=r(993);function c(e,t,r={},c=s.p_.INFO,u,d=(0,i.t)()){(0,n.p)(a.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(s.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(s.p_).some((t=>t===e.toUpperCase().trim()))}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>s,TZ:()=>n,rs:()=>i,xV:()=>a});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,G4:()=>o,Qb:()=>l,TZ:()=>i,Ug:()=>a,_s:()=>s,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o={RECORD:"recordReplay",PAUSE:"pauseReplay",REPLAY_RUNNING:"replayRunning",ERROR_DURING_REPLAY:"errorDuringReplay"},a=.12,s={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api"}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,CT:()=>c,SR:()=>a,rF:()=>u});var n=r(384),i=r(7767),o=r(6154);function a(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&a(e)}function c(e,t){const r=t.correctAbsoluteTimestamp(e);return{originalTimestamp:e,correctedTimestamp:r,timestampDiff:e-r,originTime:o.WN,correctedOriginTime:t.correctedOriginTime,originTimeDiff:Math.floor(o.WN-t.correctedOriginTime)}}function u(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>s,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>a,jx:()=>l,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState",l=1e3},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>o,O2:()=>c,Qu:()=>u,TZ:()=>s,ih:()=>d,pP:()=>a,tC:()=>i});var n=r(860);const i=["click","keydown","submit","popstate"],o="api",a="initialPageLoad",s=n.K7.softNav,c={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},u={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},d={IP:"in progress",FIN:"finished",CAN:"cancelled"}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>w,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>R,dT:()=>f,e5:()=>A,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>E,uP:()=>s,wW:()=>T,xq:()=>a});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,R="-start",w="-end",x="-body",T="cb"+w,A="jsTime",E="fetch"},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(){return this.#e(i.dT)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>l,BL:()=>u,Bu:()=>o,CH:()=>g,Dl:()=>x,Fw:()=>w,PA:()=>b,Pl:()=>n,Tb:()=>h,U2:()=>s,Wb:()=>A,bt:()=>R,cD:()=>y,d3:()=>T,dT:()=>d,eY:()=>m,fF:()=>p,hG:()=>a,hw:()=>i,k6:()=>c,nb:()=>v,o5:()=>f});const n="api-",i=n+"ixn-",o={},a="addPageAction",s="addToTrace",c="addRelease",u="finished",d="interaction",l="log",f="noticeError",h="pauseReplay",p="recordCustomEvent",g="recordReplay",m="register",v="setApplicationVersion",b="setCurrentRouteName",y="setCustomAttribute",R="setErrorHandler",w="setPageViewName",x="setUserId",T="start",A="wrapLogger"},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),a=r(3333);const s=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{marks:!1,measures:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{allow_registered_children:!0,duplicate_registered_data:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{get capture_marks(){return e.feature_flags.includes(a.$v.MARKS)||e.experimental.marks},set capture_marks(t){e.experimental.marks=t},get capture_measures(){return e.feature_flags.includes(a.$v.MEASURES)||e.experimental.measures},set capture_measures(t){e.experimental.measures=t},capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(a.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){s(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){s(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={appMetadata:{},customTransaction:void 0,denyList:void 0,disabled:!1,entityManager:void 0,harvester:void 0,isolatedBacklog:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,get harvestCount(){return++g}},b=e=>{const t=(0,d.a)(e,v),r=Object.keys(m).reduce(((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e)),{});return Object.defineProperties(t,r)};var y=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var w=r(7836),x=r(3241);const T={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,T),E=new Set;function _(e,t={},r,a){let{init:s,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();s=e.init,c=e.info,u=e.loader_config}e.init=f(s||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];E.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach((r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})}))}(e),(0,n.US)("activatedFeatures",y.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=b(d),E.has(e.agentIdentifier)||(e.ee=w.ee.get(e.agentIdentifier),e.exposed=l,(0,x.W)({agentIdentifier:e.agentIdentifier,drained:!!y.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),E.add(e.agentIdentifier)}},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>s,df:()=>o,qY:()=>n,v4:()=>a});const n="events",i="jserrors",o="browser/blobs",a="rum",s="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:a,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:s,[c.genericEvents]:"ins"}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.290.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.290.0.PROD:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){s=l;break}}if(!s){c=!0;var f={478:"sha512-2i5RxuZ/m/YpRRVXPC98p06x6ZUBqY7d79xJrE5D++qb+LyCG1zPwnIZKCLQLL+QtkfmvLgEivuK6WL26UM0JQ==",249:"sha512-N7Qvs2GMRDH89dYp0xW+p8nQjO8ETs/DHU6TdtBDUycoZhxe3xpcZ17BWLrde2Ioc6b5G8luvRJjIx/JqF1uMw==",212:"sha512-a884ddTXBI44CBhRLEnBEZP7Tgtp2YErWns6rRu0FalosJSuCAvVHb8gFJ91PZ2IJ9ro1wFfjFjK4KSSjzlDUw=="};(s=document.createElement("script")).charset="utf-8",s.timeout=120,i.nc&&s.setAttribute("nonce",i.nc),s.setAttribute("data-webpack",t+o),s.src=r,0!==s.src.indexOf(window.location.origin+"/")&&(s.crossOrigin="anonymous"),f[a]&&(s.integrity=f[a])}e[r]=[n];var h=(t,n)=>{s.onerror=s.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=h.bind(null,s.onerror),s.onload=h.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u<a.length;u++)o=a[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.290.0.PROD"]=self["webpackChunk:NRBA-1.290.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var a=i(5205);var s=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const a=o||i;!a||a[e]&&a[e]!==r.prototype[e]||(a[e]=function(){(0,s.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:e.info={...e.info,jsAttributes:{...o.jsAttributes,[t]:r}},(i||null===r)&&(0,s.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),R=i(5270),w=i(7767),x=i(6389);class T extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.abortHandler=void 0,this.featAggregate=void 0,this.onAggregateImported=void 0,this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise(((t,r)=>{this.ee.on("manual-start-all",(0,x.J)((()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()})))})):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;let o;this.onAggregateImported=new Promise((e=>{o=e}));const a=async()=>{let a;await this.deferred;try{if((0,w.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,6526));a=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),this.featureName===n.K7.sessionReplay&&this.abortHandler?.()}try{if(!this.#t(this.featureName,a,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void o(!1);const{Aggregate:n}=await t();this.featAggregate=new n(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),o(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),o(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)((()=>a()),!0):a()}#t(e,t,r){switch(e){case n.K7.sessionReplay:return(0,R.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630);class E extends T{static featureName=A.T;constructor(e){var t;super(e,A.T),t=e,p(u.Fw,(function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,s.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))}),t),this.ee.on("api-send-rum",((e,t)=>(0,s.p)("send-rum",[e,t],void 0,this.featureName,this.ee))),this.importAggregator(e,(()=>i.e(478).then(i.bind(i,1983))))}}var _=i(384);var S=i(2843),N=i(3878),O=i(782);class I extends T{static featureName=O.T;constructor(e){super(e,O.T),y.RI&&((0,S.u)((()=>(0,s.p)("docHidden",[(0,c.t)()],void 0,O.T,this.ee)),!0),(0,N.sp)("pagehide",(()=>(0,s.p)("winPagehide",[(0,c.t)()],void 0,O.T,this.ee))),this.importAggregator(e,(()=>i.e(478).then(i.bind(i,9917)))))}}class P extends T{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",(e=>{(0,s.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)})),this.importAggregator(e,(()=>i.e(478).then(i.bind(i,8351))))}}var j=i(6774),C=i(6344),k=i(3304);class L{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,k.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function H(e){return K(e)?e:new L(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic)}function M(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(K(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return H(e.reason)}const r=H(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new L(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic);return t.name=SyntaxError.name,t}return K(e.error)?e.error:H(e)}function K(e){return e instanceof Error&&!!e.stack}var U=i(2614);function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,s.p)("err",[e,o,!1,t,!!u.Bu[r.agentIdentifier],void 0,i],void 0,n.K7.jserrors,r.ee)}var B=i(3496),G=i(993),W=i(3785);function V(e,{customAttributes:t={},level:r=G.p_.INFO}={},n,i,o=(0,c.t)()){(0,W.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,s.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e){p(u.eY,(function(t){return function(e,t){const r={};let i,o;(0,l.R)(54,"newrelic.register"),e.init.api.allow_registered_children||(i=()=>(0,l.R)(55));t&&(0,B.I)(t)||(i=()=>(0,l.R)(48,t));const a={addPageAction:(n,i={})=>{u(z,[n,{...r,...i},e],t)},log:(n,i={})=>{u(V,[n,{...i,customAttributes:{...r,...i.customAttributes||{}}},e],t)},noticeError:(n,i={})=>{u(F,[n,{...r,...i},e],t)},setApplicationVersion:e=>{r["application.version"]=e},setCustomAttribute:(e,t)=>{r[e]=t},setUserId:e=>{r["enduser.id"]=e},metadata:{customAttributes:r,target:t,get connected(){return o||Promise.reject(new Error("Failed to connect"))}}};i?i():o=new Promise(((n,i)=>{try{const o=e.runtime?.entityManager;let s=!!o?.get().entityGuid,c=o?.getEntityGuidFor(t.licenseKey,t.applicationID),u=!!c;if(s&&u)t.entityGuid=c,n(a);else{const d=setTimeout((()=>i(new Error("Failed to connect - Timeout"))),15e3);function l(r){(0,B.A)(r,e)?s||=!0:t.licenseKey===r.licenseKey&&t.applicationID===r.applicationID&&(u=!0,t.entityGuid=r.entityGuid),s&&u&&(clearTimeout(d),e.ee.removeEventListener("entity-added",l),n(a))}e.ee.emit("api-send-rum",[r,t]),e.ee.on("entity-added",l)}}catch(f){i(f)}}));const u=async(t,r,a)=>{if(i)return i();const u=(0,c.t)();(0,s.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{await o;const n=e.init.api.duplicate_registered_data;(!0===n||Array.isArray(n)&&n.includes(a.entityGuid))&&t(...r,void 0,u),t(...r,a.entityGuid,u)}catch(e){(0,l.R)(50,e)}};return a}(e,t)}),e)}class q extends T{static featureName=j.T;#r=!1;constructor(e){var t;super(e,j.T),t=e,p(u.o5,((e,r)=>F(e,r,t)),t),u.Bu[t.agentIdentifier]??=U.g.OFF,t.ee.on(C.G4.REPLAY_RUNNING,(e=>{u.Bu[t.agentIdentifier]=e})),function(e){p(u.bt,(function(t){e.runtime.onerror=t}),e)}(e),function(e){let t=0;p(u.k6,(function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))}),e)}(e),Z(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",((e,t)=>{this.abortHandler&&(0,s.p)("ierr",[H(e),(0,c.t)(),!0,{},this.#r,t],void 0,this.featureName,this.ee)})),this.ee.on(C.G4.REPLAY_RUNNING,(e=>{this.#r=e})),y.gm.addEventListener("unhandledrejection",(e=>{this.abortHandler&&(0,s.p)("err",[M(e),(0,c.t)(),!1,{unhandledPromiseRejection:1},this.#r],void 0,this.featureName,this.ee)}),(0,N.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",(e=>{this.abortHandler&&(0,s.p)("err",[D(e),(0,c.t)(),!1,{},this.#r],void 0,this.featureName,this.ee)}),(0,N.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#n,this.importAggregator(e,(()=>i.e(478).then(i.bind(i,5928))))}#n(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Y=i(8990);let X=1;function J(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Y.I)(e,"nr@id",(function(){return X++}))}function Q(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,k.A)(e).length}catch(e){return}}}var ee=i(8139),te=i(7836),re=i(3434);const ne={},ie=["open","send"];function oe(e){var t=e||te.ee;const r=function(e){return(e||te.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(ne[r.debugId]++)return r;ne[r.debugId]=1,(0,ee.u)(t);var n=(0,re.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,a=y.gm.Promise,s=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(a=o,function(){var e=this;e.readyState>3&&!a.resolved&&(a.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,N.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var a;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ie,"-xhr-",b),r.on("send-xhr-start",(function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):s?s(v):(g=-g,m.data=g))}(t)})),r.on("open-xhr-start",h),o){var p=a&&a.resolve();if(!s&&!a){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===c||v()}));function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ae="fetch-",se=ae+"body-",ce=["arrayBuffer","blob","json","text","formData"],ue=y.gm.Request,de=y.gm.Response,le="prototype";const fe={};function he(e){const t=function(e){return(e||te.ee).get("fetch")}(e);if(!(ue&&de&&y.gm.fetch))return t;if(fe[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[te.P]&&o[te.P].dt&&(e=o[te.P].dt);var a=i.apply(this,r);return t.emit(n+"start",[r,e],a),a.then((function(e){return t.emit(n+"end",[null,e],a),e}),(function(e){throw t.emit(n+"end",[e],a),e}))})}return fe[t.debugId]=1,ce.forEach((e=>{r(ue[le],e,se),r(de[le],e,se)})),r(y.gm,"fetch",ae),t.on(ae+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ae+"done",[null,r],n)}else t.emit(ae+"done",[e],n)})),t}var pe=i(7485);class ge{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,e.ZF)(),s=(0,e.el)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,k.A)(a))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,pe.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var me=i(9300),ve=i(7295),be=["load","error","abort","timeout"],ye=be.length,Re=(0,_.dV)().o.REQ,we=(0,_.dV)().o.XHR;const xe="X-NewRelic-App-Data";class Te extends T{static featureName=me.T;constructor(e){super(e,me.T),this.dt=new ge(e),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach((t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Ae(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}}))}catch(e){}he(this.ee),oe(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=A,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){E(t,e)}),(0,N.jT)(!1)),y.lR||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,N.jT)(!1))}function a(e){this.params={method:e[0]},Ae(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var a=Q(i);a&&(n.txSize=a)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var s=0;s<ye;s++)r.addEventListener(be[s],this.listener,(0,N.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+J(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+J(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof we&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof we&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof we&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function R(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function w(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,pe.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)s(e[0].headers,n)&&(this.dt=n);else{var o={};for(var a in r)o[a]=r[a];o.headers=new Headers(r.headers||{}),s(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Re?r=i.url:y.gm?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),Ae(this,r);var o=(""+(i&&i instanceof Re&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.body=n.body,this.txSize=Q(n.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,ve.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function A(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<ye;t++)e.removeEventListener(be[t],this.listener,!1);t.aborted||(0,ve.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):E(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function E(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?Q(e.response):"text"===r||""===r||void 0===r?Q(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(xe)>=0){var o=r.getResponseHeader(xe);o&&((0,s.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",a),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",R),t.on("fetch-before-start",w),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,(()=>i.e(478).then(i.bind(i,3845))))}}function Ae(e,t){var r=(0,pe.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ee={},_e=["pushState","replaceState"];function Se(e){const t=function(e){return(e||te.ee).get("history")}(e);return!y.RI||Ee[t.debugId]++||(Ee[t.debugId]=1,(0,re.YM)(t).inPlace(window.history,_e,"-")),t}var Ne=i(3738);function Oe(e){p(u.BL,(function(t=(0,c.t)()){(0,s.p)(h.XG,[u.BL,{time:t}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t+y.WN,origin:"nr"}),(0,s.p)(u.Pl+u.hG,[t,u.BL],void 0,n.K7.genericEvents,e.ee)}),e)}const{He:Ie,bD:Pe,d3:je,Kp:Ce,TZ:ke,Lc:Le,uP:He,Rz:Me}=Ne;class De extends T{static featureName=ke;constructor(e){var t;super(e,ke),t=e,p(u.U2,(function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};(0,s.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)}),t),Oe(e);if(!(0,w.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Se(r),this.eventsEE=(0,ee.u)(r),this.eventsEE.on(He,(function(e,t){this.bstStart=(0,c.t)()})),this.eventsEE.on(Le,(function(e,t){(0,s.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)})),r.on(Me+je,(function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash})),r.on(Me+Ce,(function(e){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)}));try{o=new PerformanceObserver((e=>{const t=e.getEntries();(0,s.p)(Ie,[t],void 0,n.K7.sessionTrace,r)})),o.observe({type:Pe,buffered:!0})}catch(e){}this.importAggregator(e,(()=>i.e(478).then(i.bind(i,575))),{resourceObserver:o})}}class Ke extends T{static featureName=C.TZ;#i;#o;constructor(e){var t;let r;super(e,C.TZ),t=e,p(u.CH,(function(){(0,s.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)}),t),function(e){p(u.Tb,(function(){(0,s.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)}),e)}(e),this.replayRunning=!1,this.#o=e;try{r=JSON.parse(localStorage.getItem("".concat(U.H3,"_").concat(U.uh)))}catch(e){}(0,R.SR)(e.init)&&this.ee.on(C.G4.RECORD,(()=>this.#a())),this.#s(r)?(this.#i=r?.sessionReplayMode,this.#c()):this.importAggregator(this.#o,(()=>i.e(478).then(i.bind(i,6167)))),this.ee.on("err",(e=>{this.replayRunning&&(this.errorNoticed=!0,(0,s.p)(C.G4.ERROR_DURING_REPLAY,[e],void 0,this.featureName,this.ee))})),this.ee.on(C.G4.REPLAY_RUNNING,(e=>{this.replayRunning=e}))}#s(e){return e&&(e.sessionReplayMode===U.g.FULL||e.sessionReplayMode===U.g.ERROR)||(0,R.Aw)(this.#o.init)}#u=!1;async#c(e){if(!this.#u){this.#u=!0;try{const{Recorder:t}=await Promise.all([i.e(478),i.e(249)]).then(i.bind(i,8589));this.recorder??=new t({mode:this.#i,agentIdentifier:this.agentIdentifier,trigger:e,ee:this.ee,agentRef:this.#o}),this.recorder.startRecording(),this.abortHandler=this.recorder.stopRecording}catch(e){}this.importAggregator(this.#o,(()=>i.e(478).then(i.bind(i,6167))),{recorder:this.recorder,errorNoticed:this.errorNoticed})}}#a(){this.featAggregate?this.featAggregate.mode!==U.g.FULL&&this.featAggregate.initializeRecording(U.g.FULL,!0):(this.#i=U.g.FULL,this.#c(C.Qb.API),this.recorder&&this.recorder.parent.mode!==U.g.FULL&&(this.recorder.parent.mode=U.g.FULL,this.recorder.stopRecording(),this.recorder.startRecording(),this.abortHandler=this.recorder.stopRecording))}}var Ue=i(3962);function Fe(e){const t=e.ee.get("tracer");function r(){}p(u.dT,(function(e){return(new r).get("object"==typeof e?e:{})}),e);const i=r.prototype={createTracer:function(r,i){var o={},a=this,d="function"==typeof i;return(0,s.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,s.p)(u.hw+"tracer",[(0,c.t)(),r,o],a,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),a,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((t=>{p.apply(this,[t,function(){return(0,s.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])})),p(u.PA,(function(){e.runSoftNavOverSpa?(0,s.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,s.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)}),e)}class Be extends T{static featureName=Ue.TZ;constructor(e){if(super(e,Ue.TZ),Fe(e),!y.RI||!(0,_.dV)().o.MO)return;const t=Se(this.ee);Ue.tC.forEach((e=>{(0,N.sp)(e,(e=>{a(e)}),!0)}));const r=()=>(0,s.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r);try{this.removeOnAbort=new AbortController}catch(e){}(0,N.sp)("popstate",(e=>(0,s.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)),!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,_.dV)().o.MO)(((e,t)=>{n||(n=!0,requestAnimationFrame((()=>{(0,s.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1})))})),a=(0,x.s)((e=>{(0,s.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})}),100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,(()=>i.e(478).then(i.bind(i,4393))),{domObserver:o})}}var Ge=i(7378);const We={},Ve=["appendChild","insertBefore","replaceChild"];function ze(e){const t=function(e){return(e||te.ee).get("jsonp")}(e);if(!y.RI||We[t.debugId])return t;We[t.debugId]=!0;var r=(0,re.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function a(e,t){if(!e)return t;const r=e.match(o),n=r[1];return a(r[3],t[n])}return r.inPlace(Node.prototype,Ve,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(s=e.src,c=s.match(n),c?c[1]:null);var s,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:a(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,N.jT)(!1)),e.removeEventListener("error",f,(0,N.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,N.jT)(!1)),e.removeEventListener("error",f,(0,N.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,N.jT)(!1)),e.addEventListener("error",f,(0,N.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}const Ze={};function qe(e){const t=function(e){return(e||te.ee).get("promise")}(e);if(Ze[t.debugId])return t;Ze[t.debugId]=!0;var r=t.context,n=(0,re.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),a=n(r,"executor-",o,null,!1);const s=Reflect.construct(i,[a],e);return t.context(s).getCtx=function(){return o},s}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach((function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,a=r(i);a.promise=i,e[0]=n(e[0],"cb-",a,null,!1),e[1]=n(e[1],"cb-",a,null,!1);const s=o.apply(this,e);return a.nextPromise=s,t.emit("propagate",[i,!0],s,!1,!1),s},i.prototype.then[re.Jt]=o,t.on("executor-start",(function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)})),t.on("executor-err",(function(e,t,r){e[1](r)})),t.on("cb-end",(function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)})),t.on("propagate",(function(e,r,n){this.getCtx&&!r||(this.getCtx=function(){if(e instanceof Promise)var r=t.context(e);return r&&r.getCtx?r.getCtx():this})}))}(),t}const Ye={},Xe="setTimeout",$e="setInterval",Je="clearTimeout",Qe="-start",et=[Xe,"setImmediate",$e,Je,"clearImmediate"];function tt(e){const t=function(e){return(e||te.ee).get("timer")}(e);if(Ye[t.debugId]++)return t;Ye[t.debugId]=1;var r=(0,re.YM)(t);return r.inPlace(y.gm,et.slice(0,2),Xe+"-"),r.inPlace(y.gm,et.slice(2,3),$e+"-"),r.inPlace(y.gm,et.slice(3),Je+"-"),t.on($e+Qe,(function(e,t,n){e[0]=r(e[0],"fn-",null,n)})),t.on(Xe+Qe,(function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)})),t}const rt={};function nt(e){const t=function(e){return(e||te.ee).get("mutation")}(e);if(!y.RI||rt[t.debugId])return t;rt[t.debugId]=!0;var r=(0,re.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:it,d3:ot,Kp:at,$p:st,wW:ct,e5:ut,tH:dt,uP:lt,rw:ft,Lc:ht}=Ge;class pt extends T{static featureName=it;constructor(e){if(super(e,it),Fe(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=ze(this.ee),a=qe(this.ee),u=tt(this.ee),d=oe(this.ee),l=this.ee.get("events"),f=he(this.ee),h=Se(this.ee),p=nt(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[lt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[ut]=~~this[ut]+e-this[lt],this[ht]=e}function b(e,t){e.on(t,(function(){this[t]=(0,c.t)()}))}this.ee.on(lt,m),a.on(ft,m),o.on(ft,m),this.ee.on(ht,v),a.on(ct,v),o.on(ct,v),this.ee.on("fn-err",((...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,s.p)("function-err",[...t],void 0,this.featureName,this.ee)})),this.ee.buffer([lt,ht,"xhr-resolved"],this.featureName),l.buffer([lt],this.featureName),u.buffer(["setTimeout"+at,"clearTimeout"+ot,lt],this.featureName),d.buffer([lt,"new-xhr","send-xhr"+ot],this.featureName),f.buffer([dt+ot,dt+"-done",dt+st+ot,dt+st+at],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([lt],this.featureName),a.buffer(["propagate",ft,ct,"executor-err","resolve"+ot],this.featureName),n.buffer([lt,"no-"+lt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,dt+ot),b(f,dt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,N.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,N.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){g(0,r>1)}),(0,N.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#n,this.importAggregator(e,(()=>i.e(478).then(i.bind(i,5592))))}#n(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var gt=i(3333);class mt extends T{static featureName=gt.TZ;constructor(e){super(e,gt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;if(r=e,p(u.hG,((e,t)=>z(e,t,r)),r),function(e){p(u.fF,(function(){(0,s.p)(u.Pl+u.fF,[(0,c.t)(),...arguments],void 0,n.K7.genericEvents,e.ee)}),e)}(e),Oe(e),Z(e),y.RI&&(e.init.user_actions.enabled&&(gt.Zp.forEach((e=>(0,N.sp)(e,(e=>(0,s.p)("ua",[e],void 0,this.featureName,this.ee)),!0))),gt.qN.forEach((e=>{const t=(0,x.s)((e=>{(0,s.p)("ua",[e],void 0,this.featureName,this.ee)}),500,{leading:!0});(0,N.sp)(e,t)}))),e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource"))){new PerformanceObserver((e=>{e.getEntries().forEach((e=>{(0,s.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)}))})).observe({type:"resource",buffered:!0})}t.some((e=>e))?this.importAggregator(e,(()=>i.e(478).then(i.bind(i,8019)))):this.deregisterDrain()}}var vt=i(2646);const bt=new Map;function yt(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||te.ee).get("logger")}(e),o=(0,re.YM)(i),a=new vt.y(te.P);a.level=n.level,a.customAttributes=n.customAttributes;const s=t[r]?.[re.Jt]||t[r];return bt.set(s,a),o.inPlace(t,[r],"wrap-logger-",(()=>bt.get(s))),i}class Rt extends T{static featureName=G.TZ;constructor(e){var t;super(e,G.TZ),t=e,p(u.$9,((e,r)=>V(e,r,t)),t),function(e){p(u.Wb,((t,r,{customAttributes:n={},level:i=G.p_.INFO}={})=>{yt(e.ee,t,r,{customAttributes:n,level:i})}),e)}(e),Z(e);const r=this.ee;yt(r,y.gm.console,"log",{level:"info"}),yt(r,y.gm.console,"error",{level:"error"}),yt(r,y.gm.console,"warn",{level:"warn"}),yt(r,y.gm.console,"info",{level:"info"}),yt(r,y.gm.console,"debug",{level:"debug"}),yt(r,y.gm.console,"trace",{level:"trace"}),this.ee.on("wrap-logger-end",(function([e]){const{level:t,customAttributes:n}=this;(0,W.R)(r,e,n,t)})),this.importAggregator(e,(()=>i.e(478).then(i.bind(i,5288))))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,_.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(E),this.runSoftNavOverSpa=[...this.desiredFeatures].some((e=>e.featureName===n.K7.softNav)),(0,a.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,(function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)}),t),function(e){p(u.Dl,(function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)}),e)}(this),function(e){p(u.nb,(function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)}),e)}(this),function(e){p(u.d3,(function(){e.ee.emit("manual-start-all")}),e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach((r=>{t[r]=!!e[r]?.enabled})),t}(this.init),t=[...this.desiredFeatures];t.sort(((e,t)=>n.P3[e.featureName]-n.P3[t.featureName])),t.forEach((t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter((e=>!(e in this.features)));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)}))}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,_.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[Te,E,I,De,Ke,P,q,mt,Rt,Be,pt],loaderType:"spa"})})()})();
})()</script>
      <link rel="shortcut icon" href="/shared-assets/103/images/favSD.ico" type="image/x-icon">
      <link rel="icon" href="/shared-assets/103/images/favSD.ico" type="image/x-icon">
      <link rel="stylesheet" href="/us-east-1/prod/2d348b415dc48b7aaa2f48d669a232bb69813c31/arp.css">
      <link href="//cdn.pendo.io" rel="dns-prefetch">
      <link href="https://cdn.pendo.io" rel="preconnect" crossorigin="anonymous">
      <link rel="dns-prefetch" href="https://smetrics.elsevier.com">
      <script async="" id="reading-assistant-script-tag" src="/feature/assets/ai-components?componentVersion=V14" type="text/javascript"></script>
      <script type="text/javascript">
        var targetServerState = JSON.stringify({"4D6368F454EC41940A4C98A6@AdobeOrg":{"sdid":{"supplementalDataIDCurrent":"2899FEB4901ED543-49C2930915AB95EF","supplementalDataIDCurrentConsumed":{"payload:target-global-mbox":true},"supplementalDataIDLastConsumed":{}}}});
        window.appData = window.appData || [];
        window.pageTargeting = {"region":"us-east-1","platform":"sdtech","entitled":true,"crawler":"","journal":"Annals of the Rheumatic Diseases","auth":"AE"};
        window.arp = {
          config: {"adobeSuite":"elsevier-sd-prod","aiNavigation":{"enabled":true,"version":"V1"},"arsUrl":"https://ars.els-cdn.com","assetRoute":"/us-east-1/prod/2d348b415dc48b7aaa2f48d669a232bb69813c31","recommendationsFeedback":{"enabled":true,"url":"https://feedback.recs.d.elsevier.com/raw/events","timeout":60000},"googleMapsApiKey":"AIzaSyCBYU6I6lrbEU6wQXUEIte3NwGtm3jwHQc","mediaBaseUrl":"https://ars.els-cdn.com/content/image/","xocsMediaPlayerBaseUrl":"/shared-assets/147/js/ableplayer","strictMode":false,"seamlessAccess":{"enableSeamlessAccess":true,"scriptUrl":"https://unpkg.com/@theidentityselector/thiss-ds@1.0.13/dist/thiss-ds.js","persistenceUrl":"https://service.seamlessaccess.org/ps/","persistenceContext":"seamlessaccess.org","scienceDirectUrl":"https://www.sciencedirect.com","shibAuthUrl":"https://auth.elsevier.com/ShibAuth/institutionLogin"},"reaxys":{"apiUrl":"https://reaxys-sdlc.reaxys.com","origin":"sciencedirect","queryBuilderHostPath":"https://www.reaxys.com/reaxys/secured/hopinto.do","url":"https://www.reaxys.com"},"oneTrustCookie":{"enabled":true},"shadowBackend":{"abstract":true,"citedBy":true,"glossary":true},"ssrn":{"url":"https://papers.ssrn.com","path":"/sol3/papers.cfm"}},
          subscriptions: [],
          subscribe: function(cb) {
            var self = this;
            var i = this.subscriptions.push(cb) - 1;
            return function unsubscribe() {
              self.subscriptions.splice(i, 1);
            }
          },
        };
        window.addEventListener('beforeprint', () => pendo.onGuideDismissed());
      </script>
    <script data-cfasync="false" src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" data-document-language="true" data-domain-script="865ea198-88cc-4e41-8952-1df75d554d02"></script><script src="https://assets.adobedtm.com/extensions/EP31dbb9c60e404ba1aa6e746d49be6f29/AppMeasurement.min.js" async=""></script><script src="https://assets.adobedtm.com/extensions/EP31dbb9c60e404ba1aa6e746d49be6f29/AppMeasurement_Module_ActivityMap.min.js" async=""></script><meta http-equiv="origin-trial" content="AlK2UR5SkAlj8jjdEc9p3F3xuFYlF6LYjAML3EOqw1g26eCwWPjdmecULvBH5MVPoqKYrOfPhYVL71xAXI1IBQoAAAB8eyJvcmlnaW4iOiJodHRwczovL2RvdWJsZWNsaWNrLm5ldDo0NDMiLCJmZWF0dXJlIjoiV2ViVmlld1hSZXF1ZXN0ZWRXaXRoRGVwcmVjYXRpb24iLCJleHBpcnkiOjE3NTgwNjcxOTksImlzU3ViZG9tYWluIjp0cnVlfQ=="><meta http-equiv="origin-trial" content="Amm8/NmvvQfhwCib6I7ZsmUxiSCfOxWxHayJwyU1r3gRIItzr7bNQid6O8ZYaE1GSQTa69WwhPC9flq/oYkRBwsAAACCeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXN5bmRpY2F0aW9uLmNvbTo0NDMiLCJmZWF0dXJlIjoiV2ViVmlld1hSZXF1ZXN0ZWRXaXRoRGVwcmVjYXRpb24iLCJleHBpcnkiOjE3NTgwNjcxOTksImlzU3ViZG9tYWluIjp0cnVlfQ=="><meta http-equiv="origin-trial" content="A9nrunKdU5m96PSN1XsSGr3qOP0lvPFUB2AiAylCDlN5DTl17uDFkpQuHj1AFtgWLxpLaiBZuhrtb2WOu7ofHwEAAACKeyJvcmlnaW4iOiJodHRwczovL2RvdWJsZWNsaWNrLm5ldDo0NDMiLCJmZWF0dXJlIjoiQUlQcm9tcHRBUElNdWx0aW1vZGFsSW5wdXQiLCJleHBpcnkiOjE3NzQzMTA0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9"><meta http-equiv="origin-trial" content="A93bovR+QVXNx2/38qDbmeYYf1wdte9EO37K9eMq3r+541qo0byhYU899BhPB7Cv9QqD7wIbR1B6OAc9kEfYCA4AAACQeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXN5bmRpY2F0aW9uLmNvbTo0NDMiLCJmZWF0dXJlIjoiQUlQcm9tcHRBUElNdWx0aW1vZGFsSW5wdXQiLCJleHBpcnkiOjE3NzQzMTA0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9"><meta http-equiv="origin-trial" content="A1S5fojrAunSDrFbD8OfGmFHdRFZymSM/1ss3G+NEttCLfHkXvlcF6LGLH8Mo5PakLO1sCASXU1/gQf6XGuTBgwAAACQeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXRhZ3NlcnZpY2VzLmNvbTo0NDMiLCJmZWF0dXJlIjoiQUlQcm9tcHRBUElNdWx0aW1vZGFsSW5wdXQiLCJleHBpcnkiOjE3NzQzMTA0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9"><script src="https://securepubads.g.doubleclick.net/pagead/managed/js/gpt/m202510160101/pubads_impl.js?cb=31095331" async=""></script><link href="https://securepubads.g.doubleclick.net/pagead/managed/dict/m202510140101/gpt" rel="compression-dictionary"><script src="https://unpkg.com/@theidentityselector/thiss-ds@1.0.13/dist/thiss-ds.js" async=""></script><script src="https://cdn.cookielaw.org/scripttemplates/202504.1.0/otBannerSdk.js" async="" type="text/javascript"></script><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 2px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 2px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: 1em}
.MathJax_MenuRadioCheck.RTL {right: 1em; left: auto}
.MathJax_MenuLabel {padding: 2px 2em 4px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #CCCCCC; margin: 4px 1px 0px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: Highlight; color: HighlightText}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style><style type="text/css">.MJX_Assistive_MathML {position: absolute!important; top: 0; left: 0; clip: rect(1px, 1px, 1px, 1px); padding: 1px 0 0 0!important; border: 0!important; height: 1px!important; width: 1px!important; overflow: hidden!important; display: block!important; -webkit-touch-callout: none; -webkit-user-select: none; -khtml-user-select: none; -moz-user-select: none; -ms-user-select: none; user-select: none}
.MJX_Assistive_MathML.MJX_Assistive_MathML_Block {width: 100%!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MJXp-script {font-size: .8em}
.MJXp-right {-webkit-transform-origin: right; -moz-transform-origin: right; -ms-transform-origin: right; -o-transform-origin: right; transform-origin: right}
.MJXp-bold {font-weight: bold}
.MJXp-italic {font-style: italic}
.MJXp-scr {font-family: MathJax_Script,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-frak {font-family: MathJax_Fraktur,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-sf {font-family: MathJax_SansSerif,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-cal {font-family: MathJax_Caligraphic,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-mono {font-family: MathJax_Typewriter,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-largeop {font-size: 150%}
.MJXp-largeop.MJXp-int {vertical-align: -.2em}
.MJXp-math {display: inline-block; line-height: 1.2; text-indent: 0; font-family: 'Times New Roman',Times,STIXGeneral,serif; white-space: nowrap; border-collapse: collapse}
.MJXp-display {display: block; text-align: center; margin: 1em 0}
.MJXp-math span {display: inline-block}
.MJXp-box {display: block!important; text-align: center}
.MJXp-box:after {content: " "}
.MJXp-rule {display: block!important; margin-top: .1em}
.MJXp-char {display: block!important}
.MJXp-mo {margin: 0 .15em}
.MJXp-mfrac {margin: 0 .125em; vertical-align: .25em}
.MJXp-denom {display: inline-table!important; width: 100%}
.MJXp-denom > * {display: table-row!important}
.MJXp-surd {vertical-align: top}
.MJXp-surd > * {display: block!important}
.MJXp-script-box > *  {display: table!important; height: 50%}
.MJXp-script-box > * > * {display: table-cell!important; vertical-align: top}
.MJXp-script-box > *:last-child > * {vertical-align: bottom}
.MJXp-script-box > * > * > * {display: block!important}
.MJXp-mphantom {visibility: hidden}
.MJXp-munderover, .MJXp-munder {display: inline-table!important}
.MJXp-over {display: inline-block!important; text-align: center}
.MJXp-over > * {display: block!important}
.MJXp-munderover > *, .MJXp-munder > * {display: table-row!important}
.MJXp-mtable {vertical-align: .25em; margin: 0 .125em}
.MJXp-mtable > * {display: inline-table!important; vertical-align: middle}
.MJXp-mtr {display: table-row!important}
.MJXp-mtd {display: table-cell!important; text-align: center; padding: .5em 0 0 .5em}
.MJXp-mtr > .MJXp-mtd:first-child {padding-left: 0}
.MJXp-mtr:first-child > .MJXp-mtd {padding-top: 0}
.MJXp-mlabeledtr {display: table-row!important}
.MJXp-mlabeledtr > .MJXp-mtd:first-child {padding-left: 0}
.MJXp-mlabeledtr:first-child > .MJXp-mtd {padding-top: 0}
.MJXp-merror {background-color: #FFFF88; color: #CC0000; border: 1px solid #CC0000; padding: 1px 3px; font-style: normal; font-size: 90%}
.MJXp-scale0 {-webkit-transform: scaleX(.0); -moz-transform: scaleX(.0); -ms-transform: scaleX(.0); -o-transform: scaleX(.0); transform: scaleX(.0)}
.MJXp-scale1 {-webkit-transform: scaleX(.1); -moz-transform: scaleX(.1); -ms-transform: scaleX(.1); -o-transform: scaleX(.1); transform: scaleX(.1)}
.MJXp-scale2 {-webkit-transform: scaleX(.2); -moz-transform: scaleX(.2); -ms-transform: scaleX(.2); -o-transform: scaleX(.2); transform: scaleX(.2)}
.MJXp-scale3 {-webkit-transform: scaleX(.3); -moz-transform: scaleX(.3); -ms-transform: scaleX(.3); -o-transform: scaleX(.3); transform: scaleX(.3)}
.MJXp-scale4 {-webkit-transform: scaleX(.4); -moz-transform: scaleX(.4); -ms-transform: scaleX(.4); -o-transform: scaleX(.4); transform: scaleX(.4)}
.MJXp-scale5 {-webkit-transform: scaleX(.5); -moz-transform: scaleX(.5); -ms-transform: scaleX(.5); -o-transform: scaleX(.5); transform: scaleX(.5)}
.MJXp-scale6 {-webkit-transform: scaleX(.6); -moz-transform: scaleX(.6); -ms-transform: scaleX(.6); -o-transform: scaleX(.6); transform: scaleX(.6)}
.MJXp-scale7 {-webkit-transform: scaleX(.7); -moz-transform: scaleX(.7); -ms-transform: scaleX(.7); -o-transform: scaleX(.7); transform: scaleX(.7)}
.MJXp-scale8 {-webkit-transform: scaleX(.8); -moz-transform: scaleX(.8); -ms-transform: scaleX(.8); -o-transform: scaleX(.8); transform: scaleX(.8)}
.MJXp-scale9 {-webkit-transform: scaleX(.9); -moz-transform: scaleX(.9); -ms-transform: scaleX(.9); -o-transform: scaleX(.9); transform: scaleX(.9)}
</style><style id="onetrust-style">#onetrust-banner-sdk .onetrust-vendors-list-handler{cursor:pointer;color:#1f96db;font-size:inherit;font-weight:bold;text-decoration:none;margin-left:5px}#onetrust-banner-sdk .onetrust-vendors-list-handler:hover{color:#1f96db}#onetrust-banner-sdk:focus{outline:2px solid #000;outline-offset:-2px}#onetrust-banner-sdk a:focus{outline:2px solid #000}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{outline-offset:1px}#onetrust-banner-sdk.ot-bnr-w-logo .ot-bnr-logo{height:64px;width:64px}#onetrust-banner-sdk .ot-tcf2-vendor-count.ot-text-bold{font-weight:bold}#onetrust-banner-sdk .ot-button-order-0{order:0}#onetrust-banner-sdk .ot-button-order-1{order:1}#onetrust-banner-sdk .ot-button-order-2{order:2}#onetrust-banner-sdk #onetrust-close-btn-container svg{height:10px;width:10px;pointer-events:none}#onetrust-banner-sdk .ot-close-icon,#onetrust-pc-sdk .ot-close-icon,#ot-sync-ntfy .ot-close-icon{background-size:contain;background-repeat:no-repeat;background-position:center;height:12px;width:12px}#onetrust-banner-sdk .powered-by-logo,#onetrust-banner-sdk .ot-pc-footer-logo a,#onetrust-pc-sdk .powered-by-logo,#onetrust-pc-sdk .ot-pc-footer-logo a,#ot-sync-ntfy .powered-by-logo,#ot-sync-ntfy .ot-pc-footer-logo a{background-size:contain;background-repeat:no-repeat;background-position:center;height:25px;width:152px;display:block;text-decoration:none;font-size:.75em}#onetrust-banner-sdk .powered-by-logo:hover,#onetrust-banner-sdk .ot-pc-footer-logo a:hover,#onetrust-pc-sdk .powered-by-logo:hover,#onetrust-pc-sdk .ot-pc-footer-logo a:hover,#ot-sync-ntfy .powered-by-logo:hover,#ot-sync-ntfy .ot-pc-footer-logo a:hover{color:#565656}#onetrust-banner-sdk h3 *,#onetrust-banner-sdk h4 *,#onetrust-banner-sdk h6 *,#onetrust-banner-sdk button *,#onetrust-banner-sdk a[data-parent-id] *,#onetrust-pc-sdk h3 *,#onetrust-pc-sdk h4 *,#onetrust-pc-sdk h6 *,#onetrust-pc-sdk button *,#onetrust-pc-sdk a[data-parent-id] *,#ot-sync-ntfy h3 *,#ot-sync-ntfy h4 *,#ot-sync-ntfy h6 *,#ot-sync-ntfy button *,#ot-sync-ntfy a[data-parent-id] *{font-size:inherit;font-weight:inherit;color:inherit}#onetrust-banner-sdk .ot-hide,#onetrust-pc-sdk .ot-hide,#ot-sync-ntfy .ot-hide{display:none !important}#onetrust-banner-sdk button.ot-link-btn:hover,#onetrust-pc-sdk button.ot-link-btn:hover,#ot-sync-ntfy button.ot-link-btn:hover{text-decoration:underline;opacity:1}#onetrust-pc-sdk .ot-sdk-row .ot-sdk-column{padding:0}#onetrust-pc-sdk .ot-sdk-container{padding-right:0}#onetrust-pc-sdk .ot-sdk-row{flex-direction:initial;width:100%}#onetrust-pc-sdk [type=checkbox]:checked,#onetrust-pc-sdk [type=checkbox]:not(:checked){pointer-events:initial}#onetrust-pc-sdk [type=checkbox]:disabled+label::before,#onetrust-pc-sdk [type=checkbox]:disabled+label:after,#onetrust-pc-sdk [type=checkbox]:disabled+label{pointer-events:none;opacity:.8}#onetrust-pc-sdk #vendor-list-content{transform:translate3d(0, 0, 0)}#onetrust-pc-sdk li input[type=checkbox]{z-index:1}#onetrust-pc-sdk li .ot-checkbox label{z-index:2}#onetrust-pc-sdk li .ot-checkbox input[type=checkbox]{height:auto;width:auto}#onetrust-pc-sdk li .host-title a,#onetrust-pc-sdk li .ot-host-name a,#onetrust-pc-sdk li .accordion-text,#onetrust-pc-sdk li .ot-acc-txt{z-index:2;position:relative}#onetrust-pc-sdk input{margin:3px .1ex}#onetrust-pc-sdk .pc-logo,#onetrust-pc-sdk .ot-pc-logo{height:60px;width:180px;background-position:center;background-size:contain;background-repeat:no-repeat;display:inline-flex;justify-content:center;align-items:center}#onetrust-pc-sdk .pc-logo img,#onetrust-pc-sdk .ot-pc-logo img{max-height:100%;max-width:100%}#onetrust-pc-sdk .pc-logo svg,#onetrust-pc-sdk .ot-pc-logo svg{height:60px;width:180px}#onetrust-pc-sdk #close-pc-btn-handler>svg{margin:auto;display:block;height:12px;width:12px}#onetrust-pc-sdk .screen-reader-only,#onetrust-pc-sdk .ot-scrn-rdr,.ot-sdk-cookie-policy .screen-reader-only,.ot-sdk-cookie-policy .ot-scrn-rdr{border:0;clip:rect(0 0 0 0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px}#onetrust-pc-sdk.ot-fade-in,.onetrust-pc-dark-filter.ot-fade-in,#onetrust-banner-sdk.ot-fade-in{animation-name:onetrust-fade-in;animation-duration:400ms;animation-timing-function:ease-in-out}#onetrust-pc-sdk.ot-hide{display:none !important}.onetrust-pc-dark-filter.ot-hide{display:none !important}#ot-sdk-btn.ot-sdk-show-settings,#ot-sdk-btn.optanon-show-settings{color:#fff;background-color:#468254;height:auto;white-space:normal;word-wrap:break-word;padding:.8em 2em;font-size:.8em;line-height:1.2;cursor:pointer;-moz-transition:.1s ease;-o-transition:.1s ease;-webkit-transition:1s ease;transition:.1s ease}#ot-sdk-btn.ot-sdk-show-settings:hover,#ot-sdk-btn.optanon-show-settings:hover{color:#fff;background-color:#2c6415}#ot-sdk-btn.ot-sdk-show-settings:active,#ot-sdk-btn.optanon-show-settings:active{color:#fff;background-color:#2c6415;border:1px solid rgba(162,192,169,.5)}.onetrust-pc-dark-filter{background:rgba(0,0,0,.5);z-index:2147483646;width:100%;height:100%;overflow:hidden;position:fixed;top:0;bottom:0;left:0}@keyframes onetrust-fade-in{0%{opacity:0}100%{opacity:1}}.ot-cookie-label{text-decoration:underline}@media only screen and (min-width: 426px)and (max-width: 896px)and (orientation: landscape){#onetrust-pc-sdk p{font-size:.75em}}#onetrust-banner-sdk .banner-option-input:focus+label{outline:1px solid #000;outline-style:auto}.category-vendors-list-handler+a:focus,.category-vendors-list-handler+a:focus-visible{outline:2px solid #000}#onetrust-pc-sdk .ot-userid-title{margin-top:10px}#onetrust-pc-sdk .ot-userid-title>span,#onetrust-pc-sdk .ot-userid-timestamp>span{font-weight:700}#onetrust-pc-sdk .ot-userid-desc{font-style:italic}#onetrust-pc-sdk .ot-host-desc a{pointer-events:initial}#onetrust-pc-sdk .ot-ven-hdr>p a{position:relative;z-index:2;pointer-events:initial}#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info a,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info a{margin-right:auto}#onetrust-pc-sdk .ot-pc-footer-logo svg,#onetrust-pc-sdk .ot-pc-footer-logo img{width:136px;height:16px}#onetrust-pc-sdk .ot-pur-vdr-count{font-weight:400;font-size:.8em;padding-top:3px;display:block}#onetrust-banner-sdk .ot-optout-signal,#onetrust-pc-sdk .ot-optout-signal{border:1px solid #32ae88;border-radius:3px;padding:5px;margin-bottom:10px;background-color:#f9fffa;font-size:.85rem;line-height:2}#onetrust-banner-sdk .ot-optout-signal .ot-optout-icon,#onetrust-pc-sdk .ot-optout-signal .ot-optout-icon{display:inline;margin-right:5px}#onetrust-banner-sdk .ot-optout-signal svg,#onetrust-pc-sdk .ot-optout-signal svg{height:20px;width:30px}#onetrust-banner-sdk .ot-optout-signal svg.ot-source-sprite,#onetrust-pc-sdk .ot-optout-signal svg.ot-source-sprite{position:relative;bottom:-3px}#onetrust-banner-sdk .ot-optout-signal svg:not(.ot-source-sprite),#onetrust-pc-sdk .ot-optout-signal svg:not(.ot-source-sprite){transform:scale(0.5)}#onetrust-banner-sdk .ot-optout-signal svg:not(.ot-source-sprite) path,#onetrust-pc-sdk .ot-optout-signal svg:not(.ot-source-sprite) path{fill:#32ae88}#onetrust-consent-sdk .ot-general-modal{overflow:hidden;position:fixed;margin:0 auto;top:50%;left:50%;width:40%;padding:1.5rem;max-width:575px;min-width:575px;z-index:2147483647;border-radius:2.5px;transform:translate(-50%, -50%)}#onetrust-consent-sdk .ot-signature-health-group{margin-top:1rem;padding-left:1.25rem;padding-right:1.25rem;margin-bottom:.625rem;width:calc(100% - 2.5rem)}#onetrust-consent-sdk .ot-signature-health-group .ot-signature-health-form{gap:.5rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-health-form{width:70%;gap:.35rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-input{height:38px;padding:6px 10px;background-color:#fff;border:1px solid #d1d1d1;border-radius:4px;box-shadow:none;box-sizing:border-box}#onetrust-consent-sdk .ot-signature-health .ot-signature-subtitle{font-size:1.125rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-group-title{font-size:1.25rem;font-weight:bold}#onetrust-consent-sdk .ot-signature-health,#onetrust-consent-sdk .ot-signature-health-group{display:flex;flex-direction:column;gap:1rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-cont,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-cont{display:flex;flex-direction:column;gap:.25rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-paragraph,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-paragraph{margin:0;line-height:20px;font-size:max(14px,.875rem)}#onetrust-consent-sdk .ot-signature-health .ot-health-signature-error,#onetrust-consent-sdk .ot-signature-health-group .ot-health-signature-error{color:#4d4d4d;font-size:min(12px,.75rem)}#onetrust-consent-sdk .ot-signature-health .ot-signature-buttons-cont,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-buttons-cont{margin-top:max(.75rem,2%);gap:1rem;display:flex;justify-content:flex-end}#onetrust-consent-sdk .ot-signature-health .ot-signature-button,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-button{flex:1;height:auto;color:#fff;cursor:pointer;line-height:1.2;min-width:125px;font-weight:600;font-size:.813em;border-radius:2px;padding:12px 10px;white-space:normal;word-wrap:break-word;word-break:break-word;background-color:#68b631;border:2px solid #68b631}#onetrust-consent-sdk .ot-signature-health .ot-signature-button.reject,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-button.reject{background-color:#fff}#onetrust-consent-sdk .ot-input-field-cont{display:flex;flex-direction:column;gap:.5rem}#onetrust-consent-sdk .ot-input-field-cont .ot-signature-input{width:65%}#onetrust-consent-sdk .ot-signature-health-form{display:flex;flex-direction:column}#onetrust-consent-sdk .ot-signature-health-form .ot-signature-label{margin-bottom:0;line-height:20px;font-size:max(14px,.875rem)}#onetrust-consent-sdk #onetrust-sprite-svg{display:none}@media only screen and (max-width: 600px){#onetrust-consent-sdk .ot-general-modal{min-width:100%}#onetrust-consent-sdk .ot-signature-health .ot-signature-health-form{width:100%}#onetrust-consent-sdk .ot-input-field-cont .ot-signature-input{width:100%}}#onetrust-banner-sdk,#onetrust-pc-sdk,#ot-sdk-cookie-policy,#ot-sync-ntfy{font-size:16px}#onetrust-banner-sdk *,#onetrust-banner-sdk ::after,#onetrust-banner-sdk ::before,#onetrust-pc-sdk *,#onetrust-pc-sdk ::after,#onetrust-pc-sdk ::before,#ot-sdk-cookie-policy *,#ot-sdk-cookie-policy ::after,#ot-sdk-cookie-policy ::before,#ot-sync-ntfy *,#ot-sync-ntfy ::after,#ot-sync-ntfy ::before{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}#onetrust-banner-sdk div,#onetrust-banner-sdk span,#onetrust-banner-sdk h1,#onetrust-banner-sdk h2,#onetrust-banner-sdk h3,#onetrust-banner-sdk h4,#onetrust-banner-sdk h5,#onetrust-banner-sdk h6,#onetrust-banner-sdk p,#onetrust-banner-sdk img,#onetrust-banner-sdk svg,#onetrust-banner-sdk button,#onetrust-banner-sdk section,#onetrust-banner-sdk a,#onetrust-banner-sdk label,#onetrust-banner-sdk input,#onetrust-banner-sdk ul,#onetrust-banner-sdk li,#onetrust-banner-sdk nav,#onetrust-banner-sdk table,#onetrust-banner-sdk thead,#onetrust-banner-sdk tr,#onetrust-banner-sdk td,#onetrust-banner-sdk tbody,#onetrust-banner-sdk .ot-main-content,#onetrust-banner-sdk .ot-toggle,#onetrust-banner-sdk #ot-content,#onetrust-banner-sdk #ot-pc-content,#onetrust-banner-sdk .checkbox,#onetrust-pc-sdk div,#onetrust-pc-sdk span,#onetrust-pc-sdk h1,#onetrust-pc-sdk h2,#onetrust-pc-sdk h3,#onetrust-pc-sdk h4,#onetrust-pc-sdk h5,#onetrust-pc-sdk h6,#onetrust-pc-sdk p,#onetrust-pc-sdk img,#onetrust-pc-sdk svg,#onetrust-pc-sdk button,#onetrust-pc-sdk section,#onetrust-pc-sdk a,#onetrust-pc-sdk label,#onetrust-pc-sdk input,#onetrust-pc-sdk ul,#onetrust-pc-sdk li,#onetrust-pc-sdk nav,#onetrust-pc-sdk table,#onetrust-pc-sdk thead,#onetrust-pc-sdk tr,#onetrust-pc-sdk td,#onetrust-pc-sdk tbody,#onetrust-pc-sdk .ot-main-content,#onetrust-pc-sdk .ot-toggle,#onetrust-pc-sdk #ot-content,#onetrust-pc-sdk #ot-pc-content,#onetrust-pc-sdk .checkbox,#ot-sdk-cookie-policy div,#ot-sdk-cookie-policy span,#ot-sdk-cookie-policy h1,#ot-sdk-cookie-policy h2,#ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy h5,#ot-sdk-cookie-policy h6,#ot-sdk-cookie-policy p,#ot-sdk-cookie-policy img,#ot-sdk-cookie-policy svg,#ot-sdk-cookie-policy button,#ot-sdk-cookie-policy section,#ot-sdk-cookie-policy a,#ot-sdk-cookie-policy label,#ot-sdk-cookie-policy input,#ot-sdk-cookie-policy ul,#ot-sdk-cookie-policy li,#ot-sdk-cookie-policy nav,#ot-sdk-cookie-policy table,#ot-sdk-cookie-policy thead,#ot-sdk-cookie-policy tr,#ot-sdk-cookie-policy td,#ot-sdk-cookie-policy tbody,#ot-sdk-cookie-policy .ot-main-content,#ot-sdk-cookie-policy .ot-toggle,#ot-sdk-cookie-policy #ot-content,#ot-sdk-cookie-policy #ot-pc-content,#ot-sdk-cookie-policy .checkbox,#ot-sync-ntfy div,#ot-sync-ntfy span,#ot-sync-ntfy h1,#ot-sync-ntfy h2,#ot-sync-ntfy h3,#ot-sync-ntfy h4,#ot-sync-ntfy h5,#ot-sync-ntfy h6,#ot-sync-ntfy p,#ot-sync-ntfy img,#ot-sync-ntfy svg,#ot-sync-ntfy button,#ot-sync-ntfy section,#ot-sync-ntfy a,#ot-sync-ntfy label,#ot-sync-ntfy input,#ot-sync-ntfy ul,#ot-sync-ntfy li,#ot-sync-ntfy nav,#ot-sync-ntfy table,#ot-sync-ntfy thead,#ot-sync-ntfy tr,#ot-sync-ntfy td,#ot-sync-ntfy tbody,#ot-sync-ntfy .ot-main-content,#ot-sync-ntfy .ot-toggle,#ot-sync-ntfy #ot-content,#ot-sync-ntfy #ot-pc-content,#ot-sync-ntfy .checkbox{font-family:inherit;font-weight:normal;-webkit-font-smoothing:auto;letter-spacing:normal;line-height:normal;padding:0;margin:0;height:auto;min-height:0;max-height:none;width:auto;min-width:0;max-width:none;border-radius:0;border:none;clear:none;float:none;position:static;bottom:auto;left:auto;right:auto;top:auto;text-align:left;text-decoration:none;text-indent:0;text-shadow:none;text-transform:none;white-space:normal;background:none;overflow:visible;vertical-align:baseline;visibility:visible;z-index:auto;box-shadow:none}#onetrust-banner-sdk img,#onetrust-pc-sdk img,#ot-sdk-cookie-policy img,#ot-sync-ntfy img{overflow:hidden !important}#onetrust-banner-sdk label:before,#onetrust-banner-sdk label:after,#onetrust-banner-sdk .checkbox:after,#onetrust-banner-sdk .checkbox:before,#onetrust-pc-sdk label:before,#onetrust-pc-sdk label:after,#onetrust-pc-sdk .checkbox:after,#onetrust-pc-sdk .checkbox:before,#ot-sdk-cookie-policy label:before,#ot-sdk-cookie-policy label:after,#ot-sdk-cookie-policy .checkbox:after,#ot-sdk-cookie-policy .checkbox:before,#ot-sync-ntfy label:before,#ot-sync-ntfy label:after,#ot-sync-ntfy .checkbox:after,#ot-sync-ntfy .checkbox:before{content:"";content:none}#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{position:relative;width:100%;max-width:100%;margin:0 auto;padding:0 20px;box-sizing:border-box}#onetrust-banner-sdk .ot-sdk-column,#onetrust-banner-sdk .ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-column,#onetrust-pc-sdk .ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-column,#ot-sdk-cookie-policy .ot-sdk-columns{width:100%;float:left;box-sizing:border-box;padding:0;display:initial}@media(min-width: 400px){#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{width:90%;padding:0}}@media(min-width: 550px){#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{width:100%}#onetrust-banner-sdk .ot-sdk-column,#onetrust-banner-sdk .ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-column,#onetrust-pc-sdk .ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-column,#ot-sdk-cookie-policy .ot-sdk-columns{margin-left:4%}#onetrust-banner-sdk .ot-sdk-column:first-child,#onetrust-banner-sdk .ot-sdk-columns:first-child,#onetrust-pc-sdk .ot-sdk-column:first-child,#onetrust-pc-sdk .ot-sdk-columns:first-child,#ot-sdk-cookie-policy .ot-sdk-column:first-child,#ot-sdk-cookie-policy .ot-sdk-columns:first-child{margin-left:0}#onetrust-banner-sdk .ot-sdk-two.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-two.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-two.ot-sdk-columns{width:13.3333333333%}#onetrust-banner-sdk .ot-sdk-three.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-three.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-three.ot-sdk-columns{width:22%}#onetrust-banner-sdk .ot-sdk-four.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-four.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-four.ot-sdk-columns{width:30.6666666667%}#onetrust-banner-sdk .ot-sdk-eight.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-eight.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-eight.ot-sdk-columns{width:65.3333333333%}#onetrust-banner-sdk .ot-sdk-nine.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-nine.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-nine.ot-sdk-columns{width:74%}#onetrust-banner-sdk .ot-sdk-ten.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-ten.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-ten.ot-sdk-columns{width:82.6666666667%}#onetrust-banner-sdk .ot-sdk-eleven.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-eleven.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-eleven.ot-sdk-columns{width:91.3333333333%}#onetrust-banner-sdk .ot-sdk-twelve.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-twelve.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-twelve.ot-sdk-columns{width:100%;margin-left:0}}#onetrust-banner-sdk h1,#onetrust-banner-sdk h2,#onetrust-banner-sdk h3,#onetrust-banner-sdk h4,#onetrust-banner-sdk h5,#onetrust-banner-sdk h6,#onetrust-pc-sdk h1,#onetrust-pc-sdk h2,#onetrust-pc-sdk h3,#onetrust-pc-sdk h4,#onetrust-pc-sdk h5,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h1,#ot-sdk-cookie-policy h2,#ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy h5,#ot-sdk-cookie-policy h6{margin-top:0;font-weight:600;font-family:inherit}#onetrust-banner-sdk h1,#onetrust-pc-sdk h1,#ot-sdk-cookie-policy h1{font-size:1.5rem;line-height:1.2}#onetrust-banner-sdk h2,#onetrust-pc-sdk h2,#ot-sdk-cookie-policy h2{font-size:1.5rem;line-height:1.25}#onetrust-banner-sdk h3,#onetrust-pc-sdk h3,#ot-sdk-cookie-policy h3{font-size:1.5rem;line-height:1.3}#onetrust-banner-sdk h4,#onetrust-pc-sdk h4,#ot-sdk-cookie-policy h4{font-size:1.5rem;line-height:1.35}#onetrust-banner-sdk h5,#onetrust-pc-sdk h5,#ot-sdk-cookie-policy h5{font-size:1.5rem;line-height:1.5}#onetrust-banner-sdk h6,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h6{font-size:1.5rem;line-height:1.6}@media(min-width: 550px){#onetrust-banner-sdk h1,#onetrust-pc-sdk h1,#ot-sdk-cookie-policy h1{font-size:1.5rem}#onetrust-banner-sdk h2,#onetrust-pc-sdk h2,#ot-sdk-cookie-policy h2{font-size:1.5rem}#onetrust-banner-sdk h3,#onetrust-pc-sdk h3,#ot-sdk-cookie-policy h3{font-size:1.5rem}#onetrust-banner-sdk h4,#onetrust-pc-sdk h4,#ot-sdk-cookie-policy h4{font-size:1.5rem}#onetrust-banner-sdk h5,#onetrust-pc-sdk h5,#ot-sdk-cookie-policy h5{font-size:1.5rem}#onetrust-banner-sdk h6,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h6{font-size:1.5rem}}#onetrust-banner-sdk p,#onetrust-pc-sdk p,#ot-sdk-cookie-policy p{margin:0 0 1em 0;font-family:inherit;line-height:normal}#onetrust-banner-sdk a,#onetrust-pc-sdk a,#ot-sdk-cookie-policy a{color:#565656;text-decoration:underline}#onetrust-banner-sdk a:hover,#onetrust-pc-sdk a:hover,#ot-sdk-cookie-policy a:hover{color:#565656;text-decoration:none}#onetrust-banner-sdk .ot-sdk-button,#onetrust-banner-sdk button,#onetrust-pc-sdk .ot-sdk-button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy .ot-sdk-button,#ot-sdk-cookie-policy button{margin-bottom:1rem;font-family:inherit}#onetrust-banner-sdk .ot-sdk-button,#onetrust-banner-sdk button,#onetrust-pc-sdk .ot-sdk-button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy .ot-sdk-button,#ot-sdk-cookie-policy button{display:inline-block;height:38px;padding:0 30px;color:#555;text-align:center;font-size:.9em;font-weight:400;line-height:38px;letter-spacing:.01em;text-decoration:none;white-space:nowrap;background-color:rgba(0,0,0,0);border-radius:2px;border:1px solid #bbb;cursor:pointer;box-sizing:border-box}#onetrust-banner-sdk .ot-sdk-button:hover,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus,#onetrust-pc-sdk .ot-sdk-button:hover,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus,#ot-sdk-cookie-policy .ot-sdk-button:hover,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus{color:#333;border-color:#888;opacity:.9}#onetrust-banner-sdk .ot-sdk-button:focus,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:focus,#onetrust-pc-sdk .ot-sdk-button:focus,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:focus,#ot-sdk-cookie-policy .ot-sdk-button:focus,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:focus{outline:2px solid #000}#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary,#onetrust-banner-sdk button.ot-sdk-button-primary,#onetrust-banner-sdk input[type=submit].ot-sdk-button-primary,#onetrust-banner-sdk input[type=reset].ot-sdk-button-primary,#onetrust-banner-sdk input[type=button].ot-sdk-button-primary,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary,#onetrust-pc-sdk button.ot-sdk-button-primary,#onetrust-pc-sdk input[type=submit].ot-sdk-button-primary,#onetrust-pc-sdk input[type=reset].ot-sdk-button-primary,#onetrust-pc-sdk input[type=button].ot-sdk-button-primary,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary,#ot-sdk-cookie-policy button.ot-sdk-button-primary,#ot-sdk-cookie-policy input[type=submit].ot-sdk-button-primary,#ot-sdk-cookie-policy input[type=reset].ot-sdk-button-primary,#ot-sdk-cookie-policy input[type=button].ot-sdk-button-primary{color:#fff;background-color:#33c3f0;border-color:#33c3f0}#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary:hover,#onetrust-banner-sdk button.ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type=submit].ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type=reset].ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type=button].ot-sdk-button-primary:hover,#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary:focus,#onetrust-banner-sdk button.ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type=submit].ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type=reset].ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type=button].ot-sdk-button-primary:focus,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary:hover,#onetrust-pc-sdk button.ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type=submit].ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type=reset].ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type=button].ot-sdk-button-primary:hover,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary:focus,#onetrust-pc-sdk button.ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type=submit].ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type=reset].ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type=button].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary:hover,#ot-sdk-cookie-policy button.ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type=submit].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type=reset].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type=button].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary:focus,#ot-sdk-cookie-policy button.ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type=submit].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type=reset].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type=button].ot-sdk-button-primary:focus{color:#fff;background-color:#1eaedb;border-color:#1eaedb}#onetrust-banner-sdk input[type=text],#onetrust-pc-sdk input[type=text],#ot-sdk-cookie-policy input[type=text]{height:38px;padding:6px 10px;background-color:#fff;border:1px solid #d1d1d1;border-radius:4px;box-shadow:none;box-sizing:border-box}#onetrust-banner-sdk input[type=text],#onetrust-pc-sdk input[type=text],#ot-sdk-cookie-policy input[type=text]{-webkit-appearance:none;-moz-appearance:none;appearance:none}#onetrust-banner-sdk input[type=text]:focus,#onetrust-pc-sdk input[type=text]:focus,#ot-sdk-cookie-policy input[type=text]:focus{border:1px solid #000;outline:0}#onetrust-banner-sdk label,#onetrust-pc-sdk label,#ot-sdk-cookie-policy label{display:block;margin-bottom:.5rem;font-weight:600}#onetrust-banner-sdk input[type=checkbox],#onetrust-pc-sdk input[type=checkbox],#ot-sdk-cookie-policy input[type=checkbox]{display:inline}#onetrust-banner-sdk ul,#onetrust-pc-sdk ul,#ot-sdk-cookie-policy ul{list-style:circle inside}#onetrust-banner-sdk ul,#onetrust-pc-sdk ul,#ot-sdk-cookie-policy ul{padding-left:0;margin-top:0}#onetrust-banner-sdk ul ul,#onetrust-pc-sdk ul ul,#ot-sdk-cookie-policy ul ul{margin:1.5rem 0 1.5rem 3rem;font-size:90%}#onetrust-banner-sdk li,#onetrust-pc-sdk li,#ot-sdk-cookie-policy li{margin-bottom:1rem}#onetrust-banner-sdk th,#onetrust-banner-sdk td,#onetrust-pc-sdk th,#onetrust-pc-sdk td,#ot-sdk-cookie-policy th,#ot-sdk-cookie-policy td{padding:12px 15px;text-align:left;border-bottom:1px solid #e1e1e1}#onetrust-banner-sdk button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy button{margin-bottom:1rem;font-family:inherit}#onetrust-banner-sdk .ot-sdk-container:after,#onetrust-banner-sdk .ot-sdk-row:after,#onetrust-pc-sdk .ot-sdk-container:after,#onetrust-pc-sdk .ot-sdk-row:after,#ot-sdk-cookie-policy .ot-sdk-container:after,#ot-sdk-cookie-policy .ot-sdk-row:after{content:"";display:table;clear:both}#onetrust-banner-sdk .ot-sdk-row,#onetrust-pc-sdk .ot-sdk-row,#ot-sdk-cookie-policy .ot-sdk-row{margin:0;max-width:none;display:block}#onetrust-banner-sdk{box-shadow:0 0 18px rgba(0,0,0,.2)}#onetrust-banner-sdk.otFlat{position:fixed;z-index:2147483645;bottom:0;right:0;left:0;background-color:#fff;max-height:90%;overflow-x:hidden;overflow-y:auto}#onetrust-banner-sdk.otFlat.top{top:0px;bottom:auto}#onetrust-banner-sdk.otRelFont{font-size:1rem}#onetrust-banner-sdk>.ot-sdk-container{overflow:hidden}#onetrust-banner-sdk::-webkit-scrollbar{width:11px}#onetrust-banner-sdk::-webkit-scrollbar-thumb{border-radius:10px;background:#c1c1c1}#onetrust-banner-sdk{scrollbar-arrow-color:#c1c1c1;scrollbar-darkshadow-color:#c1c1c1;scrollbar-face-color:#c1c1c1;scrollbar-shadow-color:#c1c1c1}#onetrust-banner-sdk #onetrust-policy{margin:1.25em 0 .625em 2em;overflow:hidden}#onetrust-banner-sdk #onetrust-policy .ot-gv-list-handler{float:left;font-size:.82em;padding:0;margin-bottom:0;border:0;line-height:normal;height:auto;width:auto}#onetrust-banner-sdk #onetrust-policy-title{font-size:1.2em;line-height:1.3;margin-bottom:10px}#onetrust-banner-sdk #onetrust-group-container{position:relative}#onetrust-banner-sdk #onetrust-policy-text{clear:both;text-align:left;font-size:.88em;line-height:1.4}#onetrust-banner-sdk #onetrust-policy-text *{font-size:inherit;line-height:inherit}#onetrust-banner-sdk #onetrust-policy-text a{font-weight:bold;margin-left:5px}#onetrust-banner-sdk #onetrust-policy-title,#onetrust-banner-sdk #onetrust-policy-text{color:dimgray;float:left}#onetrust-banner-sdk #onetrust-button-group-parent{min-height:1px;text-align:center}#onetrust-banner-sdk #onetrust-button-group{display:inline-block}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{background-color:#68b631;color:#fff;border-color:#68b631;margin-right:1em;min-width:125px;height:auto;white-space:normal;word-break:break-word;word-wrap:break-word;padding:12px 10px;line-height:1.2;font-size:.813em;font-weight:600}#onetrust-banner-sdk #onetrust-pc-btn-handler.cookie-setting-link{background-color:#fff;border:none;color:#68b631;text-decoration:underline;padding-left:0;padding-right:0}#onetrust-banner-sdk .onetrust-close-btn-ui{width:44px;height:44px;background-size:12px;border:none;position:relative;margin:auto;padding:0}#onetrust-banner-sdk .banner_logo{display:none}#onetrust-banner-sdk.ot-bnr-w-logo .ot-bnr-logo{position:absolute;top:50%;transform:translateY(-50%);left:0px;margin-right:5px}#onetrust-banner-sdk.ot-bnr-w-logo #onetrust-policy{margin-left:65px}#onetrust-banner-sdk .ot-b-addl-desc{clear:both;float:left;display:block}#onetrust-banner-sdk #banner-options{float:left;display:table;margin-right:0;margin-left:1em;width:calc(100% - 1em)}#onetrust-banner-sdk .banner-option-input{cursor:pointer;width:auto;height:auto;border:none;padding:0;padding-right:3px;margin:0 0 10px;font-size:.82em;line-height:1.4}#onetrust-banner-sdk .banner-option-input *{pointer-events:none;font-size:inherit;line-height:inherit}#onetrust-banner-sdk .banner-option-input[aria-expanded=true]~.banner-option-details{display:block;height:auto}#onetrust-banner-sdk .banner-option-input[aria-expanded=true] .ot-arrow-container{transform:rotate(90deg)}#onetrust-banner-sdk .banner-option{margin-bottom:12px;margin-left:0;border:none;float:left;padding:0}#onetrust-banner-sdk .banner-option:first-child{padding-left:2px}#onetrust-banner-sdk .banner-option:not(:first-child){padding:0;border:none}#onetrust-banner-sdk .banner-option-header{cursor:pointer;display:inline-block}#onetrust-banner-sdk .banner-option-header :first-child{color:dimgray;font-weight:bold;float:left}#onetrust-banner-sdk .banner-option-header .ot-arrow-container{display:inline-block;border-top:6px solid rgba(0,0,0,0);border-bottom:6px solid rgba(0,0,0,0);border-left:6px solid dimgray;margin-left:10px;vertical-align:middle}#onetrust-banner-sdk .banner-option-details{display:none;font-size:.83em;line-height:1.5;padding:10px 0px 5px 10px;margin-right:10px;height:0px}#onetrust-banner-sdk .banner-option-details *{font-size:inherit;line-height:inherit;color:dimgray}#onetrust-banner-sdk .ot-arrow-container,#onetrust-banner-sdk .banner-option-details{transition:all 300ms ease-in 0s;-webkit-transition:all 300ms ease-in 0s;-moz-transition:all 300ms ease-in 0s;-o-transition:all 300ms ease-in 0s}#onetrust-banner-sdk .ot-dpd-container{float:left}#onetrust-banner-sdk .ot-dpd-title{margin-bottom:10px}#onetrust-banner-sdk .ot-dpd-title,#onetrust-banner-sdk .ot-dpd-desc{font-size:.88em;line-height:1.4;color:dimgray}#onetrust-banner-sdk .ot-dpd-title *,#onetrust-banner-sdk .ot-dpd-desc *{font-size:inherit;line-height:inherit}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-text *{margin-bottom:0}#onetrust-banner-sdk.ot-iab-2 .onetrust-vendors-list-handler{display:block;margin-left:0;margin-top:5px;clear:both;margin-bottom:0;padding:0;border:0;height:auto;width:auto}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group button{display:block}#onetrust-banner-sdk.ot-close-btn-link{padding-top:25px}#onetrust-banner-sdk.ot-close-btn-link #onetrust-close-btn-container{top:15px;transform:none;right:15px}#onetrust-banner-sdk.ot-close-btn-link #onetrust-close-btn-container button{padding:0;white-space:pre-wrap;border:none;height:auto;line-height:1.5;text-decoration:underline;font-size:.69em}#onetrust-banner-sdk #onetrust-policy-text,#onetrust-banner-sdk .ot-dpd-desc,#onetrust-banner-sdk .ot-b-addl-desc{font-size:.813em;line-height:1.5}#onetrust-banner-sdk .ot-dpd-desc{margin-bottom:10px}#onetrust-banner-sdk .ot-dpd-desc>.ot-b-addl-desc{margin-top:10px;margin-bottom:10px;font-size:1em}@media only screen and (max-width: 425px){#onetrust-banner-sdk #onetrust-close-btn-container{position:absolute;top:6px;right:2px}#onetrust-banner-sdk #onetrust-policy{margin-left:0;margin-top:3em}#onetrust-banner-sdk #onetrust-button-group{display:block}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{width:100%}#onetrust-banner-sdk .onetrust-close-btn-ui{top:auto;transform:none}#onetrust-banner-sdk #onetrust-policy-title{display:inline;float:none}#onetrust-banner-sdk #banner-options{margin:0;padding:0;width:100%}}@media only screen and (max-width: 550px){#onetrust-button-group.ot-button-order-container #onetrust-accept-btn-handler,#onetrust-button-group.ot-button-order-container #onetrust-reject-all-handler,#onetrust-button-group.ot-button-order-container #onetrust-pc-btn-handler{margin-right:0}#onetrust-banner-sdk .has-reject-all-button div#onetrust-button-group.ot-button-order-container #onetrust-accept-btn-handler,#onetrust-banner-sdk .has-reject-all-button div#onetrust-button-group.ot-button-order-container #onetrust-reject-all-handler,#onetrust-banner-sdk .has-reject-all-button div#onetrust-button-group.ot-button-order-container #onetrust-pc-btn-handler{margin-right:0}}@media only screen and (min-width: 426px)and (max-width: 896px){#onetrust-banner-sdk #onetrust-close-btn-container{position:absolute;top:0;right:0}#onetrust-banner-sdk #onetrust-policy{margin-left:1em;margin-right:1em}#onetrust-banner-sdk .onetrust-close-btn-ui{top:10px;right:10px}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{width:95%}#onetrust-banner-sdk.ot-iab-2 #onetrust-group-container{width:100%}#onetrust-banner-sdk.ot-bnr-w-logo #onetrust-button-group-parent{padding-left:50px}#onetrust-banner-sdk #onetrust-button-group-parent{width:100%;position:relative;margin-left:0}#onetrust-banner-sdk #onetrust-button-group button{display:inline-block}#onetrust-banner-sdk #onetrust-button-group{margin-right:0;text-align:center}#onetrust-banner-sdk #onetrust-button-group.ot-button-order-container #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-button-group.ot-button-order-container #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-button-group.ot-button-order-container #onetrust-pc-btn-handler{width:auto}#onetrust-banner-sdk .has-reject-all-button #onetrust-button-group.ot-button-order-container{display:inline-flex;flex-wrap:wrap}#onetrust-banner-sdk .has-reject-all-button #onetrust-button-group.ot-button-order-container #onetrust-pc-btn-handler,#onetrust-banner-sdk .has-reject-all-button #onetrust-button-group.ot-button-order-container #onetrust-reject-all-handler,#onetrust-banner-sdk .has-reject-all-button #onetrust-button-group.ot-button-order-container #onetrust-accept-btn-handler{float:none}#onetrust-banner-sdk .has-reject-all-button #onetrust-button-group.ot-button-order-container *[class*=ot-button-order-]:nth-of-type(1){margin-right:auto !important}#onetrust-banner-sdk .has-reject-all-button #onetrust-pc-btn-handler{float:left}#onetrust-banner-sdk .has-reject-all-button #onetrust-reject-all-handler,#onetrust-banner-sdk .has-reject-all-button #onetrust-accept-btn-handler{float:right}#onetrust-banner-sdk .has-reject-all-button #onetrust-button-group{width:calc(100% - 2em);margin-right:0}#onetrust-banner-sdk .has-reject-all-button #onetrust-pc-btn-handler.cookie-setting-link{padding-left:0px;text-align:left}#onetrust-banner-sdk.ot-buttons-fw .ot-sdk-three button{width:100%;text-align:center}#onetrust-banner-sdk.ot-buttons-fw #onetrust-button-group-parent button{float:none}#onetrust-banner-sdk.ot-buttons-fw #onetrust-pc-btn-handler.cookie-setting-link{text-align:center}}@media only screen and (min-width: 550px){#onetrust-banner-sdk .banner-option:not(:first-child){border-left:1px solid #d8d8d8;padding-left:25px}}@media only screen and (min-width: 425px)and (max-width: 550px){#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group,#onetrust-banner-sdk.ot-iab-2 #onetrust-policy,#onetrust-banner-sdk.ot-iab-2 .banner-option{width:100%}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-accept-btn-handler,#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-reject-all-handler,#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-pc-btn-handler{width:100%}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-accept-btn-handler,#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-reject-all-handler{float:left}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group.ot-button-order-container{width:auto}}@media only screen and (min-width: 769px){#onetrust-banner-sdk #onetrust-button-group{margin-right:30%}#onetrust-banner-sdk #banner-options{margin-left:2em;margin-right:5em;margin-bottom:1.25em;width:calc(100% - 7em)}}@media only screen and (min-width: 897px)and (max-width: 1023px){#onetrust-banner-sdk.vertical-align-content #onetrust-button-group-parent{position:absolute;top:50%;left:80%;transform:translateY(-50%)}#onetrust-banner-sdk #onetrust-close-btn-container{top:50%;margin:auto;transform:translate(-50%, -50%);position:absolute;padding:0;right:0}#onetrust-banner-sdk #onetrust-close-btn-container button{position:relative;margin:0;right:-22px;top:2px}}@media only screen and (min-width: 1024px){#onetrust-banner-sdk #onetrust-close-btn-container{top:50%;margin:auto;transform:translate(-50%, -50%);position:absolute;right:0}#onetrust-banner-sdk #onetrust-close-btn-container button{right:-12px}#onetrust-banner-sdk #onetrust-policy{margin-left:2em}#onetrust-banner-sdk.vertical-align-content #onetrust-button-group-parent{position:absolute;top:50%;left:60%;transform:translateY(-50%)}#onetrust-banner-sdk .ot-optout-signal{width:50%}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-title{width:50%}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-text,#onetrust-banner-sdk.ot-iab-2 :not(.ot-dpd-desc)>.ot-b-addl-desc{margin-bottom:1em;width:50%;border-right:1px solid #d8d8d8;padding-right:1rem}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-text{margin-bottom:0;padding-bottom:1em}#onetrust-banner-sdk.ot-iab-2 :not(.ot-dpd-desc)>.ot-b-addl-desc{margin-bottom:0;padding-bottom:1em}#onetrust-banner-sdk.ot-iab-2 .ot-dpd-container{width:45%;padding-left:1rem;display:inline-block;float:none}#onetrust-banner-sdk.ot-iab-2 .ot-dpd-title{line-height:1.7}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group-parent{left:auto;right:4%;margin-left:0}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group button{display:block}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-button-group-parent{margin:auto;width:30%}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{width:60%}#onetrust-banner-sdk #onetrust-button-group{margin-right:auto}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{margin-top:1em}}@media only screen and (min-width: 890px){#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group-parent{padding-left:3%;padding-right:4%;margin-left:0}#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group{margin-right:0;margin-top:1.25em;width:100%}#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group button{width:100%;margin-bottom:5px;margin-top:5px}#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group button:last-of-type{margin-bottom:20px}}@media only screen and (min-width: 1280px){#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{width:55%}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-button-group-parent{width:44%;padding-left:2%;padding-right:2%}#onetrust-banner-sdk:not(.ot-iab-2).vertical-align-content #onetrust-button-group-parent{position:absolute;left:55%}}
        #onetrust-consent-sdk #onetrust-banner-sdk {background-color: #FFF;}
            #onetrust-consent-sdk #onetrust-policy-title,
                    #onetrust-consent-sdk #onetrust-policy-text,
                    #onetrust-consent-sdk .ot-b-addl-desc,
                    #onetrust-consent-sdk .ot-dpd-desc,
                    #onetrust-consent-sdk .ot-dpd-title,
                    #onetrust-consent-sdk #onetrust-policy-text *:not(.onetrust-vendors-list-handler),
                    #onetrust-consent-sdk .ot-dpd-desc *:not(.onetrust-vendors-list-handler),
                    #onetrust-consent-sdk #onetrust-banner-sdk #banner-options *,
                    #onetrust-banner-sdk .ot-cat-header,
                    #onetrust-banner-sdk .ot-optout-signal
                    {
                        color: #2E2E2E;
                    }
            #onetrust-consent-sdk #onetrust-banner-sdk .banner-option-details {
                    background-color: #E9E9E9;}
             #onetrust-consent-sdk #onetrust-banner-sdk a[href],
                    #onetrust-consent-sdk #onetrust-banner-sdk a[href] font,
                    #onetrust-consent-sdk #onetrust-banner-sdk .ot-link-btn
                        {
                            color: #007398;
                        }#onetrust-consent-sdk #onetrust-accept-btn-handler,
                         #onetrust-banner-sdk #onetrust-reject-all-handler {
                            background-color: #007398;border-color: #007398;
                color: #FFF;
            }
            #onetrust-consent-sdk #onetrust-banner-sdk *:focus,
            #onetrust-consent-sdk #onetrust-banner-sdk:focus {
               outline-color: #000000;
               outline-width: 1px;
            }
            #onetrust-consent-sdk #onetrust-pc-btn-handler,
            #onetrust-consent-sdk #onetrust-pc-btn-handler.cookie-setting-link {
                color: #6CC04A; border-color: #6CC04A;
                background-color:
                #FFF;
            }/*! Extra code to blur out background */
.onetrust-pc-dark-filter{
background:rgba(0,0,0,.5);
z-index:2147483646;
width:100%;
height:100%;
overflow:hidden;
position:fixed;
top:0;
bottom:0;
left:0;
backdrop-filter: initial
}

/*! v6.12.0 2021-01-19 */
div#onetrust-consent-sdk #onetrust-banner-sdk{border-top:2px solid #eb6500!important;outline:1px solid transparent;box-shadow:none;padding:24px}div#onetrust-consent-sdk button{border-radius:0!important;box-shadow:none!important;box-sizing:border-box!important;font-size:20px!important;font-weight:400!important;letter-spacing:0!important;max-width:none!important;white-space:nowrap!important}div#onetrust-consent-sdk button:not(.ot-link-btn){background-color:#007398!important;border:2px solid #007398!important;color:#fff!important;height:48px!important;padding:0 1em!important;width:auto!important}div#onetrust-consent-sdk button:hover{background-color:#fff!important;border-color:#eb6500!important;color:#2e2e2e!important}div#onetrust-consent-sdk button.ot-link-btn{color:#007398!important;font-size:16px!important;text-decoration:underline}div#onetrust-consent-sdk button.ot-link-btn:hover{color: #2e2e2e!important;text-decoration-color:#eb6500!important}div#onetrust-consent-sdk a,div#onetrust-pc-sdk a{color:#007398!important;text-decoration:underline!important}div#onetrust-consent-sdk a,div#onetrust-consent-sdk button,div#onetrust-consent-sdk p:hover{opacity:1!important}div#onetrust-consent-sdk a:focus,div#onetrust-consent-sdk button:focus,div#onetrust-consent-sdk input:focus{outline:2px solid #eb6500!important;outline-offset:1px!important}div#onetrust-banner-sdk .ot-sdk-container{padding:0;width:auto}div#onetrust-banner-sdk .ot-sdk-row{align-items:flex-start;box-sizing:border-box;display:flex;flex-direction:column;justify-content:space-between;margin:auto;max-width:1152px}div#onetrust-banner-sdk .ot-sdk-row:after{display:none}div#onetrust-banner-sdk #onetrust-group-container,div#onetrust-banner-sdk.ot-bnr-flift:not(.ot-iab-2) #onetrust-group-container,div#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{flex-grow:1;width:auto}div#onetrust-banner-sdk #onetrust-policy,div#onetrust-banner-sdk.ot-bnr-flift #onetrust-policy{margin:0;overflow:visible}div#onetrust-banner-sdk.ot-bnr-flift #onetrust-policy-text,div#onetrust-consent-sdk #onetrust-policy-text{font-size:16px;line-height:24px;max-width:44em;margin:0}div#onetrust-consent-sdk #onetrust-policy-text a[href]{font-weight:400;margin-left:8px}div#onetrust-banner-sdk #onetrust-button-group-parent{flex:0 0 auto;margin:32px 0 0;width:100%}div#onetrust-banner-sdk #onetrust-button-group{display:flex;flex-direction:row;flex-wrap:wrap;justify-content:flex-end;margin:-8px}div#onetrust-banner-sdk .banner-actions-container{display:flex;flex:1 0 auto}div#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group button:last-of-type,div#onetrust-consent-sdk #onetrust-accept-btn-handler,div#onetrust-consent-sdk #onetrust-pc-btn-handler{flex:1 0 auto;margin:8px;width:auto}div#onetrust-consent-sdk #onetrust-pc-btn-handler{background-color:#fff!important;color:#2e2e2e!important}div#onetrust-banner-sdk #onetrust-close-btn-container{display:none}@media only screen and (min-width:556px){div#onetrust-consent-sdk #onetrust-banner-sdk{padding:40px}div#onetrust-banner-sdk #onetrust-policy{margin:0 40px 0 0}div#onetrust-banner-sdk .ot-sdk-row{align-items:center;flex-direction:row}div#onetrust-banner-sdk #onetrust-button-group-parent,div#onetrust-banner-sdk.ot-bnr-flift:not(.ot-iab-2) #onetrust-button-group-parent,div#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-button-group-parent{margin:0;padding:0;width:auto}div#onetrust-banner-sdk #onetrust-button-group,div#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group{align-items:stretch;flex-direction:column-reverse;margin:0}div#onetrust-consent-sdk #onetrust-accept-btn-handler,div#onetrust-consent-sdk #onetrust-pc-btn-handler{flex:1 0 auto}}@media only screen and (min-width:768px){div#onetrust-banner-sdk #onetrust-policy{margin:0 48px 0 0}div#onetrust-consent-sdk #onetrust-banner-sdk{padding:48px}}div#onetrust-consent-sdk #onetrust-pc-sdk h5{font-size:16px;line-height:24px}div#onetrust-consent-sdk #onetrust-pc-sdk p,div#onetrust-pc-sdk #ot-pc-desc,div#onetrust-pc-sdk .category-host-list-handler,div#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header{font-size:16px;font-weight:400;line-height:24px}div#onetrust-consent-sdk a:hover,div#onetrust-pc-sdk a:hover{color:#2e2e2e!important;text-decoration-color:#eb6500!important}div#onetrust-pc-sdk{border-radius:0;bottom:0;height:auto;left:0;margin:auto;max-width:100%;overflow:hidden;right:0;top:0;width:512px;max-height:800px}div#onetrust-pc-sdk .ot-pc-header{display:none}div#onetrust-pc-sdk #ot-pc-content{overscroll-behavior:contain;padding:0 12px 0 24px;margin:16px 4px 0 0;top:0;right:16px;left:0;width:auto}div#onetrust-pc-sdk #ot-category-title,div#onetrust-pc-sdk #ot-pc-title{font-size:24px;font-weight:400;line-height:32px;margin:0 0 16px}div#onetrust-pc-sdk #ot-pc-desc{padding:0}div#onetrust-pc-sdk #ot-pc-desc a{display:inline}div#onetrust-pc-sdk #accept-recommended-btn-handler{display:none!important}div#onetrust-pc-sdk input[type=checkbox]:focus+.ot-acc-hdr{outline:2px solid #eb6500;outline-offset:-1px;transition:none}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item{border-width:0 0 2px}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item:first-of-type{border-width:2px 0}div#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{padding:8px 0;width:100%}div#onetrust-pc-sdk .ot-plus-minus{transform:translateY(2px)}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item>button{background:0 0!important;border:0!important;height:44px!important;max-width:none!important;width:calc(100% - 48px)!important}div#onetrust-consent-sdk #onetrust-pc-sdk h5{font-weight:700}div#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr{padding:0}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item .ot-acc-grpdesc{padding:0;width:100%}div#onetrust-pc-sdk .ot-acc-grpcntr .ot-subgrp-cntr{border:0;padding:0}div#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp{margin:0}div#onetrust-pc-sdk .ot-always-active-group .ot-cat-header{width:calc(100% - 160px)}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header{width:calc(100% - 88px)}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active{color:#2e2e2e;font-size:12px;font-weight:400;line-height:1.5;padding-right:48px}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active:before{border-radius:12px;position:absolute;right:0;top:0;content:'';background:#fff;border:2px solid #939393;box-sizing:border-box;height:20px;width:40px}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active:after{border-radius:50%;position:absolute;right:5px;top:4px;content:'';background-color:#eb6500;height:12px;width:12px}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active,div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl{right:2px}div#onetrust-pc-sdk .ot-switch{display:block;height:20px;width:40px}div#onetrust-pc-sdk .ot-tgl input+.ot-switch .ot-switch-nob,div#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob{background:#fff;border:2px solid #939393;box-sizing:border-box;height:20px;width:40px}div#onetrust-pc-sdk .ot-tgl input+.ot-switch .ot-switch-nob:before{background-color:#737373;height:8px;left:4px;top:4px;width:8px}div#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob:before{background-color:#eb6500;height:12px;left:0;top:2px;width:12px}div#onetrust-pc-sdk .ot-tgl input:focus+.ot-switch .ot-switch-nob{box-shadow:0 0;outline:2px solid #eb6500!important;outline-offset:1px;transition:none}div#onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-grpcntr.ot-acc-txt{background-color:transparent;padding-left:3px}div#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr,div#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr{overflow:visible;width:100%}div#onetrust-pc-sdk .ot-pc-footer{border-top:0 solid}div#onetrust-pc-sdk .ot-btn-container{padding-top:24px;text-align:center}div#onetrust-pc-sdk .ot-pc-footer button{margin:8px 0;background-color:#fff}div#onetrust-pc-sdk .ot-pc-footer-logo{background-color:#fff}div#onetrust-pc-sdk #ot-lst-title span{font-size:24px;font-weight:400;line-height:32px}div#onetrust-pc-sdk #ot-host-lst .ot-host-desc,div#onetrust-pc-sdk #ot-host-lst .ot-host-expand,div#onetrust-pc-sdk #ot-host-lst .ot-host-name,div#onetrust-pc-sdk #ot-host-lst .ot-host-name a,div#onetrust-pc-sdk .back-btn-handler,div#onetrust-pc-sdk .ot-host-opt li>div div{font-size:16px;font-weight:400;line-height:24px}div#onetrust-pc-sdk #ot-host-lst .ot-acc-txt{width:100%}div#onetrust-pc-sdk #ot-pc-lst{top:0}div#onetrust-pc-sdk .back-btn-handler{text-decoration:none!important}div#onetrust-pc-sdk #filter-btn-handler:hover svg{filter:invert(1)}div#onetrust-pc-sdk .back-btn-handler svg{width:16px;height:16px}div#onetrust-pc-sdk .ot-host-item>button{background:0 0!important;border:0!important;height:66px!important;max-width:none!important;width:calc(100% - 5px)!important;transform:translate(2px,2px)}div#onetrust-pc-sdk .ot-host-item{border-bottom:2px solid #b9b9b9;padding:0}div#onetrust-pc-sdk .ot-host-item .ot-acc-hdr{margin:0 0 -6px;padding:8px 0}div#onetrust-pc-sdk ul li:first-child{border-top:2px solid #b9b9b9}div#onetrust-pc-sdk .ot-host-item .ot-plus-minus{margin:0 8px 0 0}div#onetrust-pc-sdk .ot-search-cntr{width:calc(100% - 48px)}div#onetrust-pc-sdk .ot-host-opt .ot-host-info{background-color:transparent}div#onetrust-pc-sdk .ot-host-opt li>div div{padding:0}div#onetrust-pc-sdk #vendor-search-handler{border-radius:0;border-color:#939393;border-style:solid;border-width:2px 0 2px 2px;font-size:20px;height:48px;margin:0}div#onetrust-pc-sdk #ot-pc-hdr{margin-left:24px}div#onetrust-pc-sdk .ot-lst-subhdr{width:calc(100% - 24px)}div#onetrust-pc-sdk .ot-lst-subhdr svg{right:0;top:8px}div#onetrust-pc-sdk .ot-fltr-cntr{box-sizing:border-box;right:0;width:48px}div#onetrust-pc-sdk #filter-btn-handler{width:48px!important;padding:8px!important}div#onetrust-consent-sdk #onetrust-pc-sdk #clear-filters-handler,div#onetrust-pc-sdk button#filter-apply-handler,div#onetrust-pc-sdk button#filter-cancel-handler{height:2em!important;padding-left:14px!important;padding-right:14px!important}div#onetrust-pc-sdk #ot-fltr-cnt{box-shadow:0 0;border:1px solid #8e8e8e;border-radius:0}div#onetrust-pc-sdk .ot-fltr-scrlcnt{max-height:calc(100% - 80px)}div#onetrust-pc-sdk #ot-fltr-modal{max-height:400px}div#onetrust-pc-sdk .ot-fltr-opt{margin-bottom:16px}div#onetrust-pc-sdk #ot-lst-cnt{margin-left:24px;width:calc(100% - 48px)}div#onetrust-pc-sdk #ot-anchor{display:none!important}

/* 2023-12-04  Fix for button order in mobile view*/
@media (max-width: 550px) {
  #onetrust-accept-btn-handler {order: 1;  }
  #onetrust-reject-all-handler { order: 2;  }
  #onetrust-pc-btn-handler { order: 3;  }
}


/*! Extra code to blur our background */
.onetrust-pc-dark-filter{
backdrop-filter: blur(3px)
}
#onetrust-pc-sdk.otPcCenter{overflow:hidden;position:fixed;margin:0 auto;top:5%;right:0;left:0;width:40%;max-width:575px;min-width:575px;border-radius:2.5px;z-index:2147483647;background-color:#fff;-webkit-box-shadow:0px 2px 10px -3px #999;-moz-box-shadow:0px 2px 10px -3px #999;box-shadow:0px 2px 10px -3px #999}#onetrust-pc-sdk.otPcCenter[dir=rtl]{right:0;left:0}#onetrust-pc-sdk.otRelFont{font-size:1rem}#onetrust-pc-sdk .ot-optout-signal{margin-top:.625rem}#onetrust-pc-sdk #ot-addtl-venlst .ot-arw-cntr,#onetrust-pc-sdk #ot-addtl-venlst .ot-plus-minus,#onetrust-pc-sdk .ot-hide-tgl{visibility:hidden}#onetrust-pc-sdk #ot-addtl-venlst .ot-arw-cntr *,#onetrust-pc-sdk #ot-addtl-venlst .ot-plus-minus *,#onetrust-pc-sdk .ot-hide-tgl *{visibility:hidden}#onetrust-pc-sdk #ot-gn-venlst .ot-ven-item .ot-acc-hdr{min-height:40px}#onetrust-pc-sdk .ot-pc-header{height:39px;padding:10px 0 10px 30px;border-bottom:1px solid #e9e9e9}#onetrust-pc-sdk #ot-pc-title,#onetrust-pc-sdk #ot-category-title,#onetrust-pc-sdk .ot-cat-header,#onetrust-pc-sdk #ot-lst-title,#onetrust-pc-sdk .ot-ven-hdr .ot-ven-name,#onetrust-pc-sdk .ot-always-active{font-weight:bold;color:dimgray}#onetrust-pc-sdk .ot-always-active-group .ot-cat-header{width:55%;font-weight:700}#onetrust-pc-sdk .ot-cat-item p{clear:both;float:left;margin-top:10px;margin-bottom:5px;line-height:1.5;font-size:.812em;color:dimgray}#onetrust-pc-sdk .ot-close-icon{height:44px;width:44px;background-size:10px}#onetrust-pc-sdk #ot-pc-title{float:left;font-size:1em;line-height:1.5;margin-bottom:10px;margin-top:10px;width:100%}#onetrust-pc-sdk #accept-recommended-btn-handler{margin-right:10px;margin-bottom:25px;position:relative;outline-offset:-1px}#onetrust-pc-sdk #ot-pc-desc{clear:both;width:100%;font-size:.812em;line-height:1.5;margin-bottom:25px}#onetrust-pc-sdk #ot-pc-desc *{font-size:inherit;line-height:inherit}#onetrust-pc-sdk #ot-pc-desc ul li{padding:10px 0px}#onetrust-pc-sdk a{color:#656565;cursor:pointer}#onetrust-pc-sdk a:hover{color:#3860be}#onetrust-pc-sdk label{margin-bottom:0}#onetrust-pc-sdk #vdr-lst-dsc{font-size:.812em;line-height:1.5;padding:10px 15px 5px 15px}#onetrust-pc-sdk button{max-width:394px;padding:12px 30px;line-height:1;word-break:break-word;word-wrap:break-word;white-space:normal;font-weight:bold;height:auto}#onetrust-pc-sdk .ot-link-btn{padding:0;margin-bottom:0;border:0;font-weight:normal;line-height:normal;width:auto;height:auto}#onetrust-pc-sdk #ot-pc-content{position:absolute;overflow-y:scroll;padding-left:2px;padding-right:30px;top:60px;bottom:110px;margin:1px 3px 0 30px;width:calc(100% - 63px)}#onetrust-pc-sdk .ot-vs-list .ot-always-active,#onetrust-pc-sdk .ot-cat-grp .ot-always-active{float:right;clear:none;color:#3860be;margin:0;font-size:.813em;line-height:1.3}#onetrust-pc-sdk .ot-pc-scrollbar::-webkit-scrollbar-track{margin-right:20px}#onetrust-pc-sdk .ot-pc-scrollbar::-webkit-scrollbar{width:11px}#onetrust-pc-sdk .ot-pc-scrollbar::-webkit-scrollbar-thumb{border-radius:10px;background:#d8d8d8}#onetrust-pc-sdk input[type=checkbox]:focus+.ot-acc-hdr{outline:#000 1px solid}#onetrust-pc-sdk .ot-pc-scrollbar{scrollbar-arrow-color:#d8d8d8;scrollbar-darkshadow-color:#d8d8d8;scrollbar-face-color:#d8d8d8;scrollbar-shadow-color:#d8d8d8}#onetrust-pc-sdk .save-preference-btn-handler{margin-right:20px}#onetrust-pc-sdk .ot-pc-refuse-all-handler{margin-right:10px}#onetrust-pc-sdk #ot-pc-desc .privacy-notice-link{margin-left:0;margin-right:8px}#onetrust-pc-sdk #ot-pc-desc .ot-imprint-handler{margin-left:0;margin-right:8px}#onetrust-pc-sdk .ot-subgrp-cntr{display:inline-block;clear:both;width:100%;padding-top:15px}#onetrust-pc-sdk .ot-switch+.ot-subgrp-cntr{padding-top:10px}#onetrust-pc-sdk ul.ot-subgrps{margin:0;font-size:initial}#onetrust-pc-sdk ul.ot-subgrps li p,#onetrust-pc-sdk ul.ot-subgrps li h5{font-size:.813em;line-height:1.4;color:dimgray}#onetrust-pc-sdk ul.ot-subgrps .ot-switch{min-height:auto}#onetrust-pc-sdk ul.ot-subgrps .ot-switch-nob{top:0}#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr{display:inline-block;width:100%}#onetrust-pc-sdk ul.ot-subgrps .ot-acc-txt{margin:0}#onetrust-pc-sdk ul.ot-subgrps li{padding:0;border:none}#onetrust-pc-sdk ul.ot-subgrps li h5{position:relative;top:5px;font-weight:bold;margin-bottom:0;float:left}#onetrust-pc-sdk li.ot-subgrp{margin-left:20px;overflow:auto}#onetrust-pc-sdk li.ot-subgrp>h5{width:calc(100% - 100px)}#onetrust-pc-sdk .ot-cat-item p>ul,#onetrust-pc-sdk li.ot-subgrp p>ul{margin:0px;list-style:disc;margin-left:15px;font-size:inherit}#onetrust-pc-sdk .ot-cat-item p>ul li,#onetrust-pc-sdk li.ot-subgrp p>ul li{font-size:inherit;padding-top:10px;padding-left:0px;padding-right:0px;border:none}#onetrust-pc-sdk .ot-cat-item p>ul li:last-child,#onetrust-pc-sdk li.ot-subgrp p>ul li:last-child{padding-bottom:10px}#onetrust-pc-sdk .ot-pc-logo{height:40px;width:120px}#onetrust-pc-sdk .ot-pc-footer{position:absolute;bottom:0px;width:100%;max-height:160px;border-top:1px solid #d8d8d8}#onetrust-pc-sdk.ot-ftr-stacked .ot-pc-refuse-all-handler{margin-bottom:0px}#onetrust-pc-sdk.ot-ftr-stacked #ot-pc-content{bottom:160px}#onetrust-pc-sdk.ot-ftr-stacked .ot-pc-footer button{width:100%;max-width:none}#onetrust-pc-sdk.ot-ftr-stacked .ot-btn-container{margin:0 30px;width:calc(100% - 60px);padding-right:0}#onetrust-pc-sdk .ot-pc-footer-logo{height:30px;width:100%;text-align:right;background:#f4f4f4}#onetrust-pc-sdk .ot-pc-footer-logo a{display:inline-block;margin-top:5px;margin-right:10px}#onetrust-pc-sdk[dir=rtl] .ot-pc-footer-logo{direction:rtl}#onetrust-pc-sdk[dir=rtl] .ot-pc-footer-logo a{margin-right:25px}#onetrust-pc-sdk .ot-tgl{float:right;position:relative;z-index:1}#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob{background-color:#468254;border:1px solid #fff}#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob:before{-webkit-transform:translateX(20px);-ms-transform:translateX(20px);transform:translateX(20px);background-color:#fff;border-color:#fff}#onetrust-pc-sdk .ot-tgl input:focus+.ot-switch{outline:#000 solid 1px}#onetrust-pc-sdk .ot-switch{position:relative;display:inline-block;width:45px;height:25px}#onetrust-pc-sdk .ot-switch-nob{position:absolute;cursor:pointer;top:0;left:0;right:0;bottom:0;background-color:#767676;border:1px solid #ddd;transition:all .2s ease-in 0s;-moz-transition:all .2s ease-in 0s;-o-transition:all .2s ease-in 0s;-webkit-transition:all .2s ease-in 0s;border-radius:20px}#onetrust-pc-sdk .ot-switch-nob:before{position:absolute;content:"";height:18px;width:18px;bottom:3px;left:3px;background-color:#fff;-webkit-transition:.4s;transition:.4s;border-radius:20px}#onetrust-pc-sdk .ot-chkbox input:checked~label::before{background-color:#3860be}#onetrust-pc-sdk .ot-chkbox input+label::after{content:none;color:#fff}#onetrust-pc-sdk .ot-chkbox input:checked+label::after{content:""}#onetrust-pc-sdk .ot-chkbox input:focus+label::before{outline-style:solid;outline-width:2px;outline-style:auto}#onetrust-pc-sdk .ot-chkbox input[aria-checked=mixed]~label::before{background-color:#3860be}#onetrust-pc-sdk .ot-chkbox input[aria-checked=mixed]+label::after{content:""}#onetrust-pc-sdk .ot-chkbox label{position:relative;display:inline-block;padding-left:30px;cursor:pointer;font-weight:500}#onetrust-pc-sdk .ot-chkbox label::before,#onetrust-pc-sdk .ot-chkbox label::after{position:absolute;content:"";display:inline-block;border-radius:3px}#onetrust-pc-sdk .ot-chkbox label::before{height:18px;width:18px;border:1px solid #3860be;left:0px;top:auto}#onetrust-pc-sdk .ot-chkbox label::after{height:5px;width:9px;border-left:3px solid;border-bottom:3px solid;transform:rotate(-45deg);-o-transform:rotate(-45deg);-ms-transform:rotate(-45deg);-webkit-transform:rotate(-45deg);left:4px;top:5px}#onetrust-pc-sdk .ot-label-txt{display:none}#onetrust-pc-sdk .ot-chkbox input,#onetrust-pc-sdk .ot-tgl input{position:absolute;opacity:0;width:0;height:0}#onetrust-pc-sdk .ot-arw-cntr{float:right;position:relative;pointer-events:none}#onetrust-pc-sdk .ot-arw-cntr .ot-arw{width:16px;height:16px;margin-left:5px;color:dimgray;display:inline-block;vertical-align:middle;-webkit-transition:all 150ms ease-in 0s;-moz-transition:all 150ms ease-in 0s;-o-transition:all 150ms ease-in 0s;transition:all 150ms ease-in 0s}#onetrust-pc-sdk input:checked~.ot-acc-hdr .ot-arw,#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-arw-cntr svg{transform:rotate(90deg);-o-transform:rotate(90deg);-ms-transform:rotate(90deg);-webkit-transform:rotate(90deg)}#onetrust-pc-sdk input[type=checkbox]:focus+.ot-acc-hdr{outline:#000 1px solid}#onetrust-pc-sdk .ot-tgl-cntr,#onetrust-pc-sdk .ot-arw-cntr{display:inline-block}#onetrust-pc-sdk .ot-tgl-cntr{float:right;margin-top:2px}#onetrust-pc-sdk #ot-lst-cnt .ot-tgl-cntr{margin-top:10px}#onetrust-pc-sdk .ot-always-active-subgroup{width:auto;padding-left:0px !important;top:3px;position:relative}#onetrust-pc-sdk .ot-label-status{font-size:.75em;display:none;font-size:.75em;position:relative;top:2px;padding-right:5px;float:left}#onetrust-pc-sdk .ot-arw-cntr{margin-top:-1px}#onetrust-pc-sdk .ot-arw-cntr svg{-webkit-transition:all 300ms ease-in 0s;-moz-transition:all 300ms ease-in 0s;-o-transition:all 300ms ease-in 0s;transition:all 300ms ease-in 0s;height:10px;width:10px}#onetrust-pc-sdk input:checked~.ot-acc-hdr .ot-arw{transform:rotate(90deg);-o-transform:rotate(90deg);-ms-transform:rotate(90deg);-webkit-transform:rotate(90deg)}#onetrust-pc-sdk .ot-arw{width:10px;margin-left:15px;transition:all 300ms ease-in 0s;-webkit-transition:all 300ms ease-in 0s;-moz-transition:all 300ms ease-in 0s;-o-transition:all 300ms ease-in 0s}#onetrust-pc-sdk .ot-vlst-cntr{margin-bottom:0}#onetrust-pc-sdk .ot-hlst-cntr{margin-top:5px;display:inline-block;width:100%}#onetrust-pc-sdk .category-vendors-list-handler,#onetrust-pc-sdk .category-vendors-list-handler+a,#onetrust-pc-sdk .category-host-list-handler{clear:both;color:#3860be;margin-left:0;font-size:.813em;text-decoration:none;float:left;overflow:hidden}#onetrust-pc-sdk .category-vendors-list-handler:hover,#onetrust-pc-sdk .category-vendors-list-handler+a:hover,#onetrust-pc-sdk .category-host-list-handler:hover{text-decoration-line:underline}#onetrust-pc-sdk .category-vendors-list-handler+a{clear:none}#onetrust-pc-sdk .ot-vlst-cntr .ot-ext-lnk,#onetrust-pc-sdk .ot-ven-hdr .ot-ext-lnk{display:inline-block;height:13px;width:13px;background-repeat:no-repeat;margin-left:1px;margin-top:6px;cursor:pointer}#onetrust-pc-sdk .ot-ven-hdr .ot-ext-lnk{margin-bottom:-1px}#onetrust-pc-sdk .back-btn-handler{font-size:1em;text-decoration:none}#onetrust-pc-sdk .back-btn-handler:hover{opacity:.6}#onetrust-pc-sdk #ot-lst-title h3{display:inline-block;word-break:break-word;word-wrap:break-word;margin-bottom:0;color:#656565;font-size:1em;font-weight:bold;margin-left:15px}#onetrust-pc-sdk #ot-lst-title{margin:10px 0 10px 0px;font-size:1em;text-align:left}#onetrust-pc-sdk #ot-pc-hdr{margin:0 0 0 30px;height:auto;width:auto}#onetrust-pc-sdk #ot-pc-hdr input::placeholder{color:#707070;font-style:italic}#onetrust-pc-sdk #vendor-search-handler{height:31px;width:100%;border-radius:50px;font-size:.8em;padding-right:35px;padding-left:15px;float:left;margin-left:15px}#onetrust-pc-sdk .ot-ven-name{display:block;width:auto;padding-right:5px}#onetrust-pc-sdk #ot-lst-cnt{overflow-y:auto;margin-left:20px;margin-right:7px;width:calc(100% - 27px);max-height:calc(100% - 80px);height:100%;transform:translate3d(0, 0, 0)}#onetrust-pc-sdk #ot-pc-lst{width:100%;bottom:100px;position:absolute;top:60px}#onetrust-pc-sdk #ot-pc-lst:not(.ot-enbl-chr) .ot-tgl-cntr .ot-arw-cntr,#onetrust-pc-sdk #ot-pc-lst:not(.ot-enbl-chr) .ot-tgl-cntr .ot-arw-cntr *{visibility:hidden}#onetrust-pc-sdk #ot-pc-lst .ot-tgl-cntr{right:12px;position:absolute}#onetrust-pc-sdk #ot-pc-lst .ot-arw-cntr{float:right;position:relative}#onetrust-pc-sdk #ot-pc-lst .ot-arw{margin-left:10px}#onetrust-pc-sdk #ot-pc-lst .ot-acc-hdr{overflow:hidden;cursor:pointer}#onetrust-pc-sdk .ot-vlst-cntr{overflow:hidden}#onetrust-pc-sdk #ot-sel-blk{overflow:hidden;width:100%;position:sticky;position:-webkit-sticky;top:0;z-index:3}#onetrust-pc-sdk #ot-back-arw{height:12px;width:12px}#onetrust-pc-sdk .ot-lst-subhdr{width:100%;display:inline-block}#onetrust-pc-sdk .ot-search-cntr{float:left;width:78%;position:relative}#onetrust-pc-sdk .ot-search-cntr>svg{width:30px;height:30px;position:absolute;float:left;right:-15px}#onetrust-pc-sdk .ot-fltr-cntr{float:right;right:50px;position:relative}#onetrust-pc-sdk #ot-filter-list-header{margin-top:20px;margin-bottom:10px;float:left;max-width:150px;text-decoration:none;color:#3860be;font-size:.9em;font-weight:bold;background-color:rgba(0,0,0,0);border-color:rgba(0,0,0,0);padding:1px 1px 1px 15px;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}#onetrust-pc-sdk #filter-btn-handler{background-color:#3860be;border-radius:17px;display:inline-block;position:relative;width:32px;height:32px;-moz-transition:.1s ease;-o-transition:.1s ease;-webkit-transition:1s ease;transition:.1s ease;padding:0;margin:0}#onetrust-pc-sdk #filter-btn-handler:hover{background-color:#3860be}#onetrust-pc-sdk #filter-btn-handler svg{width:12px;height:12px;margin:3px 10px 0 10px;display:block;position:static;right:auto;top:auto}#onetrust-pc-sdk .ot-ven-link,#onetrust-pc-sdk .ot-ven-legclaim-link{color:#3860be;text-decoration:none;font-weight:100;display:inline-block;padding-top:10px;transform:translate(0, 1%);-o-transform:translate(0, 1%);-ms-transform:translate(0, 1%);-webkit-transform:translate(0, 1%);position:relative;z-index:2}#onetrust-pc-sdk .ot-ven-link *,#onetrust-pc-sdk .ot-ven-legclaim-link *{font-size:inherit}#onetrust-pc-sdk .ot-ven-link:hover,#onetrust-pc-sdk .ot-ven-legclaim-link:hover{text-decoration:underline}#onetrust-pc-sdk .ot-ven-hdr{width:calc(100% - 160px);height:auto;float:left;word-break:break-word;word-wrap:break-word;vertical-align:middle;padding-bottom:3px}#onetrust-pc-sdk .ot-ven-link,#onetrust-pc-sdk .ot-ven-legclaim-link{letter-spacing:.03em;font-size:.75em;font-weight:400}#onetrust-pc-sdk .ot-ven-dets{border-radius:2px;background-color:#f8f8f8}#onetrust-pc-sdk .ot-ven-dets li:first-child p:first-child{border-top:none}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:not(:first-child){border-top:1px solid #ddd !important}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p{display:inline-block}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p:nth-of-type(odd){width:30%}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p:nth-of-type(even){width:50%;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc p,#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc h5{padding-top:5px;padding-bottom:5px;display:block}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc h5{display:inline-block}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc p:nth-last-child(-n+1){padding-bottom:10px}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc p:nth-child(-n+2):not(.disc-pur){padding-top:10px}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc .disc-pur-cont{display:inline}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc .disc-pur{position:relative;width:50% !important;word-break:break-word;word-wrap:break-word;left:calc(30% + 17px)}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc .disc-pur:nth-child(-n+1){position:static}#onetrust-pc-sdk .ot-ven-dets p,#onetrust-pc-sdk .ot-ven-dets h5,#onetrust-pc-sdk .ot-ven-dets span{font-size:.69em;text-align:left;vertical-align:middle;word-break:break-word;word-wrap:break-word;margin:0;padding-bottom:10px;padding-left:15px;color:#2e3644}#onetrust-pc-sdk .ot-ven-dets h5{padding-top:5px}#onetrust-pc-sdk .ot-ven-dets span{color:dimgray;padding:0;vertical-align:baseline}#onetrust-pc-sdk .ot-ven-dets .ot-ven-pur h5{border-top:1px solid #e9e9e9;border-bottom:1px solid #e9e9e9;padding-bottom:5px;margin-bottom:5px;font-weight:bold}#onetrust-pc-sdk #ot-host-lst .ot-sel-all{float:right;position:relative;margin-right:42px;top:10px}#onetrust-pc-sdk #ot-host-lst .ot-sel-all input[type=checkbox]{width:auto;height:auto}#onetrust-pc-sdk #ot-host-lst .ot-sel-all label{height:20px;width:20px;padding-left:0px}#onetrust-pc-sdk #ot-host-lst .ot-acc-txt{overflow:hidden;width:95%}#onetrust-pc-sdk .ot-host-hdr{position:relative;z-index:1;pointer-events:none;width:calc(100% - 125px);float:left}#onetrust-pc-sdk .ot-host-name,#onetrust-pc-sdk .ot-host-desc{display:inline-block;width:90%}#onetrust-pc-sdk .ot-host-name{pointer-events:none}#onetrust-pc-sdk .ot-host-hdr>a{text-decoration:underline;font-size:.82em;position:relative;z-index:2;float:left;margin-bottom:5px;pointer-events:initial}#onetrust-pc-sdk .ot-host-name+a{margin-top:5px}#onetrust-pc-sdk .ot-host-name,#onetrust-pc-sdk .ot-host-name a,#onetrust-pc-sdk .ot-host-desc,#onetrust-pc-sdk .ot-host-info{color:dimgray;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-host-name,#onetrust-pc-sdk .ot-host-name a{font-weight:bold;font-size:.82em;line-height:1.3}#onetrust-pc-sdk .ot-host-name a{font-size:1em}#onetrust-pc-sdk .ot-host-expand{margin-top:3px;margin-bottom:3px;clear:both;display:block;color:#3860be;font-size:.72em;font-weight:normal}#onetrust-pc-sdk .ot-host-expand *{font-size:inherit}#onetrust-pc-sdk .ot-host-desc,#onetrust-pc-sdk .ot-host-info{font-size:.688em;line-height:1.4;font-weight:normal}#onetrust-pc-sdk .ot-host-desc{margin-top:10px}#onetrust-pc-sdk .ot-host-opt{margin:0;font-size:inherit;display:inline-block;width:100%}#onetrust-pc-sdk .ot-host-opt li>div div{font-size:.8em;padding:5px 0}#onetrust-pc-sdk .ot-host-opt li>div div:nth-child(1){width:30%;float:left}#onetrust-pc-sdk .ot-host-opt li>div div:nth-child(2){width:70%;float:left;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-host-info{border:none;display:inline-block;width:calc(100% - 10px);padding:10px;margin-bottom:10px;background-color:#f8f8f8}#onetrust-pc-sdk .ot-host-info>div{overflow:auto}#onetrust-pc-sdk #no-results{text-align:center;margin-top:30px}#onetrust-pc-sdk #no-results p{font-size:1em;color:#2e3644;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk #no-results p span{font-weight:bold}#onetrust-pc-sdk #ot-fltr-modal{width:100%;height:auto;display:none;-moz-transition:.2s ease;-o-transition:.2s ease;-webkit-transition:2s ease;transition:.2s ease;overflow:hidden;opacity:1;right:0}#onetrust-pc-sdk #ot-fltr-modal .ot-label-txt{display:inline-block;font-size:.85em;color:dimgray}#onetrust-pc-sdk #ot-fltr-cnt{z-index:2147483646;background-color:#fff;position:absolute;height:90%;max-height:300px;width:325px;left:210px;margin-top:10px;margin-bottom:20px;padding-right:10px;border-radius:3px;-webkit-box-shadow:0px 0px 12px 2px #c7c5c7;-moz-box-shadow:0px 0px 12px 2px #c7c5c7;box-shadow:0px 0px 12px 2px #c7c5c7}#onetrust-pc-sdk .ot-fltr-scrlcnt{overflow-y:auto;overflow-x:hidden;clear:both;max-height:calc(100% - 60px)}#onetrust-pc-sdk #ot-anchor{border:12px solid rgba(0,0,0,0);display:none;position:absolute;z-index:2147483647;right:55px;top:75px;transform:rotate(45deg);-o-transform:rotate(45deg);-ms-transform:rotate(45deg);-webkit-transform:rotate(45deg);background-color:#fff;-webkit-box-shadow:-3px -3px 5px -2px #c7c5c7;-moz-box-shadow:-3px -3px 5px -2px #c7c5c7;box-shadow:-3px -3px 5px -2px #c7c5c7}#onetrust-pc-sdk .ot-fltr-btns{margin-left:15px}#onetrust-pc-sdk #filter-apply-handler{margin-right:15px}#onetrust-pc-sdk .ot-fltr-opt{margin-bottom:5px;margin-left:15px;min-height:20px;width:75%;position:relative}#onetrust-pc-sdk .ot-fltr-opt p{display:inline-block;margin:0;font-size:.9em;color:#2e3644}#onetrust-pc-sdk .ot-chkbox label span{font-size:.85em;color:dimgray}#onetrust-pc-sdk .ot-chkbox input[type=checkbox]+label::after{content:none;color:#fff}#onetrust-pc-sdk .ot-chkbox input[type=checkbox]:checked+label::after{content:""}#onetrust-pc-sdk .ot-chkbox input[type=checkbox][aria-checked=mixed]+label::after{content:""}#onetrust-pc-sdk .ot-chkbox input[type=checkbox]:focus+label::before{outline-style:solid;outline-width:2px;outline-style:auto}#onetrust-pc-sdk #ot-selall-vencntr,#onetrust-pc-sdk #ot-selall-adtlvencntr,#onetrust-pc-sdk #ot-selall-hostcntr,#onetrust-pc-sdk #ot-selall-licntr,#onetrust-pc-sdk #ot-selall-gnvencntr{right:15px;position:relative;width:20px;height:20px;float:right}#onetrust-pc-sdk #ot-selall-vencntr label,#onetrust-pc-sdk #ot-selall-adtlvencntr label,#onetrust-pc-sdk #ot-selall-hostcntr label,#onetrust-pc-sdk #ot-selall-licntr label,#onetrust-pc-sdk #ot-selall-gnvencntr label{float:left;padding-left:0}#onetrust-pc-sdk #ot-ven-lst:first-child{border-top:1px solid #e2e2e2}#onetrust-pc-sdk ul{list-style:none;padding:0}#onetrust-pc-sdk ul li{position:relative;margin:0;padding:15px 15px 15px 10px;border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk ul li h3,#onetrust-pc-sdk ul li h4{font-size:.75em;color:#656565;margin:0;display:inline-block;width:70%;height:auto;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk ul li p{margin:0;font-size:.7em}#onetrust-pc-sdk ul li input[type=checkbox]{position:absolute;cursor:pointer;width:100%;height:100%;opacity:0;margin:0;top:0;left:0}#onetrust-pc-sdk .ot-cat-item>button:focus,#onetrust-pc-sdk .ot-acc-cntr>button:focus,#onetrust-pc-sdk li>button:focus{outline:#000 solid 2px}#onetrust-pc-sdk .ot-cat-item>button,#onetrust-pc-sdk .ot-acc-cntr>button,#onetrust-pc-sdk li>button{position:absolute;cursor:pointer;width:100%;height:100%;margin:0;top:0;left:0;z-index:1;max-width:none;border:none}#onetrust-pc-sdk .ot-cat-item>button[aria-expanded=false]~.ot-acc-txt,#onetrust-pc-sdk .ot-acc-cntr>button[aria-expanded=false]~.ot-acc-txt,#onetrust-pc-sdk li>button[aria-expanded=false]~.ot-acc-txt{margin-top:0;max-height:0;opacity:0;overflow:hidden;width:100%;transition:.25s ease-out;display:none}#onetrust-pc-sdk .ot-cat-item>button[aria-expanded=true]~.ot-acc-txt,#onetrust-pc-sdk .ot-acc-cntr>button[aria-expanded=true]~.ot-acc-txt,#onetrust-pc-sdk li>button[aria-expanded=true]~.ot-acc-txt{transition:.1s ease-in;margin-top:10px;width:100%;overflow:auto;display:block}#onetrust-pc-sdk .ot-cat-item>button[aria-expanded=true]~.ot-acc-grpcntr,#onetrust-pc-sdk .ot-acc-cntr>button[aria-expanded=true]~.ot-acc-grpcntr,#onetrust-pc-sdk li>button[aria-expanded=true]~.ot-acc-grpcntr{width:auto;margin-top:0px;padding-bottom:10px}#onetrust-pc-sdk .ot-host-item>button:focus,#onetrust-pc-sdk .ot-ven-item>button:focus{outline:0;border:2px solid #000}#onetrust-pc-sdk .ot-hide-acc>button{pointer-events:none}#onetrust-pc-sdk .ot-hide-acc .ot-plus-minus>*,#onetrust-pc-sdk .ot-hide-acc .ot-arw-cntr>*{visibility:hidden}#onetrust-pc-sdk .ot-hide-acc .ot-acc-hdr{min-height:30px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt){padding-right:10px;width:calc(100% - 37px);margin-top:10px;max-height:calc(100% - 90px)}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk{background-color:#f9f9fc;border:1px solid #e2e2e2;width:calc(100% - 2px);padding-bottom:5px;padding-top:5px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk.ot-vnd-list-cnt{border:unset;background-color:unset}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk.ot-vnd-list-cnt .ot-sel-all-hdr{display:none}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk.ot-vnd-list-cnt .ot-sel-all{padding-right:.5rem}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk.ot-vnd-list-cnt .ot-sel-all .ot-chkbox{right:0}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-sel-all{padding-right:34px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-sel-all-chkbox{width:auto}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) ul li{border:1px solid #e2e2e2;margin-bottom:10px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-acc-cntr>.ot-acc-hdr{padding:10px 0 10px 15px}#onetrust-pc-sdk.ot-addtl-vendors .ot-sel-all-chkbox{float:right}#onetrust-pc-sdk.ot-addtl-vendors .ot-plus-minus~.ot-sel-all-chkbox{right:34px}#onetrust-pc-sdk.ot-addtl-vendors #ot-ven-lst:first-child{border-top:none}#onetrust-pc-sdk .ot-acc-cntr{position:relative;border-left:1px solid #e2e2e2;border-right:1px solid #e2e2e2;border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk .ot-acc-cntr input{z-index:1}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr{background-color:#f9f9fc;padding:5px 0 5px 15px;width:auto}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr .ot-plus-minus{vertical-align:middle;top:auto}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr .ot-arw-cntr{right:10px}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr input{z-index:2}#onetrust-pc-sdk .ot-acc-cntr.ot-add-tech .ot-acc-hdr{padding:10px 0 10px 15px}#onetrust-pc-sdk .ot-acc-cntr>input[type=checkbox]:checked~.ot-acc-hdr{border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-txt{padding-left:10px;padding-right:10px}#onetrust-pc-sdk .ot-acc-cntr button[aria-expanded=true]~.ot-acc-txt{width:auto}#onetrust-pc-sdk .ot-acc-cntr .ot-addtl-venbox{display:none}#onetrust-pc-sdk .ot-vlst-cntr{margin-bottom:0;width:100%}#onetrust-pc-sdk .ot-vensec-title{font-size:.813em;vertical-align:middle;display:inline-block}#onetrust-pc-sdk .category-vendors-list-handler,#onetrust-pc-sdk .category-vendors-list-handler+a{margin-left:0;margin-top:10px}#onetrust-pc-sdk #ot-selall-vencntr.line-through label::after,#onetrust-pc-sdk #ot-selall-adtlvencntr.line-through label::after,#onetrust-pc-sdk #ot-selall-licntr.line-through label::after,#onetrust-pc-sdk #ot-selall-hostcntr.line-through label::after,#onetrust-pc-sdk #ot-selall-gnvencntr.line-through label::after{height:auto;border-left:0;transform:none;-o-transform:none;-ms-transform:none;-webkit-transform:none;left:5px;top:9px}#onetrust-pc-sdk #ot-category-title{float:left;padding-bottom:10px;font-size:1em;width:100%}#onetrust-pc-sdk .ot-cat-grp{margin-top:10px}#onetrust-pc-sdk .ot-cat-item{line-height:1.1;margin-top:10px;display:inline-block;width:100%}#onetrust-pc-sdk .ot-btn-container{text-align:right}#onetrust-pc-sdk .ot-btn-container button{display:inline-block;font-size:.75em;letter-spacing:.08em;margin-top:19px}#onetrust-pc-sdk .ot-btn-container.ot-button-order-container .ot-pc-refuse-all-handler,#onetrust-pc-sdk .ot-btn-container.ot-button-order-container .save-preference-btn-handler,#onetrust-pc-sdk .ot-btn-container.ot-button-order-container #accept-recommended-btn-handler{width:auto;margin-bottom:1rem}#onetrust-pc-sdk #close-pc-btn-handler.ot-close-icon{position:absolute;top:10px;right:0;z-index:1;padding:0;background-color:rgba(0,0,0,0);border:none}#onetrust-pc-sdk #close-pc-btn-handler.ot-close-icon svg{display:block;height:10px;width:10px}#onetrust-pc-sdk #clear-filters-handler{margin-top:20px;margin-bottom:10px;float:right;max-width:200px;text-decoration:none;color:#3860be;font-size:.9em;font-weight:bold;background-color:rgba(0,0,0,0);border-color:rgba(0,0,0,0);padding:1px}#onetrust-pc-sdk #clear-filters-handler:hover{color:#2285f7}#onetrust-pc-sdk #clear-filters-handler:focus{outline:#000 solid 1px}#onetrust-pc-sdk .ot-enbl-chr h4~.ot-tgl,#onetrust-pc-sdk .ot-enbl-chr h4~.ot-always-active{right:45px}#onetrust-pc-sdk .ot-enbl-chr h4~.ot-tgl+.ot-tgl{right:120px}#onetrust-pc-sdk .ot-enbl-chr .ot-pli-hdr.ot-leg-border-color span:first-child{width:90px}#onetrust-pc-sdk .ot-enbl-chr li.ot-subgrp>h5+.ot-tgl-cntr{padding-right:25px}#onetrust-pc-sdk .ot-plus-minus{width:20px;height:20px;font-size:1.5em;position:relative;display:inline-block;margin-right:5px;top:3px}#onetrust-pc-sdk .ot-plus-minus span{position:absolute;background:#27455c;border-radius:1px}#onetrust-pc-sdk .ot-plus-minus span:first-of-type{top:25%;bottom:25%;width:10%;left:45%}#onetrust-pc-sdk .ot-plus-minus span:last-of-type{left:25%;right:25%;height:10%;top:45%}#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-arw,#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-plus-minus span:first-of-type,#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-plus-minus span:last-of-type{transform:rotate(90deg)}#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-plus-minus span:last-of-type{left:50%;right:50%}#onetrust-pc-sdk #ot-selall-vencntr label,#onetrust-pc-sdk #ot-selall-adtlvencntr label,#onetrust-pc-sdk #ot-selall-hostcntr label,#onetrust-pc-sdk #ot-selall-licntr label{position:relative;display:inline-block;width:20px;height:20px}#onetrust-pc-sdk .ot-host-item .ot-plus-minus,#onetrust-pc-sdk .ot-ven-item .ot-plus-minus{float:left;margin-right:8px;top:10px}#onetrust-pc-sdk .ot-ven-item ul{list-style:none inside;font-size:100%;margin:0}#onetrust-pc-sdk .ot-ven-item ul li{margin:0 !important;padding:0;border:none !important}#onetrust-pc-sdk .ot-pli-hdr{color:#77808e;overflow:hidden;padding-top:7.5px;padding-bottom:7.5px;width:calc(100% - 2px);border-top-left-radius:3px;border-top-right-radius:3px}#onetrust-pc-sdk .ot-pli-hdr span:first-child{top:50%;transform:translateY(50%);max-width:90px}#onetrust-pc-sdk .ot-pli-hdr span:last-child{padding-right:10px;max-width:95px;text-align:center}#onetrust-pc-sdk .ot-li-title{float:right;font-size:.813em}#onetrust-pc-sdk .ot-pli-hdr.ot-leg-border-color{background-color:#f4f4f4;border:1px solid #d8d8d8}#onetrust-pc-sdk .ot-pli-hdr.ot-leg-border-color span:first-child{text-align:left;width:70px}#onetrust-pc-sdk li.ot-subgrp>h5,#onetrust-pc-sdk .ot-cat-header{width:calc(100% - 130px)}#onetrust-pc-sdk li.ot-subgrp>h5+.ot-tgl-cntr{padding-left:13px}#onetrust-pc-sdk .ot-acc-grpcntr .ot-acc-grpdesc{margin-bottom:5px}#onetrust-pc-sdk .ot-acc-grpcntr .ot-subgrp-cntr{border-top:1px solid #d8d8d8}#onetrust-pc-sdk .ot-acc-grpcntr .ot-vlst-cntr+.ot-subgrp-cntr{border-top:none}#onetrust-pc-sdk .ot-acc-hdr .ot-arw-cntr+.ot-tgl-cntr,#onetrust-pc-sdk .ot-acc-txt h4+.ot-tgl-cntr{padding-left:13px}#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item .ot-subgrp>h5,#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item .ot-cat-header{width:calc(100% - 145px)}#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item h5+.ot-tgl-cntr,#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item .ot-cat-header+.ot-tgl{padding-left:28px}#onetrust-pc-sdk .ot-sel-all-hdr,#onetrust-pc-sdk .ot-sel-all-chkbox{display:inline-block;width:100%;position:relative}#onetrust-pc-sdk .ot-sel-all-chkbox{z-index:1}#onetrust-pc-sdk .ot-sel-all{margin:0;position:relative;padding-right:23px;float:right}#onetrust-pc-sdk .ot-consent-hdr,#onetrust-pc-sdk .ot-li-hdr{float:right;font-size:.812em;line-height:normal;text-align:center;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-li-hdr{max-width:100px;padding-right:10px}#onetrust-pc-sdk .ot-consent-hdr{max-width:55px}#onetrust-pc-sdk #ot-selall-licntr{display:block;width:21px;height:auto;float:right;position:relative;right:80px}#onetrust-pc-sdk #ot-selall-licntr label{position:absolute}#onetrust-pc-sdk .ot-ven-ctgl{margin-left:66px}#onetrust-pc-sdk .ot-ven-litgl+.ot-arw-cntr{margin-left:81px}#onetrust-pc-sdk .ot-enbl-chr .ot-host-cnt .ot-tgl-cntr{width:auto}#onetrust-pc-sdk #ot-lst-cnt:not(.ot-host-cnt) .ot-tgl-cntr{width:auto;top:auto;height:20px}#onetrust-pc-sdk #ot-lst-cnt .ot-chkbox{position:relative;display:inline-block;width:20px;height:20px}#onetrust-pc-sdk #ot-lst-cnt .ot-chkbox label{position:absolute;padding:0;width:20px;height:20px}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info-cntr{border:1px solid #d8d8d8;padding:.75rem 2rem;padding-bottom:0;width:auto;margin-top:.5rem}#onetrust-pc-sdk .ot-acc-grpdesc+.ot-leg-btn-container{padding-left:20px;padding-right:20px;width:calc(100% - 40px);margin-bottom:5px}#onetrust-pc-sdk .ot-subgrp .ot-leg-btn-container{margin-bottom:5px}#onetrust-pc-sdk #ot-ven-lst .ot-leg-btn-container{margin-top:10px}#onetrust-pc-sdk .ot-leg-btn-container{display:inline-block;width:100%;margin-bottom:10px}#onetrust-pc-sdk .ot-leg-btn-container button{height:auto;padding:6.5px 8px;margin-bottom:0;letter-spacing:0;font-size:.75em;line-height:normal}#onetrust-pc-sdk .ot-leg-btn-container svg{display:none;height:14px;width:14px;padding-right:5px;vertical-align:sub}#onetrust-pc-sdk .ot-active-leg-btn{cursor:default;pointer-events:none}#onetrust-pc-sdk .ot-active-leg-btn svg{display:inline-block}#onetrust-pc-sdk .ot-remove-objection-handler{text-decoration:underline;padding:0;font-size:.75em;font-weight:600;line-height:1;padding-left:10px}#onetrust-pc-sdk .ot-obj-leg-btn-handler span{font-weight:bold;text-align:center;font-size:inherit;line-height:1.5}#onetrust-pc-sdk.ot-close-btn-link #close-pc-btn-handler{border:none;height:auto;line-height:1.5;text-decoration:underline;font-size:.69em;background:none;right:15px;top:15px;width:auto;font-weight:normal}#onetrust-pc-sdk .ot-pgph-link{font-size:.813em !important;margin-top:10px;position:relative}#onetrust-pc-sdk .ot-pgph-link.ot-pgph-link-subgroup{margin-bottom:1rem}#onetrust-pc-sdk .ot-accordion-layout .ot-pgph-link{margin-top:5px}#onetrust-pc-sdk .ot-pgph-contr{margin:0 2.5rem}#onetrust-pc-sdk .ot-pgph-title{font-size:1.18rem;margin-bottom:2rem}#onetrust-pc-sdk .ot-pgph-desc{font-size:1rem;font-weight:400;margin-bottom:2rem;line-height:1.5rem}#onetrust-pc-sdk .ot-pgph-desc:not(:last-child):after{content:"";width:96%;display:block;margin:0 auto;padding-bottom:2rem;border-bottom:1px solid #e9e9e9}#onetrust-pc-sdk .ot-cat-header{float:left;font-weight:600;font-size:.875em;line-height:1.5;max-width:90%;vertical-align:middle}#onetrust-pc-sdk .ot-vnd-item>button:focus{outline:#000 solid 2px}#onetrust-pc-sdk .ot-vnd-item>button{position:absolute;cursor:pointer;width:100%;height:100%;margin:0;top:0;left:0;z-index:1;max-width:none;border:none}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=false]~.ot-acc-txt{margin-top:0;max-height:0;opacity:0;overflow:hidden;width:100%;transition:.25s ease-out;display:none}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=true]~.ot-acc-txt{transition:.1s ease-in;margin-top:10px;width:100%;overflow:auto;display:block}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=true]~.ot-acc-grpcntr{width:auto;margin-top:0px;padding-bottom:10px}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item{position:relative;border-radius:2px;margin:0;padding:0;border:1px solid #d8d8d8;border-top:none;width:calc(100% - 2px);float:left}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item:first-of-type{margin-top:10px;border-top:1px solid #d8d8d8}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpdesc{padding-left:20px;padding-right:20px;width:calc(100% - 40px);font-size:.812em;margin-bottom:10px;margin-top:15px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpdesc>ul{padding-top:10px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpdesc>ul li{padding-top:0;line-height:1.5;padding-bottom:10px}#onetrust-pc-sdk .ot-accordion-layout div+.ot-acc-grpdesc{margin-top:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr:first-child{margin-top:10px}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr:last-child,#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr:last-child{margin-bottom:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{padding-top:11.5px;padding-bottom:11.5px;padding-left:20px;padding-right:20px;width:calc(100% - 40px);display:inline-block}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-txt{width:100%;padding:0}#onetrust-pc-sdk .ot-accordion-layout .ot-subgrp-cntr{padding-left:20px;padding-right:15px;padding-bottom:0;width:calc(100% - 35px)}#onetrust-pc-sdk .ot-accordion-layout .ot-subgrp{padding-right:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpcntr{z-index:1;position:relative}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header+.ot-arw-cntr{position:absolute;top:50%;transform:translateY(-50%);right:20px;margin-top:-2px}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header+.ot-arw-cntr .ot-arw{width:15px;height:20px;margin-left:5px;color:dimgray}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header{float:none;color:#2e3644;margin:0;display:inline-block;height:auto;word-wrap:break-word;min-height:inherit}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr,#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr{padding-left:20px;width:calc(100% - 20px);display:inline-block;margin-top:0;padding-bottom:2px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{position:relative;min-height:25px}#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl,#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active{position:absolute;top:50%;transform:translateY(-50%);right:20px}#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl+.ot-tgl{right:95px}#onetrust-pc-sdk .ot-accordion-layout .category-vendors-list-handler,#onetrust-pc-sdk .ot-accordion-layout .category-vendors-list-handler+a{margin-top:5px}#onetrust-pc-sdk #ot-lst-cnt{margin-top:1rem;max-height:calc(100% - 96px)}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info-cntr{border:1px solid #d8d8d8;padding:.75rem 2rem;padding-bottom:0;width:auto;margin-top:.5rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info{margin-bottom:1rem;padding-left:.75rem;padding-right:.75rem;display:flex;flex-direction:column}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info[data-vnd-info-key*=DPOEmail]{border-top:1px solid #d8d8d8;padding-top:1rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info[data-vnd-info-key*=DPOLink]{border-bottom:1px solid #d8d8d8;padding-bottom:1rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info .ot-vnd-lbl{font-weight:bold;font-size:.85em;margin-bottom:.5rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info .ot-vnd-cnt{margin-left:.5rem;font-weight:500;font-size:.85rem}#onetrust-pc-sdk .ot-vs-list,#onetrust-pc-sdk .ot-vnd-serv{width:auto;padding:1rem 1.25rem;padding-bottom:0}#onetrust-pc-sdk .ot-vs-list .ot-vnd-serv-hdr-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-serv-hdr-cntr{padding-bottom:.75rem;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk .ot-vs-list .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr{font-weight:600;font-size:.95em;line-height:2;margin-left:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item{border:none;margin:0;padding:0}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item button,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item button{outline:none;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item button[aria-expanded=true],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item button[aria-expanded=true]{border-bottom:none}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:first-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:first-child{margin-top:.25rem;border-top:unset}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:last-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:last-child{margin-bottom:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:last-child button,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:last-child button{border-bottom:none}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info-cntr{border:1px solid #d8d8d8;padding:.75rem 1.75rem;padding-bottom:0;width:auto;margin-top:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info{margin-bottom:1rem;padding-left:.75rem;padding-right:.75rem;display:flex;flex-direction:column}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOEmail],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOEmail]{border-top:1px solid #d8d8d8;padding-top:1rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOLink],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOLink]{border-bottom:1px solid #d8d8d8;padding-bottom:1rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info .ot-vnd-lbl,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info .ot-vnd-lbl{font-weight:bold;font-size:.85em;margin-bottom:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info .ot-vnd-cnt,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info .ot-vnd-cnt{margin-left:.5rem;font-weight:500;font-size:.85rem}#onetrust-pc-sdk .ot-vs-list.ot-vnd-subgrp-cnt,#onetrust-pc-sdk .ot-vnd-serv.ot-vnd-subgrp-cnt{padding-left:40px}#onetrust-pc-sdk .ot-vs-list.ot-vnd-subgrp-cnt .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr,#onetrust-pc-sdk .ot-vnd-serv.ot-vnd-subgrp-cnt .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr{font-size:.8em}#onetrust-pc-sdk .ot-vs-list.ot-vnd-subgrp-cnt .ot-cat-header,#onetrust-pc-sdk .ot-vnd-serv.ot-vnd-subgrp-cnt .ot-cat-header{font-size:.8em}#onetrust-pc-sdk .ot-subgrp-cntr .ot-vnd-serv{margin-bottom:1rem;padding:1rem .95rem}#onetrust-pc-sdk .ot-subgrp-cntr .ot-vnd-serv .ot-vnd-serv-hdr-cntr{padding-bottom:.75rem;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk .ot-subgrp-cntr .ot-vnd-serv .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr{font-weight:700;font-size:.8em;line-height:20px;margin-left:.82rem}#onetrust-pc-sdk .ot-subgrp-cntr .ot-cat-header{font-weight:700;font-size:.8em;line-height:20px}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-vnd-serv .ot-vnd-lst-cont .ot-accordion-layout .ot-acc-hdr div.ot-chkbox{margin-left:.82rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr{padding:.7rem 0;margin:0;display:flex;width:100%;align-items:center;justify-content:space-between}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr div:first-child,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr div:first-child{margin-left:.5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr div:last-child,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr div:last-child{margin-right:.5rem;margin-left:.5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-always-active{position:relative;right:unset;top:unset;transform:unset}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-plus-minus{top:0}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-arw-cntr{float:none;top:unset;right:unset;transform:unset;margin-top:-2px;position:relative}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-cat-header{flex:1;margin:0 .5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-tgl{position:relative;transform:none;right:0;top:0;float:none}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox{position:relative;margin:0 .5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox label{padding:0}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox label::before{position:relative}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox input{position:absolute;cursor:pointer;width:100%;height:100%;opacity:0;margin:0;top:0;left:0;z-index:1}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp .ot-acc-hdr h5.ot-cat-header,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp .ot-acc-hdr h4.ot-cat-header{margin:0}#onetrust-pc-sdk .ot-vs-config .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp h5{top:0;line-height:20px}#onetrust-pc-sdk .ot-vs-list{display:flex;flex-direction:column;padding:0;margin:.5rem 4px}#onetrust-pc-sdk .ot-vs-selc-all{display:flex;padding:0;float:unset;align-items:center;justify-content:flex-start}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf{justify-content:flex-end}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf.ot-caret-conf .ot-sel-all-chkbox{margin-right:48px}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf .ot-sel-all-chkbox{margin:0;padding:0;margin-right:14px;justify-content:flex-end}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr.ot-chkbox,#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr.ot-tgl{display:inline-block;right:unset;width:auto;height:auto;float:none}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr label{width:45px;height:25px}#onetrust-pc-sdk .ot-vs-selc-all .ot-sel-all-chkbox{margin-right:11px;margin-left:.75rem;display:flex;align-items:center}#onetrust-pc-sdk .ot-vs-selc-all .sel-all-hdr{margin:0 1.25rem;font-size:.812em;line-height:normal;text-align:center;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-vnd-list-cnt #ot-selall-vencntr.ot-chkbox{float:unset;right:0}#onetrust-pc-sdk[dir=rtl] #ot-back-arw,#onetrust-pc-sdk[dir=rtl] input~.ot-acc-hdr .ot-arw{transform:rotate(180deg);-o-transform:rotate(180deg);-ms-transform:rotate(180deg);-webkit-transform:rotate(180deg)}#onetrust-pc-sdk[dir=rtl] input:checked~.ot-acc-hdr .ot-arw{transform:rotate(270deg);-o-transform:rotate(270deg);-ms-transform:rotate(270deg);-webkit-transform:rotate(270deg)}#onetrust-pc-sdk[dir=rtl] .ot-chkbox label::after{transform:rotate(45deg);-webkit-transform:rotate(45deg);-o-transform:rotate(45deg);-ms-transform:rotate(45deg);border-left:0;border-right:3px solid}#onetrust-pc-sdk[dir=rtl] .ot-search-cntr>svg{right:0}@media only screen and (max-width: 600px){#onetrust-pc-sdk.otPcCenter{left:0;min-width:100%;height:100%;top:0;border-radius:0}#onetrust-pc-sdk #ot-pc-content,#onetrust-pc-sdk.ot-ftr-stacked .ot-btn-container{margin:1px 3px 0 10px;padding-right:10px;width:calc(100% - 23px)}#onetrust-pc-sdk .ot-btn-container button{max-width:none;letter-spacing:.01em}#onetrust-pc-sdk #close-pc-btn-handler{top:10px;right:17px}#onetrust-pc-sdk p{font-size:.7em}#onetrust-pc-sdk #ot-pc-hdr{margin:10px 10px 0 5px;width:calc(100% - 15px)}#onetrust-pc-sdk .vendor-search-handler{font-size:1em}#onetrust-pc-sdk #ot-back-arw{margin-left:12px}#onetrust-pc-sdk #ot-lst-cnt{margin:0;padding:0 5px 0 10px;min-width:95%}#onetrust-pc-sdk .switch+p{max-width:80%}#onetrust-pc-sdk .ot-ftr-stacked button{width:100%}#onetrust-pc-sdk #ot-fltr-cnt{max-width:320px;width:90%;border-top-right-radius:0;border-bottom-right-radius:0;margin:0;margin-left:15px;left:auto;right:40px;top:85px}#onetrust-pc-sdk .ot-fltr-opt{margin-left:25px;margin-bottom:10px}#onetrust-pc-sdk .ot-pc-refuse-all-handler{margin-bottom:0}#onetrust-pc-sdk #ot-fltr-cnt{right:40px}}@media only screen and (max-width: 476px){#onetrust-pc-sdk .ot-fltr-cntr,#onetrust-pc-sdk #ot-fltr-cnt{right:10px}#onetrust-pc-sdk #ot-anchor{right:25px}#onetrust-pc-sdk button{width:100%}#onetrust-pc-sdk:not(.ot-addtl-vendors) #ot-pc-lst:not(.ot-enbl-chr) .ot-sel-all{padding-right:9px}#onetrust-pc-sdk:not(.ot-addtl-vendors) #ot-pc-lst:not(.ot-enbl-chr) .ot-tgl-cntr{right:0}#onetrust-pc-sdk .ot-btn-container.ot-button-order-container .ot-pc-refuse-all-handler,#onetrust-pc-sdk .ot-btn-container.ot-button-order-container .save-preference-btn-handler,#onetrust-pc-sdk .ot-btn-container.ot-button-order-container #accept-recommended-btn-handler{width:100%}}@media(min-width: 768px){#onetrust-pc-sdk.ot-tgl-with-label .ot-label-status{display:inline}#onetrust-pc-sdk.ot-tgl-with-label #ot-pc-lst .ot-label-status{display:none}}@media only screen and (max-width: 896px)and (max-height: 425px)and (orientation: landscape){#onetrust-pc-sdk.otPcCenter{left:0;top:0;min-width:100%;height:100%;border-radius:0}#onetrust-pc-sdk .ot-pc-header{height:auto;min-height:20px}#onetrust-pc-sdk .ot-pc-header .ot-pc-logo{max-height:30px}#onetrust-pc-sdk .ot-pc-footer{max-height:60px;overflow-y:auto}#onetrust-pc-sdk #ot-pc-content,#onetrust-pc-sdk #ot-pc-lst{bottom:70px}#onetrust-pc-sdk.ot-ftr-stacked #ot-pc-content{bottom:70px}#onetrust-pc-sdk #ot-anchor{left:initial;right:50px}#onetrust-pc-sdk #ot-lst-title{margin-top:12px}#onetrust-pc-sdk #ot-lst-title *{font-size:inherit}#onetrust-pc-sdk #ot-pc-hdr input{margin-right:0;padding-right:45px}#onetrust-pc-sdk .switch+p{max-width:85%}#onetrust-pc-sdk #ot-sel-blk{position:static}#onetrust-pc-sdk #ot-pc-lst{overflow:auto}#onetrust-pc-sdk #ot-lst-cnt{max-height:none;overflow:initial}#onetrust-pc-sdk #ot-lst-cnt.no-results{height:auto}#onetrust-pc-sdk input{font-size:1em !important}#onetrust-pc-sdk p{font-size:.6em}#onetrust-pc-sdk #ot-fltr-modal{width:100%;top:0}#onetrust-pc-sdk ul li p,#onetrust-pc-sdk .category-vendors-list-handler,#onetrust-pc-sdk .category-vendors-list-handler+a,#onetrust-pc-sdk .category-host-list-handler{font-size:.6em}#onetrust-pc-sdk.ot-shw-fltr #ot-anchor{display:none !important}#onetrust-pc-sdk.ot-shw-fltr #ot-pc-lst{height:100% !important;overflow:hidden;top:0px}#onetrust-pc-sdk.ot-shw-fltr #ot-fltr-cnt{margin:0;height:100%;max-height:none;padding:10px;top:0;width:calc(100% - 20px);position:absolute;right:0;left:0;max-width:none}#onetrust-pc-sdk.ot-shw-fltr .ot-fltr-scrlcnt{max-height:calc(100% - 65px)}}
            #onetrust-consent-sdk #onetrust-pc-sdk,
                #onetrust-consent-sdk #ot-search-cntr,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-switch.ot-toggle,
                #onetrust-consent-sdk #onetrust-pc-sdk ot-grp-hdr1 .checkbox,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-title:after
                ,#onetrust-consent-sdk #onetrust-pc-sdk #ot-sel-blk,
                        #onetrust-consent-sdk #onetrust-pc-sdk #ot-fltr-cnt,
                        #onetrust-consent-sdk #onetrust-pc-sdk #ot-anchor {
                    background-color: #FFF;
                }
               
            #onetrust-consent-sdk #onetrust-pc-sdk h3,
                #onetrust-consent-sdk #onetrust-pc-sdk h4,
                #onetrust-consent-sdk #onetrust-pc-sdk h5,
                #onetrust-consent-sdk #onetrust-pc-sdk h6,
                #onetrust-consent-sdk #onetrust-pc-sdk p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-ven-lst .ot-ven-opts p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-desc,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-title,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-li-title,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-sel-all-hdr span,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-fltr-modal #modal-header,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-checkbox label span,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-sel-blk p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-lst-title h3,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst .back-btn-handler p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst .ot-ven-name,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-ven-lst .consent-category,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-inactive-leg-btn,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-label-status,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-chkbox label span,
                #onetrust-consent-sdk #onetrust-pc-sdk #clear-filters-handler,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-optout-signal
                {
                    color: #2E2E2E;
                }
             #onetrust-consent-sdk #onetrust-pc-sdk .privacy-notice-link,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-pgph-link,
                    #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler,
                    #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler + a,
                    #onetrust-consent-sdk #onetrust-pc-sdk .category-host-list-handler,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-ven-link,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-ven-legclaim-link,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-name a,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-acc-hdr .ot-host-expand,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info a,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-content #ot-pc-desc .ot-link-btn,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info a,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info a
                    {
                        color: #007398;
                    }
            #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler:hover { text-decoration: underline;}
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-grpcntr.ot-acc-txt,
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-txt .ot-subgrp-tgl .ot-switch.ot-toggle
             {
                background-color: #F8F8F8;
            }
             #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-txt .ot-ven-dets
                            {
                                background-color: #F8F8F8;
                            }
        #onetrust-consent-sdk #onetrust-pc-sdk
            button:not(#clear-filters-handler):not(.ot-close-icon):not(#filter-btn-handler):not(.ot-remove-objection-handler):not(.ot-obj-leg-btn-handler):not([aria-expanded]):not(.ot-link-btn),
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-active-leg-btn {
                background-color: #007398;border-color: #007398;
                color: #FFF;
            }
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-active-menu {
                border-color: #007398;
            }
            
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-remove-objection-handler{
                background-color: transparent;
                border: 1px solid transparent;
            }
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-inactive-leg-btn {
                background-color: #FFFFFF;
                color: #4D4D4D; border-color: #4D4D4D;
            }
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-tgl input:focus + .ot-switch, .ot-switch .ot-switch-nob, .ot-switch .ot-switch-nob:before,
            #onetrust-pc-sdk .ot-checkbox input[type="checkbox"]:focus + label::before,
            #onetrust-pc-sdk .ot-chkbox input[type="checkbox"]:focus + label::before {
                outline-color: #000000;
                outline-width: 1px;
                outline-offset: 1px;
            }
            #onetrust-pc-sdk .ot-host-item > button:focus, #onetrust-pc-sdk .ot-ven-item > button:focus {
                border: 1px solid #000000;
            }
            #onetrust-consent-sdk #onetrust-pc-sdk *:focus,
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-vlst-cntr > a:focus {
               outline: 1px solid #000000;
               outline-offset: 1px;
            }#onetrust-pc-sdk .ot-vlst-cntr .ot-ext-lnk,  #onetrust-pc-sdk .ot-ven-hdr .ot-ext-lnk{
                    background-image: url('https://cdn.cookielaw.org/logos/static/ot_external_link.svg');
                }
            /*! Extra code to blur out background */
.onetrust-pc-dark-filter{
background:rgba(0,0,0,.5);
z-index:2147483646;
width:100%;
height:100%;
overflow:hidden;
position:fixed;
top:0;
bottom:0;
left:0;
backdrop-filter: initial
}

/*! v6.12.0 2021-01-19 */
div#onetrust-consent-sdk #onetrust-banner-sdk{border-top:2px solid #eb6500!important;outline:1px solid transparent;box-shadow:none;padding:24px}div#onetrust-consent-sdk button{border-radius:0!important;box-shadow:none!important;box-sizing:border-box!important;font-size:20px!important;font-weight:400!important;letter-spacing:0!important;max-width:none!important;white-space:nowrap!important}div#onetrust-consent-sdk button:not(.ot-link-btn){background-color:#007398!important;border:2px solid #007398!important;color:#fff!important;height:48px!important;padding:0 1em!important;width:auto!important}div#onetrust-consent-sdk button:hover{background-color:#fff!important;border-color:#eb6500!important;color:#2e2e2e!important}div#onetrust-consent-sdk button.ot-link-btn{color:#007398!important;font-size:16px!important;text-decoration:underline}div#onetrust-consent-sdk button.ot-link-btn:hover{color: #2e2e2e!important;text-decoration-color:#eb6500!important}div#onetrust-consent-sdk a,div#onetrust-pc-sdk a{color:#007398!important;text-decoration:underline!important}div#onetrust-consent-sdk a,div#onetrust-consent-sdk button,div#onetrust-consent-sdk p:hover{opacity:1!important}div#onetrust-consent-sdk a:focus,div#onetrust-consent-sdk button:focus,div#onetrust-consent-sdk input:focus{outline:2px solid #eb6500!important;outline-offset:1px!important}div#onetrust-banner-sdk .ot-sdk-container{padding:0;width:auto}div#onetrust-banner-sdk .ot-sdk-row{align-items:flex-start;box-sizing:border-box;display:flex;flex-direction:column;justify-content:space-between;margin:auto;max-width:1152px}div#onetrust-banner-sdk .ot-sdk-row:after{display:none}div#onetrust-banner-sdk #onetrust-group-container,div#onetrust-banner-sdk.ot-bnr-flift:not(.ot-iab-2) #onetrust-group-container,div#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{flex-grow:1;width:auto}div#onetrust-banner-sdk #onetrust-policy,div#onetrust-banner-sdk.ot-bnr-flift #onetrust-policy{margin:0;overflow:visible}div#onetrust-banner-sdk.ot-bnr-flift #onetrust-policy-text,div#onetrust-consent-sdk #onetrust-policy-text{font-size:16px;line-height:24px;max-width:44em;margin:0}div#onetrust-consent-sdk #onetrust-policy-text a[href]{font-weight:400;margin-left:8px}div#onetrust-banner-sdk #onetrust-button-group-parent{flex:0 0 auto;margin:32px 0 0;width:100%}div#onetrust-banner-sdk #onetrust-button-group{display:flex;flex-direction:row;flex-wrap:wrap;justify-content:flex-end;margin:-8px}div#onetrust-banner-sdk .banner-actions-container{display:flex;flex:1 0 auto}div#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group button:last-of-type,div#onetrust-consent-sdk #onetrust-accept-btn-handler,div#onetrust-consent-sdk #onetrust-pc-btn-handler{flex:1 0 auto;margin:8px;width:auto}div#onetrust-consent-sdk #onetrust-pc-btn-handler{background-color:#fff!important;color:#2e2e2e!important}div#onetrust-banner-sdk #onetrust-close-btn-container{display:none}@media only screen and (min-width:556px){div#onetrust-consent-sdk #onetrust-banner-sdk{padding:40px}div#onetrust-banner-sdk #onetrust-policy{margin:0 40px 0 0}div#onetrust-banner-sdk .ot-sdk-row{align-items:center;flex-direction:row}div#onetrust-banner-sdk #onetrust-button-group-parent,div#onetrust-banner-sdk.ot-bnr-flift:not(.ot-iab-2) #onetrust-button-group-parent,div#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-button-group-parent{margin:0;padding:0;width:auto}div#onetrust-banner-sdk #onetrust-button-group,div#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group{align-items:stretch;flex-direction:column-reverse;margin:0}div#onetrust-consent-sdk #onetrust-accept-btn-handler,div#onetrust-consent-sdk #onetrust-pc-btn-handler{flex:1 0 auto}}@media only screen and (min-width:768px){div#onetrust-banner-sdk #onetrust-policy{margin:0 48px 0 0}div#onetrust-consent-sdk #onetrust-banner-sdk{padding:48px}}div#onetrust-consent-sdk #onetrust-pc-sdk h5{font-size:16px;line-height:24px}div#onetrust-consent-sdk #onetrust-pc-sdk p,div#onetrust-pc-sdk #ot-pc-desc,div#onetrust-pc-sdk .category-host-list-handler,div#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header{font-size:16px;font-weight:400;line-height:24px}div#onetrust-consent-sdk a:hover,div#onetrust-pc-sdk a:hover{color:#2e2e2e!important;text-decoration-color:#eb6500!important}div#onetrust-pc-sdk{border-radius:0;bottom:0;height:auto;left:0;margin:auto;max-width:100%;overflow:hidden;right:0;top:0;width:512px;max-height:800px}div#onetrust-pc-sdk .ot-pc-header{display:none}div#onetrust-pc-sdk #ot-pc-content{overscroll-behavior:contain;padding:0 12px 0 24px;margin:16px 4px 0 0;top:0;right:16px;left:0;width:auto}div#onetrust-pc-sdk #ot-category-title,div#onetrust-pc-sdk #ot-pc-title{font-size:24px;font-weight:400;line-height:32px;margin:0 0 16px}div#onetrust-pc-sdk #ot-pc-desc{padding:0}div#onetrust-pc-sdk #ot-pc-desc a{display:inline}div#onetrust-pc-sdk #accept-recommended-btn-handler{display:none!important}div#onetrust-pc-sdk input[type=checkbox]:focus+.ot-acc-hdr{outline:2px solid #eb6500;outline-offset:-1px;transition:none}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item{border-width:0 0 2px}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item:first-of-type{border-width:2px 0}div#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{padding:8px 0;width:100%}div#onetrust-pc-sdk .ot-plus-minus{transform:translateY(2px)}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item>button{background:0 0!important;border:0!important;height:44px!important;max-width:none!important;width:calc(100% - 48px)!important}div#onetrust-consent-sdk #onetrust-pc-sdk h5{font-weight:700}div#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr{padding:0}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item .ot-acc-grpdesc{padding:0;width:100%}div#onetrust-pc-sdk .ot-acc-grpcntr .ot-subgrp-cntr{border:0;padding:0}div#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp{margin:0}div#onetrust-pc-sdk .ot-always-active-group .ot-cat-header{width:calc(100% - 160px)}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header{width:calc(100% - 88px)}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active{color:#2e2e2e;font-size:12px;font-weight:400;line-height:1.5;padding-right:48px}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active:before{border-radius:12px;position:absolute;right:0;top:0;content:'';background:#fff;border:2px solid #939393;box-sizing:border-box;height:20px;width:40px}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active:after{border-radius:50%;position:absolute;right:5px;top:4px;content:'';background-color:#eb6500;height:12px;width:12px}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active,div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl{right:2px}div#onetrust-pc-sdk .ot-switch{display:block;height:20px;width:40px}div#onetrust-pc-sdk .ot-tgl input+.ot-switch .ot-switch-nob,div#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob{background:#fff;border:2px solid #939393;box-sizing:border-box;height:20px;width:40px}div#onetrust-pc-sdk .ot-tgl input+.ot-switch .ot-switch-nob:before{background-color:#737373;height:8px;left:4px;top:4px;width:8px}div#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob:before{background-color:#eb6500;height:12px;left:0;top:2px;width:12px}div#onetrust-pc-sdk .ot-tgl input:focus+.ot-switch .ot-switch-nob{box-shadow:0 0;outline:2px solid #eb6500!important;outline-offset:1px;transition:none}div#onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-grpcntr.ot-acc-txt{background-color:transparent;padding-left:3px}div#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr,div#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr{overflow:visible;width:100%}div#onetrust-pc-sdk .ot-pc-footer{border-top:0 solid}div#onetrust-pc-sdk .ot-btn-container{padding-top:24px;text-align:center}div#onetrust-pc-sdk .ot-pc-footer button{margin:8px 0;background-color:#fff}div#onetrust-pc-sdk .ot-pc-footer-logo{background-color:#fff}div#onetrust-pc-sdk #ot-lst-title span{font-size:24px;font-weight:400;line-height:32px}div#onetrust-pc-sdk #ot-host-lst .ot-host-desc,div#onetrust-pc-sdk #ot-host-lst .ot-host-expand,div#onetrust-pc-sdk #ot-host-lst .ot-host-name,div#onetrust-pc-sdk #ot-host-lst .ot-host-name a,div#onetrust-pc-sdk .back-btn-handler,div#onetrust-pc-sdk .ot-host-opt li>div div{font-size:16px;font-weight:400;line-height:24px}div#onetrust-pc-sdk #ot-host-lst .ot-acc-txt{width:100%}div#onetrust-pc-sdk #ot-pc-lst{top:0}div#onetrust-pc-sdk .back-btn-handler{text-decoration:none!important}div#onetrust-pc-sdk #filter-btn-handler:hover svg{filter:invert(1)}div#onetrust-pc-sdk .back-btn-handler svg{width:16px;height:16px}div#onetrust-pc-sdk .ot-host-item>button{background:0 0!important;border:0!important;height:66px!important;max-width:none!important;width:calc(100% - 5px)!important;transform:translate(2px,2px)}div#onetrust-pc-sdk .ot-host-item{border-bottom:2px solid #b9b9b9;padding:0}div#onetrust-pc-sdk .ot-host-item .ot-acc-hdr{margin:0 0 -6px;padding:8px 0}div#onetrust-pc-sdk ul li:first-child{border-top:2px solid #b9b9b9}div#onetrust-pc-sdk .ot-host-item .ot-plus-minus{margin:0 8px 0 0}div#onetrust-pc-sdk .ot-search-cntr{width:calc(100% - 48px)}div#onetrust-pc-sdk .ot-host-opt .ot-host-info{background-color:transparent}div#onetrust-pc-sdk .ot-host-opt li>div div{padding:0}div#onetrust-pc-sdk #vendor-search-handler{border-radius:0;border-color:#939393;border-style:solid;border-width:2px 0 2px 2px;font-size:20px;height:48px;margin:0}div#onetrust-pc-sdk #ot-pc-hdr{margin-left:24px}div#onetrust-pc-sdk .ot-lst-subhdr{width:calc(100% - 24px)}div#onetrust-pc-sdk .ot-lst-subhdr svg{right:0;top:8px}div#onetrust-pc-sdk .ot-fltr-cntr{box-sizing:border-box;right:0;width:48px}div#onetrust-pc-sdk #filter-btn-handler{width:48px!important;padding:8px!important}div#onetrust-consent-sdk #onetrust-pc-sdk #clear-filters-handler,div#onetrust-pc-sdk button#filter-apply-handler,div#onetrust-pc-sdk button#filter-cancel-handler{height:2em!important;padding-left:14px!important;padding-right:14px!important}div#onetrust-pc-sdk #ot-fltr-cnt{box-shadow:0 0;border:1px solid #8e8e8e;border-radius:0}div#onetrust-pc-sdk .ot-fltr-scrlcnt{max-height:calc(100% - 80px)}div#onetrust-pc-sdk #ot-fltr-modal{max-height:400px}div#onetrust-pc-sdk .ot-fltr-opt{margin-bottom:16px}div#onetrust-pc-sdk #ot-lst-cnt{margin-left:24px;width:calc(100% - 48px)}div#onetrust-pc-sdk #ot-anchor{display:none!important}

/* 2023-12-04  Fix for button order in mobile view*/
@media (max-width: 550px) {
  #onetrust-accept-btn-handler {order: 1;  }
  #onetrust-reject-all-handler { order: 2;  }
  #onetrust-pc-btn-handler { order: 3;  }
}


/*! Extra code to blur our background */
.onetrust-pc-dark-filter{
backdrop-filter: blur(3px)
}
.ot-sdk-cookie-policy{font-family:inherit;font-size:16px}.ot-sdk-cookie-policy.otRelFont{font-size:1rem}.ot-sdk-cookie-policy h3,.ot-sdk-cookie-policy h4,.ot-sdk-cookie-policy h6,.ot-sdk-cookie-policy p,.ot-sdk-cookie-policy li,.ot-sdk-cookie-policy a,.ot-sdk-cookie-policy th,.ot-sdk-cookie-policy #cookie-policy-description,.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group,.ot-sdk-cookie-policy #cookie-policy-title{color:dimgray}.ot-sdk-cookie-policy #cookie-policy-description{margin-bottom:1em}.ot-sdk-cookie-policy h4{font-size:1.2em}.ot-sdk-cookie-policy h6{font-size:1em;margin-top:2em}.ot-sdk-cookie-policy th{min-width:75px}.ot-sdk-cookie-policy a,.ot-sdk-cookie-policy a:hover{background:#fff}.ot-sdk-cookie-policy thead{background-color:#f6f6f4;font-weight:bold}.ot-sdk-cookie-policy .ot-mobile-border{display:none}.ot-sdk-cookie-policy section{margin-bottom:2em}.ot-sdk-cookie-policy table{border-collapse:inherit}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy{font-family:inherit;font-size:1rem}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h6,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy p,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-title{color:dimgray}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description{margin-bottom:1em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup{margin-left:1.5em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group-desc,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-table-header,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy span,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td{font-size:.9em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td span,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td a{font-size:inherit}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group{font-size:1em;margin-bottom:.6em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-title{margin-bottom:1.2em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy>section{margin-bottom:1em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th{min-width:75px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a:hover{background:#fff}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead{background-color:#f6f6f4;font-weight:bold}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-mobile-border{display:none}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy section{margin-bottom:2em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup ul li{list-style:disc;margin-left:1.5em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup ul li h4{display:inline-block}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table{border-collapse:inherit;margin:auto;border:1px solid #d7d7d7;border-radius:5px;border-spacing:initial;width:100%;overflow:hidden}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table td{border-bottom:1px solid #d7d7d7;border-right:1px solid #d7d7d7}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td{border-bottom:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr th:last-child,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr td:last-child{border-right:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-host,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-cookies-type{width:25%}.ot-sdk-cookie-policy[dir=rtl]{text-align:left}#ot-sdk-cookie-policy h3{font-size:1.5em}@media only screen and (max-width: 530px){.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) table,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) thead,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tbody,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) th,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr{display:block}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) thead tr{position:absolute;top:-9999px;left:-9999px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr{margin:0 0 1em 0}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr:nth-child(odd),.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr:nth-child(odd) a{background:#f6f6f4}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td{border:none;border-bottom:1px solid #eee;position:relative;padding-left:50%}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td:before{position:absolute;height:100%;left:6px;width:40%;padding-right:10px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) .ot-mobile-border{display:inline-block;background-color:#e4e4e4;position:absolute;height:100%;top:0;left:45%;width:2px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td:before{content:attr(data-label);font-weight:bold}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) li{word-break:break-word;word-wrap:break-word}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table{overflow:hidden}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table td{border:none;border-bottom:1px solid #d7d7d7}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tbody,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tr{display:block}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-host,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-cookies-type{width:auto}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tr{margin:0 0 1em 0}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td:before{height:100%;width:40%;padding-right:10px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td:before{content:attr(data-label);font-weight:bold}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li{word-break:break-word;word-wrap:break-word}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead tr{position:absolute;top:-9999px;left:-9999px;z-index:-9999}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td{border-bottom:1px solid #d7d7d7;border-right:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td:last-child{border-bottom:0px}}
                
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h5,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h6,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy p,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy span,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description {
                        color: #696969;
                    }
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th {
                        color: #696969;
                    }
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group {
                        color: #696969;
                    }
                    
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-title {
                            color: #696969;
                        }
                    
            
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table th {
                            background-color: #F8F8F8;
                        }
                    
            .ot-floating-button__front{background-image:url('https://cdn.cookielaw.org/logos/static/ot_persistent_cookie_icon.png')}</style><link type="text/css" rel="stylesheet" href="https://pendo-static-5661679399600128.storage.googleapis.com/guide.-323232.1737640081997.css" id="_pendo-css_"><style type="text/css" scoped="scoped" class=" pendo-style-D_T2uHq_M1r-XQq8htU6Z3GjHfE" style="white-space: pre-wrap;"></style><script src="https://assets.adobedtm.com/4a848ae9611a/032db4f73473/91f4b2637c06/RCa16d232f95a944c0aabdea6621a2ef94-source.min.js" async=""></script><link type="text/css" rel="stylesheet" href="https://pendo-static-5661679399600128.storage.googleapis.com/guide-content/D_T2uHq_M1r-XQq8htU6Z3GjHfE/9BcFvkCLLiElWp6hocDK3ZG6Z4E/OgzgLyBtDFpmC_5omJlJtXR7YEk.guide.css?sha256=Ap0bhsi_jBWSOlbiiOdfq2Q9t8MEGpHE5PjRnrKmkPI"></head>
    <body data-sd-ui-layer-boundary="true"><div id="MathJax_Message" style="display: none;"></div>
      <script type="text/javascript">
        window.__PRELOADED_STATE__ = {"abstracts":{"content":[{"$$":[{"$":{"id":"cesectitle0001"},"#name":"section-title","_":"ABSTRACT"},{"$$":[{"$":{"id":"cesectitle0002"},"#name":"section-title","_":"Objectives"},{"$":{"view":"all","id":"spara016"},"#name":"simple-para","_":"To assess the efficacy, safety, and tolerability of the investigational, oral, allosteric, highly selective, and potent tyrosine kinase 2 inhibitor zasocitinib (TAK-279) in patients with active psoriatic arthritis (PsA)."}],"$":{"view":"all","id":"abss0001"},"#name":"abstract-sec"},{"$$":[{"$":{"id":"cesectitle0003"},"#name":"section-title","_":"Methods"},{"$":{"view":"all","id":"spara017"},"#name":"simple-para","_":"In this phase 2b, randomised, multicentre, double-blind, placebo-controlled, multiple-dose study, patients (¡Ý18 years, with PsA symptoms for ¡Ý6 months) received 30 mg, 15 mg, or 5 mg zasocitinib or placebo (1:1:1:1) once daily for 12 weeks, with a 4-week safety follow-up. The primary endpoint was American College of Rheumatology (ACR)20 response at week 12. Secondary efficacy endpoints included ACR50 response, ACR70 response, Psoriasis Area and Severity Index (PASI) 75 response among those with ¡Ý3% body surface area at baseline and minimal disease activity (MDA) at week 12."}],"$":{"view":"all","role":"materials-methods","id":"abss0002"},"#name":"abstract-sec"},{"$$":[{"$":{"id":"cesectitle0004"},"#name":"section-title","_":"Results"},{"$$":[{"#name":"__text__","_":"Overall, 290 patients (mean [SD] age, 49.9 [11.6] years; 57.2% female) received treatment. At week 12, 30 mg or 15 mg zasocitinib treatment resulted in significantly higher ACR20 responses (54.2%; "},{"#name":"italic","_":"P"},{"#name":"__text__","_":" = .002 and 53.3%; "},{"#name":"italic","_":"P"},{"#name":"__text__","_":" = .002, respectively) than placebo (29.2%). A numerically higher number of ACR50 responses were achieved at week 12 with 30 mg (26.4%; nominal "},{"#name":"italic","_":"P"},{"#name":"__text__","_":" = .009) or 15 mg (26.7%; nominal "},{"#name":"italic","_":"P"},{"#name":"__text__","_":" = .005) zasocitinib than placebo (9.7%). In addition, 30 mg zasocitinib demonstrated a numerically higher number of ACR70 responses (13.9% versus 5.6%, respectively; nominal "},{"#name":"italic","_":"P"},{"#name":"__text__","_":" = .158), PASI 75 responses (45.7% versus 15.4%, respectively; nominal "},{"#name":"italic","_":"P"},{"#name":"__text__","_":" = .002), and MDA (29.2% versus 12.5%, respectively; nominal "},{"#name":"italic","_":"P"},{"#name":"__text__","_":" = .014) at week 12 versus placebo. In this small study of limited duration, most adverse events were mild/moderate and were more frequently observed in the higher dose group. In this small sample size, no new safety signals or clear dose-dependent laboratory parameter changes were identified."}],"$":{"view":"all","id":"spara018"},"#name":"simple-para"}],"$":{"view":"all","role":"results","id":"abss0003"},"#name":"abstract-sec"},{"$$":[{"$":{"id":"cesectitle0005"},"#name":"section-title","_":"Conclusions"},{"$":{"view":"all","id":"spara019"},"#name":"simple-para","_":"Here, 30 mg and 15 mg zasocitinib demonstrated efficacy across core domains in patients with active PsA with no new safety signals. These findings will be confirmed in ongoing larger studies of longer duration."}],"$":{"view":"all","role":"conclusion","id":"abss0004"},"#name":"abstract-sec"}],"$":{"view":"all","id":"abs0001","class":"author"},"#name":"abstract"},{"$$":[{"$":{"id":"cesectitle0006"},"#name":"section-title","_":"Graphical abstract"},{"$$":[{"$$":[{"$$":[{"$$":[{"$":{"role":"short","id":"alttx001"},"#name":"alt-text","_":"Image, graphical abstract"},{"$":{"role":"http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4","xmlns:xlink":true,"id":"celink0006","href":"pii:S0003496725010416/ga1","type":"simple","locator":"ga1"},"#name":"link"}],"$":{"id":"fig0006"},"#name":"figure"}],"#name":"display"}],"$":{"view":"all","id":"spara020"},"#name":"simple-para"}],"$":{"view":"all","id":"abss0005"},"#name":"abstract-sec"}],"$":{"view":"all","id":"abs0002","class":"graphical"},"#name":"abstract"}],"floats":[],"footnotes":[],"attachments":[{"attachment-eid":"1-s2.0-S0003496725010416-ga1.jpg","ucs-locator":"https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0003496725010416/ga1/DOWNSAMPLED/image/jpeg/54028c90e635ff0ef7d92efbf296bbd8/ga1.jpg","file-basename":"ga1","abstract-attachment":"true","filename":"ga1.jpg","extension":"jpg","filesize":"47988","pixel-height":"200","pixel-width":"358","attachment-type":"IMAGE-DOWNSAMPLED"},{"attachment-eid":"1-s2.0-S0003496725010416-ga1.sml","ucs-locator":"https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0003496725010416/ga1/THUMBNAIL/image/gif/938d3b2296e3d1edd76be1cfdc7946a1/ga1.sml","file-basename":"ga1","abstract-attachment":"true","filename":"ga1.sml","extension":"sml","filesize":"15044","pixel-height":"122","pixel-width":"219","attachment-type":"IMAGE-THUMBNAIL"},{"attachment-eid":"1-s2.0-S0003496725010416-ga1_lrg.jpg","ucs-locator":"https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0003496725010416/HIGHRES/image/jpeg/18f28c3262662e6927e2754ebfb4cd87/ga1_lrg.jpg","file-basename":"ga1","abstract-attachment":"true","filename":"ga1_lrg.jpg","extension":"jpg","filesize":"412611","pixel-height":"886","pixel-width":"1588","attachment-type":"IMAGE-HIGH-RES"}]},"accessbarConfig":{"fallback":false,"id":"accessbar","version":"0.0.1","analytics":{"location":"accessbar","eventName":"ctaImpression"},"label":{},"ariaLabel":{"accessbar":"Download options and search","componentsList":"PDF Options"},"banners":[{"id":"BannerSsrn"}],"components":[{"target":"_blank","analytics":[{"ids":["accessbar:fta:single-article"],"eventName":"ctaClick"}],"label":"View&nbsp;**PDF**","ariaLabel":"View PDF. Opens in a new window.","id":"ViewPDF"},{"analytics":[{"ids":["accessbar:fta:full-issue"],"eventName":"ctaClick"}],"label":"Download full issue","id":"DownloadFullIssue"},{"id":"ViewClinicalKeyFullText","analytics":[{"eventName":"ctaClick","ids":["accessbar:fta:clinical-key"]}],"label":"View full text","rel":"noopener noreferrer","target":"_blank","href":"https://www.clinicalkey.com/#!/content/journal/1-s2.0-S0003496725010416"}],"search":{"inputPlaceHolder":"Search ScienceDirect","ariaLabel":{"input":"Search ScienceDirect","submit":"Submit search"},"formAction":"/search#submit","analytics":[{"ids":["accessbar:search"],"eventName":"searchStart"}],"id":"QuickSearch"}},"adobeTarget":{"client-new-ui-test":{"variation":"A"}},"article":{"analyticsMetadata":{"accountId":"228598","accountName":"ScienceDirect Guests","loginStatus":"anonymous","userId":"12975512","isLoggedIn":false},"cid":"788981","content-family":"serial","copyright-line":"? 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","cover-date-years":["2025"],"cover-date-start":"2025-10-01","cover-date-text":"October 2025","document-subtype":"fla","document-type":"article","entitledToken":"0B5C8D8D3B02ECEF66F5C09D18930E5B7032A0847D43D1328C630D99FA4F26CD96BD50FB7BD677CE","genAiToken":"eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJhdWQiOiJnZW5BaUFwcHMiLCJwaWkiOiJTMDAwMzQ5NjcyNTAxMDQxNiIsInN1YiI6IjIyODU5OCIsImlzcyI6ImFycCIsInNlc3Npb25JZCI6IjNhYjdiOTg1NTUxMjQwNGI3ZDM4OGUwMTUwNzk1YTgwOWM3M2d4cnFhIiwiZXhwIjoxNzYxMDU2MjY5LCJpYXQiOjE3NjEwNDkwNjksInZlcnNpb24iOjEsImp0aSI6IjJkZDg4ZWRhLTAxMzQtNDUzYS04ODNhLWViNjIwNzA0M2U5ZSJ9.9JztFZQwDt-QzaO5c2CK_nZFyEvILSZu6zUHr7xXMgs","eid":"1-s2.0-S0003496725010416","doi":"10.1016/j.ard.2025.05.023","first-fp":"1660","hub-eid":"1-s2.0-S0003496725X00121","issuePii":"S0003496725X00121","iss-first":"10","item-weight":"FULL-TEXT","language":"en","last-lp":"1674","last-author":{"#name":"last-author","$":{"xmlns:ce":true,"xmlns:dm":true,"xmlns:sb":true},"$$":[{"#name":"author","$":{"id":"au0018","author-id":"S0003496725010416-e35b34429f48f6d20d744cfc337ef012","orcid":"0000-0003-0696-4129"},"$$":[{"#name":"given-name","_":"Apinya"},{"#name":"surname","_":"Lertratanakul"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-original-draft"},"_":"Writing ¨C original draft"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/visualization"},"_":"Visualization"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/supervision"},"_":"Supervision"},{"#name":"cross-ref","$":{"id":"crf0021","refid":"aff0003"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"3"}]}]}]},"normalized-first-auth-initial":"A","normalized-first-auth-surname":"KIVITZ","open-research":{"#name":"open-research","$":{"xmlns:xocs":true},"$$":[{"#name":"or-embargo-opening-date","_":"2026-10-01T00:00:00.000Z"}]},"pages":[{"last-page":"1674","first-page":"1660"}],"pii":"S0003496725010416","self-archiving":{"#name":"self-archiving","$":{"xmlns:xocs":true},"$$":[{"#name":"sa-start-date","_":"2026-10-01T00:00:00.000Z"},{"#name":"sa-user-license","_":"http://creativecommons.org/licenses/by-nc-nd/4.0/"}]},"srctitle":"Annals of the Rheumatic Diseases","timestamp":"2025-10-01T15:54:37.918037Z","title":{"content":[{"#name":"article-footnote","$":{"id":"aep-article-footnote-id1"},"$$":[{"#name":"note-para","$":{"id":"notep0002","view":"all"},"_":"Affiliations for Bhaskar Srivastava, Sue Dasen, Xinyan Zhang, Mona Trivedi and Apinya Lertratanakul are reported at the time of the study."}]},{"#name":"article-footnote","$":{"id":"aep-article-footnote-id2"},"$$":[{"#name":"note-para","$":{"id":"notep0003","view":"all"},"$$":[{"#name":"bold","_":"Handling editor"},{"#name":"__text__","_":" Josef S Smolen"}]}]},{"#name":"dochead","$":{"id":"dchd0001"},"$$":[{"#name":"textfn","$":{"id":"dhtxt0001"},"_":"Psoriatic arthritis"}]},{"#name":"title","$":{"id":"tte0002"},"_":"Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study"}],"floats":[],"footnotes":[{"#name":"article-footnote","$":{"id":"aep-article-footnote-id1"},"$$":[{"#name":"note-para","$":{"id":"notep0002","view":"all"},"_":"Affiliations for Bhaskar Srivastava, Sue Dasen, Xinyan Zhang, Mona Trivedi and Apinya Lertratanakul are reported at the time of the study."}]},{"#name":"article-footnote","$":{"id":"aep-article-footnote-id2"},"$$":[{"#name":"note-para","$":{"id":"notep0003","view":"all"},"$$":[{"#name":"bold","_":"Handling editor"},{"#name":"__text__","_":" Josef S Smolen"}]}]}],"attachments":[]},"vol-first":"84","vol-iss-suppl-text":"Volume 84, Issue 10","userSettings":{"forceAbstract":false,"creditCardPurchaseAllowed":true,"blockFullTextForAnonymousAccess":false,"disableWholeIssueDownload":false,"preventTransactionalAccess":false,"preventDocumentDelivery":true},"contentType":"JL","crossmark":false,"document-references":39,"freeHtmlGiven":false,"userProfile":{"departmentName":"ScienceDirect Guests","accessType":"GUEST","accountId":"228598","webUserId":"12975512","accountName":"ScienceDirect Guests","departmentId":"291352","userType":"NORMAL","hasMultipleOrganizations":false,"accountNumber":"C000228598"},"access":{"openAccess":true,"openArchive":false,"license":"http://creativecommons.org/licenses/by/4.0/"},"accessTypeLabel":"Open access","aipType":"none","articleEntitlement":{"entitled":true,"isCasaUser":false,"usageInfo":"(12975512,U|291352,D|228598,A|3,P|2,PL)(SDFE,CON|3ab7b9855512404b7d388e0150795a809c73gxrqa,SSO|ANON_GUEST,ACCESS_TYPE)","entitledByAccount":false,"entitlementOrigin":"SD"},"authorToken":"eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJhdWQiOiJhcnBDbGllbnQiLCJwaWkiOiJTMDAwMzQ5NjcyNTAxMDQxNiIsImlzcyI6ImFydCIsInNlc3Npb25JZCI6IjNhYjdiOTg1NTUxMjQwNGI3ZDM4OGUwMTUwNzk1YTgwOWM3M2d4cnFhIiwiZXhwIjoxNzYxMDUwODY5LCJpYXQiOjE3NjEwNDkwNjksInZlcnNpb24iOjEsImp0aSI6ImViZGFlM2E3LWU4NzktNDkzZC1hOTAyLWU5YmIwMDY5NjhlOSJ9.8W5biWJO4SlPxrzC1PMyDqojDLQLoIXKWi4Ro4_GjoM","crawlerInformation":{"canCrawlPDFContent":false,"isCrawler":false},"dates":{"Available online":"4 July 2025","Received":"31 January 2025","Revised":[],"Accepted":"30 May 2025","Publication date":"1 October 2025","Version of Record":"1 October 2025"},"documentTypeLabel":"Research article","downloadFullIssue":true,"entitlementReason":"openaccess","entitlementReasonByOrigin":{"SD":"openaccess","CK":"unsubscribed"},"features":["references","preview"],"hasBody":true,"has-large-authors":false,"hasScholarlyAbstract":true,"headerConfig":{"contactUrl":"https://service.elsevier.com/app/contact/supporthub/sciencedirect/","userName":"","userEmail":"","orgName":"ScienceDirect Guests","webUserId":"12975512","libraryBanner":null,"shib_regUrl":"","tick_regUrl":"","recentInstitutions":[],"canActivatePersonalization":false,"hasInstitutionalAssociation":false,"hasMultiOrg":false,"userType":"GUEST","userAnonymity":"ANON_GUEST","allowCart":true,"environment":"prod","cdnAssetsHost":""},"isCorpReq":false,"isPdfFullText":false,"issn":"00034967","issn-primary-formatted":"0003-4967","issRange":"10","isThirdParty":false,"licenseLink":{"prefix":"Under a Creative Commons ","text":"license","url":"http://creativecommons.org/licenses/by/4.0/"},"pageCount":15,"pdfDownload":{"isPdfFullText":false,"urlMetadata":{"queryParams":{"md5":"c45412591fe7fc561cc3fd8321a841ed","pid":"1-s2.0-S0003496725010416-main.pdf"},"pii":"S0003496725010416","pdfExtension":"/pdfft","path":"science/article/pii"}},"publication-content":{"noElsevierLogo":false,"imprintPublisher":{"displayName":"Elsevier","id":"47"},"isSpecialIssue":false,"isSampleIssue":false,"transactionsBlocked":false,"publicationOpenAccess":{"oaStatus":"","oaArticleCount":1703,"openArchiveStatus":false,"openArchiveArticleCount":533,"openAccessStartDate":"","oaAllowsAuthorPaid":true},"issue-cover":{"attachment":[{"attachment-eid":"1-s2.0-S0003496725X00121-cov200h.gif","file-basename":"cov200h","extension":"gif","filename":"cov200h.gif","ucs-locator":["https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0003496725X00121/cover/DOWNSAMPLED200/image/gif/066fa0d2ed40e77cef7cfa566a158732/cov200h.gif"],"attachment-type":"IMAGE-COVER-H200","filesize":"13616","pixel-height":"200","pixel-width":"141"},{"attachment-eid":"1-s2.0-S0003496725X00121-cov150h.gif","file-basename":"cov150h","extension":"gif","filename":"cov150h.gif","ucs-locator":["https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0003496725X00121/cover/DOWNSAMPLED/image/gif/69d3044ab453e45c360bb50a058f9fec/cov150h.gif"],"attachment-type":"IMAGE-COVER-H150","filesize":"8674","pixel-height":"150","pixel-width":"106"}]},"smallCoverUrl":"https://ars.els-cdn.com/content/image/S00034967.gif","title":"annals-of-the-rheumatic-diseases","contentTypeCode":"JL","images":{"coverImage":"https://ars.els-cdn.com/content/image/1-s2.0-S0003496725X00121-cov150h.gif","logo":"/us-east-1/prod/2d348b415dc48b7aaa2f48d669a232bb69813c31/image/elsevier-non-solus.svg","logoAltText":"Elsevier"},"publicationCoverImageUrl":"https://ars.els-cdn.com/content/image/1-s2.0-S0003496725X00121-cov150h.gif"},"rightsLink":"https://s100.copyright.com/AppDispatchServlet?publisherName=ELS&contentID=S0003496725010416&orderBeanReset=true","volRange":"84","titleString":"Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study","ssrn":{},"renderingMode":"Article","isAbstract":false,"isContentVisible":false,"ajaxLinks":{"citingArticles":true,"referenceLinks":true,"references":true,"referredToBy":true,"toc":true,"body":true,"recommendations":true,"authorMetadata":true},"pdfEmbed":false,"displayViewFullText":false},"authors":{"content":[{"#name":"author-group","$":{"id":"aut0001"},"$$":[{"#name":"author","$":{"id":"au0001","author-id":"S0003496725010416-cff579a1cdc2b69b27a25c1c5e058d86","orcid":"0000-0002-1045-1310"},"$$":[{"#name":"given-name","_":"Alan"},{"#name":"surname","_":"Kivitz"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/visualization"},"_":"Visualization"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/supervision"},"_":"Supervision"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/resources"},"_":"Resources"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/investigation"},"_":"Investigation"},{"#name":"cross-ref","$":{"id":"crf0001","refid":"aff0001"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"1"}]},{"#name":"cross-ref","$":{"id":"crf0002","refid":"fn1"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"a"}]}]},{"#name":"author","$":{"id":"au0002","author-id":"S0003496725010416-edf26d7c735d924e9c9bc444172b9bdf","orcid":"0000-0002-9475-9362"},"$$":[{"#name":"given-name","_":"Xenofon"},{"#name":"surname","_":"Baraliakos"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/supervision"},"_":"Supervision"},{"#name":"cross-ref","$":{"id":"crf0003","refid":"aff0002"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"2"}]},{"#name":"cross-ref","$":{"id":"crf0004","refid":"fn1"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"a"}]}]},{"#name":"author","$":{"id":"au0003","author-id":"S0003496725010416-7f1189139151bb26ad7d7d3195ad98e5","orcid":"0009-0007-8916-3680"},"$$":[{"#name":"given-name","_":"Elena Tomaselli"},{"#name":"surname","_":"Muensterman"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-original-draft"},"_":"Writing ¨C original draft"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/formal-analysis"},"_":"Formal analysis"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/data-curation"},"_":"Data curation"},{"#name":"cross-ref","$":{"id":"crf0005","refid":"aff0003"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"3"}]},{"#name":"cross-ref","$":{"id":"crf0006","refid":"cor0001"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"?"}]},{"#name":"encoded-e-address","__encoded":"JTdCJTIyJTIzbmFtZSUyMiUzQSUyMmUtYWRkcmVzcyUyMiUyQyUyMiUyNCUyMiUzQSU3QiUyMnhtbG5zJTNBeGxpbmslMjIlM0F0cnVlJTJDJTIyaWQlMjIlM0ElMjJlYWQwMDAxJTIyJTJDJTIydHlwZSUyMiUzQSUyMmVtYWlsJTIyJTJDJTIyaHJlZiUyMiUzQSUyMm1haWx0byUzQWVsZW5hLm11ZW5zdGVybWFuJTQwdGFrZWRhLmNvbSUyMiU3RCUyQyUyMl8lMjIlM0ElMjJlbGVuYS5tdWVuc3Rlcm1hbiU0MHRha2VkYS5jb20lMjIlN0Q="}]},{"#name":"author","$":{"id":"au0004","author-id":"S0003496725010416-fb03d26fcbc4123b63889cb06fbb2e34","orcid":"0000-0001-6942-5830"},"$$":[{"#name":"given-name","_":"Arthur"},{"#name":"surname","_":"Kavanaugh"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/conceptualization"},"_":"Conceptualization"},{"#name":"cross-ref","$":{"id":"crf0007","refid":"aff0004"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"4"}]}]},{"#name":"author","$":{"id":"au0005","author-id":"S0003496725010416-d296ca8bf0368beb4d0ee11d5c588500","orcid":"0000-0002-5781-158X"},"$$":[{"#name":"given-name","_":"D¨¦sir¨¦e"},{"#name":"surname","_":"van der Heijde"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/methodology"},"_":"Methodology"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/conceptualization"},"_":"Conceptualization"},{"#name":"cross-ref","$":{"id":"crf0008","refid":"aff0005"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"5"}]}]},{"#name":"author","$":{"id":"au0006","author-id":"S0003496725010416-697919278994655822467b7b9e5bc55f","orcid":"0000-0003-3457-6203"},"$$":[{"#name":"given-name","_":"Piotr A"},{"#name":"surname","_":"Klimiuk"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/investigation"},"_":"Investigation"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/data-curation"},"_":"Data curation"},{"#name":"cross-ref","$":{"id":"crf0009","refid":"aff0006"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"6"}]}]},{"#name":"author","$":{"id":"au0007","author-id":"S0003496725010416-881afea36bc520b84728cc78a7cc56f6","orcid":"0000-0003-4283-9683"},"$$":[{"#name":"given-name","_":"Guillermo"},{"#name":"surname","_":"Valenzuela"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/investigation"},"_":"Investigation"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/conceptualization"},"_":"Conceptualization"},{"#name":"cross-ref","$":{"id":"crf0010","refid":"aff0007"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"7"}]}]},{"#name":"author","$":{"id":"au0008","author-id":"S0003496725010416-faddf467f5860305ac49d5ab0336c79d","orcid":"0009-0003-9363-145X"},"$$":[{"#name":"given-name","_":"Eva"},{"#name":"surname","_":"Dokoupilova"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/investigation"},"_":"Investigation"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/data-curation"},"_":"Data curation"},{"#name":"cross-ref","$":{"id":"crf0011","refid":"aff0008"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"8"}]}]},{"#name":"author","$":{"id":"au0009","author-id":"S0003496725010416-e050cf83353280ddb68b278d8257434a"},"$$":[{"#name":"given-name","_":"Gabrielle"},{"#name":"surname","_":"Poirier"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/supervision"},"_":"Supervision"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/project-administration"},"_":"Project administration"},{"#name":"cross-ref","$":{"id":"crf0012","refid":"aff0009"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"9"}]}]},{"#name":"author","$":{"id":"au0010","author-id":"S0003496725010416-c00a34e822ce08e0e311a8c3d3734a8a","orcid":"0009-0000-9859-4203"},"$$":[{"#name":"given-name","_":"Bhaskar"},{"#name":"surname","_":"Srivastava"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/supervision"},"_":"Supervision"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/methodology"},"_":"Methodology"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/investigation"},"_":"Investigation"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/conceptualization"},"_":"Conceptualization"},{"#name":"cross-ref","$":{"id":"crf0013","refid":"aff0009"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"9"}]}]},{"#name":"author","$":{"id":"au0011","author-id":"S0003496725010416-ed6b2928194d6b79d0c56265b16b14ce","orcid":"0009-0000-8877-1384"},"$$":[{"#name":"given-name","_":"Sue"},{"#name":"surname","_":"Dasen"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/supervision"},"_":"Supervision"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/methodology"},"_":"Methodology"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/data-curation"},"_":"Data curation"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/conceptualization"},"_":"Conceptualization"},{"#name":"cross-ref","$":{"id":"crf0014","refid":"aff0009"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"9"}]}]},{"#name":"author","$":{"id":"au0012","author-id":"S0003496725010416-7897fd74d64f9e6fbf606b928db6fda5","orcid":"0009-0001-6419-425X"},"$$":[{"#name":"given-name","_":"Xinyan"},{"#name":"surname","_":"Zhang"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/methodology"},"_":"Methodology"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/formal-analysis"},"_":"Formal analysis"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/data-curation"},"_":"Data curation"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/conceptualization"},"_":"Conceptualization"},{"#name":"cross-ref","$":{"id":"crf0015","refid":"aff0009"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"9"}]}]},{"#name":"author","$":{"id":"au0013","author-id":"S0003496725010416-b2f4fe375c5bb1c2879edac8d72909f2","orcid":"0009-0007-7464-3462"},"$$":[{"#name":"given-name","_":"Ting"},{"#name":"surname","_":"Hong"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/methodology"},"_":"Methodology"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/formal-analysis"},"_":"Formal analysis"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/data-curation"},"_":"Data curation"},{"#name":"cross-ref","$":{"id":"crf0016","refid":"aff0003"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"3"}]}]},{"#name":"author","$":{"id":"au0014","author-id":"S0003496725010416-bd6b7a33f0a91a2adb5b749d503f05e7","orcid":"0000-0003-4252-9255"},"$$":[{"#name":"given-name","_":"Jingjing"},{"#name":"surname","_":"Chen"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/methodology"},"_":"Methodology"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/formal-analysis"},"_":"Formal analysis"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/data-curation"},"_":"Data curation"},{"#name":"cross-ref","$":{"id":"crf0017","refid":"aff0003"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"3"}]}]},{"#name":"author","$":{"id":"au0015","author-id":"S0003496725010416-87d21bc2d139c17fc798775921d1e59e","orcid":"0000-0002-0531-4127"},"$$":[{"#name":"given-name","_":"Peter"},{"#name":"surname","_":"Pothula"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-original-draft"},"_":"Writing ¨C original draft"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/formal-analysis"},"_":"Formal analysis"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/data-curation"},"_":"Data curation"},{"#name":"cross-ref","$":{"id":"crf0018","refid":"aff0003"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"3"}]}]},{"#name":"author","$":{"id":"au0016","author-id":"S0003496725010416-0cbf8e41ccaae941b726967795c321b6","orcid":"0009-0002-8484-3955"},"$$":[{"#name":"given-name","_":"Haoling Holly"},{"#name":"surname","_":"Weng"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/supervision"},"_":"Supervision"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/methodology"},"_":"Methodology"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/formal-analysis"},"_":"Formal analysis"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/conceptualization"},"_":"Conceptualization"},{"#name":"cross-ref","$":{"id":"crf0019","refid":"aff0010"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"10"}]}]},{"#name":"author","$":{"id":"au0017","author-id":"S0003496725010416-84d72fa612d0ea4fbd748aed392026b7","orcid":"0009-0000-4586-0619"},"$$":[{"#name":"given-name","_":"Mona"},{"#name":"surname","_":"Trivedi"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-original-draft"},"_":"Writing ¨C original draft"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/visualization"},"_":"Visualization"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/supervision"},"_":"Supervision"},{"#name":"cross-ref","$":{"id":"crf0020","refid":"aff0003"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"3"}]}]},{"#name":"author","$":{"id":"au0018","author-id":"S0003496725010416-e35b34429f48f6d20d744cfc337ef012","orcid":"0000-0003-0696-4129"},"$$":[{"#name":"given-name","_":"Apinya"},{"#name":"surname","_":"Lertratanakul"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-review-editing"},"_":"Writing ¨C review & editing"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/writing-original-draft"},"_":"Writing ¨C original draft"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/visualization"},"_":"Visualization"},{"#name":"contributor-role","$":{"role":"http://credit.niso.org/contributor-roles/supervision"},"_":"Supervision"},{"#name":"cross-ref","$":{"id":"crf0021","refid":"aff0003"},"$$":[{"#name":"sup","$":{"loc":"post"},"_":"3"}]}]},{"#name":"affiliation","$":{"id":"aff0001","affiliation-id":"S0003496725010416-81a7f4c1fc003e92e6d55ce5b5e8caa6"},"$$":[{"#name":"label","_":"1"},{"#name":"textfn","$":{"id":"cetextfn0001"},"_":"Altoona Center for Clinical Research, Duncansville, PA, USA"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Altoona Center for Clinical Research"},{"#name":"city","_":"Duncansville"},{"#name":"state","_":"PA"},{"#name":"country","$":{"iso3166-1-alpha-3":"USA"},"_":"USA"}]},{"#name":"source-text","$":{"id":"staff0001"},"_":"1Altoona Center for Clinical Research, Duncansville, PA, USA"}]},{"#name":"affiliation","$":{"id":"aff0002","affiliation-id":"S0003496725010416-8f8ee26f9b74c7c419f4ee882082ff57"},"$$":[{"#name":"label","_":"2"},{"#name":"textfn","$":{"id":"cetextfn0002"},"_":"Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Rheumazentrum Ruhrgebiet Herne"},{"#name":"organization","_":"Ruhr-University Bochum"},{"#name":"country","$":{"iso3166-1-alpha-3":"DEU"},"_":"Germany"}]},{"#name":"source-text","$":{"id":"staff0002"},"_":"2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany"}]},{"#name":"affiliation","$":{"id":"aff0003","affiliation-id":"S0003496725010416-40ec0bb8661b53aabbf7b6236b3d6915"},"$$":[{"#name":"label","_":"3"},{"#name":"textfn","$":{"id":"cetextfn0003"},"_":"Takeda Development Center Americas, Inc, Cambridge, MA, USA"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Takeda Development Center Americas, Inc"},{"#name":"city","_":"Cambridge"},{"#name":"state","_":"MA"},{"#name":"country","$":{"iso3166-1-alpha-3":"USA"},"_":"USA"}]},{"#name":"source-text","$":{"id":"staff0003"},"_":"3Takeda Development Center Americas, Inc, Cambridge, MA, USA"}]},{"#name":"affiliation","$":{"id":"aff0004","affiliation-id":"S0003496725010416-503e24355bea318877e202c9582da95d"},"$$":[{"#name":"label","_":"4"},{"#name":"textfn","$":{"id":"cetextfn0004"},"_":"Division of Rheumatology, Autoimmunity and Inflammation, University of California San Diego Medical School, San Diego, CA, USA"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Division of Rheumatology"},{"#name":"organization","_":"Autoimmunity and Inflammation"},{"#name":"organization","_":"University of California San Diego Medical School"},{"#name":"city","_":"San Diego"},{"#name":"state","_":"CA"},{"#name":"country","$":{"iso3166-1-alpha-3":"USA"},"_":"USA"}]},{"#name":"source-text","$":{"id":"staff0004"},"_":"4Division of Rheumatology, Autoimmunity and Inflammation, University of California San Diego Medical School, San Diego, CA, USA"}]},{"#name":"affiliation","$":{"id":"aff0005","affiliation-id":"S0003496725010416-8724f06a2e4249a6089c67becd0483ba"},"$$":[{"#name":"label","_":"5"},{"#name":"textfn","$":{"id":"cetextfn0005"},"_":"Leiden University Medical Center, Leiden, Netherlands"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Leiden University Medical Center"},{"#name":"city","_":"Leiden"},{"#name":"country","$":{"iso3166-1-alpha-3":"NLD"},"_":"Netherlands"}]},{"#name":"source-text","$":{"id":"staff0005"},"_":"5Leiden University Medical Center, Leiden, Netherlands"}]},{"#name":"affiliation","$":{"id":"aff0006","affiliation-id":"S0003496725010416-5840bf467d019eb0c1fba71697d129be"},"$$":[{"#name":"label","_":"6"},{"#name":"textfn","$":{"id":"cetextfn0006"},"_":"Department of Rheumatology and Internal Diseases, Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Bia?ystok, Poland"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Department of Rheumatology and Internal Diseases"},{"#name":"organization","_":"Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk"},{"#name":"city","_":"Bia?ystok"},{"#name":"country","$":{"iso3166-1-alpha-3":"POL"},"_":"Poland"}]},{"#name":"source-text","$":{"id":"staff0006"},"_":"6Department of Rheumatology and Internal Diseases, Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Bia?ystok, Poland"}]},{"#name":"affiliation","$":{"id":"aff0007","affiliation-id":"S0003496725010416-cd0c32870eb2ed4ca3ec55b7a0a33031"},"$$":[{"#name":"label","_":"7"},{"#name":"textfn","$":{"id":"cetextfn0007"},"_":"Integral Rheumatology & Immunology Specialists, Plantation, FL, USA"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Integral Rheumatology & Immunology Specialists"},{"#name":"city","_":"Plantation"},{"#name":"state","_":"FL"},{"#name":"country","$":{"iso3166-1-alpha-3":"USA"},"_":"USA"}]},{"#name":"source-text","$":{"id":"staff0007"},"_":"7Integral Rheumatology & Immunology Specialists, Plantation, FL, USA"}]},{"#name":"affiliation","$":{"id":"aff0008","affiliation-id":"S0003496725010416-b33c1b09b0da7d38d402a1149004e450"},"$$":[{"#name":"label","_":"8"},{"#name":"textfn","$":{"id":"cetextfn0008"},"_":"Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic and MEDICAL PLUS, s.r.o., Uhersk¨¦ Hradi?t¨§, Czech Republic"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Department of Pharmaceutical Technology"},{"#name":"organization","_":"Faculty of Pharmacy"},{"#name":"organization","_":"Masaryk University"},{"#name":"organization","_":"Czech Republic and MEDICAL PLUS, s.r.o., Uhersk¨¦ Hradi?t¨§"},{"#name":"city","_":"Brno"},{"#name":"country","$":{"iso3166-1-alpha-3":"CZE"},"_":"Czech Republic"}]},{"#name":"source-text","$":{"id":"staff0008"},"_":"8Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic and MEDICAL PLUS, s.r.o., Uhersk¨¦ Hradi?t¨§, Czech Republic"}]},{"#name":"affiliation","$":{"id":"aff0009","affiliation-id":"S0003496725010416-f644b39240db31ef84a74a2c63dac758"},"$$":[{"#name":"label","_":"9"},{"#name":"textfn","$":{"id":"cetextfn0009"},"_":"Nimbus Discovery, Inc, Boston, MA, USA"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Nimbus Discovery, Inc"},{"#name":"city","_":"Boston"},{"#name":"state","_":"MA"},{"#name":"country","$":{"iso3166-1-alpha-3":"USA"},"_":"USA"}]},{"#name":"source-text","$":{"id":"staff0009"},"_":"9Nimbus Discovery, Inc, Boston, MA, USA"}]},{"#name":"affiliation","$":{"id":"aff0010","affiliation-id":"S0003496725010416-c89eb6c4f0bfd24ef26c57b547d07f0f"},"$$":[{"#name":"label","_":"10"},{"#name":"textfn","$":{"id":"cetextfn0010"},"_":"HW MedAdvice LLC, San Diego, CA, USA"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"HW MedAdvice LLC"},{"#name":"city","_":"San Diego"},{"#name":"state","_":"CA"},{"#name":"country","$":{"iso3166-1-alpha-3":"USA"},"_":"USA"}]},{"#name":"source-text","$":{"id":"staff0010"},"_":"10HW MedAdvice LLC, San Diego, CA, USA"}]},{"#name":"correspondence","$":{"id":"cor0001"},"$$":[{"#name":"label","_":"?"},{"#name":"text","$":{"id":"cetext0001"},"$$":[{"#name":"bold","_":"Correspondence to"},{"#name":"__text__","_":" Dr Elena Tomaselli Muensterman."}]}]},{"#name":"footnote","$":{"id":"fn1"},"$$":[{"#name":"label","_":"a"},{"#name":"note-para","$":{"id":"notep0001","view":"all"},"_":"Dr Alan Kivitz and Dr Xenofon Baraliakos are cofirst authors."}]}]}],"floats":[],"footnotes":[{"#name":"footnote","$":{"id":"fn1"},"$$":[{"#name":"label","_":"a"},{"#name":"note-para","$":{"id":"notep0001","view":"all"},"_":"Dr Alan Kivitz and Dr Xenofon Baraliakos are cofirst authors."}]}],"affiliations":{"aff0001":{"#name":"affiliation","$":{"id":"aff0001","affiliation-id":"S0003496725010416-81a7f4c1fc003e92e6d55ce5b5e8caa6"},"$$":[{"#name":"label","_":"1"},{"#name":"textfn","$":{"id":"cetextfn0001"},"_":"Altoona Center for Clinical Research, Duncansville, PA, USA"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Altoona Center for Clinical Research"},{"#name":"city","_":"Duncansville"},{"#name":"state","_":"PA"},{"#name":"country","$":{"iso3166-1-alpha-3":"USA"},"_":"USA"}]},{"#name":"source-text","$":{"id":"staff0001"},"_":"1Altoona Center for Clinical Research, Duncansville, PA, USA"}]},"aff0002":{"#name":"affiliation","$":{"id":"aff0002","affiliation-id":"S0003496725010416-8f8ee26f9b74c7c419f4ee882082ff57"},"$$":[{"#name":"label","_":"2"},{"#name":"textfn","$":{"id":"cetextfn0002"},"_":"Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Rheumazentrum Ruhrgebiet Herne"},{"#name":"organization","_":"Ruhr-University Bochum"},{"#name":"country","$":{"iso3166-1-alpha-3":"DEU"},"_":"Germany"}]},{"#name":"source-text","$":{"id":"staff0002"},"_":"2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany"}]},"aff0003":{"#name":"affiliation","$":{"id":"aff0003","affiliation-id":"S0003496725010416-40ec0bb8661b53aabbf7b6236b3d6915"},"$$":[{"#name":"label","_":"3"},{"#name":"textfn","$":{"id":"cetextfn0003"},"_":"Takeda Development Center Americas, Inc, Cambridge, MA, USA"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Takeda Development Center Americas, Inc"},{"#name":"city","_":"Cambridge"},{"#name":"state","_":"MA"},{"#name":"country","$":{"iso3166-1-alpha-3":"USA"},"_":"USA"}]},{"#name":"source-text","$":{"id":"staff0003"},"_":"3Takeda Development Center Americas, Inc, Cambridge, MA, USA"}]},"aff0004":{"#name":"affiliation","$":{"id":"aff0004","affiliation-id":"S0003496725010416-503e24355bea318877e202c9582da95d"},"$$":[{"#name":"label","_":"4"},{"#name":"textfn","$":{"id":"cetextfn0004"},"_":"Division of Rheumatology, Autoimmunity and Inflammation, University of California San Diego Medical School, San Diego, CA, USA"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Division of Rheumatology"},{"#name":"organization","_":"Autoimmunity and Inflammation"},{"#name":"organization","_":"University of California San Diego Medical School"},{"#name":"city","_":"San Diego"},{"#name":"state","_":"CA"},{"#name":"country","$":{"iso3166-1-alpha-3":"USA"},"_":"USA"}]},{"#name":"source-text","$":{"id":"staff0004"},"_":"4Division of Rheumatology, Autoimmunity and Inflammation, University of California San Diego Medical School, San Diego, CA, USA"}]},"aff0005":{"#name":"affiliation","$":{"id":"aff0005","affiliation-id":"S0003496725010416-8724f06a2e4249a6089c67becd0483ba"},"$$":[{"#name":"label","_":"5"},{"#name":"textfn","$":{"id":"cetextfn0005"},"_":"Leiden University Medical Center, Leiden, Netherlands"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Leiden University Medical Center"},{"#name":"city","_":"Leiden"},{"#name":"country","$":{"iso3166-1-alpha-3":"NLD"},"_":"Netherlands"}]},{"#name":"source-text","$":{"id":"staff0005"},"_":"5Leiden University Medical Center, Leiden, Netherlands"}]},"aff0006":{"#name":"affiliation","$":{"id":"aff0006","affiliation-id":"S0003496725010416-5840bf467d019eb0c1fba71697d129be"},"$$":[{"#name":"label","_":"6"},{"#name":"textfn","$":{"id":"cetextfn0006"},"_":"Department of Rheumatology and Internal Diseases, Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Bia?ystok, Poland"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Department of Rheumatology and Internal Diseases"},{"#name":"organization","_":"Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk"},{"#name":"city","_":"Bia?ystok"},{"#name":"country","$":{"iso3166-1-alpha-3":"POL"},"_":"Poland"}]},{"#name":"source-text","$":{"id":"staff0006"},"_":"6Department of Rheumatology and Internal Diseases, Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Bia?ystok, Poland"}]},"aff0007":{"#name":"affiliation","$":{"id":"aff0007","affiliation-id":"S0003496725010416-cd0c32870eb2ed4ca3ec55b7a0a33031"},"$$":[{"#name":"label","_":"7"},{"#name":"textfn","$":{"id":"cetextfn0007"},"_":"Integral Rheumatology & Immunology Specialists, Plantation, FL, USA"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Integral Rheumatology & Immunology Specialists"},{"#name":"city","_":"Plantation"},{"#name":"state","_":"FL"},{"#name":"country","$":{"iso3166-1-alpha-3":"USA"},"_":"USA"}]},{"#name":"source-text","$":{"id":"staff0007"},"_":"7Integral Rheumatology & Immunology Specialists, Plantation, FL, USA"}]},"aff0008":{"#name":"affiliation","$":{"id":"aff0008","affiliation-id":"S0003496725010416-b33c1b09b0da7d38d402a1149004e450"},"$$":[{"#name":"label","_":"8"},{"#name":"textfn","$":{"id":"cetextfn0008"},"_":"Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic and MEDICAL PLUS, s.r.o., Uhersk¨¦ Hradi?t¨§, Czech Republic"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Department of Pharmaceutical Technology"},{"#name":"organization","_":"Faculty of Pharmacy"},{"#name":"organization","_":"Masaryk University"},{"#name":"organization","_":"Czech Republic and MEDICAL PLUS, s.r.o., Uhersk¨¦ Hradi?t¨§"},{"#name":"city","_":"Brno"},{"#name":"country","$":{"iso3166-1-alpha-3":"CZE"},"_":"Czech Republic"}]},{"#name":"source-text","$":{"id":"staff0008"},"_":"8Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic and MEDICAL PLUS, s.r.o., Uhersk¨¦ Hradi?t¨§, Czech Republic"}]},"aff0009":{"#name":"affiliation","$":{"id":"aff0009","affiliation-id":"S0003496725010416-f644b39240db31ef84a74a2c63dac758"},"$$":[{"#name":"label","_":"9"},{"#name":"textfn","$":{"id":"cetextfn0009"},"_":"Nimbus Discovery, Inc, Boston, MA, USA"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"Nimbus Discovery, Inc"},{"#name":"city","_":"Boston"},{"#name":"state","_":"MA"},{"#name":"country","$":{"iso3166-1-alpha-3":"USA"},"_":"USA"}]},{"#name":"source-text","$":{"id":"staff0009"},"_":"9Nimbus Discovery, Inc, Boston, MA, USA"}]},"aff0010":{"#name":"affiliation","$":{"id":"aff0010","affiliation-id":"S0003496725010416-c89eb6c4f0bfd24ef26c57b547d07f0f"},"$$":[{"#name":"label","_":"10"},{"#name":"textfn","$":{"id":"cetextfn0010"},"_":"HW MedAdvice LLC, San Diego, CA, USA"},{"#name":"affiliation","$":{"xmlns:sa":true},"$$":[{"#name":"organization","_":"HW MedAdvice LLC"},{"#name":"city","_":"San Diego"},{"#name":"state","_":"CA"},{"#name":"country","$":{"iso3166-1-alpha-3":"USA"},"_":"USA"}]},{"#name":"source-text","$":{"id":"staff0010"},"_":"10HW MedAdvice LLC, San Diego, CA, USA"}]}},"correspondences":{"cor0001":{"#name":"correspondence","$":{"id":"cor0001"},"$$":[{"#name":"label","_":"?"},{"#name":"text","$":{"id":"cetext0001"},"$$":[{"#name":"bold","_":"Correspondence to"},{"#name":"__text__","_":" Dr Elena Tomaselli Muensterman."}]}]}},"attachments":[],"scopusAuthorIds":{},"articles":{}},"authorMetadata":[],"banner":{"expanded":false},"biographies":{},"body":{},"chapters":{"toc":[],"isLoading":false},"changeViewLinks":{"showFullTextLink":false,"showAbstractLink":false},"citingArticles":{},"clientConfig":{"adobeSuite":"elsevier-sd-prod","aiNavigation":{"enabled":true,"version":"V1"},"arsUrl":"https://ars.els-cdn.com","assetRoute":"/us-east-1/prod/2d348b415dc48b7aaa2f48d669a232bb69813c31","recommendationsFeedback":{"enabled":true,"url":"https://feedback.recs.d.elsevier.com/raw/events","timeout":60000},"googleMapsApiKey":"AIzaSyCBYU6I6lrbEU6wQXUEIte3NwGtm3jwHQc","mediaBaseUrl":"https://ars.els-cdn.com/content/image/","xocsMediaPlayerBaseUrl":"/shared-assets/147/js/ableplayer","strictMode":false,"seamlessAccess":{"enableSeamlessAccess":true,"scriptUrl":"https://unpkg.com/@theidentityselector/thiss-ds@1.0.13/dist/thiss-ds.js","persistenceUrl":"https://service.seamlessaccess.org/ps/","persistenceContext":"seamlessaccess.org","scienceDirectUrl":"https://www.sciencedirect.com","shibAuthUrl":"https://auth.elsevier.com/ShibAuth/institutionLogin"},"reaxys":{"apiUrl":"https://reaxys-sdlc.reaxys.com","origin":"sciencedirect","queryBuilderHostPath":"https://www.reaxys.com/reaxys/secured/hopinto.do","url":"https://www.reaxys.com"},"oneTrustCookie":{"enabled":true},"shadowBackend":{"abstract":true,"citedBy":true,"glossary":true},"ssrn":{"url":"https://papers.ssrn.com","path":"/sol3/papers.cfm"}},"combinedContentItems":{},"crossMark":{"isOpen":false},"domainConfig":{"assetRoute":"/us-east-1/prod/2d348b415dc48b7aaa2f48d669a232bb69813c31","cdnAssetsHost":""},"downloadIssue":{"openOnPageLoad":false,"isOpen":false,"downloadCapOpen":false,"articles":[],"selected":[]},"enrichedContent":{"tableOfContents":false,"researchData":{"hasResearchData":false,"dataProfile":{},"openData":{},"mendeleyData":{},"databaseLinking":{}},"geospatialData":{"attachments":[]},"interactiveCaseInsights":{},"virtualMicroscope":{}},"entitledRecommendations":{"openOnPageLoad":false,"isOpen":false,"articles":[],"selected":[],"currentPage":1,"totalPages":1},"exam":{},"helpText":{"keyDates":{"html":"<div class=\"key-dates-help\"><h3 class=\"u-margin-s-bottom u-h4\">Publication milestones</h3><p class=\"u-margin-m-bottom\">The dates displayed for an article provide information on when various publication milestones were reached at the journal that has published the article. Where applicable, activities on preceding journals at which the article was previously under consideration are not shown (for instance submission, revisions, rejection).</p><p class=\"u-margin-xs-bottom\">The publication milestones include:</p><ul class=\"key-dates-help-list u-margin-m-bottom u-padding-s-left\"><li><span class=\"u-text-italic\">Received</span>: The date the article was originally submitted to the journal.</li><li><span class=\"u-text-italic\">Revised</span>: The date the most recent revision of the article was submitted to the journal. Dates corresponding to intermediate revisions are not shown.</li><li><span class=\"u-text-italic\">Accepted</span>: The date the article was accepted for publication in the journal.</li><li><span class=\"u-text-italic\">Available online</span>: The date a version of the article was made available online in the journal.</li><li><span class=\"u-text-italic\">Version of Record</span>: The date the finalized version of the article was made available in the journal.</li></ul><p>More information on publishing policies can be found on the <a class=\"anchor anchor-secondary u-display-inline anchor-underline\" href=\"https://www.elsevier.com/about/policies-and-standards/publishing-ethics\" target=\"_blank\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Publishing Ethics Policies</span></span></a> page. View our <a class=\"anchor anchor-secondary u-display-inline anchor-underline\" href=\"https://www.elsevier.com/researcher/author/submit-your-paper\" target=\"_blank\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Publishing with Elsevier: step-by-step</span></span></a> page to learn more about the publishing process. For any questions on your own submission or other questions related to publishing an article, <a class=\"anchor anchor-secondary u-display-inline anchor-underline\" href=\"https://service.elsevier.com/app/phone/supporthub/publishing\" target=\"_blank\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">contact our Researcher support team.</span></span></a></p></div>","title":"What do these dates mean?"}},"glossary":{},"issueNavigation":{"previous":{},"next":{}},"linkingHubLinks":{},"metrics":{"metricGroup":{"citations":[],"captures":[],"mentions":[],"socialMedia":[]},"isLoading":false,"error":false,"hasMetrics":false},"preview":{},"rawtext":"","recommendations":{},"references":{},"referenceLinks":{"internal":[],"internalLoaded":false,"external":[]},"refersTo":{},"referredToBy":{},"relatedContent":{"isModal":false,"isOpenSpecialIssueArticles":false,"isOpenVirtualSpecialIssueLink":false,"isOpenRecommendations":true,"isOpenSubstances":true,"citingArticles":[false,false,false,false,false,false],"recommendations":[false,false,false,false,false,false]},"seamlessAccess":{},"specialIssueArticles":{},"substances":{},"supplementaryFilesData":[],"tableOfContents":{"showEntitledTocLinks":true},"tail":{},"transientError":{"isOpen":false},"sidePanel":{"openState":1},"viewConfig":{"articleFeature":{"aiNavigation":false},"pathPrefix":""},"virtualSpecialIssue":{"showVirtualSpecialIssueLink":false},"usageProps":{"itemStage":"S300","isAip":false,"tombAip":"0","sample":false},"userCookiePreferences":{"STRICTLY_NECESSARY":true,"PERFORMANCE":true,"FUNCTIONAL":false,"CONTEXT_AD":true}};
      </script>
      <noscript>
      JavaScript is disabled on your browser.
      Please enable JavaScript to use all the features on this page.
      <img src=https://smetrics.elsevier.com/b/ss/elsevier-sd-prod/1/G.4--NS/1761049070002?pageName=sd%3Aproduct%3Ajournal%3Aarticle&c16=els%3Arp%3Ast&c2=sd&v185=img&v33=ae%3AANON_GUEST&c1=ae%3A228598&c12=ae%3A12975512 />
    </noscript>
      <div id="root"><div class="App" id="app" data-aa-name="root"><div class="page"><div class="sd-flex-container"><div class="sd-flex-content"><a class="anchor skip text-s anchor-primary" href="#screen-reader-main-content"><span class="anchor-text-container"><span class="anchor-text">Skip to main content</span></span></a><a class="anchor skip text-s anchor-primary" href="#screen-reader-main-title"><span class="anchor-text-container"><span class="anchor-text">Skip to article</span></span></a><header id="gh-cnt"><div id="gh-main-cnt" class="u-flex-center-ver u-position-relative u-padding-s-hor u-padding-l-hor-from-xl"><a id="gh-branding" class="u-flex-center-ver" href="/" aria-label="ScienceDirect home page" data-aa-region="header" data-aa-name="ScienceDirect"><img class="gh-logo" src="/shared-assets/24/images/elsevier-non-solus-new-grey.svg" alt="Elsevier logo" height="48" width="54"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" height="15" viewBox="0 0 190 23" role="img" class="gh-wordmark u-margin-s-left" aria-labelledby="gh-wm-science-direct" focusable="false" aria-hidden="true" alt="ScienceDirect Wordmark"><title id="gh-wm-science-direct">ScienceDirect</title><g><path fill="#EB6500" d="M3.81 6.9c0-1.48 0.86-3.04 3.7-3.04 1.42 0 3.1 0.43 4.65 1.32l0.13-2.64c-1.42-0.63-2.97-0.96-4.78-0.96 -4.62 0-6.6 2.44-6.6 5.45 0 5.61 8.78 6.14 8.78 9.93 0 1.48-1.15 3.04-3.86 3.04 -1.72 0-3.4-0.56-4.72-1.39l-0.36 2.64c1.55 0.76 3.57 1.06 5.15 1.06 4.26 0 6.7-2.48 6.7-5.51C12.59 11.49 3.81 10.76 3.81 6.9M20.27 9.01c0.23-0.13 0.69-0.26 1.72-0.26 1.72 0 2.41 0.3 2.41 1.58h2.38c0-0.36 0-0.79-0.03-1.09 -0.23-1.98-2.15-2.67-4.88-2.67 -3 0-6.7 2.31-6.7 7.76 0 5.22 2.77 7.99 6.63 7.99 1.68 0 3.47-0.36 4.95-1.39l-0.2-2.31c-0.99 0.82-2.84 1.52-4.06 1.52 -2.14 0-4.55-1.71-4.55-5.91C17.93 10.2 20.01 9.18 20.27 9.01"></path><rect x="29.42" y="6.97" fill="#EB6500" width="2.54" height="14.95"></rect><path fill="#EB6500" d="M30.67 0.7c-0.92 0-1.65 0.92-1.65 1.81 0 0.93 0.76 1.85 1.65 1.85 0.89 0 1.68-0.96 1.68-1.88C32.35 1.55 31.56 0.7 30.67 0.7M48.06 14.13c0-5.18-1.42-7.56-6.01-7.56 -3.86 0-6.67 2.77-6.67 7.92 0 4.92 2.97 7.82 6.73 7.82 2.81 0 4.36-0.63 5.68-1.42l-0.2-2.31c-0.89 0.79-2.94 1.55-4.69 1.55 -3.14 0-4.88-1.95-4.88-5.51v-0.49H48.06M39.91 9.18c0.17-0.17 1.29-0.46 1.98-0.46 2.48 0 3.76 0.53 3.86 3.43h-7.46C38.56 10.27 39.71 9.37 39.91 9.18zM58.82 6.57c-2.24 0-3.63 1.12-4.85 2.61l-0.4-2.21h-2.34l0.13 1.19c0.1 0.76 0.13 1.78 0.13 2.97v10.79h2.54V11.88c0.69-0.96 2.15-2.48 2.48-2.64 0.23-0.13 1.29-0.4 2.08-0.4 2.28 0 2.48 1.15 2.54 3.43 0.03 1.19 0.03 3.17 0.03 3.17 0.03 3-0.1 6.47-0.1 6.47h2.54c0 0 0.07-4.49 0.07-6.96 0-1.48 0.03-2.97-0.1-4.46C63.31 7.43 61.49 6.57 58.82 6.57M72.12 9.01c0.23-0.13 0.69-0.26 1.72-0.26 1.72 0 2.41 0.3 2.41 1.58h2.38c0-0.36 0-0.79-0.03-1.09 -0.23-1.98-2.15-2.67-4.88-2.67 -3 0-6.7 2.31-6.7 7.76 0 5.22 2.77 7.99 6.63 7.99 1.68 0 3.47-0.36 4.95-1.39l-0.2-2.31c-0.99 0.82-2.84 1.52-4.06 1.52 -2.15 0-4.55-1.71-4.55-5.91C69.77 10.2 71.85 9.18 72.12 9.01M92.74 14.13c0-5.18-1.42-7.56-6.01-7.56 -3.86 0-6.67 2.77-6.67 7.92 0 4.92 2.97 7.82 6.73 7.82 2.81 0 4.36-0.63 5.68-1.42l-0.2-2.31c-0.89 0.79-2.94 1.55-4.69 1.55 -3.14 0-4.88-1.95-4.88-5.51v-0.49H92.74M84.59 9.18c0.17-0.17 1.29-0.46 1.98-0.46 2.48 0 3.76 0.53 3.86 3.43h-7.46C83.24 10.27 84.39 9.37 84.59 9.18zM103.9 1.98h-7.13v19.93h6.83c7.26 0 9.77-5.68 9.77-10.03C113.37 7.33 110.93 1.98 103.9 1.98M103.14 19.8h-3.76V4.1h4.09c5.38 0 6.96 4.39 6.96 7.79C110.43 16.87 108.19 19.8 103.14 19.8zM118.38 0.7c-0.92 0-1.65 0.92-1.65 1.81 0 0.93 0.76 1.85 1.65 1.85 0.89 0 1.69-0.96 1.69-1.88C120.07 1.55 119.28 0.7 118.38 0.7"></path><rect x="117.13" y="6.97" fill="#EB6500" width="2.54" height="14.95"></rect><path fill="#EB6500" d="M130.2 6.6c-1.62 0-2.87 1.45-3.4 2.74l-0.43-2.37h-2.34l0.13 1.19c0.1 0.76 0.13 1.75 0.13 2.9v10.86h2.54v-9.51c0.53-1.29 1.72-3.7 3.17-3.7 0.96 0 1.06 0.99 1.06 1.22l2.08-0.6V9.18c0-0.03-0.03-0.17-0.06-0.4C132.8 7.36 131.91 6.6 130.2 6.6M145.87 14.13c0-5.18-1.42-7.56-6.01-7.56 -3.86 0-6.67 2.77-6.67 7.92 0 4.92 2.97 7.82 6.73 7.82 2.81 0 4.36-0.63 5.68-1.42l-0.2-2.31c-0.89 0.79-2.94 1.55-4.69 1.55 -3.14 0-4.89-1.95-4.89-5.51v-0.49H145.87M137.72 9.18c0.17-0.17 1.29-0.46 1.98-0.46 2.48 0 3.76 0.53 3.86 3.43h-7.46C136.37 10.27 137.52 9.37 137.72 9.18zM153.23 9.01c0.23-0.13 0.69-0.26 1.72-0.26 1.72 0 2.41 0.3 2.41 1.58h2.38c0-0.36 0-0.79-0.03-1.09 -0.23-1.98-2.14-2.67-4.88-2.67 -3 0-6.7 2.31-6.7 7.76 0 5.22 2.77 7.99 6.63 7.99 1.69 0 3.47-0.36 4.95-1.39l-0.2-2.31c-0.99 0.82-2.84 1.52-4.06 1.52 -2.15 0-4.55-1.71-4.55-5.91C150.89 10.2 152.97 9.18 153.23 9.01M170 19.44c-0.92 0.36-1.72 0.69-2.51 0.69 -1.16 0-1.58-0.66-1.58-2.34V8.95h3.93V6.97h-3.93V2.97h-2.48v3.99h-2.71v1.98h2.71v9.67c0 2.64 1.39 3.73 3.33 3.73 1.15 0 2.54-0.39 3.43-0.79L170 19.44M173.68 5.96c-1.09 0-2-0.87-2-1.97 0-1.1 0.91-1.97 2-1.97s1.98 0.88 1.98 1.98C175.66 5.09 174.77 5.96 173.68 5.96zM173.67 2.46c-0.85 0-1.54 0.67-1.54 1.52 0 0.85 0.69 1.54 1.54 1.54 0.85 0 1.54-0.69 1.54-1.54C175.21 3.13 174.52 2.46 173.67 2.46zM174.17 5.05c-0.09-0.09-0.17-0.19-0.25-0.3l-0.41-0.56h-0.16v0.87h-0.39V2.92c0.22-0.01 0.47-0.03 0.66-0.03 0.41 0 0.82 0.16 0.82 0.64 0 0.29-0.21 0.55-0.49 0.63 0.23 0.32 0.45 0.62 0.73 0.91H174.17zM173.56 3.22l-0.22 0.01v0.63h0.22c0.26 0 0.43-0.05 0.43-0.34C174 3.28 173.83 3.21 173.56 3.22z"></path></g></svg></a><div class="gh-nav-cnt u-hide-from-print"><div class="gh-nav-links-container gh-nav-links-container-h u-hide-from-print gh-nav-content-container"><nav aria-label="links" class="gh-nav gh-nav-links gh-nav-h"><ul class="gh-nav-list u-list-reset"><li class="gh-nav-item gh-move-to-spine"><a class="anchor gh-nav-action text-s anchor-secondary anchor-medium" href="/browse/journals-and-books" id="gh-journals-books-link" data-aa-region="header" data-aa-name="Journals &amp; Books"><span class="anchor-text-container"><span class="anchor-text">Journals &amp; Books</span></span></a></li></ul></nav><nav aria-label="utilities" class="gh-nav gh-nav-utilities gh-nav-h"><ul class="gh-nav-list u-list-reset"><li class="gh-nav-help text-s u-flex-center-ver u-gap-6 gh-nav-action"><div class="gh-move-to-spine gh-help-button gh-help-icon gh-nav-item"><div class="popover" id="gh-help-icon-popover"><div id="popover-trigger-gh-help-icon-popover"><input type="hidden"><button class="button-link button-link-secondary gh-icon-btn button-link-medium button-link-icon-left" type="button" aria-expanded="false" title="Help"><svg focusable="false" viewBox="0 0 114 128" height="20" width="20" class="icon icon-help gh-icon"><path d="M57 8C35.69 7.69 15.11 21.17 6.68 40.71c-8.81 19.38-4.91 43.67 9.63 59.25 13.81 15.59 36.85 21.93 56.71 15.68 21.49-6.26 37.84-26.81 38.88-49.21 1.59-21.15-10.47-42.41-29.29-52.1C74.76 10.17 65.88 7.99 57 8zm0 10c20.38-.37 39.57 14.94 43.85 34.85 4.59 18.53-4.25 39.23-20.76 48.79-17.05 10.59-40.96 7.62-54.9-6.83-14.45-13.94-17.42-37.85-6.83-54.9C26.28 26.5 41.39 17.83 57 18zm-.14 14C45.31 32.26 40 40.43 40 50v2h10v-2c0-4.22 2.22-9.66 8-9.24 5.5.4 6.32 5.14 5.78 8.14C62.68 55.06 52 58.4 52 69.4V76h10v-5.56c0-8.16 11.22-11.52 12-21.7.74-9.86-5.56-16.52-16-16.74-.39-.01-.76-.01-1.14 0zM52 82v10h10V82H52z"></path></svg></button></div></div></div></li><li class="gh-nav-search text-s u-flex-center-ver u-gap-6 gh-nav-action"><div class="gh-search-toggle gh-nav-item search-button-link"><a class="anchor button-link-secondary anchor-secondary u-margin-l-left gh-nav-action gh-icon-btn anchor-medium anchor-icon-left anchor-with-icon" href="/search" id="gh-search-link" data-aa-button="search-in-header-opened-from-article" role="button" title="Search"><svg focusable="false" viewBox="0 0 100 128" height="20" class="icon icon-search gh-icon"><path d="M19.22 76.91c-5.84-5.84-9.05-13.6-9.05-21.85s3.21-16.01 9.05-21.85c5.84-5.83 13.59-9.05 21.85-9.05 8.25 0 16.01 3.22 21.84 9.05 5.84 5.84 9.05 13.6 9.05 21.85s-3.21 16.01-9.05 21.85c-5.83 5.83-13.59 9.05-21.84 9.05-8.26 0-16.01-3.22-21.85-9.05zm80.33 29.6L73.23 80.19c5.61-7.15 8.68-15.9 8.68-25.13 0-10.91-4.25-21.17-11.96-28.88-7.72-7.71-17.97-11.96-28.88-11.96S19.9 18.47 12.19 26.18C4.47 33.89.22 44.15.22 55.06s4.25 21.17 11.97 28.88C19.9 91.65 30.16 95.9 41.07 95.9c9.23 0 17.98-3.07 25.13-8.68l26.32 26.32 7.03-7.03"></path></svg></a></div></li></ul></nav></div></div><div class="gh-profile-container gh-move-to-spine u-hide-from-print"><a class="anchor text-s u-clr-grey8 u-margin-l-left gh-icon-btn anchor-primary anchor-medium anchor-icon-left anchor-with-icon" href="/user/login?targetURL=%2Fscience%2Farticle%2Fpii%2FS0003496725010416&amp;from=globalheader" id="gh-myaccount-btn" data-aa-region="header" data-aa-name="personalsignin" title="My account"><svg focusable="false" viewBox="0 0 106 128" height="20" aria-hidden="true" class="icon icon-person gh-cta-btn-icon"><path d="M11.07 120l.84-9.29C13.88 91.92 35.25 87.78 53 87.78c17.74 0 39.11 4.13 41.08 22.84l.84 9.38h10.04l-.93-10.34C101.88 89.23 83.89 78 53 78S4.11 89.22 1.95 109.73L1.04 120h10.03M53 17.71c-9.72 0-18.24 8.69-18.24 18.59 0 13.67 7.84 23.98 18.24 23.98S71.24 49.97 71.24 36.3c0-9.9-8.52-18.59-18.24-18.59zM53 70c-15.96 0-28-14.48-28-33.67C25 20.97 37.82 8 53 8s28 12.97 28 28.33C81 55.52 68.96 70 53 70"></path></svg></a></div><a class="anchor text-s u-clr-grey8 gh-move-to-spine u-hide-from-print u-margin-l-left anchor-secondary gh-icon-btn anchor-medium anchor-icon-left anchor-with-icon" href="/user/institution/login?targetURL=%2Fscience%2Farticle%2Fpii%2FS0003496725010416" id="gh-institutionalsignin-btn" data-aa-region="header" data-aa-name="institutionalsignin" title="Sign In"><svg focusable="false" viewBox="0 0 106 128" height="20" aria-hidden="true" class="icon icon-institution gh-cta-btn-icon"><path d="M84 98h10v10H12V98h10V52h14v46h10V52h14v46h10V52h14v46zM12 36.86l41-20.84 41 20.84V42H12v-5.14zM104 52V30.74L53 4.8 2 30.74V52h10v36H2v30h102V88H94V52h10z"></path></svg></a><div id="gh-mobile-menu" class="mobile-menu u-hide-from-print"><div class="gh-hamburger u-fill-grey7"><button class="button-link u-flex-center-ver button-link-primary button-link-icon-left" type="button" aria-label="Toggle mobile menu" aria-expanded="false"><svg class="gh-hamburger-svg-el gh-hamburger-closed" role="img" aria-hidden="true" height="20" width="20"><path d="M0 14h40v2H0zm0-7h40v2H0zm0-7h40v2H0z"></path></svg></button></div><div id="gh-overlay" class="mobile-menu-overlay u-overlay u-display-none" role="button" tabindex="-1"></div><div id="gh-drawer" aria-label="Mobile menu" class="" role="navigation"></div></div></div></header><div id="sd-ai-navigation-container"></div><div id="reading-assistant-main-body-section"></div><div class="Article" id="mathjax-container" role="main"><div class="accessbar-sticky"><div id="screen-reader-main-content"></div><div role="region" aria-label="Download options and search"><div class="accessbar"><div class="accessbar-label"></div><ul aria-label="PDF Options"><li class="ViewPDF"><a class="link-button accessbar-utility-component accessbar-utility-link link-button-primary link-button-icon-left" target="_blank" aria-label="View PDF. Opens in a new window." href="/science/article/pii/S0003496725010416/pdfft?md5=c45412591fe7fc561cc3fd8321a841ed&amp;pid=1-s2.0-S0003496725010416-main.pdf" rel="nofollow"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
                1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
                .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
                1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
                2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
                2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
                2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
                24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
                1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
                2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
                1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="link-button-text-container"><span class="link-button-text"><span>View&nbsp;<strong>PDF</strong></span></span></span></a></li><li class="DownloadFullIssue"><button class="button-link accessbar-utility-component button-link-primary" type="button" aria-label="Download full issue"><span class="button-link-text-container"><span class="button-link-text"><span>Download full issue</span></span></span></button></li></ul><form class="QuickSearch" action="/search#submit" method="get" aria-label="form"><div class="text-input"><div class="text-input-container text-input-container-no-label"><label class="text-input-label u-hide-visually" for="article-quick-search">Search ScienceDirect</label><input type="search" id="article-quick-search" name="qs" class="text-input-field" aria-describedby="article-quick-search-description-message " aria-invalid="false" aria-label="Search ScienceDirect" placeholder="Search ScienceDirect" value=""></div><div class="text-input-message-container"><div class="text-input-validation-error" aria-live="polite"></div><div id="article-quick-search-description-message"></div></div></div><button type="submit" class="button u-margin-xs-left button-primary small button-icon-only" aria-disabled="false" aria-label="Submit search"><svg focusable="false" viewBox="0 0 100 128" height="20" class="icon icon-search"><path d="M19.22 76.91c-5.84-5.84-9.05-13.6-9.05-21.85s3.21-16.01 9.05-21.85c5.84-5.83 13.59-9.05 21.85-9.05 8.25 0 16.01 3.22 21.84 9.05 5.84 5.84 9.05 13.6 9.05 21.85s-3.21 16.01-9.05 21.85c-5.83 5.83-13.59 9.05-21.84 9.05-8.26 0-16.01-3.22-21.85-9.05zm80.33 29.6L73.23 80.19c5.61-7.15 8.68-15.9 8.68-25.13 0-10.91-4.25-21.17-11.96-28.88-7.72-7.71-17.97-11.96-28.88-11.96S19.9 18.47 12.19 26.18C4.47 33.89.22 44.15.22 55.06s4.25 21.17 11.97 28.88C19.9 91.65 30.16 95.9 41.07 95.9c9.23 0 17.98-3.07 25.13-8.68l26.32 26.32 7.03-7.03"></path></svg></button><input type="hidden" name="origin" value="article"><input type="hidden" name="zone" value="qSearch"></form></div></div></div><div class="article-wrapper grid row"><div role="navigation" class="u-display-block-from-lg col-lg-6 u-padding-s-top sticky-table-of-contents" aria-label="Table of contents"><div class="TableOfContents" lang="en"><div id="reading-assistant-container"></div><div class="Outline" id="toc-outline"><h2 class="u-h4">Outline</h2><ol class="u-padding-xs-bottom"><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#abs0001" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="ABSTRACT"><span class="anchor-text-container"><span class="anchor-text">ABSTRACT</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#abs0002" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Graphical abstract"><span class="anchor-text-container"><span class="anchor-text">Graphical abstract</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0004" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="INTRODUCTION"><span class="anchor-text-container"><span class="anchor-text">INTRODUCTION</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0005" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="METHODS"><span class="anchor-text-container"><span class="anchor-text">METHODS</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0014" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="RESULTS"><span class="anchor-text-container"><span class="anchor-text">RESULTS</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0018" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="DISCUSSION"><span class="anchor-text-container"><span class="anchor-text">DISCUSSION</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0003a" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="CRediT authorship contribution statement"><span class="anchor-text-container"><span class="anchor-text">CRediT authorship contribution statement</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#coi0001" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Competing interests"><span class="anchor-text-container"><span class="anchor-text">Competing interests</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0019" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Acknowledgements"><span class="anchor-text-container"><span class="anchor-text">Acknowledgements</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0020" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Funding"><span class="anchor-text-container"><span class="anchor-text">Funding</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0021" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Patient consent for publication"><span class="anchor-text-container"><span class="anchor-text">Patient consent for publication</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0022" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Ethics approval"><span class="anchor-text-container"><span class="anchor-text">Ethics approval</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0023" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Provenance and peer review"><span class="anchor-text-container"><span class="anchor-text">Provenance and peer review</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0024" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Data availability statement"><span class="anchor-text-container"><span class="anchor-text">Data availability statement</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0025" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Previous publications"><span class="anchor-text-container"><span class="anchor-text">Previous publications</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0027" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Appendix. Supplementary materials"><span class="anchor-text-container"><span class="anchor-text">Appendix. Supplementary materials</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#cebibl1" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="REFERENCES"><span class="anchor-text-container"><span class="anchor-text">REFERENCES</span></span></a></li></ol><button class="button-link u-margin-xs-top u-margin-s-bottom button-link-primary button-link-icon-right" type="button" aria-expanded="false" data-aa-button="sd:product:journal:article:type=menu:name=show-full-outline"><span class="button-link-text-container"><span class="button-link-text">Show full outline</span></span><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-navigate-down"><path d="M1 51l7-7 38 38 38-38 7 7-45 45z"></path></svg></button><div class="PageDivider"></div></div><div class="CitedBy" id="toc-cited-by"><h2 class="u-h4"><a class="anchor anchor-primary" href="#section-cited-by"><span class="anchor-text-container"><span class="anchor-text">Cited by (1)</span></span></a></h2><div class="PageDivider"></div></div><div class="Figures" id="toc-figures"><h2 class="u-h4">Figures (6)</h2><ol class="u-margin-s-bottom"><li><a class="anchor u-display-block anchor-primary anchor-icon-only anchor-with-icon" href="#fig0006" data-aa-button="sd:product:journal:article:type=anchor:name=figure"><img alt="Unlabelled figure" class="u-display-block" height="122px" src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-ga1.sml" width="219px"></a></li><li><a class="anchor u-display-block anchor-primary anchor-icon-only anchor-with-icon" href="#fig0001" data-aa-button="sd:product:journal:article:type=anchor:name=figure"><img alt="Figure 1. Patient disposition" class="u-display-block" height="164px" src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr1.sml" width="172px"></a></li><li><a class="anchor u-display-block anchor-primary anchor-icon-only anchor-with-icon" href="#fig0002" data-aa-button="sd:product:journal:article:type=anchor:name=figure"><img alt="Figure 2. ACR20, ACR50, and ACR70 responses at week 12 (FAS)" class="u-display-block" height="117px" src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr2.sml" width="219px"></a></li><li><a class="anchor u-display-block anchor-primary anchor-icon-only anchor-with-icon" href="#fig0003" data-aa-button="sd:product:journal:article:type=anchor:name=figure"><img alt="Figure 3. A, LS mean change from baseline to week 12 in PASIa scores" class="u-display-block" height="164px" src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr3.sml" width="140px"></a></li><li><a class="anchor u-display-block anchor-primary anchor-icon-only anchor-with-icon" href="#fig0004" data-aa-button="sd:product:journal:article:type=anchor:name=figure"><img alt="Figure 4. A, Proportion of patients achieving MDA" class="u-display-block" height="163px" src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr4.sml" width="128px"></a></li><li><a class="anchor u-display-block anchor-primary anchor-icon-only anchor-with-icon" href="#fig0005" data-aa-button="sd:product:journal:article:type=anchor:name=figure"><img alt="Figure 5. Key laboratory parameter changes over 16 weeks (SAS)" class="u-display-block" height="163px" src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr5.sml" width="151px"></a></li></ol><div class="PageDivider"></div></div><div class="Tables" id="toc-tables"><h2 class="u-h4">Tables (3)</h2><ol class="u-padding-s-bottom"><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary anchor-icon-left anchor-with-icon" href="#tbl0001" data-aa-button="sd:product:journal:article:type=anchor:name=table" title="Baseline demographics and disease characteristics (FAS)"><svg focusable="false" viewBox="0 0 98 128" height="20" class="icon icon-table"><path d="M54 68h32v32H54V68zm-42 0h32v32H12V68zm0-42h32v32H12V26zm42 0h32v32H54V26zM2 110h94V16H2v94z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Table 1</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary anchor-icon-left anchor-with-icon" href="#tbl0002" data-aa-button="sd:product:journal:article:type=anchor:name=table" title="Number of patients with TEAEs, reported by treatment group (SAS)"><svg focusable="false" viewBox="0 0 98 128" height="20" class="icon icon-table"><path d="M54 68h32v32H54V68zm-42 0h32v32H12V68zm0-42h32v32H12V26zm42 0h32v32H54V26zM2 110h94V16H2v94z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Table 2</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary anchor-icon-left anchor-with-icon" href="#tbl0003" data-aa-button="sd:product:journal:article:type=anchor:name=table" title="Laboratory parameters: shift from baseline to postbaseline visits (SAS)"><svg focusable="false" viewBox="0 0 98 128" height="20" class="icon icon-table"><path d="M54 68h32v32H54V68zm-42 0h32v32H12V68zm0-42h32v32H12V26zm42 0h32v32H54V26zM2 110h94V16H2v94z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Table 3</span></span></a></li></ol><div class="PageDivider"></div></div><div class="Extras" id="toc-extras"><h2 class="u-h4">Extras (7)</h2><ol class="u-padding-s-bottom"><li><span class="download-all-supplemental-data"><span class="in-toc"><iframe title="download_all" name="download_all" class="u-hide"></iframe><form method="post" action="/sdfe/pdf/download/S0003496725010416/attachments" target="download_all"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc1.mp4"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc2.pptx"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc3.docx"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc4_lrg.jpg"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc4.jpg"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc5_lrg.jpg"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc5.jpg"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc6_lrg.jpg"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc6.jpg"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc7_lrg.jpg"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc7.jpg"><button class="button-link download-all-button u-font-sans u-margin-xs-bottom button-link-primary button-link-icon-left" type="submit"><svg focusable="false" viewBox="0 0 98 128" height="20" class="icon icon-download"><path d="M77.38 56.18l-6.6-7.06L54 66.36V26H44v40.34L26.28 49.1l-7.3 7.08 29.2 29.32 29.2-29.32M88 74v20H10V74H0v30h98V74H88"></path></svg><span class="button-link-text-container"><span class="button-link-text"><span class="download-all-title">Download all </span></span></span></button></form></span></span></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary anchor-icon-left anchor-with-icon" href="#ecom0001" data-aa-button="sd:product:journal:article:type=anchor:region=outline:name=sdf" title="Video"><svg focusable="false" viewBox="0 0 120 128" height="20" class="icon icon-video-camera"><path d="M26 76h46v10H26V76zm82 8.24l-12-4.92V64.68l12-4.92v24.48zM111.8 48c-.86 0-1.72.17-2.56.51L96 53.94V53c0-8.28-6.72-15-15-15h-5.2l-5.62-16.6a4.986 4.986 0 0 0-4.74-3.4H16v10h45.86l6.78 20H81c2.76 0 5 2.24 5 5v40c0 2.76-2.24 5-5 5H17c-2.76 0-5-2.24-5-5V53c0-2.76 2.24-5 5-5h41.08l-3.4-10H17C8.72 38 2 44.72 2 53v40c0 8.28 6.72 15 15 15h64c8.28 0 15-6.72 15-15v-2.94l13.24 5.43c.84.34 1.7.51 2.56.51 3.48 0 6.2-2.78 6.2-6.33V54.33c0-3.55-2.72-6.33-6.2-6.33"></path></svg><span class="anchor-text-container"><span class="anchor-text">Video</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary anchor-icon-left anchor-with-icon" href="#ecom0002" data-aa-button="sd:product:journal:article:type=anchor:region=outline:name=sdf" title="Slideshow"><svg focusable="false" viewBox="0 0 118 128" height="20" class="icon icon-audio-slides"><path d="M106 84H30V26h76v58zM20 16v78h96V16H20zm32 56l34-17-34-17zm46 30H12V34H2v78h96z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Slideshow</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary anchor-icon-left anchor-with-icon" href="#ecom0003" data-aa-button="sd:product:journal:article:type=anchor:region=outline:name=sdf" title="Document"><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-text-document"><path d="M1 10v108h57.22L91 85.09V10H1m80 70.96L54.07 108H11V20h70v60.96zM43 100h10V80h20V70H43v30M25 32h42v10H25V32zm0 18h42v10H25V50z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Document</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary anchor-icon-left anchor-with-icon" href="#ecom0004" data-aa-button="sd:product:journal:article:type=anchor:region=outline:name=sdf" title="Image"><svg focusable="false" viewBox="0 0 106 128" height="20" class="icon icon-picture"><path d="M37 53a9 9 0 1 1-18.001-.001A9 9 0 0 1 37 53m-2.34 35l8.14-10.89 8.62 5.62 9.93-15.23L72.83 88h11.15L61.99 48.72 48.58 69.27l-8.12-5.29L22.52 88h12.14M11 96h84V36H11v60zM1 26h104v80H1V26z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Image</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary anchor-icon-left anchor-with-icon" href="#ecom0005" data-aa-button="sd:product:journal:article:type=anchor:region=outline:name=sdf" title="Image"><svg focusable="false" viewBox="0 0 106 128" height="20" class="icon icon-picture"><path d="M37 53a9 9 0 1 1-18.001-.001A9 9 0 0 1 37 53m-2.34 35l8.14-10.89 8.62 5.62 9.93-15.23L72.83 88h11.15L61.99 48.72 48.58 69.27l-8.12-5.29L22.52 88h12.14M11 96h84V36H11v60zM1 26h104v80H1V26z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Image</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary anchor-icon-left anchor-with-icon" href="#ecom0006" data-aa-button="sd:product:journal:article:type=anchor:region=outline:name=sdf" title="Image"><svg focusable="false" viewBox="0 0 106 128" height="20" class="icon icon-picture"><path d="M37 53a9 9 0 1 1-18.001-.001A9 9 0 0 1 37 53m-2.34 35l8.14-10.89 8.62 5.62 9.93-15.23L72.83 88h11.15L61.99 48.72 48.58 69.27l-8.12-5.29L22.52 88h12.14M11 96h84V36H11v60zM1 26h104v80H1V26z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Image</span></span></a></li></ol><button class="button-link u-margin-xs-top u-margin-s-bottom button-link-primary button-link-icon-right" type="button" data-aa-button="sd:product:journal:article:type=menu:name=show-extras"><span class="button-link-text-container"><span class="button-link-text">Show all extras</span></span><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-navigate-down"><path d="M1 51l7-7 38 38 38-38 7 7-45 45z"></path></svg></button><div class="PageDivider"></div></div></div></div><article class="col-lg-12 col-md-16 pad-left pad-right u-padding-s-top" lang="en"><div class="Publication" id="publication"><div class="publication-brand u-display-block-from-sm"><a class="anchor u-display-flex anchor-primary" href="/journal/annals-of-the-rheumatic-diseases" title="Go to Annals of the Rheumatic Diseases on ScienceDirect"><span class="anchor-text-container"><span class="anchor-text"><img class="publication-brand-image" src="/us-east-1/prod/2d348b415dc48b7aaa2f48d669a232bb69813c31/image/elsevier-non-solus.svg" alt="Elsevier"></span></span></a></div><div class="publication-volume u-text-center"><h2 class="publication-title u-h3" id="publication-title"><a class="anchor anchor-secondary publication-title-link" href="/journal/annals-of-the-rheumatic-diseases" title="Go to Annals of the Rheumatic Diseases on ScienceDirect"><span class="anchor-text-container"><span class="anchor-text">Annals of the Rheumatic Diseases</span></span></a></h2><div class="text-xs"><a class="anchor anchor-primary" href="/journal/annals-of-the-rheumatic-diseases/vol/84/issue/10" title="Go to table of contents for this volume/issue"><span class="anchor-text-container"><span class="anchor-text">Volume 84, Issue 10</span></span></a>, <!-- -->October 2025<!-- -->, Pages 1660-1674</div></div><div class="publication-cover u-display-block-from-sm"><a class="anchor u-display-flex anchor-primary" href="/journal/annals-of-the-rheumatic-diseases/vol/84/issue/10"><span class="anchor-text-container"><span class="anchor-text"><img class="publication-cover-image" src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725X00121-cov150h.gif" alt="Annals of the Rheumatic Diseases"></span></span></a></div></div><h1 id="screen-reader-main-title" class="Head u-font-serif u-h2 u-margin-s-ver"><div class="article-dochead"><span>Psoriatic arthritis</span></div><span class="title-text">Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study</span></h1><div class="Banner" id="banner"><div class="wrapper truncated"><div aria-live="polite"></div><div class="AuthorGroups"><div class="author-group" id="author-group"><span class="sr-only">Author links open overlay panel</span><button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0001" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Alan</span> <span class="text surname">Kivitz</span> </span><span class="author-ref" id="baff0001"><sup>1</sup></span> <span class="author-ref" id="bfn1"><sup>a</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0002" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Xenofon</span> <span class="text surname">Baraliakos</span> </span><span class="author-ref" id="baff0002"><sup>2</sup></span> <span class="author-ref" id="bfn1"><sup>a</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0003" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Elena Tomaselli</span> <span class="text surname">Muensterman</span> </span><span class="author-ref" id="baff0003"><sup>3</sup></span><svg focusable="false" viewBox="0 0 106 128" height="20" title="Correspondence author icon" class="icon icon-person react-xocs-author-icon u-fill-grey8"><path d="M11.07 120l.84-9.29C13.88 91.92 35.25 87.78 53 87.78c17.74 0 39.11 4.13 41.08 22.84l.84 9.38h10.04l-.93-10.34C101.88 89.23 83.89 78 53 78S4.11 89.22 1.95 109.73L1.04 120h10.03M53 17.71c-9.72 0-18.24 8.69-18.24 18.59 0 13.67 7.84 23.98 18.24 23.98S71.24 49.97 71.24 36.3c0-9.9-8.52-18.59-18.24-18.59zM53 70c-15.96 0-28-14.48-28-33.67C25 20.97 37.82 8 53 8s28 12.97 28 28.33C81 55.52 68.96 70 53 70"></path></svg><svg focusable="false" viewBox="0 0 102 128" height="20" title="Author email or social media contact details icon" class="icon icon-envelope react-xocs-author-icon u-fill-grey8"><path d="M55.8 57.2c-1.78 1.31-5.14 1.31-6.9 0L17.58 34h69.54L55.8 57.19zM0 32.42l42.94 32.62c2.64 1.95 6.02 2.93 9.4 2.93s6.78-.98 9.42-2.93L102 34.34V24H0zM92 88.9L73.94 66.16l-8.04 5.95L83.28 94H18.74l18.38-23.12-8.04-5.96L10 88.94V51.36L0 42.9V104h102V44.82l-10 8.46V88.9"></path></svg></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0004" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Arthur</span> <span class="text surname">Kavanaugh</span> </span><span class="author-ref" id="baff0004"><sup>4</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0005" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">D¨¦sir¨¦e</span> <span class="text surname">van der Heijde</span> </span><span class="author-ref" id="baff0005"><sup>5</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0006" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Piotr A</span> <span class="text surname">Klimiuk</span> </span><span class="author-ref" id="baff0006"><sup>6</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0007" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Guillermo</span> <span class="text surname">Valenzuela</span> </span><span class="author-ref" id="baff0007"><sup>7</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0008" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Eva</span> <span class="text surname">Dokoupilova</span> </span><span class="author-ref" id="baff0008"><sup>8</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0009" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Gabrielle</span> <span class="text surname">Poirier</span> </span><span class="author-ref" id="baff0009"><sup>9</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0010" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Bhaskar</span> <span class="text surname">Srivastava</span> </span><span class="author-ref" id="baff0009"><sup>9</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0011" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Sue</span> <span class="text surname">Dasen</span> </span><span class="author-ref" id="baff0009"><sup>9</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0012" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Xinyan</span> <span class="text surname">Zhang</span> </span><span class="author-ref" id="baff0009"><sup>9</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0013" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Ting</span> <span class="text surname">Hong</span> </span><span class="author-ref" id="baff0003"><sup>3</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0014" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Jingjing</span> <span class="text surname">Chen</span> </span><span class="author-ref" id="baff0003"><sup>3</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0015" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Peter</span> <span class="text surname">Pothula</span> </span><span class="author-ref" id="baff0003"><sup>3</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0016" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Haoling Holly</span> <span class="text surname">Weng</span> </span><span class="author-ref" id="baff0010"><sup>10</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0017" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Mona</span> <span class="text surname">Trivedi</span> </span><span class="author-ref" id="baff0003"><sup>3</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0018" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Apinya</span> <span class="text surname">Lertratanakul</span> </span><span class="author-ref" id="baff0003"><sup>3</sup></span></span></span></button></div></div></div><button class="button-link u-margin-s-ver button-link-primary button-link-icon-right" type="button" id="show-more-btn" data-aa-button="icon-expand"><span class="button-link-text-container"><span class="button-link-text">Show more</span></span><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-navigate-down"><path d="M1 51l7-7 38 38 38-38 7 7-45 45z"></path></svg></button><div class="banner-options u-padding-xs-bottom"><div class="toc-button-wrap u-display-inline-block u-display-none-from-lg u-margin-s-right"><button class="button-link button-link-secondary button-link-icon-left button-link-has-colored-icon" type="button"><svg focusable="false" viewBox="0 0 128 128" height="20" class="icon icon-list"><path d="M23 26a9 9 0 0 0-9 9 9 9 0 0 0 9 9 9 9 0 0 0 9-9 9 9 0 0 0-9-9zm23 4v10h68V30zM23 56a9 9 0 0 0-9 9 9 9 0 0 0 9 9 9 9 0 0 0 9-9 9 9 0 0 0-9-9zm23 4v10h68V60zM23 86a9 9 0 0 0-9 9 9 9 0 0 0 9 9 9 9 0 0 0 9-9 9 9 0 0 0-9-9zm23 4v10h68V90z"></path></svg><span class="button-link-text-container"><span class="button-link-text">Outline</span></span></button></div><button class="button-link AddToMendeley button-link-secondary u-margin-s-right u-display-inline-flex-from-md button-link-icon-left button-link-has-colored-icon" type="button"><svg focusable="false" viewBox="0 0 86 128" height="20" class="icon icon-plus"><path d="M48 58V20H38v38H0v10h38v38h10V68h38V58z"></path></svg><span class="button-link-text-container"><span class="button-link-text">Add to Mendeley</span></span></button><div class="Social u-display-inline-block" id="social"><div class="popover social-popover" id="social-popover"><div id="popover-trigger-social-popover"><button class="button-link button-link-secondary u-margin-s-right button-link-icon-left button-link-has-colored-icon" type="button" aria-expanded="false" aria-haspopup="true"><svg focusable="false" viewBox="0 0 114 128" height="20" class="icon icon-share"><path d="M90 112c-6.62 0-12-5.38-12-12s5.38-12 12-12 12 5.38 12 12-5.38 12-12 12zM24 76c-6.62 0-12-5.38-12-12s5.38-12 12-12 12 5.38 12 12-5.38 12-12 12zm66-60c6.62 0 12 5.38 12 12s-5.38 12-12 12-12-5.38-12-12 5.38-12 12-12zm0 62c-6.56 0-12.44 2.9-16.48 7.48L45.1 70.2c.58-1.98.9-4.04.9-6.2s-.32-4.22-.9-6.2l28.42-15.28C77.56 47.1 83.44 50 90 50c12.14 0 22-9.86 22-22S102.14 6 90 6s-22 9.86-22 22c0 1.98.28 3.9.78 5.72L40.14 49.1C36.12 44.76 30.38 42 24 42 11.86 42 2 51.86 2 64s9.86 22 22 22c6.38 0 12.12-2.76 16.14-7.12l28.64 15.38c-.5 1.84-.78 3.76-.78 5.74 0 12.14 9.86 22 22 22s22-9.86 22-22-9.86-22-22-22z"></path></svg><span class="button-link-text-container"><span class="button-link-text">Share</span></span></button></div></div></div><div class="ExportCitation u-display-inline-block" id="export-citation"><div class="popover export-citation-popover" id="export-citation-popover"><div id="popover-trigger-export-citation-popover"><button class="button-link button-link-secondary button-link-icon-left button-link-has-colored-icon" type="button" aria-expanded="false" aria-haspopup="true"><svg focusable="false" viewBox="0 0 104 128" height="20" class="icon icon-cited-by-66"><path d="M2 58.78V106h44V64H12v-5.22C12 40.28 29.08 32 46 32V22C20.1 22 2 37.12 2 58.78zM102 32V22c-25.9 0-44 15.12-44 36.78V106h44V64H68v-5.22C68 40.28 85.08 32 102 32z"></path></svg><span class="button-link-text-container"><span class="button-link-text">Cite</span></span></button></div></div></div></div></div><div class="ArticleIdentifierLinks u-margin-xs-bottom text-xs" id="article-identifier-links"><a class="anchor doi anchor-primary" href="https://doi.org/10.1016/j.ard.2025.05.023" target="_blank" rel="noreferrer noopener" aria-label="Persistent link using digital object identifier" title="Persistent link using digital object identifier"><span class="anchor-text-container"><span class="anchor-text">https://doi.org/10.1016/j.ard.2025.05.023</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor rights-and-content anchor-primary" href="https://s100.copyright.com/AppDispatchServlet?publisherName=ELS&amp;contentID=S0003496725010416&amp;orderBeanReset=true" target="_blank" rel="noreferrer noopener"><span class="anchor-text-container"><span class="anchor-text">Get rights and content</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div><div class="LicenseInfo text-xs u-margin-xs-bottom"><div class="License"><span>Under a Creative Commons </span><a class="anchor anchor-primary" href="http://creativecommons.org/licenses/by/4.0/" target="_blank" rel="noreferrer noopener"><span class="anchor-text-container"><span class="anchor-text">license</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div><div class="AccessLabel"><span class="access-indicator"></span>Open access</div></div><section class="ReferencedArticles"></section><section class="ReferencedArticles"></section><div class="PageDivider"></div><div class="Abstracts u-font-serif" id="abstracts"><div class="abstract author" id="abs0001"><h2 class="section-title u-h4 u-margin-l-top u-margin-xs-bottom">ABSTRACT</h2><div id="abss0001"><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom" id="cesectitle0002">Objectives</h3><div class="u-margin-s-bottom" id="spara016"><span>To assess the efficacy, safety, and <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/tolerability" title="Learn more about tolerability from ScienceDirect's AI-generated Topic Pages" class="topic-link">tolerability</a><span> of the investigational, oral, allosteric, highly selective, and potent <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/protein-tyrosine-kinase" title="Learn more about tyrosine kinase from ScienceDirect's AI-generated Topic Pages" class="topic-link">tyrosine kinase</a> 2 inhibitor zasocitinib (TAK-279) in patients with active </span></span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/psoriatic-arthritis" title="Learn more about psoriatic arthritis from ScienceDirect's AI-generated Topic Pages" class="topic-link">psoriatic arthritis</a> (PsA).</div></div><div id="abss0002"><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom" id="cesectitle0003">Methods</h3><div class="u-margin-s-bottom" id="spara017"><span>In this phase 2b, randomised, multicentre, double-blind, placebo-controlled, multiple-dose study, patients (¡Ý18 years, with PsA symptoms for ¡Ý6 months) received 30 mg, 15 mg, or 5 mg zasocitinib or placebo (1:1:1:1) once daily for 12 weeks, with a 4-week safety follow-up. The primary endpoint was American College of Rheumatology (ACR)20 response at week 12. Secondary efficacy endpoints included ACR50 response, ACR70 response, <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/psoriasis" title="Learn more about Psoriasis from ScienceDirect's AI-generated Topic Pages" class="topic-link">Psoriasis</a> Area and Severity Index (PASI) 75 response among those with ¡Ý3% body surface area at baseline and minimal </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/disease-activity" title="Learn more about disease activity from ScienceDirect's AI-generated Topic Pages" class="topic-link">disease activity</a> (MDA) at week 12.</div></div><div id="abss0003"><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom" id="cesectitle0004">Results</h3><div class="u-margin-s-bottom" id="spara018">Overall, 290 patients (mean [SD] age, 49.9 [11.6] years; 57.2% female) received treatment. At week 12, 30 mg or 15 mg zasocitinib treatment resulted in significantly higher ACR20 responses (54.2%; <em>P</em> = .002 and 53.3%; <em>P</em> = .002, respectively) than placebo (29.2%). A numerically higher number of ACR50 responses were achieved at week 12 with 30 mg (26.4%; nominal <em>P</em> = .009) or 15 mg (26.7%; nominal <em>P</em> = .005) zasocitinib than placebo (9.7%). In addition, 30 mg zasocitinib demonstrated a numerically higher number of ACR70 responses (13.9% versus 5.6%, respectively; nominal <em>P</em> = .158), PASI 75 responses (45.7% versus 15.4%, respectively; nominal <em>P</em> = .002), and MDA (29.2% versus 12.5%, respectively; nominal <em>P</em><span> = .014) at week 12 versus placebo. In this small study of limited duration, most <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/adverse-event" title="Learn more about adverse events from ScienceDirect's AI-generated Topic Pages" class="topic-link">adverse events</a> were mild/moderate and were more frequently observed in the higher dose group. In this small sample size, no new safety signals or clear dose-dependent laboratory parameter changes were identified.</span></div></div><div id="abss0004"><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom" id="cesectitle0005">Conclusions</h3><div class="u-margin-s-bottom" id="spara019">Here, 30 mg and 15 mg zasocitinib demonstrated efficacy across core domains in patients with active PsA with no new safety signals. These findings will be confirmed in ongoing larger studies of longer duration.</div></div></div><div class="abstract graphical" id="abs0002"><h2 class="section-title u-h4 u-margin-l-top u-margin-xs-bottom">Graphical abstract</h2><div id="abss0005"><div class="u-margin-s-bottom" id="spara020"><span class="display"><figure class="figure text-xs" id="fig0006"><span><img src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-ga1.jpg" height="200" alt="Image, graphical abstract"><ol class="u-margin-s-bottom"><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-ga1_lrg.jpg" target="_blank" download="" title="Download high-res image (403KB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download high-res image (403KB)</span></span></span></a></li><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-ga1.jpg" target="_blank" download="" title="Download full-size image"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download full-size image</span></span></span></a></li></ol></span></figure></span></div></div></div></div><ul id="issue-navigation" class="issue-navigation u-margin-s-bottom u-bg-grey1"><li class="previous move-left u-padding-s-ver u-padding-s-left"><a class="button-alternative button-alternative-tertiary u-display-flex button-alternative-icon-left" href="/science/article/pii/S000349672504244X"><svg focusable="false" viewBox="0 0 54 128" height="20" class="icon icon-navigate-left"><path d="M1 61l45-45 7 7-38 38 38 38-7 7z"></path></svg><span class="button-alternative-text-container"><span class="button-alternative-text">Previous <span class="extra-detail-1">article</span><span class="extra-detail-2"> in issue</span></span></span></a></li><li class="next move-right u-padding-s-ver u-padding-s-right"><a class="button-alternative button-alternative-tertiary u-display-flex button-alternative-icon-right" href="/science/article/pii/S000349672504186X"><span class="button-alternative-text-container"><span class="button-alternative-text">Next <span class="extra-detail-1">article</span><span class="extra-detail-2"> in issue</span></span></span><svg focusable="false" viewBox="0 0 54 128" height="20" class="icon icon-navigate-right"><path d="M1 99l38-38L1 23l7-7 45 45-45 45z"></path></svg></a></li></ul><div class="Body u-font-serif" id="body"><div><div class="u-margin-s-bottom" id="para9001"><span class="display"><div class="article-textbox" id="tbox0002" aria-label="Unlabelled box" role="region"><div><section id="sec0001"><h2 id="cesectitle0009" class="u-h4 u-margin-l-top u-margin-xs-bottom">WHAT IS ALREADY KNOWN ON THIS TOPIC</h2><div class="u-margin-s-bottom" id="para0008"><ul class="list"><li class="react-xocs-list-item"><span class="list-label">?</span><span class="list-content"><div class="u-margin-s-bottom" id="para0009">Tyrosine kinase 2 (TYK2) is a critical mediator of the proinflammatory pathways fundamental to the <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/pathophysiology" title="Learn more about pathophysiology from ScienceDirect's AI-generated Topic Pages" class="topic-link">pathophysiology</a> of some immune-mediated inflammatory diseases (IMIDs) including psoriatic arthritis (PsA).</div></span></li><li class="react-xocs-list-item"><span class="list-label">?</span><span class="list-content"><div class="u-margin-s-bottom" id="para0010">Zasocitinib (TAK-279) is an investigational, oral, allosteric, highly selective, and potent TYK2 inhibitor being developed for the treatment of IMIDs, including PsA and plaque psoriasis.</div></span></li></ul></div></section><section id="sec0002"><h2 id="cesectitle0010" class="u-h4 u-margin-l-top u-margin-xs-bottom">WHAT THIS STUDY ADDS</h2><div class="u-margin-s-bottom" id="para0011"><ul class="list"><li class="react-xocs-list-item"><span class="list-label">?</span><span class="list-content"><div class="u-margin-s-bottom" id="para0012">This phase 2b study reports a significantly higher proportion of patients achieved an American College of Rheumatology 20 response at week 12 with once daily 30 mg or 15 mg zasocitinib than with placebo.</div></span></li><li class="react-xocs-list-item"><span class="list-label">?</span><span class="list-content"><div class="u-margin-s-bottom" id="para0013">Treatment with 30 mg or 15 mg zasocitinib resulted in a numerically higher number of patients achieving low disease activity or remission across multiple composite measures of disease activity versus placebo, as early as week 12.</div></span></li><li class="react-xocs-list-item"><span class="list-label">?</span><span class="list-content"><div class="u-margin-s-bottom" id="para0014">Zasocitinib (30 mg) demonstrated numerically greater efficacy versus placebo across all skin efficacy endpoints assessed, with rapid onset evident as early as week 2.</div></span></li><li class="react-xocs-list-item"><span class="list-label">?</span><span class="list-content"><div class="u-margin-s-bottom" id="para0015">The safety and laboratory parameter profile of zasocitinib was consistent with previous studies in patients with plaque psoriasis, supporting the high selectivity of zasocitinib for TYK2.</div></span></li></ul></div></section><section id="sec0003"><h2 id="cesectitle0011" class="u-h4 u-margin-l-top u-margin-xs-bottom">HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY</h2><div class="u-margin-s-bottom" id="para0016"><ul class="list"><li class="react-xocs-list-item"><span class="list-label">?</span><span class="list-content"><div class="u-margin-s-bottom" id="para0017">The efficacy and tolerability of zasocitinib in patients with active PsA demonstrated in this phase 2b study could propel further long-term comparative <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/clinical-trial" title="Learn more about clinical trials from ScienceDirect's AI-generated Topic Pages" class="topic-link">clinical trials</a>, potentially leading to new oral therapeutic options for PsA with an improved benefit-risk profile.</div></span></li><li class="react-xocs-list-item"><span class="list-label">?</span><span class="list-content"><div class="u-margin-s-bottom" id="para0018">The rapid and meaningful clinical responses observed with zasocitinib suggest that it could become a valuable oral treatment in clinical practice for patients with PsA, providing more options for individualised patient care.</div></span></li></ul></div></section></div></div></span></div><section id="sec0004"><h2 id="cesectitle0012" class="u-h4 u-margin-l-top u-margin-xs-bottom">INTRODUCTION</h2><div class="u-margin-s-bottom" id="para0019"><span><span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/psoriatic-arthritis" title="Learn more about Psoriatic arthritis from ScienceDirect's AI-generated Topic Pages" class="topic-link">Psoriatic arthritis</a> (PsA) is a chronic, systemic, immune-mediated </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/inflammatory-disease" title="Learn more about inflammatory disease from ScienceDirect's AI-generated Topic Pages" class="topic-link">inflammatory disease</a> (IMID) with diverse manifestations [</span><a class="anchor anchor-primary" href="#bib0001" name="bbib0001" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0001"><span class="anchor-text-container"><span class="anchor-text">[1]</span></span></a>, <a class="anchor anchor-primary" href="#bib0002" name="bbib0002" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0002"><span class="anchor-text-container"><span class="anchor-text">[2]</span></span></a>, <a class="anchor anchor-primary" href="#bib0003" name="bbib0003" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0003"><span class="anchor-text-container"><span class="anchor-text">[3]</span></span></a>]. Patients with PsA have a high overall burden of disease and are more likely to develop comorbidities, including obesity, cardiovascular disease, and hypertension, than matched controls, and also have a high prevalence of anxiety and depression [<a class="anchor anchor-primary" href="#bib0004" name="bbib0004" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0004"><span class="anchor-text-container"><span class="anchor-text">4</span></span></a>,<a class="anchor anchor-primary" href="#bib0005" name="bbib0005" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0005"><span class="anchor-text-container"><span class="anchor-text">5</span></span></a><span>]. The Group for Research and Assessment of <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/psoriasis" title="Learn more about Psoriasis from ScienceDirect's AI-generated Topic Pages" class="topic-link">Psoriasis</a><span> and Psoriatic Arthritis (GRAPPA), in conjunction with Outcome Measures in Rheumatology (OMERACT), has developed a core set of domains for PsA aiming to standardise outcome measurements in <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/randomized-clinical-trial" title="Learn more about randomised clinical trials from ScienceDirect's AI-generated Topic Pages" class="topic-link">randomised clinical trials</a> and longitudinal observational studies [</span></span><a class="anchor anchor-primary" href="#bib0006" name="bbib0006" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0006"><span class="anchor-text-container"><span class="anchor-text">6</span></span></a><span>]. The goals of PsA treatment are to ameliorate <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/physical-disease-by-body-function" title="Learn more about signs and symptoms from ScienceDirect's AI-generated Topic Pages" class="topic-link">signs and symptoms</a> across multiple domains of the disease, improve physical function, prevent structural damage, and enhance health-related quality of life (HRQoL) [</span><a class="anchor anchor-primary" href="#bib0004" name="bbib0004" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0004"><span class="anchor-text-container"><span class="anchor-text">4</span></span></a>,<a class="anchor anchor-primary" href="#bib0007" name="bbib0007" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0007"><span class="anchor-text-container"><span class="anchor-text">7</span></span></a>].</div><div class="u-margin-s-bottom" id="para0020">Despite current treatment options, some patients with PsA continue to experience a high disease burden because available treatments may not adequately address all core PsA domains, while also not providing acceptable long-term safety [<a class="anchor anchor-primary" href="#bib0005" name="bbib0005" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0005"><span class="anchor-text-container"><span class="anchor-text">5</span></span></a>,<a class="anchor anchor-primary" href="#bib0008" name="bbib0008" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0008"><span class="anchor-text-container"><span class="anchor-text">8</span></span></a><span>]. This highlights the need for more comprehensive treatment strategies in patients without adequate disease control or with <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/tolerability" title="Learn more about tolerability from ScienceDirect's AI-generated Topic Pages" class="topic-link">tolerability</a><span><span> issues with current treatments and ultimately improvement in the long-term outcomes and quality of life of these patients with PsA. <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/protein-tyrosine-kinase" title="Learn more about Tyrosine kinase from ScienceDirect's AI-generated Topic Pages" class="topic-link">Tyrosine kinase</a> 2 (TYK2) is a critical mediator of the activation of proinflammatory pathways fundamental to the </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/pathophysiology" title="Learn more about pathophysiology from ScienceDirect's AI-generated Topic Pages" class="topic-link">pathophysiology</a><span> of some IMIDs, including interleukin (IL)-12, IL-23, and <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/interferon-type-i" title="Learn more about type I interferon from ScienceDirect's AI-generated Topic Pages" class="topic-link">type I interferon</a> signalling [</span></span></span><a class="anchor anchor-primary" href="#bib0009" name="bbib0009" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0009"><span class="anchor-text-container"><span class="anchor-text">9</span></span></a>,<a class="anchor anchor-primary" href="#bib0010" name="bbib0010" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0010"><span class="anchor-text-container"><span class="anchor-text">10</span></span></a>]. Loss-of-function variants in the <em>TYK2</em> gene have protective effects against psoriasis and other IMIDs without detrimental effects [<a class="anchor anchor-primary" href="#bib0011" name="bbib0011" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0011"><span class="anchor-text-container"><span class="anchor-text">11</span></span></a><span>]. Therefore, TYK2 inhibition is being investigated for the treatment of IMIDs including PsA and <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/psoriasis-vulgaris" title="Learn more about plaque psoriasis from ScienceDirect's AI-generated Topic Pages" class="topic-link">plaque psoriasis</a> [</span><a class="anchor anchor-primary" href="#bib0009" name="bbib0009" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0009"><span class="anchor-text-container"><span class="anchor-text">9</span></span></a>,<a class="anchor anchor-primary" href="#bib0010" name="bbib0010" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0010"><span class="anchor-text-container"><span class="anchor-text">10</span></span></a>,<a class="anchor anchor-primary" href="#bib0012" name="bbib0012" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0012"><span class="anchor-text-container"><span class="anchor-text">12</span></span></a>,<a class="anchor anchor-primary" href="#bib0013" name="bbib0013" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0013"><span class="anchor-text-container"><span class="anchor-text">13</span></span></a>].</div><div class="u-margin-s-bottom" id="para0021">Zasocitinib (TAK-279) is an investigational, oral, allosteric, highly selective, and potent TYK2 inhibitor being developed for the treatment of IMIDs, including PsA and plaque psoriasis [<a class="anchor anchor-primary" href="#bib0014" name="bbib0014" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0014"><span class="anchor-text-container"><span class="anchor-text">14</span></span></a><span>]. Zasocitinib was designed to maximise specific TYK2 inhibition and prevent inhibition of Janus kinase (JAK)1, <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/janus-kinase" title="Learn more about JAK2 from ScienceDirect's AI-generated Topic Pages" class="topic-link">JAK2</a>, and JAK3 [</span><a class="anchor anchor-primary" href="#bib0014" name="bbib0014" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0014"><span class="anchor-text-container"><span class="anchor-text">14</span></span></a>]. <em>In vitro</em><span> studies of zasocitinib have demonstrated selectivity for the <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/janus-kinase-2" title="Learn more about TYK2 Janus from ScienceDirect's AI-generated Topic Pages" class="topic-link">TYK2 Janus</a> homology (JH)2 domain over the JAK JH1 domain, without affecting JAK-mediated signalling [</span><a class="anchor anchor-primary" href="#bib0014" name="bbib0014" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0014"><span class="anchor-text-container"><span class="anchor-text">14</span></span></a>,<a class="anchor anchor-primary" href="#bib0015" name="bbib0015" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0015"><span class="anchor-text-container"><span class="anchor-text">15</span></span></a>].</div><div class="u-margin-s-bottom" id="para0022">The efficacy, safety, and tolerability of zasocitinib were assessed in patients with moderate-to-severe plaque psoriasis in a phase 2b study (ClinicalTrials.gov: <a class="anchor anchor-primary" href="http://clinicaltrials.gov/show/NCT04999839" target="_blank"><span class="anchor-text-container"><span class="anchor-text">NCT04999839</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a>) [<a class="anchor anchor-primary" href="#bib0016" name="bbib0016" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0016"><span class="anchor-text-container"><span class="anchor-text">16</span></span></a><span>]. The study met its primary endpoint (Psoriasis Area and Severity Index [PASI] 75 at week 12) at doses ¡Ý5 mg, with about one-third of patients in the highest dose group (30 mg) achieving PASI 100 (complete skin clearance) at week 12. Zasocitinib was generally well tolerated with no clear dose-related treatment-emergent <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/adverse-event" title="Learn more about adverse events from ScienceDirect's AI-generated Topic Pages" class="topic-link">adverse events</a> (TEAEs) observed.</span></div><div class="u-margin-s-bottom" id="para0023">The aim of this phase 2b, randomised, clinical trial was to assess the efficacy, safety, and tolerability of zasocitinib in patients with active PsA.</div></section><section id="sec0005"><h2 id="cesectitle0013" class="u-h4 u-margin-l-top u-margin-xs-bottom">METHODS</h2><section id="sec0006"><h3 id="cesectitle0014" class="u-h4 u-margin-m-top u-margin-xs-bottom">Study design</h3><div class="u-margin-s-bottom" id="para0024">This was a phase 2b, randomised, multicentre, double-blind, placebo-controlled, multiple-dose study (NCT05153148) [<a class="anchor anchor-primary" href="#bib0017" name="bbib0017" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0017"><span class="anchor-text-container"><span class="anchor-text">17</span></span></a><span>]. Patients with active <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/psoriatic-arthritis" title="Learn more about PsA from ScienceDirect's AI-generated Topic Pages" class="topic-link">PsA</a> from 45 centres across the USA (n = 17), Poland (n = 18), Germany (n = 4), and the Czech Republic (n = 6) were enrolled. Patients were randomised 1:1:1:1 to receive orally administered 5 mg, 15 mg, or 30 mg zasocitinib or an identical placebo once daily for 12 weeks, with an additional 4-week follow-up period for safety monitoring (</span><a class="anchor anchor-primary" href="#sec0026" name="bsec0026" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="sec0026"><span class="anchor-text-container"><span class="anchor-text">Supplementary Fig S1</span></span></a><span><span><span><span>). Randomisation occurred at the day ?7 visit, and patients were stratified according to region (USA/Germany, Czech Republic/Poland) and whether they had received prior treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) or any other disease-modifying antirheumatic drugs (DMARDs) except for <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/azathioprine" title="Learn more about azathioprine from ScienceDirect's AI-generated Topic Pages" class="topic-link">azathioprine</a>, </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/chloroquine" title="Learn more about chloroquine from ScienceDirect's AI-generated Topic Pages" class="topic-link">chloroquine</a>, </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/ciclosporin" title="Learn more about ciclosporin from ScienceDirect's AI-generated Topic Pages" class="topic-link">ciclosporin</a>, </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/hydroxychloroquine" title="Learn more about hydroxychloroquine from ScienceDirect's AI-generated Topic Pages" class="topic-link">hydroxychloroquine</a><span><span>, <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/leflunomide" title="Learn more about leflunomide from ScienceDirect's AI-generated Topic Pages" class="topic-link">leflunomide</a><span>, <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/methotrexate" title="Learn more about methotrexate from ScienceDirect's AI-generated Topic Pages" class="topic-link">methotrexate</a>, and </span></span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/sulfasalazine" title="Learn more about sulfasalazine from ScienceDirect's AI-generated Topic Pages" class="topic-link">sulfasalazine</a>.</span></span></div></section><section id="sec0007"><h3 id="cesectitle0015" class="u-h4 u-margin-m-top u-margin-xs-bottom">Patient involvement</h3><div class="u-margin-s-bottom" id="para0025">Patients and/or the public were not involved in the design, conduction, reporting, or dissemination of this research.</div></section><section id="sec0008"><h3 id="cesectitle0016" class="u-h4 u-margin-m-top u-margin-xs-bottom">Patient population</h3><div class="u-margin-s-bottom" id="para0026">Eligible patients were aged ¡Ý18 years with active PsA and a history of PsA symptoms for ¡Ý6 months before screening (screening occurred ¡Ü30 days before day 1 of the study), had ¡Ý3 tender and ¡Ý3 swollen joints, and met the Classification Criteria for Psoriatic Arthritis (CASPAR) [<a class="anchor anchor-primary" href="#bib0003" name="bbib0003" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0003"><span class="anchor-text-container"><span class="anchor-text">3</span></span></a><span><span>]. Additionally, eligible patients had active PsA despite previous therapy with nonsteroidal anti-inflammatory drugs; DMARDs including azathioprine, chloroquine, ciclosporin, hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine, or <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/tumor-necrosis-factor-inhibitor" title="Learn more about tumour necrosis factor inhibitors from ScienceDirect's AI-generated Topic Pages" class="topic-link">tumour necrosis factor inhibitors</a> (TNFis). Alternatively, eligible patients were intolerant to these treatments. There was no limit to number or class of prior bDMARD exposure (excluding those with lack of response after 12 weeks of treatment or </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/adverse-event" title="Learn more about adverse events from ScienceDirect's AI-generated Topic Pages" class="topic-link">adverse events</a> [AEs]) or minimum high-sensitivity C-reactive protein (hsCRP) requirement at baseline.</span></div><div class="u-margin-s-bottom" id="para0027">Patients were excluded if they previously had a lack of response to any therapeutic agent targeting IL-12, IL-17, and/or IL-23 (and/or received 1 of these therapies ¡Ü6 months before baseline [day 1]) or to more than 1 TNFi or had any other disease that might confound evaluation of the benefit of zasocitinib.</div><div class="u-margin-s-bottom" id="para0028">Full inclusion and exclusion criteria are reported in the Supplementary Material.</div><div class="u-margin-s-bottom" id="para0029">The intent-to-treat analysis set included all patients who were randomised. The full analysis set comprised all patients who were randomised and received at least 1 dose of the study drug. The safety analysis set included all patients who were randomised and received at least one dose of the study drug, with patients analysed based on the actual treatment they received.</div></section><section id="sec0009"><h3 id="cesectitle0017" class="u-h4 u-margin-m-top u-margin-xs-bottom">Endpoints</h3><section id="sec0010"><h4 id="cesectitle0018" class="u-margin-m-top u-margin-xs-bottom">Efficacy</h4><div class="u-margin-s-bottom" id="para0030"><span><span>The primary efficacy endpoint was the proportion of patients achieving an American College of Rheumatology (ACR)20 response at week 12. Secondary efficacy endpoints at week 12 were the proportion of patients achieving ACR50 response; proportion of patients achieving ACR70 response; proportion of patients achieving <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/psoriasis" title="Learn more about PASI from ScienceDirect's AI-generated Topic Pages" class="topic-link">PASI</a><span> 75 response among those with ¡Ý3% body surface area (BSA) psoriatic involvement at baseline; proportion of patients achieving a Physician Global Assessment of Psoriasis (PGA-PsO) score of 0 (clear) or 1 (almost clear) and a ¡Ý2-point improvement from baseline; change from baseline in Physician Global Assessment (PGA) score (investigator-assessed change from baseline in the patients¡¯ overall disease status using a visual analogue scale [VAS]: 0 indicated ¡®asymptomatic¡¯ and 100 indicated ¡®very severe symptoms¡¯); proportion of patients achieving minimal <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/disease-activity" title="Learn more about disease activity from ScienceDirect's AI-generated Topic Pages" class="topic-link">disease activity</a> (MDA) (the patient met at least 5 of the following criteria: (1) tender joint count [TJC] ¡Ü1; (2) swollen joint count [SJC] ¡Ü1; (3) PASI score ¡Ü1 or ¡Ü3% BSA; (4) pain VAS ¡Ü15; (5) Patient Global Assessment [PtGA], using VAS score ¡Ü20; (6) Health Assessment Questionnaire Disability Index [HAQ-DI] score ¡Ü0.5; and (7) tender entheseal points, using the Leeds </span></span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/enthesitis" title="Learn more about Enthesitis from ScienceDirect's AI-generated Topic Pages" class="topic-link">Enthesitis</a><span> Index ¡Ü1); change from baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) score; change from baseline in pain VAS; change from baseline in TJC (TJC68); change from baseline in SJC (SJC66); change from baseline in <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/dactylitis" title="Learn more about dactylitis from ScienceDirect's AI-generated Topic Pages" class="topic-link">dactylitis</a> count among patients who had dactylitis at baseline; and change from baseline in Leeds Enthesitis Index among patients who had enthesitis at baseline. The proportion of patients achieving low disease activity (LDA; DAPSA &gt;4 and ¡Ü14) and remission (REM; DAPSA ¡Ü4) was assessed </span></span><em>post hoc</em>.</div><div class="u-margin-s-bottom" id="para0031">Patient-reported secondary efficacy endpoints assessed at week 12 were change from baseline in PtGA (patients rated their PsA using a VAS score in which 0 indicated ¡®very good, no symptoms¡¯ and 100 indicated ¡®very poor, severe symptoms¡¯) and HAQ-DI. Change from baseline to week 12 in Psoriatic Arthritis <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/disease-activity-score" title="Learn more about Disease Activity Score from ScienceDirect's AI-generated Topic Pages" class="topic-link">Disease Activity Score</a> (PASDAS) was assessed as an exploratory endpoint. Further exploratory endpoints are reported in the Supplementary Material.</div><div class="u-margin-s-bottom" id="para0032">Additional skin endpoints analyses included least-squares mean (LSM) change from baseline in PASI response and the proportion of patients achieving PASI 90 or PASI 100 responses (among those with baseline BSA ¡Ý3%).</div></section><section id="sec0011"><h4 id="cesectitle0019" class="u-margin-m-top u-margin-xs-bottom">Safety and tolerability</h4><div class="u-margin-s-bottom" id="para0033"><span><span>The severity of AEs was classified using Common Terminology Criteria for Adverse Events (CTCAE v5.0) and AEs were coded using <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/meddra" title="Learn more about Medical Dictionary for Regulatory Activities from ScienceDirect's AI-generated Topic Pages" class="topic-link">Medical Dictionary for Regulatory Activities</a> Version 26.0 or higher. Safety and </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/tolerability" title="Learn more about tolerability from ScienceDirect's AI-generated Topic Pages" class="topic-link">tolerability</a><span><span> endpoints comprised the incidence of TEAEs, treatment-emergent serious AEs, TEAEs of special interest (TEAESIs), and changes in vital signs, clinical laboratory parameters, and proportion of patients with clinically relevant electrocardiogram findings and physical examinations. TEAESIs included <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/cytopenia" title="Learn more about cytopenia from ScienceDirect's AI-generated Topic Pages" class="topic-link">cytopenia</a><span> (Grade ¡Ý2), elevation of <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/creatine-kinase" title="Learn more about creatine kinase from ScienceDirect's AI-generated Topic Pages" class="topic-link">creatine kinase</a><span> (Grade ¡Ý3), major adverse cardiovascular events (MACEs), <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/thromboembolism" title="Learn more about thromboembolic from ScienceDirect's AI-generated Topic Pages" class="topic-link">thromboembolic</a> events, </span></span></span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/digestive-system-perforation" title="Learn more about gastrointestinal perforation from ScienceDirect's AI-generated Topic Pages" class="topic-link">gastrointestinal perforation</a>, malignancies, infections, AEs of abnormal liver function tests, and renal dysfunction. Liver function tests included Hy¡¯s Law, hepatobiliary investigations, liver-related investigations, </span></span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/physical-disease-by-body-function" title="Learn more about signs and symptoms from ScienceDirect's AI-generated Topic Pages" class="topic-link">signs and symptoms</a> (including increase in liver enzymes), and drug-related hepatic disorders (CTCAE grades considered).</div></section></section><section id="sec0012"><h3 id="cesectitle0020" class="u-h4 u-margin-m-top u-margin-xs-bottom">Statistical analysis</h3><div class="u-margin-s-bottom" id="para0034">A sample size of 260 patients (65 patients per group) was determined to provide 83% power to detect an ACR20 response rate of 55% in each zasocitinib treatment group at a significance level of ¦Á = 0.05 using a 2-sided chi-square test, assuming a placebo response rate of 30%. The sample size was calculated in nQuery 8.7 (Dotmatics) using a pooled variance estimate for difference of proportions.</div><div class="u-margin-s-bottom" id="para0035">Patient demographics and baseline clinical characteristics were summarised using descriptive statistics. Comparisons of the primary and binary secondary endpoints between each treatment group and placebo were made using a 2-sided Mantel¨CHaenszel test stratified by the randomisation stratification factors.</div><div class="u-margin-s-bottom" id="para0036">A fixed-sequence hierarchical testing approach was applied to the primary endpoint at a 2-sided significance level of 0.05 in the following prespecified order: 30 mg, 15 mg, and 5 mg zasocitinib versus placebo. If one comparison was found not to be significant, all subsequent comparisons of lower doses could not be claimed and <em>P</em> values were considered nominal. No multiplicity adjustment was planned for other efficacy endpoints in this study, and nominal <em>P</em> values are presented where appropriate.</div><div class="u-margin-s-bottom" id="para0037">Patients who discontinued the study drug, used a prohibited medication expected to influence PsA clinical outcomes or with missing data for binary endpoints at week 12 were imputed as nonresponders.</div><div class="u-margin-s-bottom" id="para0038">Subgroup analysis for the primary efficacy endpoint was conducted using the same framework as the primary efficacy analysis. Longitudinal continuous secondary efficacy endpoints were analysed using a mixed model for repeated measures, in which the change from baseline was the dependent variable. The following were the fixed effects: treatment group, visit, treatment-by-visit interaction, and randomisation stratification factors. Baseline score was included as a covariate.</div><div class="u-margin-s-bottom" id="para0039">An analysis of the safety endpoints in the safety analysis set was conducted using descriptive statistics.</div></section><section id="sec0013"><h3 id="cesectitle0021" class="u-h4 u-margin-m-top u-margin-xs-bottom">Ethics</h3><div class="u-margin-s-bottom" id="para0040">This study was performed in accordance with ethical principles originating from the Declaration of Helsinki, which are consistent with Good Clinical Practice and applicable regulatory requirements. Patients provided written, informed consent before starting the study. The clinical study protocol (and amendments), investigator brochure, samples of informed consent forms, and other study-related documents were reviewed and approved by institutional review boards or independent ethics committees of all study sites.</div></section></section><section id="sec0014"><h2 id="cesectitle0022" class="u-h4 u-margin-l-top u-margin-xs-bottom">RESULTS</h2><section id="sec0015"><h3 id="cesectitle0023" class="u-h4 u-margin-m-top u-margin-xs-bottom">Patients</h3><div class="u-margin-s-bottom"><div id="para0041">The study was conducted from January 6, 2022 to June 2, 2023. In total, 387 patients were screened for eligibility, of whom 305 were randomised to 1 of the 3 active treatment groups or placebo (intention-to-treat population), 290 received at least one dose of study treatment (full analysis set and safety analysis set populations), and 245 (84.5%) completed 12 weeks of treatment. Reasons for study discontinuation before receiving the first study drug dose are summarised in <a class="anchor anchor-primary" href="#fig0001" name="bfig0001" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fig0001"><span class="anchor-text-container"><span class="anchor-text">Figure 1</span></span></a>.</div><figure class="figure text-xs" id="fig0001"><span><img src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr1.jpg" height="774" alt="Figure 1" aria-describedby="cap0001"><ol class="u-margin-s-bottom"><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr1_lrg.jpg" target="_blank" download="" title="Download high-res image (1MB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download high-res image (1MB)</span></span></span></a></li><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr1.jpg" target="_blank" download="" title="Download full-size image"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download full-size image</span></span></span></a></li></ol></span><span class="captions text-s"><span id="cap0001"><p id="spara001"><span class="label">Figure 1</span>. Patient disposition. <sup>a</sup>Patients who received ¡Ý1 dose of study drug (randomised patients).</p></span></span></figure></div><div class="u-margin-s-bottom"><div id="para0042">Patient demographics and disease characteristics at baseline were generally similar across groups, except for a higher proportion of females in the 30 mg (59.7%) and 15 mg (61.3%) groups than in the 5 mg (56.3%) and placebo groups (51.4%) (<a class="anchor anchor-primary" href="#tbl0001" name="btbl0001" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tbl0001"><span class="anchor-text-container"><span class="anchor-text">Table 1</span></span></a>, <a class="anchor anchor-primary" href="#sec0026" name="bsec0026" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="sec0026"><span class="anchor-text-container"><span class="anchor-text">Supplementary Table S1</span></span></a>). Lower mean TJC (14.0 vs 18.0-18.5) and SJC (8.5 vs 9.0-9.7) were observed in the zasocitinib 30 mg group compared with the other groups (<a class="anchor anchor-primary" href="#tbl0001" name="btbl0001" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tbl0001"><span class="anchor-text-container"><span class="anchor-text">Table 1</span></span></a><span><span><span><span>). The mean (SD) age of patients was 49.9 (11.6) years, and the patient population was predominantly White (95.2%), female (57.2%), and from Eastern Europe (76.9%). At baseline, 62.4% of patients were receiving <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/azathioprine" title="Learn more about azathioprine from ScienceDirect's AI-generated Topic Pages" class="topic-link">azathioprine</a>, </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/chloroquine" title="Learn more about chloroquine from ScienceDirect's AI-generated Topic Pages" class="topic-link">chloroquine</a>, </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/ciclosporin" title="Learn more about ciclosporin from ScienceDirect's AI-generated Topic Pages" class="topic-link">ciclosporin</a>, </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/hydroxychloroquine" title="Learn more about hydroxychloroquine from ScienceDirect's AI-generated Topic Pages" class="topic-link">hydroxychloroquine</a><span><span>, <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/leflunomide" title="Learn more about leflunomide from ScienceDirect's AI-generated Topic Pages" class="topic-link">leflunomide</a><span>, <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/methotrexate" title="Learn more about methotrexate from ScienceDirect's AI-generated Topic Pages" class="topic-link">methotrexate</a>, and/or </span></span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/sulfasalazine" title="Learn more about sulfasalazine from ScienceDirect's AI-generated Topic Pages" class="topic-link">sulfasalazine</a><span>; 57.6% of patients were receiving methotrexate. Approximately one-third of patients had received previous treatment with <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/disease-modifying-antirheumatic-drug" title="Learn more about bDMARDs from ScienceDirect's AI-generated Topic Pages" class="topic-link">bDMARDs</a><span> at baseline (31.0-33.3%), and the patient population contained both bDMARD-inadequate responders (reasons for discontinuing bDMARDs before the study included lack of efficacy, safety, and other; 7.2% of patients reported lack of efficacy as the reason for discontinuing TNFis) and bDMARD-exposed patients in each treatment group. Among enrolled patients with coexistent psoriasis, the mean (SD) PASI score in those with ¡Ý3% BSA (n = 169 [58.3%]) was 6.2 (5.5). At baseline, 45.9% of patients had elevated <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/c-reactive-protein" title="Learn more about hsCRP from ScienceDirect's AI-generated Topic Pages" class="topic-link">hsCRP</a> (¡Ý3.0 mg/L).</span></span></span></span></div><div class="tables rowsep-0 colsep-0 frame-topbot" id="tbl0001"><span class="captions text-s"><span id="cap0006"><p id="spara006"><span class="label">Table 1</span>. Baseline demographics and disease characteristics (FAS)</p></span></span><div class="groups"><table><thead><tr class="rowsep-1"><td scope="col" class="align-left valign-top" id="en0001"><span class="screen-reader-only">Empty Cell</span></td><th scope="col" class="align-left valign-top" id="en0002">Placebo<br>(N = 72)</th><th scope="col" class="align-left valign-top" id="en0003">Zasocitinib<br>5 mg once daily<br>(N = 71)</th><th scope="col" class="align-left valign-top" id="en0004">Zasocitinib<br>15 mg once daily<br>(N = 75)</th><th scope="col" class="align-left valign-top" id="en0005">Zasocitinib<br>30 mg once daily<br>(N = 72)</th><th scope="col" class="align-left valign-top" id="en0006">Total<br>(N = 290)</th></tr></thead><tbody><tr><td class="align-left valign-top" id="en0007" colspan="6">Demographics</td></tr><tr><th class="align-left valign-top" id="en0008" scope="row">Age, y, mean (SD)</th><td class="align-left valign-top" id="en0009">49.7 (11.8)</td><td class="align-left valign-top" id="en0010">48.3 (10.4)</td><td class="align-left valign-top" id="en0011">52.5 (12.2)</td><td class="align-left valign-top" id="en0012">49.0 (11.5)</td><td class="align-left valign-top" id="en0013">49.9 (11.6)</td></tr><tr><th class="align-left valign-top" id="en0014" scope="row">Female, n (%)</th><td class="align-left valign-top" id="en0015">37 (51.4)</td><td class="align-left valign-top" id="en0016">40 (56.3)</td><td class="align-left valign-top" id="en0017">46 (61.3)</td><td class="align-left valign-top" id="en0018">43 (59.7)</td><td class="align-left valign-top" id="en0019">166 (57.2)</td></tr><tr><th class="align-left valign-top" id="en0020" scope="row">Race, n (%)<br>?American Indian/Alaskan Native<br>?Asian<br>?Black/African American<br>?Native Hawaiian/Other Pacific Islander<br>?White<br>?Unknown<br>?Not available</th><td class="align-left valign-top" id="en0021"><br>0<br>0<br>1 (1.4)<br>0<br>69 (95.8)<br>2 (2.8)<br>0</td><td class="align-left valign-top" id="en0022"><br>1 (1.4)<br>0<br>1 (1.4)<br>1 (1.4)<br>67 (94.4)<br>0<br>2 (2.8)</td><td class="align-left valign-top" id="en0023"><br>0<br>2 (2.7)<br>2 (2.7)<br>0<br>71 (94.7)<br>0<br>0</td><td class="align-left valign-top" id="en0024"><br>0<br>0<br>3 (4.2)<br>0<br>69 (95.8)<br>0<br>0</td><td class="align-left valign-top" id="en0025"><br>1 (0.3)<br>2 (0.7)<br>7 (2.4)<br>1 (0.3)<br>276 (95.2)<br>2 (0.7)<br>2 (0.7)</td></tr><tr><th class="align-left valign-top" id="en0026" scope="row">BMI, kg/m<sup>2</sup>, mean (SD)</th><td class="align-left valign-top" id="en0027">29.5 (6.9)</td><td class="align-left valign-top" id="en0028">29.8 (8.2)</td><td class="align-left valign-top" id="en0029">30.0 (7.9)</td><td class="align-left valign-top" id="en0030">30.2 (6.6)</td><td class="align-left valign-top" id="en0031">29.9 (7.4)</td></tr><tr><th class="align-left valign-top" id="en0032" scope="row">Baseline DMARD treatment,<a class="anchor anchor-primary" href="#tb1fn1" name="btb1fn1" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb1fn1"><span class="anchor-text-container"><span class="anchor-text"><sup>a</sup></span></span></a> n (%)</th><td class="align-left valign-top" id="en0033">43 (59.7)</td><td class="align-left valign-top" id="en0034">45 (63.4)</td><td class="align-left valign-top" id="en0035">46 (61.3)</td><td class="align-left valign-top" id="en0036">47 (65.3)</td><td class="align-left valign-top" id="en0037">181 (62.4)</td></tr><tr><th class="align-left valign-top" id="en0038" scope="row">&nbsp;Baseline methotrexate treatment,<a class="anchor anchor-primary" href="#tb1fn2" name="btb1fn2" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb1fn2"><span class="anchor-text-container"><span class="anchor-text"><sup>b</sup></span></span></a> n (%)</th><td class="align-left valign-top" id="en0039">38 (52.8)</td><td class="align-left valign-top" id="en0040">44 (62.0)</td><td class="align-left valign-top" id="en0041">43 (57.3)</td><td class="align-left valign-top" id="en0042">42 (58.3)</td><td class="align-left valign-top" id="en0043">167 (57.6)</td></tr><tr><th class="align-left valign-top" id="en0044" scope="row">&nbsp;Baseline sulfasalazine treatment, n (%)</th><td class="align-left valign-top" id="en0045">5 (6.9)</td><td class="align-left valign-top" id="en0046">2 (2.8)</td><td class="align-left valign-top" id="en0047">3 (4.0)</td><td class="align-left valign-top" id="en0048">6 (8.3)</td><td class="align-left valign-top" id="en0049">16 (5.5)</td></tr><tr><th class="align-left valign-top" id="en0050" scope="row">&nbsp;Baseline hydroxychloroquine,<a class="anchor anchor-primary" href="#tb1fn3" name="btb1fn3" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb1fn3"><span class="anchor-text-container"><span class="anchor-text"><sup>c</sup></span></span></a> treatment, n (%)</th><td class="align-left valign-top" id="en0051">0</td><td class="align-left valign-top" id="en0052">0</td><td class="align-left valign-top" id="en0053">1 (1.3)</td><td class="align-left valign-top" id="en0054">0</td><td class="align-left valign-top" id="en0055">1 (0.3)</td></tr><tr><th class="align-left valign-top" id="en0056" scope="row">&nbsp;Baseline leflunomide treatment, n (%)</th><td class="align-left valign-top" id="en0057">1 (1.4)</td><td class="align-left valign-top" id="en0058">0</td><td class="align-left valign-top" id="en0059">0</td><td class="align-left valign-top" id="en0060">0</td><td class="align-left valign-top" id="en0061">1 (0.3)</td></tr><tr><th class="align-left valign-top" id="en0062" scope="row">Previous DMARD treatment,<a class="anchor anchor-primary" href="#tb1fn1" name="btb1fn1" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb1fn1"><span class="anchor-text-container"><span class="anchor-text"><sup>a</sup></span></span></a> n (%)</th><td class="align-left valign-top" id="en0063">33 (45.8)</td><td class="align-left valign-top" id="en0064">35 (49.3)</td><td class="align-left valign-top" id="en0065">32 (42.7)</td><td class="align-left valign-top" id="en0066">31 (43.1)</td><td class="align-left valign-top" id="en0067">131 (45.2)</td></tr><tr><th class="align-left valign-top" id="en0068" scope="row">Previous bDMARD treatment, n (%)</th><td class="align-left valign-top" id="en0069">24 (33.3)</td><td class="align-left valign-top" id="en0070">22 (31.0)</td><td class="align-left valign-top" id="en0071">24 (32.0)</td><td class="align-left valign-top" id="en0072">23 (31.9)</td><td class="align-left valign-top" id="en0073">93 (32.1)</td></tr><tr><th class="align-left valign-top" id="en0074" scope="row">Previous TNF inhibitor use, n (%)</th><td class="align-left valign-top" id="en0075">16 (22.2)</td><td class="align-left valign-top" id="en0076">17 (23.9)</td><td class="align-left valign-top" id="en0077">16 (21.3)</td><td class="align-left valign-top" id="en0078">11 (15.3)</td><td class="align-left valign-top" id="en0079">60 (20.7)</td></tr><tr><td class="align-left valign-top" id="en0080" colspan="6">Disease characteristics</td></tr><tr><th class="align-left valign-top" id="en0081" scope="row">Disease duration, y, median (range)</th><td class="align-left valign-top" id="en0082">4.0 (0.2-30.9)</td><td class="align-left valign-top" id="en0083">4.0 (0.5-37.7)</td><td class="align-left valign-top" id="en0084">5.1 (0.1-24.3)</td><td class="align-left valign-top" id="en0085">4.3 (0.1-30.7)</td><td class="align-left valign-top" id="en0086">4.2 (0.1-37.7)</td></tr><tr><th class="align-left valign-top" id="en0087" scope="row">TJC, mean (SD)</th><td class="align-left valign-top" id="en0088">18.5 (14.7)</td><td class="align-left valign-top" id="en0089">18.4 (15.2)</td><td class="align-left valign-top" id="en0090">18.0 (12.8)</td><td class="align-left valign-top" id="en0091">14.0 (9.4)</td><td class="align-left valign-top" id="en0092">17.2 (13.3)</td></tr><tr><th class="align-left valign-top" id="en0093" scope="row">SJC, mean (SD)</th><td class="align-left valign-top" id="en0094">9.0 (6.1)</td><td class="align-left valign-top" id="en0095">9.7 (6.6)</td><td class="align-left valign-top" id="en0096">9.7 (6.1)</td><td class="align-left valign-top" id="en0097">8.5 (5.7)</td><td class="align-left valign-top" id="en0098">9.2 (6.1)</td></tr><tr><th class="align-left valign-top" id="en0099" scope="row">PGA,<a class="anchor anchor-primary" href="#tb1fn4" name="btb1fn4" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb1fn4"><span class="anchor-text-container"><span class="anchor-text"><sup>d</sup></span></span></a> mean (SD)</th><td class="align-left valign-top" id="en0100">59.9 (16.0)</td><td class="align-left valign-top" id="en0101">59.6 (17.4)</td><td class="align-left valign-top" id="en0102">62.0 (15.1)</td><td class="align-left valign-top" id="en0103">57.6 (19.8)</td><td class="align-left valign-top" id="en0104">59.8 (17.1)</td></tr><tr><th class="align-left valign-top" id="en0105" scope="row">PtGA,<a class="anchor anchor-primary" href="#tb1fn5" name="btb1fn5" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb1fn5"><span class="anchor-text-container"><span class="anchor-text"><sup>e</sup></span></span></a> mean (SD)</th><td class="align-left valign-top" id="en0106">55.3 (22.7)</td><td class="align-left valign-top" id="en0107">52.2 (19.8)</td><td class="align-left valign-top" id="en0108">59.6 (19.4)</td><td class="align-left valign-top" id="en0109">53.2 (20.6)</td><td class="align-left valign-top" id="en0110">55.1 (20.7)</td></tr><tr><th class="align-left valign-top" id="en0111" scope="row">Pain VAS,<a class="anchor anchor-primary" href="#tb1fn6" name="btb1fn6" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb1fn6"><span class="anchor-text-container"><span class="anchor-text"><sup>f</sup></span></span></a> mean (SD)</th><td class="align-left valign-top" id="en0112">53.6 (24.1)</td><td class="align-left valign-top" id="en0113">48.2 (21.0)</td><td class="align-left valign-top" id="en0114">58.3 (20.9)</td><td class="align-left valign-top" id="en0115">49.8 (22.4)</td><td class="align-left valign-top" id="en0116">52.5 (22.4)</td></tr><tr><th class="align-left valign-top" id="en0117" scope="row">HAQ-DI, mean (SD)</th><td class="align-left valign-top" id="en0118">1.1 (0.6)</td><td class="align-left valign-top" id="en0119">1.1 (0.6)</td><td class="align-left valign-top" id="en0120">1.2 (0.6)</td><td class="align-left valign-top" id="en0121">1.1 (0.6)</td><td class="align-left valign-top" id="en0122">1.1 (0.6)</td></tr><tr><th class="align-left valign-top" id="en0123" scope="row">hsCRP, mg/L, mean (SD)</th><td class="align-left valign-top" id="en0124">5.8 (9.1)</td><td class="align-left valign-top" id="en0125">8.1 (15.2)</td><td class="align-left valign-top" id="en0126">6.4 (11.5)</td><td class="align-left valign-top" id="en0127">7.6 (12.3)</td><td class="align-left valign-top" id="en0128">7.0 (12.2)</td></tr><tr><th class="align-left valign-top" id="en0129" scope="row">Psoriasis BSA ¡Ý3%, n (%)</th><td class="align-left valign-top" id="en0130">39 (54.2)</td><td class="align-left valign-top" id="en0131">39 (54.9)</td><td class="align-left valign-top" id="en0132">46 (61.3)</td><td class="align-left valign-top" id="en0133">46 (63.9)</td><td class="align-left valign-top" id="en0134">170 (58.6)</td></tr><tr><th class="align-left valign-top" id="en0135" scope="row">PASI in patients with ¡Ý3% BSA,<a class="anchor anchor-primary" href="#tb1fn7" name="btb1fn7" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb1fn7"><span class="anchor-text-container"><span class="anchor-text"><sup>g</sup></span></span></a> mean (SD)</th><td class="align-left valign-top" id="en0136">7.1 (7.0)</td><td class="align-left valign-top" id="en0137">5.9 (4.6)</td><td class="align-left valign-top" id="en0138">5.4 (3.9)</td><td class="align-left valign-top" id="en0139">6.5 (6.2)</td><td class="align-left valign-top" id="en0140">6.2 (5.5)</td></tr><tr><th class="align-left valign-top" id="en0141" scope="row">Dactylitis count ¡Ý1, n (%)</th><td class="align-left valign-top" id="en0142">17 (23.6)</td><td class="align-left valign-top" id="en0143">16 (22.5)</td><td class="align-left valign-top" id="en0144">14 (18.7)</td><td class="align-left valign-top" id="en0145">17 (23.6)</td><td class="align-left valign-top" id="en0146">64 (22.1)</td></tr><tr><th class="align-left valign-top" id="en0147" scope="row">Dactylitis count,<a class="anchor anchor-primary" href="#tb1fn8" name="btb1fn8" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb1fn8"><span class="anchor-text-container"><span class="anchor-text"><sup>h</sup></span></span></a> mean (SD)</th><td class="align-left valign-top" id="en0148">1.8 (1.2)</td><td class="align-left valign-top" id="en0149">4.1 (4.3)</td><td class="align-left valign-top" id="en0150">2.1 (1.8)</td><td class="align-left valign-top" id="en0151">2.8 (3.7)</td><td class="align-left valign-top" id="en0152">2.7 (3.1)</td></tr><tr><th class="align-left valign-top" id="en0153" scope="row">Enthesitis (LEI ¡Ý1), n (%)</th><td class="align-left valign-top" id="en0154">36 (50.0)</td><td class="align-left valign-top" id="en0155">36 (50.7)</td><td class="align-left valign-top" id="en0156">40 (53.3)</td><td class="align-left valign-top" id="en0157">35 (48.6)</td><td class="align-left valign-top" id="en0158">147 (50.7)</td></tr><tr><th class="align-left valign-top" id="en0159" scope="row">LEI absolute values,<a class="anchor anchor-primary" href="#tb1fn9" name="btb1fn9" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb1fn9"><span class="anchor-text-container"><span class="anchor-text"><sup>i</sup></span></span></a> mean (SD)</th><td class="align-left valign-top" id="en0160">2.5 (1.5)</td><td class="align-left valign-top" id="en0161">2.5 (1.7)</td><td class="align-left valign-top" id="en0162">2.5 (1.5)</td><td class="align-left valign-top" id="en0163">2.3 (1.4)</td><td class="align-left valign-top" id="en0164">2.5 (1.5)</td></tr></tbody></table></div><div class="legend"><div class="u-margin-s-bottom" id="spara007">bDMARD, biologic disease-modifying antirheumatic drug; BMI, body mass index; BSA, body surface area; DMARD, disease-modifying antirheumatic drug; FAS, full analysis set; HAQ-DI, Health Assessment Questionnaire Disability Index; hsCRP, high-sensitivity C-reactive protein; LEI, Leeds Enthesitis Index; PASI, Psoriasis Area and Severity Index; PGA, Physician Global Assessment; PtGA, Patient Global Assessment; SJC, swollen joint count; TJC, tender joint count; <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/tumor-necrosis-factor" title="Learn more about TNF from ScienceDirect's AI-generated Topic Pages" class="topic-link">TNF</a><span>, <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/tumor-necrosis" title="Learn more about tumour necrosis from ScienceDirect's AI-generated Topic Pages" class="topic-link">tumour necrosis</a> factor; VAS, visual analogue scale.</span></div><div class="u-margin-s-bottom" id="spara008">BMI was calculated based on the collected weight and height values. Disease duration (years) was calculated as (date of day 1 visit - date of initial disease diagnosis + 1)/365.25. Mean (SD) values were based on nonmissing observations at baseline for continuous endpoints.</div></div><dl class="footnotes"><dt id="tb1fn1">a</dt><dd><div class="u-margin-s-bottom" id="notep0006">DMARDs included azathioprine, chloroquine, ciclosporin, hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine.</div></dd><dt id="tb1fn2">b</dt><dd><div class="u-margin-s-bottom" id="notep0007">Includes medications coded to methotrexate or methotrexate sodium.</div></dd><dt id="tb1fn3">c</dt><dd><div class="u-margin-s-bottom" id="notep0008">Includes medications coded to hydroxychloroquine or hydroxychloroquine phosphate.</div></dd><dt id="tb1fn4">d</dt><dd><div class="u-margin-s-bottom" id="notep0009">The investigator or qualified subinvestigator assessed the patients¡¯ overall disease status by considering the signs, symptoms, and function of all components of joint and skin affected at the time of the visit. This overall status was then rated using a VAS: 0 indicated ¡®very good, asymptomatic and no limitation of normal activities¡¯ and 100 indicated ¡®very poor, very severe symptoms that were intolerable and inability to carry out all normal activities¡¯.</div></dd><dt id="tb1fn5">e</dt><dd><div class="u-margin-s-bottom" id="notep0010">Patients rated their assessment of their PsA using a VAS: 0 indicated ¡®very good, no symptoms¡¯ and 100 indicated ¡®very poor, severe symptoms¡¯.</div></dd><dt id="tb1fn6">f</dt><dd><div class="u-margin-s-bottom" id="notep0011">Patients rated their assessment of their PsA pain using a VAS: 0 indicated ¡®no pain¡¯ and 100 indicated ¡®most severe pain¡¯.</div></dd><dt id="tb1fn7">g</dt><dd><div class="u-margin-s-bottom" id="notep0012">Placebo: n = 38; zasocitinib 5 mg: n = 39; zasocitinib 15 mg: n = 46: zasocitinib 30 mg: n = 46; total: n = 169. One patient in the placebo group had a missing PASI score at baseline.</div></dd><dt id="tb1fn8">h</dt><dd><div class="u-margin-s-bottom" id="notep0013">In patients with dactylitis count ¡Ý1.</div></dd><dt id="tb1fn9">i</dt><dd><div class="u-margin-s-bottom" id="notep0014">In patients with LEI score ¡Ý1.</div></dd></dl></div></div></section><section id="sec0016"><h3 id="cesectitle0024" class="u-h4 u-margin-m-top u-margin-xs-bottom">Efficacy outcomes</h3><div class="u-margin-s-bottom"><div id="para0043">The primary endpoint of this study was met, with a significantly higher proportion of patients (95% CI) receiving 30 mg or 15 mg zasocitinib achieving ACR20 response at week 12 (54.2% [42.7, 65.7] and 53.3% [42.0, 64.6], respectively; both <em>P</em> = .002) than those receiving placebo (29.2% [18.7, 39.7]) (<a class="anchor anchor-primary" href="#fig0002" name="bfig0002" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fig0002"><span class="anchor-text-container"><span class="anchor-text">Fig 2</span></span></a>). The ACR20 response rate for the 5 mg zasocitinib group was 35.2% (24.1, 46.3; <em>P</em> = .446) at week 12. The proportions of patients achieving an ACR20 response in the 30 mg and 15 mg zasocitinib groups increased from baseline to week 12 (<a class="anchor anchor-primary" href="#sec0026" name="bsec0026" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="sec0026"><span class="anchor-text-container"><span class="anchor-text">Supplementary Fig S2</span></span></a>). Generally, numerically higher LSM improvements were observed at week 12 for the 30 mg or 15 mg zasocitinib groups across most of the ACR subcomponents versus placebo (nominal <em>P</em> = .003-.675) (<a class="anchor anchor-primary" href="#sec0026" name="bsec0026" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="sec0026"><span class="anchor-text-container"><span class="anchor-text">Supplementary Table S2</span></span></a>).</div><figure class="figure text-xs" id="fig0002"><span><img src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr2.jpg" height="427" alt="Figure 2" aria-describedby="cap0002"><ol class="u-margin-s-bottom"><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr2_lrg.jpg" target="_blank" download="" title="Download high-res image (306KB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download high-res image (306KB)</span></span></span></a></li><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr2.jpg" target="_blank" download="" title="Download full-size image"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download full-size image</span></span></span></a></li></ol></span><span class="captions text-s"><span id="cap0002"><p id="spara002"><span class="label">Figure 2</span>. ACR20, ACR50<strong><em>,</em></strong> and ACR70 responses at week 12 (FAS). **<em>P</em> ¡Ü .01. <em>P</em> values for secondary endpoints (ACR50/70) are nominal. ACR20/50/70 are composite measures defined as improvements from baseline of ¡Ý20%/50%/70% in both the number of tender joints and swollen joints and ¡Ý20%/50%/70% improvement from baseline in 3 of the following 5 criteria: Patient Global Assessment of psoriatic arthritis, Physician Global Assessment of psoriatic arthritis, Patient Global Assessment of psoriatic arthritis pain, Health Assessment Questionnaire Disability Index, and high-sensitivity C-reactive protein. ACR, American College of Rheumatology; FAS, full analysis set.</p></span></span></figure></div><div class="u-margin-s-bottom" id="para0044">Data for all secondary endpoints are presented in <a class="anchor anchor-primary" href="#sec0026" name="bsec0026" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="sec0026"><span class="anchor-text-container"><span class="anchor-text">Supplementary Table S2</span></span></a>. ACR50 response rate (95% CI) at week 12 was numerically higher in the 30 mg (26.4% [16.2, 36.6], nominal <em>P</em> = .009) and 15 mg (26.7% [16.7, 36.7], nominal <em>P</em> = .005) zasocitinib groups versus the placebo (9.7% [2.9, 16.6]) group (<a class="anchor anchor-primary" href="#fig0002" name="bfig0002" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fig0002"><span class="anchor-text-container"><span class="anchor-text">Fig 2</span></span></a>). A numerically higher proportion of patients achieved an ACR70 response (95% CI) in the zasocitinib 30 mg (13.9% [5.9, 21.9], nominal <em>P</em> = .158) and 15 mg (14.7% [6.7, 22.7], nominal <em>P</em> = .101) groups compared with placebo (5.6% [1.5, 13.6]). In addition, patients in the 30 mg and 15 mg zasocitinib groups reported numerically higher LSM (SE) reductions from baseline in PtGA scores of PsA at week 12 when compared with placebo (placebo: ?11.1 [2.9]; 30 mg: ?19.8 [2.9], nominal <em>P</em> = .030; 15 mg: ?20.2 [2.9], nominal <em>P</em> = .021; <a class="anchor anchor-primary" href="#sec0026" name="bsec0026" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="sec0026"><span class="anchor-text-container"><span class="anchor-text">Supplementary Table S2</span></span></a>). Across all zasocitinib-treated groups, a numerical reduction from baseline in PGA was observed compared with placebo (nominal <em>P</em> = .003-.016) (<a class="anchor anchor-primary" href="#sec0026" name="bsec0026" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="sec0026"><span class="anchor-text-container"><span class="anchor-text">Supplementary Table S2</span></span></a>). Results for efficacy endpoint response rates stratified by geographic region are presented in <a class="anchor anchor-primary" href="#sec0026" name="bsec0026" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="sec0026"><span class="anchor-text-container"><span class="anchor-text">Supplementary Table S3</span></span></a>. Numerical differences between regions were observed in patients receiving zasocitinib 30 mg or placebo, with the Eastern Europe subgroup demonstrating generally higher response rates than those in the USA/Germany subgroup. The ACR20 treatment response differences versus placebo for the 30 mg, 15 mg, or 5 mg zasocitinib groups were 21.7%, 17.2%, and 2.6%, respectively, in the Eastern Europe subgroup and 29.7%, 39.1%, and 12.6%, respectively, in the USA/Germany subgroup, highlighting considerable variability in placebo response across regions.</div><div class="u-margin-s-bottom"><div id="para0045"><span>Treatment with zasocitinib led to improvements in multiple skin <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/disease-activity" title="Learn more about disease activity from ScienceDirect's AI-generated Topic Pages" class="topic-link">disease activity</a> endpoints, with the greatest improvements observed at the highest dose of zasocitinib. A numerically higher reduction in the LSM (SE) PASI score from baseline was observed in the 30 mg zasocitinib group compared with the placebo group as early as week 2 (?1.7 [0.4] vs ?0.7 [0.4], nominal </span><em>P</em> = .023) and persisted through week 12 (<a class="anchor anchor-primary" href="#fig0003" name="bfig0003" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fig0003"><span class="anchor-text-container"><span class="anchor-text">Fig 3</span></span></a>A). There were numerical improvements in PASI 75 response rate (95% CI) at week 12 for all zasocitinib groups compared with placebo (placebo: 15.4% [4.1, 26.7]; 30 mg: 45.7% [31.3, 60.0], nominal <em>P</em> = .002; 15 mg: 28.3% [15.2, 41.3], nominal <em>P</em> = .101; 5 mg: 25.6% [11.9, 39.3], nominal <em>P</em> = .186; <a class="anchor anchor-primary" href="#fig0003" name="bfig0003" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fig0003"><span class="anchor-text-container"><span class="anchor-text">Fig 3</span></span></a>B). Consistent with PASI 75, similar trends were observed with higher threshold efficacy endpoints such as PASI 90 and PASI 100 (among patients with ¡Ý3% BSA). Compared with placebo, a numerically higher proportion of patients achieved PASI 90 (37.0% versus 10.3%, nominal <em>P</em> = .0054) and PASI 100 responses (26.1% versus 10.3%, nominal <em>P</em> = .0941) at week 12 in the 30 mg zasocitinib group (<a class="anchor anchor-primary" href="#fig0003" name="bfig0003" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fig0003"><span class="anchor-text-container"><span class="anchor-text">Fig 3</span></span></a>B). Numerical improvements at week 12 were also observed in the proportions of patients (95% CI) achieving a PGA-PsO score of 0 or 1 and ¡Ý2-point improvement from baseline in the 30 mg zasocitinib group compared with placebo (placebo: 15.8% [6.3, 25.3]; 30 mg: 32.8% [20.7, 44.8], nominal <em>P</em> = .034; 15 mg: 20.6% [10.6, 30.6], nominal <em>P</em> = .466; 5 mg: 20.4% [9.6, 31.1], nominal <em>P</em> = .540; <a class="anchor anchor-primary" href="#fig0003" name="bfig0003" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fig0003"><span class="anchor-text-container"><span class="anchor-text">Fig 3</span></span></a>C).</div><figure class="figure text-xs" id="fig0003"><span><img src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr3.jpg" height="930" alt="Figure 3" aria-describedby="cap0003"><ol class="u-margin-s-bottom"><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr3_lrg.jpg" target="_blank" download="" title="Download high-res image (748KB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download high-res image (748KB)</span></span></span></a></li><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr3.jpg" target="_blank" download="" title="Download full-size image"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download full-size image</span></span></span></a></li></ol></span><span class="captions text-s"><span id="cap0003"><p id="spara003"><span class="label">Figure 3</span>. A, LS mean change from baseline to week 12 in PASI<sup>a</sup> scores. B, Week 12 PASI 75/90/100 response rates<sup>a</sup>. C, Patients achieving PGA-PsO score of 0 or 1 and ¡Ý2-point improvement from baseline<sup>b</sup> (FAS)<em>.</em> *<em>P</em> ¡Ü .05; **<em>P</em> ¡Ü .01. <em>P</em> values for secondary endpoints are nominal. FAS included all randomised patients who received ¡Ý1 dose of the study drug. Patients were included in the analysis as randomised. <sup>a</sup>In patients with ¡Ý3% BSA involvement at baseline. <sup>b</sup>Among those with a PGA-PsO score ¡Ý2 at baseline. BSA, body surface area; FAS, full analysis set; LS, least-squares; PASI, Psoriasis Area and Severity Index; PGA, Physician Global Assessment; PsO, psoriasis.</p></span></span></figure></div><div class="u-margin-s-bottom"><div id="para0046"><span>Treatment with zasocitinib led to improvements in various composite outcomes and <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/disease-activity-score" title="Learn more about disease activity scores from ScienceDirect's AI-generated Topic Pages" class="topic-link">disease activity scores</a>, such as MDA, DAPSA, and PASDAS. Numerically higher improvements in MDA (95% CI) at week 12 were observed in patients treated with 30 mg or 15 mg zasocitinib than those treated with placebo (placebo: 12.5% [4.9, 20.1]; 30 mg: 29.2% [18.7, 39.7]; 15 mg: 28.0% [17.8, 38.2]; 5 mg: 18.3% [9.3, 27.3]; nominal </span><em>P</em> = .014, <em>P</em> = .017, and <em>P</em> = .349, respectively, <a class="anchor anchor-primary" href="#fig0004" name="bfig0004" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fig0004"><span class="anchor-text-container"><span class="anchor-text">Fig 4</span></span></a>A). Relative to placebo, the LS mean change from baseline in DAPSA score (SE) at week 12 was numerically higher in all zasocitinib-treated groups (placebo: ?11.6 [1.9]; 30 mg: ?16.8 [2.0]; 15 mg: ?18.0 [1.9]; 5 mg, ?15.3 [1.9]; nominal <em>P</em> = .056, <em>P</em> = .018, and <em>P</em> = .167, respectively, <a class="anchor anchor-primary" href="#fig0004" name="bfig0004" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fig0004"><span class="anchor-text-container"><span class="anchor-text">Fig 4</span></span></a>B). Numerically higher proportions of patients achieved LDA (4 &lt; DAPSA ¡Ü 14 or 1.9 &lt; PASDAS &lt; 3.2) and REM (DAPSA ¡Ü 4 or PASDAS ¡Ü 1.9) at week 12 in the 30 mg and 15 mg zasocitinib groups than in the placebo group (<a class="anchor anchor-primary" href="#fig0004" name="bfig0004" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fig0004"><span class="anchor-text-container"><span class="anchor-text">Fig 4</span></span></a>C,D).</div><figure class="figure text-xs" id="fig0004"><span><img src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr4.jpg" height="997" alt="Figure 4" aria-describedby="cap0004"><ol class="u-margin-s-bottom"><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr4_lrg.jpg" target="_blank" download="" title="Download high-res image (1MB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download high-res image (1MB)</span></span></span></a></li><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr4.jpg" target="_blank" download="" title="Download full-size image"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download full-size image</span></span></span></a></li></ol></span><span class="captions text-s"><span id="cap0004"><p id="spara004"><span class="label">Figure 4</span>. A, Proportion of patients achieving MDA. B, Change from baseline in DAPSA score. C, DAPSA state. D, PASDAS state at week 12 (FAS). *<em>P</em> ¡Ü .05. <em>P</em> values in secondary endpoints are nominal. FAS included all randomised patients who received ¡Ý1 dose of the study drug. Patients were included in the analysis as randomised. LDA = 4&lt;DAPSA¡Ü14 or 1.9&lt;PASDAS&lt;3.2; REM = DAPSA ¡Ü4 or PASDAS ¡Ü1.9. MDA is measured as the patient meeting ¡Ý5 of the 7 criteria. The criteria are 1) tender joint count ¡Ü1; 2) swollen joint count ¡Ü1; 3) PASI score ¡Ü1 or ¡Ü3% BSA; 4) Patient Global Assessment of psoriatic arthritis pain, VAS ¡Ü15; 5) Patient Global Assessment of psoriatic arthritis, VAS ¡Ü20; 6) HAQ-DI score ¡Ü0.5; 7) tender entheseal points, using the LEI score ¡Ü1. DAPSA, Disease Activity in Psoriatic Arthritis; FAS, full analysis set; HiDA, high disease activity; LEI, Leeds Enthesitis Index; LowDA, low disease activity; LS, least squares; MDA, minimal disease activity; ModDA, moderate disease activity; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area and Severity Index; REM, remission; VAS, visual analogue scale.</p></span></span></figure></div></section><section id="sec0017"><h3 id="cesectitle0025" class="u-h4 u-margin-m-top u-margin-xs-bottom">Safety outcomes</h3><div class="u-margin-s-bottom"><div id="para0047"><span><span>TEAEs occurred in 77.8%, 60.0%, 59.2%, and 54.2% of patients receiving zasocitinib 30 mg, 15 mg, 5 mg, or placebo, respectively. TEAEs leading to study treatment discontinuation occurred in 8.5% to 12.5% of patients in the zasocitinib treatment groups and 5.6% in the placebo group. The majority of TEAEs leading to study discontinuation were not considered related to the study drug, as assessed by the investigator. The most common TEAEs were <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/rhinopharyngitis" title="Learn more about nasopharyngitis from ScienceDirect's AI-generated Topic Pages" class="topic-link">nasopharyngitis</a> (occurring in 9.7%, 9.3%, 8.5%, and 4.2% of patients receiving zasocitinib 30 mg, 15 mg, 5 mg, or placebo, respectively) and </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/upper-respiratory-tract-infection" title="Learn more about upper respiratory tract infections from ScienceDirect's AI-generated Topic Pages" class="topic-link">upper respiratory tract infections</a> (occurring in 9.7%, 4.0%, 11.3%, and 2.8% of patients receiving zasocitinib 30 mg, 15 mg, 5 mg, or placebo, respectively) (</span><a class="anchor anchor-primary" href="#tbl0002" name="btbl0002" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tbl0002"><span class="anchor-text-container"><span class="anchor-text">Table 2</span></span></a>). One patient in each of the placebo and 15 mg zasocitinib groups experienced a nondisseminated case of herpes zoster infection (<a class="anchor anchor-primary" href="#sec0026" name="bsec0026" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="sec0026"><span class="anchor-text-container"><span class="anchor-text">Supplementary Table S4</span></span></a><span><span>). Most TEAEs were Grade 1 or 2 in severity. In total, 22 (7.6%) patients reported at least one Grade 3 TEAE (placebo: n = 7 [9.7%]; zasocitinib 30 mg: n = 3 [4.2%]; 15 mg: n = 7 [9.3%]; 5 mg: n = 5 [7.0%]), and 1 patient in the 5 mg group had a Grade 4 <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/coronary-artery-disease" title="Learn more about coronary artery disease from ScienceDirect's AI-generated Topic Pages" class="topic-link">coronary artery disease</a> event that was considered unrelated to study treatment, as assessed by the investigator. A higher rate of transient, Grade 1 or 2 dermatological events was observed in the 30 mg and 15 mg zasocitinib groups than in the other groups. All dermatological events resolved within a mean of 34 days mostly without pharmacologic intervention, except for 1 patient who experienced a Grade 2 </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/maculopapular-rash" title="Learn more about maculopapular rash from ScienceDirect's AI-generated Topic Pages" class="topic-link">maculopapular rash</a> considered related to the study drug, which resolved with medication. Acneiform dermatitis (Grade 2), related to the study drug, led to study discontinuation in one patient. No deaths were reported in the study.</span></div><div class="tables rowsep-0 colsep-0 frame-topbot" id="tbl0002"><span class="captions text-s"><span id="cap0007"><p id="spara009"><span class="label">Table 2</span>. Number of patients with TEAEs, reported by treatment group (SAS)</p></span></span><div class="groups"><table><thead><tr class="rowsep-1"><th scope="col" class="align-left valign-top" id="en0165">n (%) [#]</th><th scope="col" class="align-left valign-top" id="en0166">Placebo<br>(N = 72)</th><th scope="col" class="align-left valign-top" id="en0167">Zasocitinib <br>5 mg once daily<br>(N = 71)</th><th scope="col" class="align-left valign-top" id="en0168">Zasocitinib 15 mg once daily<br>(N = 75)</th><th scope="col" class="align-left valign-top" id="en0169">Zasocitinib 30 mg once daily<br>(N = 72)</th></tr></thead><tbody><tr><td class="align-left valign-top" id="en0170">Any TEAE</td><td class="align-left valign-top" id="en0171">39 (54.2) [87]</td><td class="align-left valign-top" id="en0172">42 (59.2) [88]</td><td class="align-left valign-top" id="en0173">45 (60.0) [106]</td><td class="align-left valign-top" id="en0174">56 (77.8) [135]</td></tr><tr><td class="align-left valign-top" id="en0175">Drug-related TEAEs</td><td class="align-left valign-top" id="en0176">11 (15.3) [13]</td><td class="align-left valign-top" id="en0177">15 (21.1) [23]</td><td class="align-left valign-top" id="en0178">20 (26.7) [49]</td><td class="align-left valign-top" id="en0179">29 (40.3) [61]</td></tr><tr><td class="align-left valign-top" id="en0180">TEAEs leading to study drug discontinuation</td><td class="align-left valign-top" id="en0181">4 (5.6) [4]</td><td class="align-left valign-top" id="en0182">6 (8.5) [6]</td><td class="align-left valign-top" id="en0183">7 (9.3) [9]</td><td class="align-left valign-top" id="en0184">9 (12.5) [11]</td></tr><tr><td class="align-left valign-top" id="en0185">TEAEs leading to study discontinuation</td><td class="align-left valign-top" id="en0186">1 (1.4) [1]</td><td class="align-left valign-top" id="en0187">0</td><td class="align-left valign-top" id="en0188">3 (4.0) [5]</td><td class="align-left valign-top" id="en0189">5 (6.9) [5]</td></tr><tr><td class="align-left valign-top" id="en0190">Serious TEAEs</td><td class="align-left valign-top" id="en0191">4 (5.6) [4]</td><td class="align-left valign-top" id="en0192">4 (5.6) [4]</td><td class="align-left valign-top" id="en0193">3 (4.0) [3]</td><td class="align-left valign-top" id="en0194">2 (2.8) [2]</td></tr><tr><td class="align-left valign-top" id="en0195">Grade 3 or higher TEAE</td><td class="align-left valign-top" id="en0196">7 (9.7) [8]</td><td class="align-left valign-top" id="en0197">6 (8.5) [6]</td><td class="align-left valign-top" id="en0198">7 (9.3) [9]</td><td class="align-left valign-top" id="en0199">3 (4.2) [3]</td></tr><tr><td class="align-left valign-top" id="en0200">TEAEs leading to death</td><td class="align-left valign-top" id="en0201">0</td><td class="align-left valign-top" id="en0202">0</td><td class="align-left valign-top" id="en0203">0</td><td class="align-left valign-top" id="en0204">0</td></tr><tr><td class="align-left valign-top" id="en0205">TEAESI<a class="anchor anchor-primary" href="#tb2fn1" name="btb2fn1" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb2fn1"><span class="anchor-text-container"><span class="anchor-text"><sup>a</sup></span></span></a></td><td class="align-left valign-top" id="en0206">19 (26.4) [27]</td><td class="align-left valign-top" id="en0207">33 (46.5) [43]</td><td class="align-left valign-top" id="en0208">22 (29.3) [25]</td><td class="align-left valign-top" id="en0209">38 (52.8) [50]</td></tr><tr><td class="align-left valign-top" id="en0210">&nbsp;Serious infections</td><td class="align-left valign-top" id="en0211">0</td><td class="align-left valign-top" id="en0212">2 (2.8) [2]</td><td class="align-left valign-top" id="en0213">0</td><td class="align-left valign-top" id="en0214">1 (1.4) [1]</td></tr><tr><td class="align-left valign-top" id="en0215" colspan="5">Most frequent TEAEs, n (%)<a class="anchor anchor-primary" href="#tb2fn2" name="btb2fn2" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb2fn2"><span class="anchor-text-container"><span class="anchor-text"><sup>b</sup></span></span></a></td></tr><tr><td class="align-left valign-top" id="en0216">&nbsp;Nasopharyngitis</td><td class="align-left valign-top" id="en0217">3 (4.2) [4]</td><td class="align-left valign-top" id="en0218">6 (8.5) [6]</td><td class="align-left valign-top" id="en0219">7 (9.3) [7]</td><td class="align-left valign-top" id="en0220">7 (9.7) [7]</td></tr><tr><td class="align-left valign-top" id="en0221">&nbsp;URTIs</td><td class="align-left valign-top" id="en0222">2 (2.8) [3]</td><td class="align-left valign-top" id="en0223">8 (11.3) [8]</td><td class="align-left valign-top" id="en0224">3 (4.0) [4]</td><td class="align-left valign-top" id="en0225">7 (9.7) [7]</td></tr><tr><td class="align-left valign-top" id="en0226">&nbsp;Headache</td><td class="align-left valign-top" id="en0227">3 (4.2) [3]</td><td class="align-left valign-top" id="en0228">2 (2.8) [3]</td><td class="align-left valign-top" id="en0229">6 (8.0) [6]</td><td class="align-left valign-top" id="en0230">4 (5.6) [6]</td></tr><tr><td class="align-left valign-top" id="en0231">&nbsp;Rash</td><td class="align-left valign-top" id="en0232">0</td><td class="align-left valign-top" id="en0233">3 (4.2) [4]</td><td class="align-left valign-top" id="en0234">6 (8.0) [6]</td><td class="align-left valign-top" id="en0235">4 (5.6) [4]</td></tr><tr><td class="align-left valign-top" id="en0236">&nbsp;Blood CK increased<a class="anchor anchor-primary" href="#tb2fn3" name="btb2fn3" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb2fn3"><span class="anchor-text-container"><span class="anchor-text"><sup>c</sup></span></span></a></td><td class="align-left valign-top" id="en0237">3 (4.2) [3]</td><td class="align-left valign-top" id="en0238">2 (2.8) [2]</td><td class="align-left valign-top" id="en0239">4 (5.3) [4]</td><td class="align-left valign-top" id="en0240">1 (1.4) [1]</td></tr><tr><td class="align-left valign-top" id="en0241">&nbsp;Dermatitis acneiform</td><td class="align-left valign-top" id="en0242">0</td><td class="align-left valign-top" id="en0243">0</td><td class="align-left valign-top" id="en0244">2 (2.7) [4]</td><td class="align-left valign-top" id="en0245">6 (8.3) [7]</td></tr><tr><td class="align-left valign-top" id="en0246">&nbsp;Psoriatic arthropathy</td><td class="align-left valign-top" id="en0247">5 (6.9) [6]</td><td class="align-left valign-top" id="en0248">0</td><td class="align-left valign-top" id="en0249">2 (2.7) [2]</td><td class="align-left valign-top" id="en0250">1 (1.4) [1]</td></tr><tr><td class="align-left valign-top" id="en0251">&nbsp;Rash papular</td><td class="align-left valign-top" id="en0252">0</td><td class="align-left valign-top" id="en0253">1 (1.4) [1]</td><td class="align-left valign-top" id="en0254">3 (4.0) [3]</td><td class="align-left valign-top" id="en0255">4 (5.6) [4]</td></tr><tr><td class="align-left valign-top" id="en0256">&nbsp;Aphthous ulcer</td><td class="align-left valign-top" id="en0257">0</td><td class="align-left valign-top" id="en0258">0</td><td class="align-left valign-top" id="en0259">1 (1.3) [1]</td><td class="align-left valign-top" id="en0260">6 (8.3) [7]</td></tr><tr><td class="align-left valign-top" id="en0261">&nbsp;Dermatitis allergic</td><td class="align-left valign-top" id="en0262">0</td><td class="align-left valign-top" id="en0263">1 (1.4) [1]</td><td class="align-left valign-top" id="en0264">1 (1.3) [1]</td><td class="align-left valign-top" id="en0265">4 (5.6) [5]</td></tr><tr><td class="align-left valign-top" id="en0266">&nbsp;Rash maculopapular</td><td class="align-left valign-top" id="en0267">0</td><td class="align-left valign-top" id="en0268">0</td><td class="align-left valign-top" id="en0269">2 (2.7) [4]</td><td class="align-left valign-top" id="en0270">4 (5.6) [5]</td></tr><tr><td class="align-left valign-top" id="en0271">Any TEAEs related to cytopenia<a class="anchor anchor-primary" href="#tb2fn3" name="btb2fn3" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb2fn3"><span class="anchor-text-container"><span class="anchor-text"><sup>c</sup></span></span></a></td><td class="align-left valign-top" id="en0272"></td><td class="align-left valign-top" id="en0273"></td><td class="align-left valign-top" id="en0274"></td><td class="align-left valign-top" id="en0275"></td></tr><tr><td class="align-left valign-top" id="en0276">&nbsp;Anaemia</td><td class="align-left valign-top" id="en0277">0</td><td class="align-left valign-top" id="en0278">0</td><td class="align-left valign-top" id="en0279">0</td><td class="align-left valign-top" id="en0280">3 (4.2) [4]</td></tr><tr><td class="align-left valign-top" id="en0281">&nbsp;Leukopenia<a class="anchor anchor-primary" href="#tb2fn4" name="btb2fn4" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb2fn4"><span class="anchor-text-container"><span class="anchor-text"><sup>d</sup></span></span></a></td><td class="align-left valign-top" id="en0282">1 (1.4) [1]</td><td class="align-left valign-top" id="en0283">1 (1.4) [1]</td><td class="align-left valign-top" id="en0284">0</td><td class="align-left valign-top" id="en0285">0</td></tr><tr><td class="align-left valign-top" id="en0286">&nbsp;Lymphopenia<a class="anchor anchor-primary" href="#tb2fn4" name="btb2fn4" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb2fn4"><span class="anchor-text-container"><span class="anchor-text"><sup>d</sup></span></span></a></td><td class="align-left valign-top" id="en0287">2 (2.8) [2]</td><td class="align-left valign-top" id="en0288">4 (5.6) [5]</td><td class="align-left valign-top" id="en0289">1 (1.3) [2]</td><td class="align-left valign-top" id="en0290">3 (4.2) [3]</td></tr><tr><td class="align-left valign-top" id="en0291">Any rash-related TEAEs<a class="anchor anchor-primary" href="#tb2fn5" name="btb2fn5" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb2fn5"><span class="anchor-text-container"><span class="anchor-text"><sup>e</sup></span></span></a></td><td class="align-left valign-top" id="en0292">0</td><td class="align-left valign-top" id="en0293">6 (8.5) [7]</td><td class="align-left valign-top" id="en0294">11 (14.7) [13]</td><td class="align-left valign-top" id="en0295">13 (18.1) [15]</td></tr><tr><td class="align-left valign-top" id="en0296">&nbsp;Rash erythematous</td><td class="align-left valign-top" id="en0297">0</td><td class="align-left valign-top" id="en0298">2 (2.8) [2]</td><td class="align-left valign-top" id="en0299">0</td><td class="align-left valign-top" id="en0300">2 (2.8) [2]</td></tr></tbody></table></div><div class="legend"><div class="u-margin-s-bottom" id="spara010"><span>AE, adverse event; CK, creatine kinase; CTCAE, Common Terminology Criteria for Adverse Events; <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/meddra" title="Learn more about MedDRA from ScienceDirect's AI-generated Topic Pages" class="topic-link">MedDRA</a>, Medical Dictionary for Regulatory Activities; SAS, safety analysis set; TEAE, treatment-emergent adverse event; TEAESI, treatment-emergent adverse event of special interest; URTI, </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/upper-respiratory-tract-infection" title="Learn more about upper respiratory tract infection from ScienceDirect's AI-generated Topic Pages" class="topic-link">upper respiratory tract infection</a>.</div><div class="u-margin-s-bottom" id="spara011">AEs were coded using MedDRA Version 26.0 or higher. The SAS included all randomised patients who received ¡Ý1 dose of the study drug. Patients were included in the analysis based on actual treatment received, regardless of the treatment group to which they were randomised.</div><div class="u-margin-s-bottom" id="spara012">[#] is the number of individual occurrences of the TEAE in that category.</div></div><dl class="footnotes"><dt id="tb2fn1">a</dt><dd><div class="u-margin-s-bottom" id="notep0018">Patients with at least one TEAESI including laboratory TEAESIs.</div></dd><dt id="tb2fn2">b</dt><dd><div class="u-margin-s-bottom" id="notep0019">TEAEs occurring at &gt;5% in any treatment group, categorised by preferred term.</div></dd><dt id="tb2fn3">c</dt><dd><div class="u-margin-s-bottom" id="notep0020">According to the defined criteria in the study protocol, CTCAE Grade ¡Ý2 cytopenia and ¡Ý3 CK elevations are considered AESIs.</div></dd><dt id="tb2fn4">d</dt><dd><div class="u-margin-s-bottom" id="notep0021">One patient in the placebo group reported both a <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/leukopenia" title="Learn more about leukopenia from ScienceDirect's AI-generated Topic Pages" class="topic-link">leukopenia</a><span> and <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/lymphocytopenia" title="Learn more about lymphopenia from ScienceDirect's AI-generated Topic Pages" class="topic-link">lymphopenia</a> AE.</span></div></dd><dt id="tb2fn5">e</dt><dd><div class="u-margin-s-bottom" id="notep0022">Rash-related TEAEs included rash, rash popular, rash macropapular, and rash erythematous.</div></dd></dl></div></div><div class="u-margin-s-bottom" id="para0048"><span><span>In this small study of limited duration, no systemic <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/opportunistic-infection" title="Learn more about opportunistic infection from ScienceDirect's AI-generated Topic Pages" class="topic-link">opportunistic infection</a><span>, MACEs, <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/thromboembolism" title="Learn more about thromboembolic from ScienceDirect's AI-generated Topic Pages" class="topic-link">thromboembolic</a> event, </span></span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/digestive-system-perforation" title="Learn more about gastrointestinal perforation from ScienceDirect's AI-generated Topic Pages" class="topic-link">gastrointestinal perforation</a>, or malignancy TEAESIs were observed in patients treated with zasocitinib (</span><a class="anchor anchor-primary" href="#sec0026" name="bsec0026" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="sec0026"><span class="anchor-text-container"><span class="anchor-text">Supplementary Table S4</span></span></a><span>). Rates of discontinuation due to TEAESIs were numerically similar across study groups. One patient in each treatment group reported a treatment-related adverse event of special interest (AESI) that led to study drug discontinuation. Overall, serious infections were observed in 3 (1.0%) patients. These were observed in the 5 mg (n = 2; <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/cellulitis" title="Learn more about cellulitis from ScienceDirect's AI-generated Topic Pages" class="topic-link">cellulitis</a><span><span> and respiratory tract infection) and 30 mg (n = 1; pharyngitis) treatment groups, all of which resolved. According to the defined criteria in the study protocol, Grade ¡Ý2 <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/cytopenia" title="Learn more about cytopenia from ScienceDirect's AI-generated Topic Pages" class="topic-link">cytopenia</a><span> and ¡Ý3 elevations of <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/creatine-kinase" title="Learn more about creatine kinase from ScienceDirect's AI-generated Topic Pages" class="topic-link">creatine kinase</a><span> were considered AESIs. Overall, 24 patients reported any cytopenia (n = 14) or creatine kinase (n = 10) related events. One patient in the placebo group reported both a <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/leukopenia" title="Learn more about leukopenia from ScienceDirect's AI-generated Topic Pages" class="topic-link">leukopenia</a> and </span></span></span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/lymphocytopenia" title="Learn more about lymphopenia from ScienceDirect's AI-generated Topic Pages" class="topic-link">lymphopenia</a> event. Infrequent Grade ¡Ý3 events of elevated creatine kinase (placebo: n = 1; 5 mg: n = 2; 15 mg: n = 3; 30 mg: n = 0) and Grade ¡Ý2 cytopenia (placebo: n = 2; 5 mg: n = 5; 15 mg: n = 1; 30 mg: n = 5) were observed. Overall, 2 patients (one each in the 5 mg and 30 mg zasocitinib groups) with Grade ¡Ý2 cytopenia reported clinical events with similar onset (lymphopenia and nasopharyngitis).</span></span></div><div class="u-margin-s-bottom"><div id="para0049">Laboratory parameters generally stayed within the normal range, with no clinically meaningful longitudinal changes observed across any groups and no clear dose-dependency in the zasocitinib groups. Shifts from baseline to postbaseline for haematology, lipid, and serum chemistry parameters were generally similar between all groups (<a class="anchor anchor-primary" href="#tbl0003" name="btbl0003" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tbl0003"><span class="anchor-text-container"><span class="anchor-text">Table 3</span></span></a>). Over the study period, no notable differences in laboratory shifts and the frequency of Grade ¡Ý2 changes between placebo and zasocitinib groups were observed (<a class="anchor anchor-primary" href="#sec0026" name="bsec0026" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="sec0026"><span class="anchor-text-container"><span class="anchor-text">Supplementary Table S5</span></span></a><span>). There were no clinically meaningful longitudinal changes throughout the 12-week study observed in haematology parameters (neutrophils, platelet counts, haemoglobin, lymphocytes), serum chemistry (creatine kinase, <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/alanine-aminotransferase" title="Learn more about alanine aminotransferase from ScienceDirect's AI-generated Topic Pages" class="topic-link">alanine aminotransferase</a><span><span>, aspartate aminotransferase, <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/bilirubin" title="Learn more about bilirubin from ScienceDirect's AI-generated Topic Pages" class="topic-link">bilirubin</a>, creatinine), and no clinically meaningful elevations in cholesterol or </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/triacylglycerol" title="Learn more about triglyceride from ScienceDirect's AI-generated Topic Pages" class="topic-link">triglyceride</a> levels were observed at week 12 (</span></span><a class="anchor anchor-primary" href="#fig0005" name="bfig0005" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fig0005"><span class="anchor-text-container"><span class="anchor-text">Fig 5</span></span></a>, <a class="anchor anchor-primary" href="#sec0026" name="bsec0026" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="sec0026"><span class="anchor-text-container"><span class="anchor-text">Supplementary Fig S3</span></span></a>).</div><div class="tables rowsep-0 colsep-0 frame-topbot" id="tbl0003"><span class="captions text-s"><span id="cap0008"><p id="spara013"><span class="label">Table 3</span>. Laboratory parameters: shift from baseline to postbaseline visits (SAS)</p></span></span><div class="groups"><table><thead><tr class="rowsep-1"><td scope="col" class="align-left valign-top" id="en0301"><span class="screen-reader-only">Empty Cell</span></td><th scope="col" class="align-left valign-top" id="en0302">Placebo<br>(N = 72)</th><th scope="col" class="align-left valign-top" id="en0303">Zasocitinib<br>5 mg once daily<br>(N = 71)</th><th scope="col" class="align-left valign-top" id="en0304">Zasocitinib<br>15 mg once daily<br>(N = 75)</th><th scope="col" class="align-left valign-top" id="en0305">Zasocitinib<br>30 mg once daily<br>(N = 72)</th></tr></thead><tbody><tr><td class="align-left valign-top" id="en0306" colspan="5">Haematology: shift from normal to low values, n (%)</td></tr><tr><th class="align-left valign-top" id="en0307" scope="row">&nbsp;Haemoglobin</th><td class="align-left valign-top" id="en0308">10 (13.9)</td><td class="align-left valign-top" id="en0309">9 (12.7)</td><td class="align-left valign-top" id="en0310">10 (13.3)</td><td class="align-left valign-top" id="en0311">10 (13.9)</td></tr><tr><th class="align-left valign-top" id="en0312" scope="row">&nbsp;Lymphocytes</th><td class="align-left valign-top" id="en0313">7 (9.7)</td><td class="align-left valign-top" id="en0314">8 (11.3)</td><td class="align-left valign-top" id="en0315">3 (4.0)</td><td class="align-left valign-top" id="en0316">6 (8.3)</td></tr><tr><th class="align-left valign-top" id="en0317" scope="row">&nbsp;Neutrophils</th><td class="align-left valign-top" id="en0318">0 (0.0)</td><td class="align-left valign-top" id="en0319">0 (0.0)</td><td class="align-left valign-top" id="en0320">0 (0.0)</td><td class="align-left valign-top" id="en0321">0 (0.0)</td></tr><tr><th class="align-left valign-top" id="en0322" scope="row">&nbsp;Platelets</th><td class="align-left valign-top" id="en0323">1 (1.4)</td><td class="align-left valign-top" id="en0324">3 (4.2)</td><td class="align-left valign-top" id="en0325">0 (0.0)</td><td class="align-left valign-top" id="en0326">1 (1.4)</td></tr><tr><td class="align-left valign-top" id="en0327" colspan="5">Serum chemistry: shift from normal to high values, n (%)</td></tr><tr><th class="align-left valign-top" id="en0328" scope="row">&nbsp;ALT</th><td class="align-left valign-top" id="en0329">9 (12.5)</td><td class="align-left valign-top" id="en0330">7 (9.9)</td><td class="align-left valign-top" id="en0331">11 (14.7)</td><td class="align-left valign-top" id="en0332">11 (15.3)</td></tr><tr><th class="align-left valign-top" id="en0333" scope="row">&nbsp;AST</th><td class="align-left valign-top" id="en0334">6 (8.3)</td><td class="align-left valign-top" id="en0335">3 (4.2)</td><td class="align-left valign-top" id="en0336">10 (13.3)</td><td class="align-left valign-top" id="en0337">9 (12.5)</td></tr><tr><th class="align-left valign-top" id="en0338" scope="row">&nbsp;CK</th><td class="align-left valign-top" id="en0339">13 (18.1)</td><td class="align-left valign-top" id="en0340">14 (19.7)</td><td class="align-left valign-top" id="en0341">10 (13.3)</td><td class="align-left valign-top" id="en0342">10 (13.9)</td></tr><tr><th class="align-left valign-top" id="en0343" scope="row">&nbsp;Creatinine</th><td class="align-left valign-top" id="en0344">5 (6.9)</td><td class="align-left valign-top" id="en0345">6 (8.5)</td><td class="align-left valign-top" id="en0346">11 (14.7)</td><td class="align-left valign-top" id="en0347">8 (11.1)</td></tr><tr><td class="align-left valign-top" id="en0348" colspan="5">Lipids: shift from normal to high values, n (%)</td></tr><tr><th class="align-left valign-top" id="en0349" scope="row">&nbsp;Cholesterol</th><td class="align-left valign-top" id="en0350">8 (11.1)</td><td class="align-left valign-top" id="en0351">7 (9.9)</td><td class="align-left valign-top" id="en0352">11 (14.7)</td><td class="align-left valign-top" id="en0353">8 (11.1)</td></tr><tr><th class="align-left valign-top" id="en0354" scope="row">&nbsp;LDL cholesterol</th><td class="align-left valign-top" id="en0355">5 (6.9)</td><td class="align-left valign-top" id="en0356">9 (12.7)</td><td class="align-left valign-top" id="en0357">7 (9.3)</td><td class="align-left valign-top" id="en0358">12 (16.7)</td></tr><tr><th class="align-left valign-top" id="en0359" scope="row">&nbsp;Triglycerides</th><td class="align-left valign-top" id="en0360">5 (6.9)</td><td class="align-left valign-top" id="en0361">3 (4.2)</td><td class="align-left valign-top" id="en0362">6 (8.0)</td><td class="align-left valign-top" id="en0363">5 (6.9)</td></tr></tbody></table></div><div class="legend"><div class="u-margin-s-bottom" id="spara014">ALT, <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/alanine-aminotransferase" title="Learn more about alanine aminotransferase from ScienceDirect's AI-generated Topic Pages" class="topic-link">alanine aminotransferase</a>; AST, aspartate aminotransferase; CK, creatine kinase; LDL, low-density lipoprotein; SAS, safety analysis set.</div><div class="u-margin-s-bottom" id="spara015">Laboratory parameter values were categorised as low, normal, or high based on the reference range for each laboratory variable. Data represent laboratory parameter shifts in patients who had normal values at baseline. The lowest/highest postbaseline value for each laboratory parameter was used to determine whether patients had shifted from a normal to a low/high value.</div></div></div><figure class="figure text-xs" id="fig0005"><span><img src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr5.jpg" height="860" alt="Figure 5" aria-describedby="cap0005"><ol class="u-margin-s-bottom"><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr5_lrg.jpg" target="_blank" download="" title="Download high-res image (1MB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download high-res image (1MB)</span></span></span></a></li><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-gr5.jpg" target="_blank" download="" title="Download full-size image"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download full-size image</span></span></span></a></li></ol></span><span class="captions text-s"><span id="cap0005"><p id="spara005"><span class="label">Figure 5</span>. <span>Key laboratory parameter changes over 16 weeks (SAS). A, Neutrophils. B, Platelets. C, Haemoglobin. D, Lymphocytes. E, Cholesterol. F, <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/triacylglycerol" title="Learn more about Triglycerides from ScienceDirect's AI-generated Topic Pages" class="topic-link">Triglycerides</a>. Data are observed values from the safety analysis set and presented as mean ¡À SD. Dashed lines represent upper and lower limits of the normal range for each parameter. </span><sup>a</sup>For graphs with 4 dashed lines, the black lines represent the male limits, and the grey lines represent the female limits. ALC, absolute lymphocyte count; ANC, absolute neutrophil count; SAS, safety analysis set.</p></span></span></figure></div><div class="u-margin-s-bottom" id="para0050">Evaluated vital signs included diastolic and systolic blood pressure, heart rate, temperature and body weight. No TEAEs related to these were reported.</div></section></section><section id="sec0018"><h2 id="cesectitle0026" class="u-h4 u-margin-l-top u-margin-xs-bottom">DISCUSSION</h2><div class="u-margin-s-bottom" id="para0051"><span>Zasocitinib is an investigational, oral, allosteric, highly selective, and potent <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/protein-tyrosine-kinase" title="Learn more about TYK2 from ScienceDirect's AI-generated Topic Pages" class="topic-link">TYK2</a> inhibitor in late-stage clinical development for the treatment of </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/inflammatory-disease" title="Learn more about IMIDs from ScienceDirect's AI-generated Topic Pages" class="topic-link">IMIDs</a>. In this phase 2b trial of patients with active PsA, the primary endpoint (ACR20 response at week 12) was met in the 30 mg and 15 mg groups. Treatment with once daily 30 mg or 15 mg zasocitinib was associated with numerically greater improvements in musculoskeletal and skin signs and symptoms, as well as in patient-reported and physician-assessed outcomes, compared with placebo. Notably, the ACR20 response curve observed with 30 mg or 15 mg zasocitinib increased over 12 weeks; studies of a longer duration will help determine whether the ACR20 response will further increase with treatment with zasocitinib.</div><div class="u-margin-s-bottom" id="para0052">PsA prevalence is equal in male and female patients; however, female patients typically exhibit higher disease activity, greater disease burden, increased pain, and poorer physical function than male patients [<a class="anchor anchor-primary" href="#bib0018" name="bbib0018" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0018"><span class="anchor-text-container"><span class="anchor-text">[18]</span></span></a>, <a class="anchor anchor-primary" href="#bib0019" name="bbib0019" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0019"><span class="anchor-text-container"><span class="anchor-text">[19]</span></span></a>, <a class="anchor anchor-primary" href="#bib0020" name="bbib0020" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0020"><span class="anchor-text-container"><span class="anchor-text">[20]</span></span></a>, <a class="anchor anchor-primary" href="#bib0021" name="bbib0021" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0021"><span class="anchor-text-container"><span class="anchor-text">[21]</span></span></a>]. Additionally, female patients appear more likely than male patients to experience a poorer clinical response to bDMARDs (including IL-17 and IL-23 inhibitors) versus targeted synthetic DMARDs (tsDMARDs) [<a class="anchor anchor-primary" href="#bib0022" name="bbib0022" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0022"><span class="anchor-text-container"><span class="anchor-text">22</span></span></a><span>]. This was an all-comers study design, and a greater proportion of patients in the 30 mg and 15 mg groups were female compared with the 5 mg and placebo groups. Treatment with 30 mg and 15 mg zasocitinib resulted in greater ACR20 responses than placebo, regardless of sex, supporting the hypothesis that female patients may exhibit improved outcomes versus <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/pharmacotherapy" title="Learn more about bDMARD treatment from ScienceDirect's AI-generated Topic Pages" class="topic-link">bDMARD treatment</a> with tsDMARD treatment like zasocitinib [</span><a class="anchor anchor-primary" href="#bib0023" name="bbib0023" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0023"><span class="anchor-text-container"><span class="anchor-text">23</span></span></a>]; these findings would need to be validated in studies of a longer duration.</div><div class="u-margin-s-bottom" id="para0053"><span>The patient population in this study was not selectively enriched for elevated hsCRP levels. As such, baseline mean hsCRP concentrations across the study groups were comparatively low compared with some hsCRP levels reported in other PsA <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/clinical-trial" title="Learn more about clinical trials from ScienceDirect's AI-generated Topic Pages" class="topic-link">clinical trials</a> [</span><a class="anchor anchor-primary" href="#bib0024" name="bbib0024" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0024"><span class="anchor-text-container"><span class="anchor-text">[24]</span></span></a>, <a class="anchor anchor-primary" href="#bib0025" name="bbib0025" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0025"><span class="anchor-text-container"><span class="anchor-text">[25]</span></span></a>, <a class="anchor anchor-primary" href="#bib0026" name="bbib0026" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0026"><span class="anchor-text-container"><span class="anchor-text">[26]</span></span></a>]. However, as hsCRP levels are not consistently elevated in active PsA, the hsCRP levels in this study may be more reflective of a real-world PsA population [<a class="anchor anchor-primary" href="#bib0027" name="bbib0027" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0027"><span class="anchor-text-container"><span class="anchor-text">27</span></span></a>].</div><div class="u-margin-s-bottom" id="para0054">Skin disease is one of the core domains of PsA [<a class="anchor anchor-primary" href="#bib0028" name="bbib0028" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0028"><span class="anchor-text-container"><span class="anchor-text">28</span></span></a>,<a class="anchor anchor-primary" href="#bib0029" name="bbib0029" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0029"><span class="anchor-text-container"><span class="anchor-text">29</span></span></a>], and it is estimated that as many as 82% of patients with PsA have coexisting psoriasis [<a class="anchor anchor-primary" href="#bib0030" name="bbib0030" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0030"><span class="anchor-text-container"><span class="anchor-text">30</span></span></a>]. Patients with PsA and psoriasis exhibit worse physical function and higher disease activity scores, utilise more health care resources, and report greater impairment on HRQoL than those with PsA or psoriasis alone [<a class="anchor anchor-primary" href="#bib0031" name="bbib0031" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0031"><span class="anchor-text-container"><span class="anchor-text">[31]</span></span></a>, <a class="anchor anchor-primary" href="#bib0032" name="bbib0032" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0032"><span class="anchor-text-container"><span class="anchor-text">[32]</span></span></a>, <a class="anchor anchor-primary" href="#bib0033" name="bbib0033" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0033"><span class="anchor-text-container"><span class="anchor-text">[33]</span></span></a>, <a class="anchor anchor-primary" href="#bib0034" name="bbib0034" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0034"><span class="anchor-text-container"><span class="anchor-text">[34]</span></span></a>, <a class="anchor anchor-primary" href="#bib0035" name="bbib0035" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0035"><span class="anchor-text-container"><span class="anchor-text">[35]</span></span></a><span>]. However, treatment with zasocitinib demonstrated early and greater improvements versus placebo across skin efficacy endpoints. Differences in PASI scores were observed between patients receiving zasocitinib 30 mg and placebo as early as week 2. At week 12, 26.1% of patients with skin involvement treated with 30 mg of zasocitinib experienced complete skin clearance (PASI 100), and 32.8% achieved clear or almost clear skin (PGA-PsO score of 0 or 1 with a ¡Ý2-point improvement from baseline). The skin activity response data from this study are consistent with those observed in the phase 2b study of zasocitinib in moderate-to-severe <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/psoriasis-vulgaris" title="Learn more about plaque psoriasis from ScienceDirect's AI-generated Topic Pages" class="topic-link">plaque psoriasis</a>, in which one-third of patients receiving 30 mg zasocitinib achieved complete skin clearance after 12 weeks of treatment [</span><a class="anchor anchor-primary" href="#bib0016" name="bbib0016" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0016"><span class="anchor-text-container"><span class="anchor-text">16</span></span></a>].</div><div class="u-margin-s-bottom" id="para0055">Several guidelines for PsA treatment support LDA and REM as treat-to-target goals [<a class="anchor anchor-primary" href="#bib0004" name="bbib0004" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0004"><span class="anchor-text-container"><span class="anchor-text">4</span></span></a>,<a class="anchor anchor-primary" href="#bib0007" name="bbib0007" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0007"><span class="anchor-text-container"><span class="anchor-text">7</span></span></a>,<a class="anchor anchor-primary" href="#bib0036" name="bbib0036" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0036"><span class="anchor-text-container"><span class="anchor-text">36</span></span></a>,<a class="anchor anchor-primary" href="#bib0037" name="bbib0037" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0037"><span class="anchor-text-container"><span class="anchor-text">37</span></span></a>]. MDA is a PsA specific composite measure, and achievement is shown to correspond with quality of life and a level of symptoms that are acceptable to patients [<a class="anchor anchor-primary" href="#bib0037" name="bbib0037" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0037"><span class="anchor-text-container"><span class="anchor-text">37</span></span></a>]. Treatment with 30 mg and 15 mg zasocitinib consistently ameliorated disease activity, assessed by achievement of MDA and improvement in DAPSA and PASDAS. By week 12, 30 mg or 15 mg zasocitinib treatment resulted in higher rates of patients achieving LDA or REM versus placebo across multiple disease activity composite instruments.</div><div class="u-margin-s-bottom" id="para0056">Zasocitinib was generally well tolerated at all doses, with a low proportion of patients discontinuing the study owing to TEAEs across all groups. However, the number of discontinuations was numerically higher in the zasocitinib groups than the placebo group. These findings were consistent with those observed in healthy volunteers and patients with plaque psoriasis [<a class="anchor anchor-primary" href="#bib0016" name="bbib0016" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0016"><span class="anchor-text-container"><span class="anchor-text">16</span></span></a>,<a class="anchor anchor-primary" href="#bib0038" name="bbib0038" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0038"><span class="anchor-text-container"><span class="anchor-text">38</span></span></a><span><span><span>]. In the present study, an increase in dermatological TEAEs was observed with increasing doses of zasocitinib. However, these were generally mild to moderate in severity and resolved within a mean duration of 34 days mostly without pharmacological intervention; only 1 event led to study drug discontinuation. Few serious infections were observed. MACEs, systemic <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/opportunistic-infection" title="Learn more about opportunistic infections from ScienceDirect's AI-generated Topic Pages" class="topic-link">opportunistic infections</a>, thromboembolic events, and malignancies were not observed in any zasocitinib group; larger studies will be needed to confirm the safety profile of zasocitinib. Over the study period, zasocitinib did not result in any dose-dependent clinically meaningful changes in the laboratory parameters, and there were no notable differences in laboratory shifts or frequency of Grade ¡Ý2 changes between placebo and treatment groups. No correlations between laboratory changes associated with JAK1, </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/janus-kinase" title="Learn more about JAK2 from ScienceDirect's AI-generated Topic Pages" class="topic-link">JAK2</a>, and </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/janus-kinase-3-inhibitor" title="Learn more about JAK3 inhibitors from ScienceDirect's AI-generated Topic Pages" class="topic-link">JAK3 inhibitors</a><span> (eg, cytopenia, renal and <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/liver-enzyme" title="Learn more about liver enzyme from ScienceDirect's AI-generated Topic Pages" class="topic-link">liver enzyme</a> elevations, and lipid elevations) and zasocitinib were observed, consistent with the high selectivity of zasocitinib for TYK2.</span></span></div><div class="u-margin-s-bottom" id="para0057"><span><span>This study had some limitations, including a potential lack of statistical power and a lack of hierarchical testing approach for secondary and exploratory endpoints, owing to the small sample size. This was particularly evident for endpoints with impacts on domains only present in subsets of patients, such as <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/dactylitis" title="Learn more about dactylitis from ScienceDirect's AI-generated Topic Pages" class="topic-link">dactylitis</a> and </span><a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/enthesitis" title="Learn more about enthesitis from ScienceDirect's AI-generated Topic Pages" class="topic-link">enthesitis</a>. Larger studies are required to further assess the effect of zasocitinib on these disease domains. As shown by the lack of a plateau observed in ACR20 response at week 12, longer studies are also required to determine the timing of the maximal response associated with zasocitinib treatment across various endpoints representing the core domains of the disease. Finally, patient recruitment focused on 4 countries, with the majority of patients being recruited from Eastern Europe. The numerical differences in ACR20 responses for the placebo group between regions in this study are not uncommon and have also been observed between other randomised, placebo-controlled PsA trials; such variability in response may be due to several factors including differences in csDMARD treatment, publication year, and number of study sites [</span><a class="anchor anchor-primary" href="#bib0039" name="bbib0039" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0039"><span class="anchor-text-container"><span class="anchor-text">39</span></span></a>].</div><div class="u-margin-s-bottom" id="para0058">In conclusion, 30 mg and 15 mg zasocitinib demonstrated efficacy versus placebo across key PsA domains (musculoskeletal and skin activity), with the highest dose consistently providing numerically superior responses on skin activity measures. Safety results were consistent with data previously reported in patients with plaque psoriasis and healthy volunteers [<a class="anchor anchor-primary" href="#bib0016" name="bbib0016" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0016"><span class="anchor-text-container"><span class="anchor-text">16</span></span></a>,<a class="anchor anchor-primary" href="#bib0038" name="bbib0038" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0038"><span class="anchor-text-container"><span class="anchor-text">38</span></span></a>]. The lack of safety events associated with JAK1, JAK2, or JAK3 inhibition is reflective of the highly selective TYK2 inhibition of zasocitinib. These results highlight the potential of zasocitinib as a new oral therapeutic option in patients with active PsA. Consequently, phase 3 studies are ongoing (NCT06671483 and NCT06671496) to explore its full potential and to confirm these preliminary results in larger, more diverse patient populations, aiming to improve management and outcomes for patients with PsA.</div></section><section id="sec0003a"><h2 id="cesectitle0011a" class="u-h4 u-margin-l-top u-margin-xs-bottom">CRediT authorship contribution statement</h2><div class="u-margin-s-bottom" id="para0018a"><strong>Alan Kivitz:</strong> Writing ¨C review &amp; editing, Visualization, Supervision, Resources, Investigation. <strong>Xenofon Baraliakos:</strong> Writing ¨C review &amp; editing, Supervision. <strong>Elena Tomaselli Muensterman:</strong> Writing ¨C review &amp; editing, Writing ¨C original draft, Formal analysis, Data curation. <strong>Arthur Kavanaugh:</strong> Writing ¨C review &amp; editing, Conceptualization. <strong>D¨¦sir¨¦e van der Heijde:</strong> Writing ¨C review &amp; editing, Methodology, Conceptualization. <strong>Piotr A Klimiuk:</strong> Writing ¨C review &amp; editing, Investigation, Data curation. <strong>Guillermo Valenzuela:</strong> Writing ¨C review &amp; editing, Investigation, Conceptualization. <strong>Eva Dokoupilova:</strong> Writing ¨C review &amp; editing, Investigation, Data curation. <strong>Gabrielle Poirier:</strong> Supervision, Project administration. <strong>Bhaskar Srivastava:</strong> Writing ¨C review &amp; editing, Supervision, Methodology, Investigation, Conceptualization. <span>Sue <a href="/topics/pharmacology-toxicology-and-pharmaceutical-science/serratiopeptidase" title="Learn more about Dasen from ScienceDirect's AI-generated Topic Pages" class="topic-link">Dasen</a>:</span> Writing ¨C review &amp; editing, Supervision, Methodology, Data curation, Conceptualization. <strong>Xinyan Zhang:</strong> Methodology, Formal analysis, Data curation, Conceptualization. <strong>Ting Hong:</strong> Writing ¨C review &amp; editing, Methodology, Formal analysis, Data curation. <strong>Jingjing Chen:</strong> Writing ¨C review &amp; editing, Methodology, Formal analysis, Data curation. <strong>Peter Pothula:</strong> Writing ¨C review &amp; editing, Writing ¨C original draft, Formal analysis, Data curation. <strong>Haoling Holly Weng:</strong> Writing ¨C review &amp; editing, Supervision, Methodology, Formal analysis, Conceptualization. <strong>Mona Trivedi:</strong> Writing ¨C review &amp; editing, Writing ¨C original draft, Visualization, Supervision. <strong>Apinya Lertratanakul:</strong> Writing ¨C review &amp; editing, Writing ¨C original draft, Visualization, Supervision.</div></section></div><section id="coi0001"><h2 id="cesectitle0029" class="u-h4 u-margin-l-top u-margin-xs-bottom">Competing interests</h2><div class="u-margin-s-bottom" id="para0067">A Kivitz has received consulting fees from Fresenius Kabi, Genzyme, Gilead, Grunenthal, GSK, Horizon, Janssen, Pfizer, Selecta Biosciences, SynAct Pharma, and Takeda; has received payments or fees for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Amgen, Eli Lilly, GSK, Pfizer, and UCB; has been part of a board or advisory board for ChemoCentryx, Horizon Therapeutics, Janssen, Novartis, Princeton Biopartners, and UCB; and has stock or stock options in Amgen, Gilead, GSK, Novartis, and Pfizer. XB has received research grants and been a consultant and member of advisory boards for AbbVie, Alfasigma, Amgen, Bristol Myers Squibb, Celltrion, Cesas, Eli Lilly, Galapagos, Janssen, Moonlake Immunotherapies, Novartis, Pfizer, Roche, Sandoz, Springer, STADA, Takeda, UCB, and Zuellig Pharma. Non-commercial disclosures: ASAS President and EULAR President-Elect. ETM, TH, JC, and PP are employees and equity holders of Takeda Development Center Americas, Inc. A Kavanaugh has received consulting fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Takeda, and UCB. DvdH has received consulting fees from AbbVie, Alfasigma, Argenx, Bristol Myers Squibb, Eli Lilly, Grey-Wolf Therapeutics, Janssen, Novartis, Pfizer, Takeda, and UCB Pharma and is an Associate Editor for <em>Annals of the Rheumatic Diseases</em>, an Editorial Board member for <em>The Journal of Rheumatology</em> and <em>RMD Open</em>, an advisor for the Assessment of Spondyloarthritis International Society, and Director of Imaging Rheumatology B.V. PAK has no potential conflicts of interest to disclose. GV has received grant/research support from Mallinckrodt Pharmaceuticals and has received consulting fees from, or been involved in, speakers bureaus for AbbVie, Alexion, Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Esaote, Exagen, Genentech, Gilead, Global Health Living, Horizon Therapeutics, Image Analysis Group, Janssen, Mallinckrodt Pharmaceuticals, Merck, Novartis, Pfizer, Pharmacia, Radius, Regeneron, Sandoz, Sanofi, Takeda, and UCB. ED has received grant/research support from AbbVie, UCB Biopharma SPRL, Eli Lilly, Galapagos, Gilead, GSK, Hexal AG, Janssen, Nimbus Lakshmi, Inc, Novartis, Pfizer, Sanofi, and Samsung. GP is an employee and equity holder of Nimbus.* BS, SD, and XZ were employees and equity holders of Nimbus* at the time of the study. HHW is an employee of HW MedAdvice, LLC and received consultancy fees in relation to the conduct of this study. MT and AL were employees and equity holders of Takeda Development Center Americas, Inc, at the time of the study. *Nimbus refers to the group of entities including Nimbus Therapeutics, LLC; Nimbus Discovery, Inc; and Nimbus Lakshmi, Inc. (NB: Nimbus Lakshmi, Inc was acquired by Takeda Pharmaceuticals in February 2023). A video abstract of this article can be found in the Supplementary Materials.</div></section><section id="sec0019"><h2 id="cesectitle0027" class="u-h4 u-margin-l-top u-margin-xs-bottom">Acknowledgements</h2><div class="u-margin-s-bottom" id="para0065">The authors would like to thank Bharani Guttikonda, Deepak Khambadakone, Lily Xu, and Michael Williams for their programming support during this study.</div></section><section id="sec0020"><h2 id="cesectitle0028" class="u-h4 u-margin-l-top u-margin-xs-bottom">Funding</h2><div class="u-margin-s-bottom" id="para0066">This study was funded by Nimbus Discovery, Inc, and Takeda Development Center Americas, Inc. Nimbus refers to the group of entities including Nimbus Therapeutics, LLC; Nimbus Discovery, Inc; and Nimbus Lakshmi, Inc (NB: Nimbus Lakshmi, Inc was acquired by Takeda Pharmaceuticals in February 2023). Medical writing support was provided by Alexandra Smith, MSc, of Oxford PharmaGenesis, Oxford, UK, under the direction of the authors, and was funded by Takeda Development Center Americas, Inc. Technical and editing support for the author video was provided by Oxford PharmaGenesis, Oxford, UK, and was funded by Takeda Development Center Americas, Inc.</div></section><section id="sec0021"><h2 id="cesectitle0030" class="u-h4 u-margin-l-top u-margin-xs-bottom">Patient consent for publication</h2><div class="u-margin-s-bottom" id="para0068">Not applicable.</div></section><section id="sec0022"><h2 id="cesectitle0031" class="u-h4 u-margin-l-top u-margin-xs-bottom">Ethics approval</h2><div class="u-margin-s-bottom" id="para0069">This study was performed in accordance with ethical principles originating from the Declaration of Helsinki, which are consistent with Good Clinical Practice and applicable regulatory requirements. Patients provided written, informed consent before starting the study. The clinical study protocol (and amendments), investigator brochure, samples of informed consent forms and other study-related documents were reviewed and approved by institutional review boards or independent ethics committees of all study sites.</div></section><section id="sec0023"><h2 id="cesectitle0032" class="u-h4 u-margin-l-top u-margin-xs-bottom">Provenance and peer review</h2><div class="u-margin-s-bottom" id="para0070">Not commissioned; externally peer reviewed.</div></section><section id="sec0024"><h2 id="cesectitle0033" class="u-h4 u-margin-l-top u-margin-xs-bottom">Data availability statement</h2><div class="u-margin-s-bottom" id="para0071">The data sets, including the redacted study protocol, redacted statistical analysis plan, and individual participants¡¯ data supporting the results reported in this article, will be made available within 3 months from initial request to researchers who provide a methodologically sound proposal. The data will be provided after its deidentification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymisation.</div></section><section id="sec0025"><h2 id="cesectitle0034" class="u-h4 u-margin-l-top u-margin-xs-bottom">Previous publications</h2><div class="u-margin-s-bottom" id="para0072">1. ACR Convergence (2023) American College of Rheumatology 2023 Annual Scientific Meeting. Kivitz A, et al. Efficacy and safety outcomes of TAK-279, a selective oral tyrosine kinase 2 (TYK2) inhibitor, from a randomized, double-blind, placebo-controlled phase 2b trial in patients with active psoriatic arthritis. Poster presentation: 10¨C15 November, 2023.</div><div class="u-margin-s-bottom" id="para0073">2. IDEOM Annual Meeting (2024) International Dermatology Outcome Measures Annual Meeting. Winkelman W, et al. Efficacy and safety outcomes of TAK-279, a selective oral tyrosine kinase 2 (TYK2) inhibitor, from a randomized, double-blind, placebo-controlled phase 2b trial in patients with active psoriatic arthritis. Poster presentation: 4¨C6 April, 2024.</div><div class="u-margin-s-bottom" id="para0074">3. JCR Meeting (2024) Japan College of Rheumatology Meeting. Tanaka N, et al. Phase 2b study of tyrosine kinase 2 (TYK2) inhibitor TAK-279 in psoriatic arthritis (PsA) patients. Poster presentation: 18¨C20 April, 2024.</div><div class="u-margin-s-bottom" id="para0075">4. EULAR Congress (2024) European Alliance of Associations for Rheumatology Congress. Kivitz A, et al. Efficacy and safety outcomes of TAK-279, a selective oral tyrosine kinase 2 (TYK2) inhibitor, from a randomized, double-blind, placebo-controlled phase 2b trial in patients with active psoriatic arthritis. Oral presentation: 12¨C15 June, 2024.</div><div class="u-margin-s-bottom" id="para0076">5. IFPA Conference (2024) International Federation of Psoriasis Associations Conference. Kivitz A, et al. Efficacy and safety of zasocitinib (TAK-279), a selective oral TYK2 inhibitor, in a randomized, placebo-controlled phase 2b trial in psoriatic arthritis. Poster presentation: and oral presentation: 27¨C29 June, 2024.</div><div class="u-margin-s-bottom" id="para0077">6. APLAR Congress (2024) Asia-Pacific League of Associations for Rheumatology Congress. Kivitz A, et al. Efficacy and safety of zasocitinib (TAK-279), a selective, oral TYK2 inhibitor: a randomized, placebo-controlled phase 2b trial in psoriatic arthritis. Oral presentation: 21¨C25 August, 2024.</div><div class="u-margin-s-bottom" id="para0078">7. EADV Congress (2024) European Academy of Dermatology and Venereology Congress. Gottlieb A, et al. Zasocitinib (TAK-279), a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, elicits early skin responses and minimal disease activity in patients with active psoriatic arthritis: results from a randomized phase 2b study. Oral presentation: 25¨C28 September, 2024.</div><div class="u-margin-s-bottom" id="para0079">8. ACR Convergence (2024) American College of Rheumatology 2024 Annual Scientific Meeting. Kavanaugh A, et al. Assessment of laboratory parameter changes in a phase 2b trial of zasocitinib (TAK-279), an oral, selective TYK2 inhibitor, in patients with active psoriatic arthritis. Poster presentation: 14¨C19 November, 2024.</div><div class="u-margin-s-bottom" id="para0080">9. ACR Convergence (2024) American College of Rheumatology 2024 Annual Scientific Meeting. Gottlieb A, et al. Zasocitinib (TAK-279), a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, elicits early skin responses and minimal disease activity in patients with active psoriatic arthritis: results from a randomized phase 2b study. Poster presentation: 14¨C19 November, 2024.</div><div class="u-margin-s-bottom" id="para0081">10. ACR Convergence (2024) American College of Rheumatology 2024 Annual Scientific Meeting. Mease P, et al. Zasocitinib (TAK-279), an oral, selective tyrosine kinase 2 inhibitor: additional improvements in disease activity and achievement of remission in patients with psoriatic arthritis enrolled in a phase 2b Trial. Oral presentation: 14¨C19 November, 2024.</div></section><div class="Appendices"><section id="sec0027"><h2 id="cesectitle9002" class="u-h4 u-margin-l-top u-margin-xs-bottom">Appendix. Supplementary materials</h2><span class="download-all-supplemental-data"><span class="article-attachment"><iframe title="download_all" name="download_all" class="u-hide"></iframe><form method="post" action="/sdfe/pdf/download/S0003496725010416/attachments" target="download_all"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc1.mp4"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc2.pptx"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc3.docx"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc4_lrg.jpg"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc4.jpg"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc5_lrg.jpg"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc5.jpg"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc6_lrg.jpg"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc6.jpg"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc7_lrg.jpg"><input name="eids" type="hidden" value="1-s2.0-S0003496725010416-mmc7.jpg"><button class="button-link download-all-button u-font-sans button-link-primary button-link-icon-left" type="submit"><svg focusable="false" viewBox="0 0 98 128" height="20" class="icon icon-download"><path d="M77.38 56.18l-6.6-7.06L54 66.36V26H44v40.34L26.28 49.1l-7.3 7.08 29.2 29.32 29.2-29.32M88 74v20H10V74H0v30h98V74H88"></path></svg><span class="button-link-text-container"><span class="button-link-text"><span class="download-all-title">Download all </span>supplementary files<span class="u-show-inline-from-sm"> included with this article</span></span></span></button></form><a class="anchor help-link u-font-sans u-margin-s-left anchor-primary anchor-has-colored-icon anchor-icon-left anchor-with-icon" href="https://service.elsevier.com/app/answers/detail/a_id/19286/supporthub/sciencedirect/" target="_blank" title="What¡¯s this? (Opens in new window)"><svg focusable="false" viewBox="0 0 114 128" height="20" class="icon icon-help"><path d="M57 8C35.69 7.69 15.11 21.17 6.68 40.71c-8.81 19.38-4.91 43.67 9.63 59.25 13.81 15.59 36.85 21.93 56.71 15.68 21.49-6.26 37.84-26.81 38.88-49.21 1.59-21.15-10.47-42.41-29.29-52.1C74.76 10.17 65.88 7.99 57 8zm0 10c20.38-.37 39.57 14.94 43.85 34.85 4.59 18.53-4.25 39.23-20.76 48.79-17.05 10.59-40.96 7.62-54.9-6.83-14.45-13.94-17.42-37.85-6.83-54.9C26.28 26.5 41.39 17.83 57 18zm-.14 14C45.31 32.26 40 40.43 40 50v2h10v-2c0-4.22 2.22-9.66 8-9.24 5.5.4 6.32 5.14 5.78 8.14C62.68 55.06 52 58.4 52 69.4V76h10v-5.56c0-8.16 11.22-11.52 12-21.7.74-9.86-5.56-16.52-16-16.74-.39-.01-.76-.01-1.14 0zM52 82v10h10V82H52z"></path></svg><span class="anchor-text-container"><span class="anchor-text">What¡¯s this?</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></span></span><div class="u-margin-s-bottom" id="para0059a"><span class="display"><span class="e-component e-component-mmc1" id="ecom0001"><span class="article-attachment u-margin-xs-bottom"><span class="video-player"><video controls="" crossorigin="anonymous" preload="auto" style="width: 100%;"><source src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc1.mp4" type="video/mp4"></video></span><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc1.mp4" target="_blank" download="" title="Download video (57MB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download video (57MB)</span></span></span></a></span><span class="captions text-s"><span id="cap00011"><p id="spara0011"><span class="label">Video</span>. Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study</p></span></span></span></span><span class="display"><span class="e-component e-component-mmc2" id="ecom0002"><span class="article-attachment u-margin-xs-bottom"><a class="anchor download-link u-font-sans anchor-primary anchor-icon-left anchor-with-icon" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc2.pptx" target="_blank" download="" title="Download Powerpoint document (405KB)"><svg focusable="false" viewBox="0 0 118 128" height="20" width="20" class="icon icon-audio-slides"><path d="M106 84H30V26h76v58zM20 16v78h96V16H20zm32 56l34-17-34-17zm46 30H12V34H2v78h96z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download Powerpoint document (405KB)</span></span></span></a></span></span></span><span class="display"><span class="e-component e-component-mmc3" id="ecom0003"><span class="article-attachment u-margin-xs-bottom"><a class="anchor download-link u-font-sans anchor-primary anchor-icon-left anchor-with-icon" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc3.docx" target="_blank" download="" title="Download Word document (5MB)"><svg focusable="false" viewBox="0 0 92 128" height="20" width="20" class="icon icon-text-document"><path d="M1 10v108h57.22L91 85.09V10H1m80 70.96L54.07 108H11V20h70v60.96zM43 100h10V80h20V70H43v30M25 32h42v10H25V32zm0 18h42v10H25V50z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download Word document (5MB)</span></span></span></a></span></span></span><span class="display"><span class="e-component e-component-mmc4" id="ecom0004"><span class="article-attachment u-margin-xs-bottom"><a class="anchor icon-link anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc4_lrg.jpg" target="_blank" rel="noreferrer noopener" download="" title="Download high-res image (439KB)"><span class="anchor-text-container"><span class="anchor-text"><img src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc4.sml" alt="Thumbnail"></span></span></a><ul><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc4_lrg.jpg" target="_blank" download="" title="Download high-res image (439KB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download high-res image (439KB)</span></span></span></a></li><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc4.jpg" target="_blank" download="" title="Download full-size image (47KB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download full-size image (47KB)</span></span></span></a></li></ul></span></span></span><span class="display"><span class="e-component e-component-mmc5" id="ecom0005"><span class="article-attachment u-margin-xs-bottom"><a class="anchor icon-link anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc5_lrg.jpg" target="_blank" rel="noreferrer noopener" download="" title="Download high-res image (814KB)"><span class="anchor-text-container"><span class="anchor-text"><img src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc5.sml" alt="Thumbnail"></span></span></a><ul><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc5_lrg.jpg" target="_blank" download="" title="Download high-res image (814KB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download high-res image (814KB)</span></span></span></a></li><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc5.jpg" target="_blank" download="" title="Download full-size image (83KB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download full-size image (83KB)</span></span></span></a></li></ul></span></span></span><span class="display"><span class="e-component e-component-mmc6" id="ecom0006"><span class="article-attachment u-margin-xs-bottom"><a class="anchor icon-link anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc6_lrg.jpg" target="_blank" rel="noreferrer noopener" download="" title="Download high-res image (2MB)"><span class="anchor-text-container"><span class="anchor-text"><img src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc6.sml" alt="Thumbnail"></span></span></a><ul><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc6_lrg.jpg" target="_blank" download="" title="Download high-res image (2MB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download high-res image (2MB)</span></span></span></a></li><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc6.jpg" target="_blank" download="" title="Download full-size image (223KB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download full-size image (223KB)</span></span></span></a></li></ul></span></span></span><span class="display"><span class="e-component e-component-mmc7" id="ecom00016"><span class="article-attachment u-margin-xs-bottom"><a class="anchor icon-link anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc7_lrg.jpg" target="_blank" rel="noreferrer noopener" download="" title="Download high-res image (300KB)"><span class="anchor-text-container"><span class="anchor-text"><img src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc7.sml" alt="Thumbnail"></span></span></a><ul><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc7_lrg.jpg" target="_blank" download="" title="Download high-res image (300KB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download high-res image (300KB)</span></span></span></a></li><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725010416-mmc7.jpg" target="_blank" download="" title="Download full-size image (37KB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download full-size image (37KB)</span></span></span></a></li></ul></span></span></span></div></section></div></div><div class="related-content-links u-display-none-from-md"><button class="button-link button-link-primary button-link-small" type="button"><span class="button-link-text-container"><span class="button-link-text">Recommended articles</span></span></button></div><div class="Tail"></div><div><section class="bibliography u-font-serif text-s" id="cebibl1"><h2 class="section-title u-h4 u-margin-l-top u-margin-xs-bottom">REFERENCES</h2><section class="bibliography-sec" id="cebibsec1"><ol class="references" id="reference-links-cebibsec1"><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0001" id="ref-id-bib0001" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[1]</span></span></a></span><span class="reference" id="sbref0001"><div class="contribution"><div class="authors u-font-sans">A. Ogdie, L.C. Coates, D.D. Gladman</div><div id="ref-id-sbref0001" class="title text-m">Treatment guidelines in psoriatic arthritis</div></div><div class="host u-font-sans">Rheumatology (Oxford), 59 (2020), pp. i37-i46</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1093/rheumatology/kez383" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0001"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Treatment%20guidelines%20in%20psoriatic%20arthritis&amp;publication_year=2020&amp;author=A.%20Ogdie&amp;author=L.C.%20Coates&amp;author=D.D.%20Gladman" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0001"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0002" id="ref-id-bib0002" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[2]</span></span></a></span><span class="reference" id="sbref0002"><div class="contribution"><div class="authors u-font-sans">C.T. Ritchlin, R.A. Colbert, D.D. Gladman</div><div id="ref-id-sbref0002" class="title text-m">Psoriatic arthritis</div></div><div class="host u-font-sans">N Engl J Med, 376 (2017), pp. 957-970</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85015676592&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0002"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Psoriatic%20arthritis&amp;publication_year=2017&amp;author=C.T.%20Ritchlin&amp;author=R.A.%20Colbert&amp;author=D.D.%20Gladman" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0002"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0003" id="ref-id-bib0003" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[3]</span></span></a></span><span class="reference" id="sbref0003"><div class="contribution"><div class="authors u-font-sans">W. Taylor, D. Gladman, P. Helliwell, A. Marchesoni, P. Mease, H. Mielants, <em> et al.</em></div><div id="ref-id-sbref0003" class="title text-m">Classification criteria for psoriatic arthritis: development of new criteria from a large international study</div></div><div class="host u-font-sans">Arthritis Rheum, 54 (2006), pp. 2665-2673</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1002/art.21972" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0003"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-33746951437&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0003"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Classification%20criteria%20for%20psoriatic%20arthritis%3A%20development%20of%20new%20criteria%20from%20a%20large%20international%20study&amp;publication_year=2006&amp;author=W.%20Taylor&amp;author=D.%20Gladman&amp;author=P.%20Helliwell&amp;author=A.%20Marchesoni&amp;author=P.%20Mease&amp;author=H.%20Mielants" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0003"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0004" id="ref-id-bib0004" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[4]</span></span></a></span><span class="reference" id="sbref0004"><div class="contribution"><div class="authors u-font-sans">L.C. Coates, E.R. Soriano, N. Corp, H. Bertheussen, K. Callis Duffin, <em> et al.</em></div><div id="ref-id-sbref0004" class="title text-m">Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021</div></div><div class="host u-font-sans">Nat Rev Rheumatol, 18 (2022), pp. 465-479</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1038/s41584-022-00798-0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0004"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85133751616&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0004"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Group%20for%20Research%20and%20Assessment%20of%20Psoriasis%20and%20Psoriatic%20Arthritis%20%3A%20updated%20treatment%20recommendations%20for%20psoriatic%20arthritis%202021&amp;publication_year=2022&amp;author=L.C.%20Coates&amp;author=E.R.%20Soriano&amp;author=N.%20Corp&amp;author=H.%20Bertheussen&amp;author=K.%20Callis%20Duffin" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0004"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0005" id="ref-id-bib0005" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[5]</span></span></a></span><span class="reference" id="sbref0005"><div class="contribution"><div class="authors u-font-sans">O. FitzGerald, A. Ogdie, V. Chandran, L.C. Coates, A. Kavanaugh, W. Tillett, <em> et al.</em></div><div id="ref-id-sbref0005" class="title text-m">Psoriatic arthritis</div></div><div class="host u-font-sans">Nat Rev Dis Primers, 7 (2021), p. 59</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85112697594&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0005"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Psoriatic%20arthritis&amp;publication_year=2021&amp;author=O.%20FitzGerald&amp;author=A.%20Ogdie&amp;author=V.%20Chandran&amp;author=L.C.%20Coates&amp;author=A.%20Kavanaugh&amp;author=W.%20Tillett" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0005"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0006" id="ref-id-bib0006" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[6]</span></span></a></span><span class="reference" id="sbref0006"><div class="contribution"><div class="authors u-font-sans">A.M. Orbai, M. de Wit, P. Mease, J.A. Shea, L. Gossec, Y.Y. Leung, <em> et al.</em></div><div id="ref-id-sbref0006" class="title text-m">International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials</div></div><div class="host u-font-sans">Ann Rheum Dis, 76 (2017), pp. 673-680</div><div class="ReferenceLinks u-font-sans"><a class="anchor pdf link anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S0003496724028115/pdfft?md5=628501497541d195fe33d6a5cf96cb47&amp;pid=1-s2.0-S0003496724028115-main.pdf" target="_blank" rel="nofollow" aria-describedby="ref-id-sbref0006"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
                1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
                .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
                1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
                2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
                2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
                2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
                24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
                1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
                2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
                1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a><a class="anchor link anchor-primary" href="/science/article/pii/S0003496724028115" aria-describedby="ref-id-sbref0006"><span class="anchor-text-container"><span class="anchor-text">View article</span></span></a><a class="anchor link anchor-primary" href="https://doi.org/10.1136/annrheumdis-2016-210242" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0006"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-84987811299&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0006"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=International%20patient%20and%20physician%20consensus%20on%20a%20psoriatic%20arthritis%20core%20outcome%20set%20for%20clinical%20trials&amp;publication_year=2017&amp;author=A.M.%20Orbai&amp;author=M.%20de%20Wit&amp;author=P.%20Mease&amp;author=J.A.%20Shea&amp;author=L.%20Gossec&amp;author=Y.Y.%20Leung" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0006"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0007" id="ref-id-bib0007" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[7]</span></span></a></span><span class="reference" id="sbref0007"><div class="contribution"><div class="authors u-font-sans">L. Gossec, A. Kerschbaumer, R.J.O. Ferreira, D. Aletaha, X. Baraliakos, H. Bertheussen, <em> et al.</em></div><div id="ref-id-sbref0007" class="title text-m">EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update</div></div><div class="host u-font-sans">Ann Rheum Dis, 83 (2024), pp. 706-719</div><div class="ReferenceLinks u-font-sans"><a class="anchor pdf link anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S0003496724001274/pdfft?md5=a1538f3e832b89e03b30a5472fc78c93&amp;pid=1-s2.0-S0003496724001274-main.pdf" target="_blank" rel="nofollow" aria-describedby="ref-id-sbref0007"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
                1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
                .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
                1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
                2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
                2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
                2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
                24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
                1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
                2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
                1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a><a class="anchor link anchor-primary" href="/science/article/pii/S0003496724001274" aria-describedby="ref-id-sbref0007"><span class="anchor-text-container"><span class="anchor-text">View article</span></span></a><a class="anchor link anchor-primary" href="https://doi.org/10.1136/ard-2024-225531" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0007"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85188577159&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0007"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=EULAR%20recommendations%20for%20the%20management%20of%20psoriatic%20arthritis%20with%20pharmacological%20therapies%3A%202023%20update&amp;publication_year=2024&amp;author=L.%20Gossec&amp;author=A.%20Kerschbaumer&amp;author=R.J.O.%20Ferreira&amp;author=D.%20Aletaha&amp;author=X.%20Baraliakos&amp;author=H.%20Bertheussen" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0007"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0008" id="ref-id-bib0008" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[8]</span></span></a></span><span class="reference" id="sbref0008"><div class="contribution"><div class="authors u-font-sans">P.J. Mease, A.W. Armstrong</div><div id="ref-id-sbref0008" class="title text-m">Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis</div></div><div class="host u-font-sans">Drugs, 74 (2014), pp. 423-441</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1007/s40265-014-0191-y" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0008"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-84897110560&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0008"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Managing%20patients%20with%20psoriatic%20disease%3A%20the%20diagnosis%20and%20pharmacologic%20treatment%20of%20psoriatic%20arthritis%20in%20patients%20with%20psoriasis&amp;publication_year=2014&amp;author=P.J.%20Mease&amp;author=A.W.%20Armstrong" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0008"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0009" id="ref-id-bib0009" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[9]</span></span></a></span><span class="reference" id="sbref0009"><div class="contribution"><div class="authors u-font-sans">L. Shang, J. Cao, S. Zhao, J. Zhang, Y. He</div><div id="ref-id-sbref0009" class="title text-m">TYK2 in immune responses and treatment of psoriasis</div></div><div class="host u-font-sans">J Inflamm Res, 15 (2022), pp. 5373-5385</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.2147/jir.s380686" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0009"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85138010199&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0009"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=TYK2%20in%20immune%20responses%20and%20treatment%20of%20psoriasis&amp;publication_year=2022&amp;author=L.%20Shang&amp;author=J.%20Cao&amp;author=S.%20Zhao&amp;author=J.%20Zhang&amp;author=Y.%20He" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0009"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0010" id="ref-id-bib0010" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[10]</span></span></a></span><span class="reference" id="sbref0010"><div class="contribution"><div class="authors u-font-sans">R. Muromoto, K. Oritani, T. Matsuda</div><div id="ref-id-sbref0010" class="title text-m">Current understanding of the role of tyrosine kinase 2 signaling in immune responses</div></div><div class="host u-font-sans">World J Biol Chem, 13 (2022), pp. 1-14</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.4331/wjbc.v13.i1.1" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0010"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Current%20understanding%20of%20the%20role%20of%20tyrosine%20kinase%202%20signaling%20in%20immune%20responses&amp;publication_year=2022&amp;author=R.%20Muromoto&amp;author=K.%20Oritani&amp;author=T.%20Matsuda" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0010"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0011" id="ref-id-bib0011" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[11]</span></span></a></span><span class="reference" id="sbref0011"><div class="contribution"><div class="authors u-font-sans">C.A. Dendrou, A. Cortes, L. Shipman, H.G. Evans, K.E. Attfield, L. Jostins, <em> et al.</em></div><div id="ref-id-sbref0011" class="title text-m">Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity</div></div><div class="host u-font-sans">Sci Transl Med, 8 (2016), p. 363ra149</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-84994528744&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0011"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Resolving%20TYK2%20locus%20genotype-to-phenotype%20differences%20in%20autoimmunity&amp;publication_year=2016&amp;author=C.A.%20Dendrou&amp;author=A.%20Cortes&amp;author=L.%20Shipman&amp;author=H.G.%20Evans&amp;author=K.E.%20Attfield&amp;author=L.%20Jostins" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0011"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0012" id="ref-id-bib0012" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[12]</span></span></a></span><span class="reference" id="sbref0012"><div class="contribution"><div class="authors u-font-sans">M. Gonciarz, K. Pawlak-Bu?, P. Leszczy¨½ski, W. Owczarek</div><div id="ref-id-sbref0012" class="title text-m">TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases</div></div><div class="host u-font-sans">Immunotherapy, 13 (2021), pp. 1135-1150</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.2217/imt-2021-0096" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0012"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85112058463&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0012"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=TYK2%20as%20a%20therapeutic%20target%20in%20the%20treatment%20of%20autoimmune%20and%20inflammatory%20diseases&amp;publication_year=2021&amp;author=M.%20Gonciarz&amp;author=K.%20Pawlak-Bu%C5%9B&amp;author=P.%20Leszczy%C5%84ski&amp;author=W.%20Owczarek" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0012"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0013" id="ref-id-bib0013" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[13]</span></span></a></span><span class="reference" id="sbref0013"><div class="contribution"><div class="authors u-font-sans">J.J. McElwee, S. Garcet, X. Li, I. Ceuto, N. Kunjravia, D. Rambhia, <em> et al.</em></div><div id="ref-id-sbref0013" class="title text-m">Analysis of histologic, molecular and clinical improvement in moderate-to-severe psoriasis: results from a phase 1b trial of the novel allosteric TYK2 inhibitor NDI-034858 [poster]</div></div><div class="host u-font-sans">Presented at the American Academy of Dermatology (25¨C29 March 2022)</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar?q=McElwee%20JJ%2C%20Garcet%20S%2C%20Li%20X%2C%20Ceuto%2C%20I%2C%20Kunjravia%20N%2C%20Rambhia%20D%2C%20et%20al.%20Analysis%20of%20histologic%2C%20molecular%20and%20clinical%20improvement%20in%20moderate-to-severe%20psoriasis%3A%20results%20from%20a%20phase%201b%20trial%20of%20the%20novel%20allosteric%20TYK2%20inhibitor%20NDI-034858%20%5Bposter%5D.%20Presented%20at%20the%20American%20Academy%20of%20Dermatology%2C%2025%E2%80%9329%20March%202022." target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0013"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0014" id="ref-id-bib0014" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[14]</span></span></a></span><span class="reference" id="sbref0014"><div class="contribution"><div class="authors u-font-sans">S. Leit, J. Greenwood, S. Carriero, S. Mondal, R. Abel, M. Ashwell, <em> et al.</em></div><div id="ref-id-sbref0014" class="title text-m">Discovery of a potent and selective tyrosine kinase 2 inhibitor: TAK-279</div></div><div class="host u-font-sans">J Med Chem, 66 (2023), pp. 10473-10496</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="/science/article/pii/S1520480423002971" aria-describedby="ref-id-sbref0014"><span class="anchor-text-container"><span class="anchor-text">View article</span></span></a><a class="anchor link anchor-primary" href="https://doi.org/10.1021/acs.jmedchem.3c00600" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0014"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85165682327&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0014"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Discovery%20of%20a%20potent%20and%20selective%20tyrosine%20kinase%202%20inhibitor%3A%20TAK-279&amp;publication_year=2023&amp;author=S.%20Leit&amp;author=J.%20Greenwood&amp;author=S.%20Carriero&amp;author=S.%20Mondal&amp;author=R.%20Abel&amp;author=M.%20Ashwell" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0014"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0015" id="ref-id-bib0015" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[15]</span></span></a></span><span class="reference" id="sbref0015"><div class="contribution"><div class="authors u-font-sans">S. Mehrotra, Y. Sano, P. Halkowycz, E. Wilson, C. Durairaj, K.F. Kong, <em> et al.</em></div><div id="ref-id-sbref0015" class="title text-m">Pharmacological characterization of zasocitinib (TAK-279): an oral, highly selective and potent allosteric TYK2 inhibitor</div></div><div class="host u-font-sans">J Invest Dermatol (2025), <a class="anchor anchor-primary" href="https://doi.org/10.1016/j.jid.2025.05.014" target="_blank"><span class="anchor-text-container"><span class="anchor-text">10.1016/j.jid.2025.05.014</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Pharmacological%20characterization%20of%20zasocitinib%20%3A%20an%20oral%2C%20highly%20selective%20and%20potent%20allosteric%20TYK2%20inhibitor&amp;publication_year=2025&amp;author=S.%20Mehrotra&amp;author=Y.%20Sano&amp;author=P.%20Halkowycz&amp;author=E.%20Wilson&amp;author=C.%20Durairaj&amp;author=K.F.%20Kong" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0015"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0016" id="ref-id-bib0016" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[16]</span></span></a></span><span class="reference" id="sbref0016"><div class="contribution"><div class="authors u-font-sans">A.W. Armstrong, M. Gooderham, C. Lynde, C. Maari, S. Forman, L. Green, <em> et al.</em></div><div id="ref-id-sbref0016" class="title text-m">Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial</div></div><div class="host u-font-sans">JAMA Dermatol, 160 (2024), pp. 1066-1074</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1001/jamadermatol.2024.2701" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0016"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85206597218&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0016"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Tyrosine%20kinase%202%20inhibition%20with%20zasocitinib%20%20in%20psoriasis%3A%20a%20randomized%20clinical%20trial&amp;publication_year=2024&amp;author=A.W.%20Armstrong&amp;author=M.%20Gooderham&amp;author=C.%20Lynde&amp;author=C.%20Maari&amp;author=S.%20Forman&amp;author=L.%20Green" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0016"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0017" id="ref-id-bib0017" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[17]</span></span></a></span><span class="reference" id="sbref0017"><div class="other-ref"><span>ClinicalTrials.gov. A study to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with active psoriatic arthritis [Internet]. 2024 [cited 2025 May]. Available from:<a class="anchor anchor-primary" href="https://clinicaltrials.gov/study/NCT05153148" target="_blank"><span class="anchor-text-container"><span class="anchor-text">https://clinicaltrials.gov/study/NCT05153148</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></span></div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar?q=ClinicalTrials.gov.%20A%20study%20to%20evaluate%20the%20efficacy%2C%20safety%2C%20and%20tolerability%20of%20NDI-034858%20in%20participants%20with%20active%20psoriatic%20arthritis%20%5BInternet%5D.%202024%20%5Bcited%202025%20May%5D.%20Available%20from%3Ahttps%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05153148" target="_blank" rel="noopener noreferrer"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0018" id="ref-id-bib0018" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[18]</span></span></a></span><span class="reference" id="sbref0018"><div class="contribution"><div class="authors u-font-sans">E. Lubrano, S. Scriffignano, M. Fatica, P. Triggianese, P. Conigliaro, F.M. Perrotta, <em> et al.</em></div><div id="ref-id-sbref0018" class="title text-m">Psoriatic arthritis in males and females: differences and similarities</div></div><div class="host u-font-sans">Rheumatol Ther, 10 (2023), pp. 589-599</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1007/s40744-023-00535-3" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0018"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85148238431&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0018"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Psoriatic%20arthritis%20in%20males%20and%20females%3A%20differences%20and%20similarities&amp;publication_year=2023&amp;author=E.%20Lubrano&amp;author=S.%20Scriffignano&amp;author=M.%20Fatica&amp;author=P.%20Triggianese&amp;author=P.%20Conigliaro&amp;author=F.M.%20Perrotta" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0018"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0019" id="ref-id-bib0019" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[19]</span></span></a></span><span class="reference" id="sbref0019"><div class="contribution"><div class="authors u-font-sans">E. Passia, M. Vis, L.C. Coates, A. Soni, I. Tchetverikov, A.H. Gerards, <em> et al.</em></div><div id="ref-id-sbref0019" class="title text-m">Sex-specific differences and how to handle them in early psoriatic arthritis</div></div><div class="host u-font-sans">Arthritis Res Ther, 24 (2022), p. 22</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85122833397&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0019"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Sex-specific%20differences%20and%20how%20to%20handle%20them%20in%20early%20psoriatic%20arthritis&amp;publication_year=2022&amp;author=E.%20Passia&amp;author=M.%20Vis&amp;author=L.C.%20Coates&amp;author=A.%20Soni&amp;author=I.%20Tchetverikov&amp;author=A.H.%20Gerards" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0019"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0020" id="ref-id-bib0020" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[20]</span></span></a></span><span class="reference" id="sbref0020"><div class="contribution"><div class="authors u-font-sans">L.S. Coates, C. Mease, P. Ogdie, A. Nantel, F. Lavie, F. Sharaf, <em> et al.</em></div><div id="ref-id-sbref0020" class="title text-m">Sex-related differences in baseline patient and disease characteristics: post hoc analyses of three phase 3, randomized, double-blind, placebo-controlled studies in patients with active psoriatic arthritis [abstract]</div></div><div class="host u-font-sans">Arthritis Rheumatol (2024), p. 76</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Sex-related%20differences%20in%20baseline%20patient%20and%20disease%20characteristics%3A%20post%20hoc%20analyses%20of%20three%20phase%203%2C%20randomized%2C%20double-blind%2C%20placebo-controlled%20studies%20in%20patients%20with%20active%20psoriatic%20arthritis%20abstract&amp;publication_year=2024&amp;author=L.S.%20Coates&amp;author=C.%20Mease&amp;author=P.%20Ogdie&amp;author=A.%20Nantel&amp;author=F.%20Lavie&amp;author=F.%20Sharaf" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0020"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0021" id="ref-id-bib0021" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[21]</span></span></a></span><span class="reference" id="sbref0021"><div class="contribution"><div class="authors u-font-sans">L. Eder, P. Richette, L.C. Coates, V.F. Azevedo, J.C. Cappelleri, E.P. Johnson, <em> et al.</em></div><div id="ref-id-sbref0021" class="title text-m">Gender differences in perceptions of psoriatic arthritis disease impact, management, and physician interactions: results from a global patient survey</div></div><div class="host u-font-sans">Rheumatol Ther, 11 (2024), pp. 1115-1134</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1007/s40744-024-00678-x" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0021"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85197461724&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0021"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Gender%20differences%20in%20perceptions%20of%20psoriatic%20arthritis%20disease%20impact%2C%20management%2C%20and%20physician%20interactions%3A%20results%20from%20a%20global%20patient%20survey&amp;publication_year=2024&amp;author=L.%20Eder&amp;author=P.%20Richette&amp;author=L.C.%20Coates&amp;author=V.F.%20Azevedo&amp;author=J.C.%20Cappelleri&amp;author=E.P.%20Johnson" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0021"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0022" id="ref-id-bib0022" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[22]</span></span></a></span><span class="reference" id="sbref0022"><div class="contribution"><div class="authors u-font-sans">L. Eder, S. Mylvaganam, J. Pardo Pardo, J. Petkovic, V. Strand, P. Mease, <em> et al.</em></div><div id="ref-id-sbref0022" class="title text-m">Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis</div></div><div class="host u-font-sans">Lancet Rheumatol, 5 (2023), pp. e716-e727</div><div class="ReferenceLinks u-font-sans"><a class="anchor pdf link anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S2665991323002643/pdfft?md5=1a78e5cb5cc8323fa21480e5121306c5&amp;pid=1-s2.0-S2665991323002643-main.pdf" target="_blank" rel="nofollow" aria-describedby="ref-id-sbref0022"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
                1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
                .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
                1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
                2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
                2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
                2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
                24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
                1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
                2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
                1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a><a class="anchor link anchor-primary" href="/science/article/pii/S2665991323002643" aria-describedby="ref-id-sbref0022"><span class="anchor-text-container"><span class="anchor-text">View article</span></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85176447392&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0022"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Sex-related%20differences%20in%20patient%20characteristics%2C%20and%20efficacy%20and%20safety%20of%20advanced%20therapies%20in%20randomised%20clinical%20trials%20in%20psoriatic%20arthritis%3A%20a%20systematic%20literature%20review%20and%20meta-analysis&amp;publication_year=2023&amp;author=L.%20Eder&amp;author=S.%20Mylvaganam&amp;author=J.%20Pardo%20Pardo&amp;author=J.%20Petkovic&amp;author=V.%20Strand&amp;author=P.%20Mease" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0022"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0023" id="ref-id-bib0023" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[23]</span></span></a></span><span class="reference" id="sbref0023"><div class="contribution"><div class="authors u-font-sans">L. Eder, E. Muensterman, D. van der Heijde, A. Kivitz, M. Trivedi, T. Hong, <em> et al.</em></div><div id="ref-id-sbref0023" class="title text-m">AB0403 influence of body weight, sex and prior biologic history on treatment outcomes associated with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in a phase 2b randomized trial in patients with active psoriatic arthritis</div></div><div class="host u-font-sans">Ann Rheum Dis, 83 (2024), p. 1449</div><div class="ReferenceLinks u-font-sans"><a class="anchor pdf link anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S0003496724170847/pdfft?md5=997c68b55ba8a94562892f8f9ffa433e&amp;pid=1-s2.0-S0003496724170847-main.pdf" target="_blank" rel="nofollow" aria-describedby="ref-id-sbref0023"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
                1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
                .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
                1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
                2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
                2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
                2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
                24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
                1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
                2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
                1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a><a class="anchor link anchor-primary" href="/science/article/pii/S0003496724170847" aria-describedby="ref-id-sbref0023"><span class="anchor-text-container"><span class="anchor-text">View article</span></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=AB0403%20influence%20of%20body%20weight%2C%20sex%20and%20prior%20biologic%20history%20on%20treatment%20outcomes%20associated%20with%20TAK-279%2C%20a%20highly%20selective%20oral%20tyrosine%20kinase%202%20%20inhibitor%2C%20in%20a%20phase%202b%20randomized%20trial%20in%20patients%20with%20active%20psoriatic%20arthritis&amp;publication_year=2024&amp;author=L.%20Eder&amp;author=E.%20Muensterman&amp;author=D.%20van%20der%20Heijde&amp;author=A.%20Kivitz&amp;author=M.%20Trivedi&amp;author=T.%20Hong" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0023"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0024" id="ref-id-bib0024" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[24]</span></span></a></span><span class="reference" id="sbref0024"><div class="contribution"><div class="authors u-font-sans">P.J. Mease, A.A. Deodhar, D. van der Heijde, F. Behrens, A.J. Kivitz, J. Neal, <em> et al.</em></div><div id="ref-id-sbref0024" class="title text-m">Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis</div></div><div class="host u-font-sans">Ann Rheum Dis, 81 (2022), pp. 815-822</div><div class="ReferenceLinks u-font-sans"><a class="anchor pdf link anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S0003496724210761/pdfft?md5=278e4570c273558bafb926c1a726f1b9&amp;pid=1-s2.0-S0003496724210761-main.pdf" target="_blank" rel="nofollow" aria-describedby="ref-id-sbref0024"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
                1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
                .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
                1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
                2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
                2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
                2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
                24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
                1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
                2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
                1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a><a class="anchor link anchor-primary" href="/science/article/pii/S0003496724210761" aria-describedby="ref-id-sbref0024"><span class="anchor-text-container"><span class="anchor-text">View article</span></span></a><a class="anchor link anchor-primary" href="https://doi.org/10.1136/annrheumdis-2021-221664" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0024"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85130638585&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0024"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20selective%20TYK2%20inhibitor%2C%20deucravacitinib%2C%20in%20a%20phase%20II%20trial%20in%20psoriatic%20arthritis&amp;publication_year=2022&amp;author=P.J.%20Mease&amp;author=A.A.%20Deodhar&amp;author=D.%20van%20der%20Heijde&amp;author=F.%20Behrens&amp;author=A.J.%20Kivitz&amp;author=J.%20Neal" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0024"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0025" id="ref-id-bib0025" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[25]</span></span></a></span><span class="reference" id="sbref0025"><div class="contribution"><div class="authors u-font-sans">P.J. Mease, A. Lertratanakul, J.K. Anderson, K. Papp, F. Van den Bosch, S. Tsuji, <em> et al.</em></div><div id="ref-id-sbref0025" class="title text-m">Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2</div></div><div class="host u-font-sans">Ann Rheum Dis, 80 (2021), pp. 312-320</div><div class="ReferenceLinks u-font-sans"><a class="anchor pdf link anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S0003496724005247/pdfft?md5=6f1c4fc0dd912fa8dbc76b1549cb4eba&amp;pid=1-s2.0-S0003496724005247-main.pdf" target="_blank" rel="nofollow" aria-describedby="ref-id-sbref0025"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
                1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
                .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
                1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
                2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
                2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
                2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
                24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
                1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
                2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
                1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a><a class="anchor link anchor-primary" href="/science/article/pii/S0003496724005247" aria-describedby="ref-id-sbref0025"><span class="anchor-text-container"><span class="anchor-text">View article</span></span></a><a class="anchor link anchor-primary" href="https://doi.org/10.1136/annrheumdis-2020-218870" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0025"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85097240962&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0025"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Upadacitinib%20for%20psoriatic%20arthritis%20refractory%20to%20biologics%3A%20SELECT-PsA%202&amp;publication_year=2021&amp;author=P.J.%20Mease&amp;author=A.%20Lertratanakul&amp;author=J.K.%20Anderson&amp;author=K.%20Papp&amp;author=F.%20Van%20den%20Bosch&amp;author=S.%20Tsuji" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0025"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0026" id="ref-id-bib0026" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[26]</span></span></a></span><span class="reference" id="sbref0026"><div class="contribution"><div class="authors u-font-sans">P.J. Mease, D.D. Gladman, C.T. Ritchlin, E.M. Ruderman, S.D. Steinfeld, E.H. Choy, <em> et al.</em></div><div id="ref-id-sbref0026" class="title text-m">Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial</div></div><div class="host u-font-sans">Arthritis Rheum, 52 (2005), pp. 3279-3289</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1002/art.21306" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0026"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-26844432745&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0026"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Adalimumab%20for%20the%20treatment%20of%20patients%20with%20moderately%20to%20severely%20active%20psoriatic%20arthritis%3A%20results%20of%20a%20double-blind%2C%20randomized%2C%20placebo-controlled%20trial&amp;publication_year=2005&amp;author=P.J.%20Mease&amp;author=D.D.%20Gladman&amp;author=C.T.%20Ritchlin&amp;author=E.M.%20Ruderman&amp;author=S.D.%20Steinfeld&amp;author=E.H.%20Choy" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0026"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0027" id="ref-id-bib0027" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[27]</span></span></a></span><span class="reference" id="sbref0027"><div class="contribution"><div class="authors u-font-sans">C. Houttekiet, K. de Vlam, B. Neerinckx, R. Lories</div><div id="ref-id-sbref0027" class="title text-m">Systematic review of the use of CRP in clinical trials for psoriatic arthritis: a concern for clinical practice?</div></div><div class="host u-font-sans">RMD Open, 8 (2022), Article e001756</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1136/rmdopen-2021-001756" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0027"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85124268561&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0027"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Systematic%20review%20of%20the%20use%20of%20CRP%20in%20clinical%20trials%20for%20psoriatic%20arthritis%3A%20a%20concern%20for%20clinical%20practice&amp;publication_year=2022&amp;author=C.%20Houttekiet&amp;author=K.%20de%20Vlam&amp;author=B.%20Neerinckx&amp;author=R.%20Lories" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0027"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0028" id="ref-id-bib0028" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[28]</span></span></a></span><span class="reference" id="sbref0028"><div class="contribution"><div class="authors u-font-sans">A. Ogdie, P. Weiss</div><div id="ref-id-sbref0028" class="title text-m">The epidemiology of psoriatic arthritis</div></div><div class="host u-font-sans">Rheum Dis Clin North Am, 41 (2015), pp. 545-568</div><div class="ReferenceLinks u-font-sans"><a class="anchor pdf link anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S0889857X15000502/pdfft?md5=cea404f367da3aac2862b580ebf693cb&amp;pid=1-s2.0-S0889857X15000502-main.pdf" target="_blank" rel="nofollow" aria-describedby="ref-id-sbref0028"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
                1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
                .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
                1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
                2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
                2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
                2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
                24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
                1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
                2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
                1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a><a class="anchor link anchor-primary" href="/science/article/pii/S0889857X15000502" aria-describedby="ref-id-sbref0028"><span class="anchor-text-container"><span class="anchor-text">View article</span></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-84945438141&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0028"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=The%20epidemiology%20of%20psoriatic%20arthritis&amp;publication_year=2015&amp;author=A.%20Ogdie&amp;author=P.%20Weiss" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0028"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0029" id="ref-id-bib0029" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[29]</span></span></a></span><span class="reference" id="sbref0029"><div class="contribution"><div class="authors u-font-sans">D.D. Gladman</div><div id="ref-id-sbref0029" class="title text-m">Consensus exercise on domains in psoriatic arthritis</div></div><div class="host u-font-sans">Ann Rheum Dis, 64 (Suppl 2) (2005)</div><div class="comment">ii113-4</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Consensus%20exercise%20on%20domains%20in%20psoriatic%20arthritis&amp;publication_year=2005&amp;author=D.D.%20Gladman" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0029"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0030" id="ref-id-bib0030" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[30]</span></span></a></span><span class="reference" id="sbref0030"><div class="contribution"><div class="authors u-font-sans">M.M. Asgari, J.J. Wu, J.M. Gelfand, C. Salman, J.R. Curtis, L.R. Harrold, <em> et al.</em></div><div id="ref-id-sbref0030" class="title text-m">Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996¨C2009</div></div><div class="host u-font-sans">Pharmacoepidemiol Drug Saf, 22 (2013), pp. 842-849</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1002/pds.3447" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0030"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-84880756778&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0030"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Validity%20of%20diagnostic%20codes%20and%20prevalence%20of%20psoriasis%20and%20psoriatic%20arthritis%20in%20a%20managed%20care%20population%2C%2019962009&amp;publication_year=2013&amp;author=M.M.%20Asgari&amp;author=J.J.%20Wu&amp;author=J.M.%20Gelfand&amp;author=C.%20Salman&amp;author=J.R.%20Curtis&amp;author=L.R.%20Harrold" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0030"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0031" id="ref-id-bib0031" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[31]</span></span></a></span><span class="reference" id="sbref0031"><div class="contribution"><div class="authors u-font-sans">K. Houghton, D. Patil, B. Gomez, S.R. Feldman</div><div id="ref-id-sbref0031" class="title text-m">Correlation between change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in patients with psoriasis: pooled analysis from four phase 3 clinical trials of secukinumab</div></div><div class="host u-font-sans">Dermatol Ther (Heidelb), 11 (2021), pp. 1373-1384</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1007/s13555-021-00564-2" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0031"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85107474851&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0031"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Correlation%20between%20change%20in%20Psoriasis%20Area%20and%20Severity%20Index%20and%20Dermatology%20Life%20Quality%20Index%20in%20patients%20with%20psoriasis%3A%20pooled%20analysis%20from%20four%20phase%203%20clinical%20trials%20of%20secukinumab&amp;publication_year=2021&amp;author=K.%20Houghton&amp;author=D.%20Patil&amp;author=B.%20Gomez&amp;author=S.R.%20Feldman" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0031"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0032" id="ref-id-bib0032" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[32]</span></span></a></span><span class="reference" id="sbref0032"><div class="contribution"><div class="authors u-font-sans">J.A. Walsh, A. Ogdie, K. Michaud, S. Peterson, E.A. Holdsworth, C.S. Karyekar, <em> et al.</em></div><div id="ref-id-sbref0032" class="title text-m">Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe</div></div><div class="host u-font-sans">Joint Bone Spine, 90 (2023), Article 105534</div><div class="ReferenceLinks u-font-sans"><a class="anchor pdf link anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S1297319X23000131/pdfft?md5=0d2df2e83bd164229d77b1a739938e2b&amp;pid=1-s2.0-S1297319X23000131-main.pdf" target="_blank" rel="nofollow" aria-describedby="ref-id-sbref0032"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
                1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
                .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
                1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
                2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
                2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
                2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
                24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
                1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
                2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
                1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a><a class="anchor link anchor-primary" href="/science/article/pii/S1297319X23000131" aria-describedby="ref-id-sbref0032"><span class="anchor-text-container"><span class="anchor-text">View article</span></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85149319558&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0032"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Impact%20of%20key%20manifestations%20of%20psoriatic%20arthritis%20on%20patient%20quality%20of%20life%2C%20functional%20status%2C%20and%20work%20productivity%3A%20findings%20from%20a%20real-world%20study%20in%20the%20United%20States%20and%20Europe&amp;publication_year=2023&amp;author=J.A.%20Walsh&amp;author=A.%20Ogdie&amp;author=K.%20Michaud&amp;author=S.%20Peterson&amp;author=E.A.%20Holdsworth&amp;author=C.S.%20Karyekar" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0032"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0033" id="ref-id-bib0033" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[33]</span></span></a></span><span class="reference" id="sbref0033"><div class="contribution"><div class="authors u-font-sans">W. Tillett, J.F. Merola, D. Tha?i, E. Holdsworth, N. Booth, L.S. Lobosco, <em> et al.</em></div><div id="ref-id-sbref0033" class="title text-m">Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey</div></div><div class="host u-font-sans">Rheumatol Ther, 7 (2020), pp. 617-637</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1007/s40744-020-00221-8" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0033"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85105300943&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0033"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Disease%20characteristics%20and%20the%20burden%20of%20joint%20and%20skin%20involvement%20amongst%20people%20with%20psoriatic%20arthritis%3A%20a%20population%20survey&amp;publication_year=2020&amp;author=W.%20Tillett&amp;author=J.F.%20Merola&amp;author=D.%20Tha%C3%A7i&amp;author=E.%20Holdsworth&amp;author=N.%20Booth&amp;author=L.S.%20Lobosco" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0033"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0034" id="ref-id-bib0034" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[34]</span></span></a></span><span class="reference" id="sbref0034"><div class="contribution"><div class="authors u-font-sans">A. Duvetorp, M. ?stergaard, L. Skov, O. Seifert, K.S. Tveit, K. Danielsen, <em> et al.</em></div><div id="ref-id-sbref0034" class="title text-m">Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP)</div></div><div class="host u-font-sans">Arch Dermatol Res, 311 (2019), pp. 351-360</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1007/s00403-019-01906-z" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0034"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85062978346&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0034"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Quality%20of%20life%20and%20contact%20with%20healthcare%20systems%20among%20patients%20with%20psoriasis%20and%20psoriatic%20arthritis%3A%20results%20from%20the%20NORdic%20PAtient%20survey%20of%20Psoriasis%20and%20Psoriatic%20arthritis%20&amp;publication_year=2019&amp;author=A.%20Duvetorp&amp;author=M.%20%C3%98stergaard&amp;author=L.%20Skov&amp;author=O.%20Seifert&amp;author=K.S.%20Tveit&amp;author=K.%20Danielsen" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0034"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0035" id="ref-id-bib0035" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[35]</span></span></a></span><span class="reference" id="sbref0035"><div class="contribution"><div class="authors u-font-sans">K. de Vlam, J.F. Merola, J.A. Birt, D.M. Sandoval, S. Lobosco, R. Moon, <em> et al.</em></div><div id="ref-id-sbref0035" class="title text-m">Skin involvement in psoriatic arthritis worsens overall disease activity, patient-reported outcomes, and increases healthcare resource utilization: an observational, cross-sectional study</div></div><div class="host u-font-sans">Rheumatol Ther, 5 (2018), pp. 423-436</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1007/s40744-018-0120-8" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0035"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85059920009&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0035"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Skin%20involvement%20in%20psoriatic%20arthritis%20worsens%20overall%20disease%20activity%2C%20patient-reported%20outcomes%2C%20and%20increases%20healthcare%20resource%20utilization%3A%20an%20observational%2C%20cross-sectional%20study&amp;publication_year=2018&amp;author=K.%20de%20Vlam&amp;author=J.F.%20Merola&amp;author=J.A.%20Birt&amp;author=D.M.%20Sandoval&amp;author=S.%20Lobosco&amp;author=R.%20Moon" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0035"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0036" id="ref-id-bib0036" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[36]</span></span></a></span><span class="reference" id="sbref0036"><div class="contribution"><div class="authors u-font-sans">D.D. Gladman</div><div id="ref-id-sbref0036" class="title text-m">Toward treating to target in psoriatic arthritis</div></div><div class="host u-font-sans">J Rheumatol Suppl, 93 (2015), pp. 14-16</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.3899/jrheum.150626" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0036"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-84962840910&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0036"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Toward%20treating%20to%20target%20in%20psoriatic%20arthritis&amp;publication_year=2015&amp;author=D.D.%20Gladman" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0036"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0037" id="ref-id-bib0037" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[37]</span></span></a></span><span class="reference" id="sbref0037"><div class="contribution"><div class="authors u-font-sans">E. Dures, S. Shepperd, S. Mukherjee, J. Robson, I. Vlaev, N. Walsh, <em> et al.</em></div><div id="ref-id-sbref0037" class="title text-m">Treat-to-target in PsA: methods and necessity</div></div><div class="host u-font-sans">RMD Open, 6 (2020), Article e001083</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1136/rmdopen-2019-001083" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0037"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85079825504&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0037"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Treat-to-target%20in%20PsA%3A%20methods%20and%20necessity&amp;publication_year=2020&amp;author=E.%20Dures&amp;author=S.%20Shepperd&amp;author=S.%20Mukherjee&amp;author=J.%20Robson&amp;author=I.%20Vlaev&amp;author=N.%20Walsh" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0037"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0038" id="ref-id-bib0038" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[38]</span></span></a></span><span class="reference" id="sbref0038"><div class="contribution"><div class="authors u-font-sans">E. Gangolli, S. Carreiro, S. Leit, J.J. McElwee, N. Dave, A. Lombardi, <em> et al.</em></div><div id="ref-id-sbref0038" class="title text-m">Characterization of pharmacokinetics, pharmacodynamics, tolerability and clinical activity in Phase I studies of the novel allosteric tyrosine kinase 2 (TYK2) inhibitor NDI-034858 [poster]</div></div><div class="host u-font-sans">Presented at the Society for Investigative Dermatology, Portland, OR, USA (18¨C21 May 2022)</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar?q=Gangolli%20E%2C%20Carreiro%20S%2C%20Leit%20S%2C%20McElwee%20JJ%2C%20Dave%20N%2C%20Lombardi%20A%2C%20et%20al.%20Characterization%20of%20pharmacokinetics%2C%20pharmacodynamics%2C%20tolerability%20and%20clinical%20activity%20in%20Phase%20I%20studies%20of%20the%20novel%20allosteric%20tyrosine%20kinase%202%20(TYK2)%20inhibitor%20NDI-034858%20%5Bposter%5D.%20Presented%20at%20the%20Society%20for%20Investigative%20Dermatology%2C%2018%E2%80%9321%20May%202022%2C%20Portland%2C%20OR%2C%20USA." target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0038"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0039" id="ref-id-bib0039" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[39]</span></span></a></span><span class="reference" id="sbref0039"><div class="contribution"><div class="authors u-font-sans">G.L. Erre, D. Mavridis, R.J. Woodman, A.A. Mangoni</div><div id="ref-id-sbref0039" class="title text-m">Placebo response in psoriatic arthritis clinical trials: a systematic review and meta-analysis</div></div><div class="host u-font-sans">Rheumatology (Oxford), 61 (2022), pp. 1328-1340</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1093/rheumatology/keab774" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0039"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85128488500&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0039"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Placebo%20response%20in%20psoriatic%20arthritis%20clinical%20trials%3A%20a%20systematic%20review%20and%20meta-analysis&amp;publication_year=2022&amp;author=G.L.%20Erre&amp;author=D.%20Mavridis&amp;author=R.J.%20Woodman&amp;author=A.A.%20Mangoni" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0039"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li></ol></section></section></div><div id="section-cited-by"><section aria-label="Cited by" class="ListArticles preview"><div class="PageDivider"></div><header id="citing-articles-header"><h2 class="u-h4 u-margin-l-ver u-font-serif">Cited by (1)</h2></header><div aria-describedby="citing-articles-header"><div class="citing-articles u-margin-l-bottom"><ul><li class="ListArticleItem u-margin-l-bottom"><div class="sub-heading u-margin-xs-bottom"><h3 class="u-font-serif" id="citing-articles-article-0-title"><a class="anchor anchor-primary" href="/science/article/pii/S1521694225000580"><span class="anchor-text-container"><span class="anchor-text">Pipeline treatments on psoriatic disease</span></span></a></h3><div>2025, Best Practice and Research Clinical Rheumatology</div></div><div class="buttons"><button class="button-link button-link-primary button-link-icon-right" type="button" data-aa-button="sd:product:journal:article:location=citing-articles:type=view-details" aria-describedby="citing-articles-article-0-title" aria-controls="citing-articles-article-0" aria-expanded="false"><span class="button-link-text-container"><span class="button-link-text">Show abstract</span></span><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-navigate-down"><path d="M1 51l7-7 38 38 38-38 7 7-45 45z"></path></svg></button></div><div class="u-display-none" aria-hidden="true"><div class="abstract u-margin-xs-top u-margin-m-bottom u-font-serif" id="reference-abstract"><div class="u-margin-ver-m"><div class="u-margin-s-bottom" id="abspara0010">Psoriatic disease is a heterogeneous and multifaceted disease affecting musculoskeletal, dermatologic, and systemic domains, with low sustained remission rates despite advances in therapy. Current treatments, primarily targeting TNF, IL-17, IL-23, PDE4 inhibitors and JAK-STAT pathways, remain insufficient for many patients, highlighting the need for novel therapeutic approaches. This review explores pipeline treatments in psoriatic disease, including new JAK-STAT inhibitors (TYK2, JAK1), next-generation IL-17 inhibitors, IL-23-targeted therapies, and novel immune-modulating agents. The emerging role of combination therapy is also discussed, with dual biologic and small-molecule approaches showing potential in refractory disease. Additionally, microbiome-targeted therapies and metabolic interventions, including probiotics and GLP-1 receptor agonists, are being investigated as adjunctive strategies to improve disease control. While these innovations offer exciting opportunities for personalized medicine, challenges remain regarding long-term safety, optimal treatment sequencing, and combination strategies. Further randomized controlled trials and real-world data are necessary to define the most effective and sustainable treatment approaches for psoriatic disease.</div></div></div></div></li></ul></div></div></section></div><div class="Footnotes text-xs"><dl class="footnote"><dt class="footnote-label"></dt><dd class="footnote-detail u-padding-xs-top"><div class="u-margin-s-bottom" id="notep0002">Affiliations for Bhaskar Srivastava, Sue Dasen, Xinyan Zhang, Mona Trivedi and Apinya Lertratanakul are reported at the time of the study.</div></dd></dl><dl class="footnote"><dt class="footnote-label"></dt><dd class="footnote-detail u-padding-xs-top"><div class="u-margin-s-bottom" id="notep0003"><strong>Handling editor</strong> Josef S Smolen</div></dd></dl><dl class="footnote"><dt class="footnote-label"><a class="anchor u-padding-s-hor u-padding-xs u-display-inline-block anchor-primary" href="#bfn1"><span class="anchor-text-container"><span class="anchor-text"><sup>a</sup></span></span></a></dt><dd class="footnote-detail u-padding-xs-top"><div class="u-margin-s-bottom" id="notep0001">Dr Alan Kivitz and Dr Xenofon Baraliakos are cofirst authors.</div></dd></dl></div><div class="Copyright"><span class="copyright-line">? 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).</span></div></article><div class="u-display-block-from-md col-lg-6 col-md-8 pad-right u-padding-s-top"><aside class="RelatedContent u-clr-grey8" aria-label="Related content"><section class="RelatedContentPanel u-margin-s-bottom"><header id="recommended-articles-header" class="related-content-panel-header u-margin-s-bottom"><button class="button-link button-link-secondary related-content-panel-toggle is-up button-link-icon-right button-link-has-colored-icon" type="button" aria-expanded="true" data-aa-button="sd:product:journal:article:location=recommended-articles:type=close"><span class="button-link-text-container"><span class="button-link-text"><h2 class="section-title u-h4"><span class="related-content-panel-title-text">Recommended articles</span></h2></span></span><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-navigate-down"><path d="M1 51l7-7 38 38 38-38 7 7-45 45z"></path></svg></button></header><div class="" aria-hidden="false" aria-describedby="recommended-articles-header"><div id="recommended-articles" class="text-xs"><ul><li class="RelatedContentPanelItem u-display-block"><div class="sub-heading u-padding-xs-bottom"><h3 class="related-content-panel-list-entry-outline-padding text-s u-font-serif" id="recommended-articles-article0-title"><a class="anchor u-clamp-2-lines anchor-primary" href="/science/article/pii/S0003496725042943" title="SLE classification criteria item relationships: implications on SLE as a disease entity"><span class="anchor-text-container"><span class="anchor-text"><span>SLE classification criteria item relationships: implications on SLE as a disease entity</span></span></span></a></h3><div class="article-source u-clr-grey6"><div class="source">Annals of the Rheumatic Diseases, 2025</div></div><div class="authors"><span>Martin</span> <span>Aringer</span>, ¡­, <span>Sindhu R.</span> <span>Johnson</span></div></div><div class="buttons"><a class="anchor anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S0003496725042943/pdfft?md5=d9eeaf341cf9e699d97b28bee8f1c66d&amp;pid=1-s2.0-S0003496725042943-main.pdf" target="_blank" rel="nofollow" aria-describedby="recommended-articles-article0-title"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
                1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
                .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
                1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
                2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
                2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
                2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
                24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
                1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
                2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
                1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a></div></li><li class="RelatedContentPanelItem u-display-block"><div class="sub-heading u-padding-xs-bottom"><h3 class="related-content-panel-list-entry-outline-padding text-s u-font-serif" id="recommended-articles-article1-title"><a class="anchor u-clamp-2-lines anchor-primary" href="/science/article/pii/S000349672504186X" title="BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis"><span class="anchor-text-container"><span class="anchor-text"><span>BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis</span></span></span></a></h3><div class="article-source u-clr-grey6"><div class="source">Annals of the Rheumatic Diseases, Volume 84, Issue 10, 2025, pp. 1675-1683</div></div><div class="authors"><span>Ziwei</span> <span>Hu</span>, ¡­, <span>Lingli</span> <span>Dong</span></div></div><div class="buttons"><a class="anchor anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S000349672504186X/pdfft?md5=7c4a7b43b350e3f5bced70a8989f331e&amp;pid=1-s2.0-S000349672504186X-main.pdf" target="_blank" rel="nofollow" aria-describedby="recommended-articles-article1-title"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
                1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
                .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
                1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
                2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
                2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
                2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
                24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
                1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
                2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
                1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a></div></li><li class="RelatedContentPanelItem u-display-block"><div class="sub-heading u-padding-xs-bottom"><h3 class="related-content-panel-list-entry-outline-padding text-s u-font-serif" id="recommended-articles-article2-title"><a class="anchor u-clamp-2-lines anchor-primary" href="/science/article/pii/S0003496725042876" title="ASAS recommendations on reporting axial spondyloarthritis clinical trials"><span class="anchor-text-container"><span class="anchor-text"><span>ASAS recommendations on reporting axial spondyloarthritis clinical trials</span></span></span></a></h3><div class="article-source u-clr-grey6"><div class="source">Annals of the Rheumatic Diseases, 2025</div></div><div class="authors"><span>Floris A.</span> <span>van Gaalen</span>, ¡­, <span>D¨¦sir¨¦e</span> <span>van der Heijde</span></div></div><div class="buttons"><a class="anchor anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S0003496725042876/pdfft?md5=c6f0d5a24ac222347ac99a9ae3fcc12d&amp;pid=1-s2.0-S0003496725042876-main.pdf" target="_blank" rel="nofollow" aria-describedby="recommended-articles-article2-title"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
                1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
                .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
                1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
                2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
                2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
                2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
                24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
                1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
                2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
                1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a></div></li><li class="RelatedContentPanelItem u-display-none"><div class="sub-heading u-padding-xs-bottom"><h3 class="related-content-panel-list-entry-outline-padding text-s u-font-serif" id="recommended-articles-article3-title"><a class="anchor u-clamp-2-lines anchor-primary" href="/science/article/pii/S0003496725042396" title="Precision medicine and the chaos theory in rheumatoid arthritis"><span class="anchor-text-container"><span class="anchor-text"><span>Precision medicine and the chaos theory in rheumatoid arthritis</span></span></span></a></h3><div class="article-source u-clr-grey6"><div class="source">Annals of the Rheumatic Diseases, 2025</div></div><div class="authors"><span>Cl¨¦ment</span> <span>Triaille</span>, ¡­, <span>Nisha</span> <span>Limaye</span></div></div><div class="buttons"><a class="anchor anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S0003496725042396/pdfft?md5=99c5752d648f3a7344a667b199cb362a&amp;pid=1-s2.0-S0003496725042396-main.pdf" target="_blank" rel="nofollow" aria-describedby="recommended-articles-article3-title"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
                1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
                .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
                1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
                2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
                2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
                2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
                24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
                1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
                2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
                1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a></div></li><li class="RelatedContentPanelItem u-display-none"><div class="sub-heading u-padding-xs-bottom"><h3 class="related-content-panel-list-entry-outline-padding text-s u-font-serif" id="recommended-articles-article4-title"><a class="anchor u-clamp-2-lines anchor-primary" href="/science/article/pii/S000349672504292X" title="Spatial mapping of rheumatoid arthritis synovial niches reveals a LYVE1+ macrophage network associated with response to therapy"><span class="anchor-text-container"><span class="anchor-text"><span>Spatial mapping of rheumatoid arthritis synovial niches reveals a LYVE1<sup>+</sup> macrophage network associated with response to therapy</span></span></span></a></h3><div class="article-source u-clr-grey6"><div class="source">Annals of the Rheumatic Diseases, 2025</div></div><div class="authors"><span>Julien</span> <span>De Lima</span>, ¡­, <span>Frederic</span> <span>Blanchard</span></div></div><div class="buttons"><a class="anchor anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S000349672504292X/pdfft?md5=521773fea6e2d78f97954db430ead223&amp;pid=1-s2.0-S000349672504292X-main.pdf" target="_blank" rel="nofollow" aria-describedby="recommended-articles-article4-title"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
                1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
                .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
                1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
                2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
                2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
                2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
                24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
                1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
                2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
                1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a></div></li><li class="RelatedContentPanelItem u-display-none"><div class="sub-heading u-padding-xs-bottom"><h3 class="related-content-panel-list-entry-outline-padding text-s u-font-serif" id="recommended-articles-article5-title"><a class="anchor u-clamp-2-lines anchor-primary" href="/science/article/pii/S0003496725043006" title="Transcriptome analysis of unmedicated heterozygous familial Mediterranean fever patients reveals a type I interferon signature driving increasing Pyrin expression"><span class="anchor-text-container"><span class="anchor-text"><span>Transcriptome analysis of unmedicated heterozygous familial Mediterranean fever patients reveals a type I interferon signature driving increasing Pyrin expression</span></span></span></a></h3><div class="article-source u-clr-grey6"><div class="source">Annals of the Rheumatic Diseases, 2025</div></div><div class="authors"><span>Erdal</span> <span>Sag</span>, ¡­, <span>Seza</span> <span>Ozen</span></div></div><div class="buttons"></div></li></ul></div><button class="button-link more-recommendations-button u-margin-s-bottom button-link-primary button-link-icon-right" type="button"><span class="button-link-text-container"><span class="button-link-text">Show 3 more articles</span></span><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-navigate-down"><path d="M1 51l7-7 38 38 38-38 7 7-45 45z"></path></svg></button></div></section><section class="RelatedContentPanel u-margin-s-bottom"><header id="metrics-header" class="related-content-panel-header u-margin-s-bottom"><button class="button-link button-link-secondary related-content-panel-toggle is-up button-link-icon-right button-link-has-colored-icon" type="button" aria-expanded="true"><span class="button-link-text-container"><span class="button-link-text"><h2 class="section-title u-h4"><span class="related-content-panel-title-text">Article Metrics</span></h2></span></span><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-navigate-down"><path d="M1 51l7-7 38 38 38-38 7 7-45 45z"></path></svg></button></header><div class="" aria-hidden="false" aria-describedby="metrics-header"><div class="plumX-metrics"><h3 class="text-s metric-title metric-title-citations">Citations</h3><ul><li class="text-xs metrics"><span>Citation Indexes</span><span>1</span></li></ul><h3 class="text-s metric-title metric-title-captures">Captures</h3><ul><li class="text-xs metrics"><span>Mendeley Readers</span><span>2</span></li></ul><h3 class="text-s metric-title metric-title-mentions">Mentions</h3><ul><li class="text-xs metrics"><span>News Mentions</span><span>8</span></li></ul><div class="metrics u-margin-m-top u-margin-s-bottom"><img src="https://cdn.plu.mx/3ba727faf225e19d2c759f6ebffc511d/plumx-logo.png" class="plumX-logo" alt="PlumX Metrics Logo"><a class="anchor text-xs anchor-primary" href="https://plu.mx/plum/a/?doi=10.1016%2Fj.ard.2025.05.023&amp;theme=plum-sciencedirect-theme&amp;hideUsage=true" target="_blank"><span class="anchor-text-container"><span class="anchor-text">View details</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></div></div></section></aside></div></div></div></div><footer role="contentinfo" class="els-footer u-bg-white text-xs u-padding-s-hor u-padding-m-hor-from-sm u-padding-l-hor-from-md u-padding-l-ver u-margin-l-top u-margin-xl-top-from-sm u-margin-l-top-from-md"><div class="els-footer-elsevier u-margin-m-bottom u-margin-0-bottom-from-md u-margin-s-right u-margin-m-right-from-md u-margin-l-right-from-lg"><a class="anchor anchor-primary anchor-icon-left anchor-with-icon" href="https://www.elsevier.com/" target="_blank" aria-label="Elsevier home page (opens in a new tab)"><img class="footer-logo" src="/shared-assets/47/images/elsevier-non-solus-new-with-wordmark.svg" alt="Elsevier logo with wordmark" height="64" width="58" loading="lazy"></a></div><div class="els-footer-content"><div class="u-remove-if-print"><ul class="els-footer-links u-margin-xs-bottom" style="list-style:none"><li><a class="anchor u-display-flex u-clr-grey8 u-margin-s-bottom u-margin-0-bottom-from-sm u-margin-m-right-from-sm u-margin-l-right-from-md anchor-primary anchor-small" href="https://www.elsevier.com/solutions/sciencedirect" target="_blank" id="els-footer-about-science-direct" rel="nofollow"><span class="anchor-text-container"><span class="anchor-text">About ScienceDirect</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></li><li><a class="anchor u-display-flex u-clr-grey8 u-margin-s-bottom u-margin-0-bottom-from-sm u-margin-m-right-from-sm u-margin-l-right-from-md anchor-primary anchor-small" href="/user/institution/login?targetURL=%2Fscience%2Farticle%2Fpii%2FS0003496725010416" id="els-footer-remote-access" rel="nofollow"><span class="anchor-text-container"><span class="anchor-text">Remote access</span></span></a></li><li><a class="anchor u-display-flex u-clr-grey8 u-margin-s-bottom u-margin-0-bottom-from-sm u-margin-m-right-from-sm u-margin-l-right-from-md anchor-primary anchor-small" href="https://service.elsevier.com/app/contact/supporthub/sciencedirect/" target="_blank" id="els-footer-contact-support" rel="nofollow"><span class="anchor-text-container"><span class="anchor-text">Contact and support</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></li><li><a class="anchor u-display-flex u-clr-grey8 u-margin-s-bottom u-margin-0-bottom-from-sm u-margin-m-right-from-sm u-margin-l-right-from-md anchor-primary anchor-small" href="https://www.elsevier.com/legal/elsevier-website-terms-and-conditions" target="_blank" id="els-footer-terms-condition" rel="nofollow"><span class="anchor-text-container"><span class="anchor-text">Terms and conditions</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></li><li><a class="anchor u-display-flex u-clr-grey8 u-margin-s-bottom u-margin-0-bottom-from-sm u-margin-m-right-from-sm u-margin-l-right-from-md anchor-primary anchor-small" href="https://www.elsevier.com/legal/privacy-policy" target="_blank" id="els-footer-privacy-policy" rel="nofollow"><span class="anchor-text-container"><span class="anchor-text">Privacy policy</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></li></ul></div><p id="els-footer-cookie-message" class="u-remove-if-print">Cookies are used by this site.<!-- -->  <button class="button-link ot-sdk-show-settings cookie-btn button-link-primary button-link-small" type="button" id="ot-sdk-btn">Cookie Settings</button></p><p id="els-footer-copyright">All content on this site: Copyright ? <!-- -->2025<!-- --> Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.</p></div><div class="els-footer-relx u-margin-0-top u-margin-m-top-from-xs u-margin-0-top-from-md"><a class="anchor anchor-primary anchor-icon-left anchor-with-icon" href="https://www.relx.com/" target="_blank" aria-label="RELX home page (opens in a new tab)" id="els-footer-relx"><img class="" src="/shared-assets/60/images/logo-relx-tm.svg" alt="RELX group home page" height="20" width="93" loading="lazy"></a></div></footer></div></div></div></div>
      <div id="floating-ui-node" class="floating-ui-node" data-sd-ui-floating-ui="true"></div>
      
      <script type="text/javascript">

		function safelyParseJson(key, value) {
	try {
		return JSON.parse(value);
	} catch {
		console.warn(`[parseValue(${key})] failed to parse ${value}`);
		return null;
	}
}
		function localStorageCache(localStorage, { propertyName: key, ttl }) {
	const freshValue = (cacheEntry) => {
		const expired = typeof cacheEntry.ttl === 'number' && cacheEntry.ttl < Date.now();
		if (expired) {
			localStorage.removeItem(key);
			return null;
		}

		return cacheEntry.value;
	};

	return {
		get() {
			const item = localStorage.getItem(key);
			if (!item) {
				return null;
			}

			const cacheEntry = safelyParseJson(key, item);
			if (!cacheEntry) {
				return null;
			}

			return freshValue(cacheEntry);
		},
		set(value) {
			const cacheEntry = { ttl: Date.now() + ttl, value };
			const item = JSON.stringify(cacheEntry);

			try {
				localStorage.setItem(key, item);
			} catch (e) {
				console.debug('[localStorageCache.set] error', e);
			}
		},
	};
}
		function withCache(cache) {
	return (supplier) => async () => {
		const cachedValue = cache.get();
		if (cachedValue) {
			return cachedValue;
		}

		const value = await supplier();
		if (value) {
			cache.set(value);
		}

		return value;
	};
}
		function setupWaitForEntitlements({ retryDelay, maxAttempts }) {
	return async () => {
		for (let attempt = 1; attempt <= maxAttempts; attempt++) {
			const rhfEntitlements = typeof window !== 'undefined' && window.rhfEntitlements;
			if (rhfEntitlements?.adobe) {
				return rhfEntitlements;
			}

			if (attempt < maxAttempts) {
				await new Promise((resolve) => setTimeout(resolve, retryDelay));
			}
		}
	};
}
		function setupGetEntitlements(options) {
	const localStorage = typeof window !== 'undefined' && window.localStorage;
	const withLocalStorageCache = localStorage
		? withCache(localStorageCache(localStorage, options))
		: undefined;

	const waitForEntitlements = setupWaitForEntitlements(options);
	return withLocalStorageCache ? withLocalStorageCache(waitForEntitlements) : waitForEntitlements;
}
		async function getVisitorDetails(options) {
	const { enabled, propertyName } = options;
	if (!enabled) {
		return null;
	}

	const getEntitlements = setupGetEntitlements(options);
	const entitlements = await getEntitlements();
	const details = entitlements?.adobe?.details;
	if (!details) {
		console.warn(
			`[getVisitorDetails] did not find ${propertyName} in local storage or rhfEntitlements.adobe.details`,
		);
		return null;
	}

	return details;
}
	

	  async function tryGetVisitorDetails(options) {
	try {
		return await getVisitorDetails(options);
	} catch (error) {
		console.error(`Error in getVisitorDetails:`, error);
		return null;
	}
}
	  async function sendPageLoadEvent(options) {
	const loadTime =
		typeof performance !== 'undefined' ? Math.round(performance.now()).toString() : '';

	const visitorDetails = await tryGetVisitorDetails(options);
	if (visitorDetails) {
		window.pageData.visitor.details = visitorDetails;
	}

	window.pageData.page.loadTime = loadTime;
	window.appData.push({
		event: 'pageLoad',
		...window.pageData,
	});
}
  
window.appData = window.appData || [];
window.pageData = {"content":[{"contentType":"JL","format":"MIME-XHTML","id":"sd:article:pii:S0003496725010416","type":"sd:article:JL:scope-full","detail":"sd:article:subtype:fla","publicationType":"journal","issn":"0003-4967","volumeNumber":"84","issueNumber":"10","provider":"elsevier","entitlementType":"SD=openaccess&CK=unsubscribed"}],"page":{"businessUnit":"ELS:RP:ST","language":"en","name":"product:journal:article","noTracking":"false","productAppVersion":"full-direct","productName":"SD","type":"CP-CA","environment":"prod","loadTimestamp":1761049069983,"loadTime":"","testId":"sd:article-page:current-ui"},"visitor":{"accessType":"ae:ANON_GUEST","accountId":"ae:228598","accountName":"ae:ScienceDirect Guests","loginStatus":"anonymous","userId":"ae:12975512","ipAddress":"156.246.93.80","appSessionId":"db4c3356-6d12-400a-abf1-9b1a2c64f4b4"}};
sendPageLoadEvent({"propertyName":"sd.ai.rhfEntitlements","enabled":true,"retryDelay":150,"maxAttempts":20,"ttl":60000});
</script>
<script async="" src="https://assets.adobedtm.com/4a848ae9611a/032db4f73473/launch-a6263b31083f.min.js" type="text/javascript"></script>
      <script nomodule="" src="/shared-assets/73/js/core-js/3.20.2/core-js.es.minified.js" type="text/javascript"></script>
      <script src="/shared-assets/108/js/react/18.3.1/react.production.min.js" type="text/javascript"></script>
      <script src="/shared-assets/108/js/react-dom/18.3.1/react-dom.production.min.js" type="text/javascript"></script>
      <script async="" src="/us-east-1/prod/2d348b415dc48b7aaa2f48d669a232bb69813c31/arp.js" type="text/javascript"></script>
      <script type="text/javascript">
    const pendoData = {"visitor":{"pageName":"SD:product:journal:article","pageType":"CP-CA","pageProduct":"SD","pageLanguage":"en","pageEnvironment":"prod","accessType":"ae:ANON_GUEST","countryCode":"JP"},"account":{"id":"ae:228598","name":"ae:ScienceDirect Guests"},"disablecookies":true,"events":{}};;
		const idPrefix = '';
    pendoData.events = {
      ready: function () {
        pendo.addAltText();
      },
    };
    async function runPendo(data, idPrefix, options) {
  const { urlPrefix, urlSuffix, apiKey } = options;
  (function (apiKey) {
    (function (p, e, n, d, o) { var v, w, x, y, z; o = p[d] = p[d] || {}; o._q = []; v = ['initialize', 'identify', 'updateOptions', 'pageLoad']; for (w = 0, x = v.length; w < x; ++w)(function (m) { o[m] = o[m] || function () { o._q[m === v[0] ? 'unshift' : 'push']([m].concat([].slice.call(arguments, 0))); }; })(v[w]); y = e.createElement(n); y.async = !0; y.src = urlPrefix + apiKey + urlSuffix; z = e.getElementsByTagName(n)[0]; z.parentNode.insertBefore(y, z); })(window, document, 'script', 'pendo');
    pendo.addAltText = function () {
      var target = document.querySelector('body');
      var observer = new MutationObserver(function (mutations) {
        mutations.forEach(function (mutation) {
          if (mutation?.addedNodes?.length) {
            if (mutation.addedNodes[0]?.className?.includes("_pendo-badge")) {
              const badge = mutation.addedNodes[0];
              const altText = badge?.attributes['aria-label']?.value || 'Feedback';
              const pendoBadgeImage = pendo.dom(`#${badge?.attributes?.id.value} img`);
              if (pendoBadgeImage.length) {
                pendoBadgeImage[0]?.setAttribute('alt', altText);
              }
            }
          }
        })
      })
      var config = {
        attributeFilter: ['data-layout'],
        attributes: true,
        childList: true,
        characterData: true,
        subtree: false
      };
      observer.observe(target, config);
    }
  })(apiKey);
  pendo.initialize(data);
  if (idPrefix.length) {
    let counter = 1;
    const isPendoReady = () => (typeof (pendo.isReady) === 'function' && pendo.isReady());
    while (counter < 20 && !isPendoReady()) {
      await new Promise(resolve => setTimeout(resolve, 250));
      counter += 1;
    }
    if (isPendoReady() && pendo.get_visitor_id()?.startsWith('_PENDO_T_')) {
      data.visitor.id = pendo.generate_unique_id(idPrefix);
      pendo.identify(data);
    }
  }

}
    window.addPendoScript = () => {
      runPendo(pendoData, idPrefix, {
        urlPrefix: 'https://cdn.pendo.io/agent/static/',
        urlSuffix: '/pendo.js',
        apiKey: 'd6c1d995-bc7e-4e53-77f1-2ea4ecbb9565',
      });
      window.addPendoScript = () => {};
    };
    addEventListener('load', () => window.addPendoScript());
  </script>
      <span id="pendo-answer-rating"></span>
      <script type="text/x-mathjax-config;executed=true">
        MathJax.Hub.Config({
          displayAlign: 'left',
          "fast-preview": {
            disabled: true
          },
          CommonHTML: { linebreaks: { automatic: true } },
          PreviewHTML: { linebreaks: { automatic: true } },
          'HTML-CSS': { linebreaks: { automatic: true } },
          SVG: {
            scale: 90,
            linebreaks: { automatic: true }
          }
        });
      </script>
      <script async="" src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=MML_SVG" type="text/javascript"></script>
      <script async="" src="https://www.googletagservices.com/tag/js/gpt.js" type="text/javascript"></script>
      <script async="" src="https://scholar.google.com/scholar_js/casa.js" type="text/javascript"></script>
      <script data-cfasync="false">
      (function initOneTrust()  {
        const monitor = {
  init: () => {},
  loaded: () => {},
};
        function enableGroup(group) {
	document.querySelectorAll(`script[type*="ot-${group}"]`).forEach((script) => {
		script.type = 'text/javascript';
		document.head.appendChild(script);
	});
}
        function runOneTrustCookies(doClear, monitor) {
	const oneTrustConsentSdkId = 'onetrust-consent-sdk';
	const emptyNodeSelectors = 'h3.ot-host-name, h4.ot-host-desc, button.ot-host-box';
	const ariaLabelledByButtonNodes = 'div.ot-accordion-layout > button';
	const ariaAttribute = 'aria-labelledby';

	function adjustOneTrustDOM() {
		const oneTrustRoot = document.getElementById('onetrust-consent-sdk');

		/* remove empty nodes */
		[...(oneTrustRoot?.querySelectorAll(emptyNodeSelectors) ?? [])]
			.filter((e) => e.textContent === '')
			.forEach((e) => e.remove());

		/* remove invalid aria-labelledby values */
		oneTrustRoot?.querySelectorAll(ariaLabelledByButtonNodes).forEach((e) => {
			const presentIdValue = e
				.getAttribute(ariaAttribute)
				?.split(' ')
				.filter((label) => document.getElementById(label))
				.join(' ');

			if (presentIdValue) {
				e.setAttribute(ariaAttribute, presentIdValue);
			}
		});
	}

	function observeOneTrustLoaded(shouldSetOTDefaults, isConsentPresent) {
		const cb = (mutationList, observer) => {
			const oneTrustRoot = mutationList
				.filter(
					(mutationRecord) =>
						mutationRecord.type === 'childList' && mutationRecord.addedNodes.length,
				)
				.flatMap((mutationRecord) => [...mutationRecord.addedNodes])
				.find((e) => e.id === oneTrustConsentSdkId);

			if (oneTrustRoot && typeof OneTrust !== 'undefined') {
				monitor.loaded(true);
				OneTrust.OnConsentChanged(() => {
					const perfAllowed =
						decodeURIComponent(document.cookie.match('(^| )OptanonConsent=([^;]+)')?.[2])
							?.match('groups=([0-9:0|1,?]+)&?')?.[1]
							?.match('2:([0|1])')[1] === '1';

					if (perfAllowed) {
						enableGroup('performance');
					}
				});

				if (
					!isConsentPresent &&
					(shouldSetOTDefaults || OneTrust.GetDomainData().ConsentModel.Name === 'implied consent')
				) {
					OneTrust.UpdateConsent(`Category`, `1:1`);
					OneTrust.UpdateConsent(`Category`, `2:1`);
					OneTrust.UpdateConsent(`Category`, `3:1`);
					OneTrust.UpdateConsent(`Category`, `8:0`);
				}

				document.dispatchEvent(new CustomEvent('@sdtech/onetrust/loaded', {}));

				observer.disconnect();
				adjustOneTrustDOM();
			}
		};

		const observer = new MutationObserver(cb);
		observer.observe(document.querySelector('body'), { childList: true });
	}

	if (doClear) {
		document.cookie =
			'OptanonAlertBoxClosed=; expires=Thu, 01 Jan 1970 00:00:00 UTC; samesite=lax; path=/';
	}

	const isConsentPresent = !!decodeURIComponent(
		document.cookie.match('(^| )OptanonConsent=([^;]+)')?.[2],
	)?.match('groups=([0-9:0|1,?]+)&?')?.[1];
	const shouldSetOTDefaults =
		'true' === 'false' && !document.cookie?.match('OptanonAlertBoxClosed=');
	if (shouldSetOTDefaults) {
		const date = new Date();
		date.setFullYear(date.getFullYear() + 1);
		document.cookie = `OptanonAlertBoxClosed=${new Date().toISOString()}; expires=${date.toUTCString()}; samesite=lax; path=/; domain=sciencedirect.com`;
	}

	observeOneTrustLoaded(shouldSetOTDefaults, isConsentPresent, monitor);

	window.addOTScript = () => {
		const otSDK = document.createElement('script');
		otSDK.setAttribute('data-cfasync', 'false');
		otSDK.setAttribute('src', 'https://cdn.cookielaw.org/scripttemplates/otSDKStub.js');
		otSDK.setAttribute('data-document-language', 'true');
		otSDK.setAttribute('data-domain-script', '865ea198-88cc-4e41-8952-1df75d554d02');
		window.addOTScript = () => {};
		document.head.appendChild(otSDK);
		monitor.init();
	};
	window.addEventListener('load', () => window.addOTScript());
}
        if (document.location.host.match(/\.sciencedirect\.com$/)) {
          runOneTrustCookies(true, monitor);
        }
        else {
          window.addEventListener('load', (event) => {
            enableGroup('performance');
          });
        }
      }());
    </script>
      
    
  <script>
var pageDataTracker = {
    eventCookieName: 'eventTrack',
    debugCookie: 'els-aa-debugmode',
    debugCounter: 1,
    warnings: [],
    measures: {},
    timeoffset: 0

    ,trackPageLoad: function(data) {
        if (window.pageData && ((pageData.page && pageData.page.noTracking == 'true') || window.pageData_isLoaded)) {
            return false;
        }

        this.updatePageData(data);

        this.initWarnings();
        if(!(window.pageData && pageData.page && pageData.page.name)) {
            console.error('pageDataTracker.trackPageLoad() called without pageData.page.name being defined!');
            return;
        }

        this.processIdPlusData(window.pageData);

        if(window.pageData && pageData.page && !pageData.page.loadTime) {
          pageData.page.loadTime = performance ? Math.round((performance.now())).toString() : '';
        }

        if(window.pageData && pageData.page) {
            var localTime = new Date().getTime();
            if(pageData.page.loadTimestamp) {
                // calculate timeoffset
                var serverTime = parseInt(pageData.page.loadTimestamp);
                if(!isNaN(serverTime)) {
                    this.timeoffset = pageData.page.loadTimestamp - localTime;
                }
            } else {
                pageData.page.loadTimestamp = localTime;
            }
        }

        this.validateData(window.pageData);

        try {
            var cookieTest = 'aa-cookie-test';
            this.setCookie(cookieTest, cookieTest);
            if(this.getCookie(cookieTest) != cookieTest) {
                this.warnings.push('dtm5');
            }
            this.deleteCookie(cookieTest);
        } catch(e){
            this.warnings.push('dtm5');
        }

        this.registerCallbacks();
        this.setAnalyticsData();

        // handle any cookied event data
        this.getEvents();

        window.pageData_isLoaded = true;

        this.debugMessage('Init - trackPageLoad()', window.pageData);

        _satellite.track('eventDispatcher', JSON.stringify({
          eventName: 'newPage',
          eventData: {eventName: 'newPage'},
          pageData: window.pageData
        }));
    }

    ,trackEvent: function(event, data, callback) {
        if (window.pageData && pageData.page && pageData.page.noTracking == 'true') {
            return false;
        }
        
        if(!window.pageData_isLoaded) {
            if(this.isDebugEnabled()) {
                console.log('[AA] pageDataTracker.trackEvent() called without calling trackPageLoad() first.');
            }
            // buffer cta impression if called before a pageLoad
            if (event === 'ctaImpression' && data && data.cta && Array.isArray(data.cta.ids) && data.cta.ids.length > 0) {
                window.pageData_ctaBuffer = window.pageData_ctaBuffer || [];
                data.cta.ids.forEach(id => window.pageData_ctaBuffer.push(id));
            }
            return false;
        }

        if (event) {
            this.initWarnings();
            if(event === 'newPage') {
                // auto fillings
                if(data && data.page && !data.page.loadTimestamp) {
                    data.page.loadTimestamp = ''+(new Date().getTime() + this.timeoffset);
                }
                this.processIdPlusData(data);
            }

            window.eventData = data ? data : {};
            window.eventData.eventName = event;
            if(!_satellite.getVar('blacklisted')) {
                this.handleEventData(event, data);
    
                if(event === 'newPage') {
                    this.validateData(window.pageData);
                }
                this.debugMessage('Event: ' + event, data);
    
                _satellite.track('eventDispatcher', JSON.stringify({
                  eventName: event,
                  eventData: window.eventData,
                  pageData: window.pageData
                }));
            } else {
                this.debugMessage('!! Blocked Event: ' + event, data);
            }
        }

        if (typeof(callback) == 'function') {
            callback.call();
        }
    }

    ,processIdPlusData: function(data) {
        if(data && data.visitor && data.visitor.idPlusData) {
            var idPlusFields = ['userId', 'accessType', 'accountId', 'accountName'];
            for(var i=0; i < idPlusFields.length; i++) {
                if(typeof data.visitor.idPlusData[idPlusFields[i]] !== 'undefined') {
                    data.visitor[idPlusFields[i]] = data.visitor.idPlusData[idPlusFields[i]];
                }
            }
            data.visitor.idPlusData = undefined;
        }
    }

    ,validateData: function(data) {
        if(!data) {
            this.warnings.push('dv0');
            return;
        }

        // top 5
        if(!(data.visitor && data.visitor.accessType)) {
            this.warnings.push('dv1');
        }
        if(data.visitor && (data.visitor.accountId || data.visitor.accountName)) {
            if(!data.visitor.accountName) {
                this.warnings.push('dv2');
            }
            if(!data.visitor.accountId) {
                this.warnings.push('dv3');
            }
        }
        if(!(data.page && data.page.productName)) {
            this.warnings.push('dv4');
        }
        if(!(data.page && data.page.businessUnit)) {
            this.warnings.push('dv5');
        }
        if(!(data.page && data.page.name)) {
            this.warnings.push('dv6');
        }

        // rp mandatory
        if(data.page && data.page.businessUnit && (data.page.businessUnit.toLowerCase().indexOf('els:rp:') !== -1 || data.page.businessUnit.toLowerCase().indexOf('els:rap:') !== -1)) {
            if(!(data.page && data.page.loadTimestamp)) {
                this.warnings.push('dv7');
            }
            if(!(data.page && data.page.loadTime)) {
                this.warnings.push('dv8');
            }
            if(!(data.visitor && data.visitor.ipAddress)) {
                this.warnings.push('dv9');
            }
            if(!(data.page && data.page.type)) {
                this.warnings.push('dv10');
            }
            if(!(data.page && data.page.language)) {
                this.warnings.push('dv11');
            }
        }

        // other
        if(data.page && data.page.environment) {
            var env = data.page.environment.toLowerCase();
            if(!(env === 'dev' || env === 'cert' || env === 'prod')) {
                this.warnings.push('dv12');
            }
        }
        if(data.content && data.content.constructor !== Array) {
            this.warnings.push('dv13');
        }

        if(data.visitor && data.visitor.accountId && data.visitor.accountId.indexOf(':') == -1) {
            this.warnings.push('dv14');
            data.visitor.accountId = "data violation"
        }
    }

    ,initWarnings: function() {
        this.warnings = [];
        try {
            var hdn = document.head.childNodes;
            var libf = false;
            for(var i=0; i<hdn.length; i++) {
                if(hdn[i].src && (hdn[i].src.indexOf('satelliteLib') !== -1 || hdn[i].src.indexOf('launch') !== -1)) {
                    libf = true;
                    break;
                }
            }
            if(!libf) {
                this.warnings.push('dtm1');
            }
        } catch(e) {}

        try {
            for (let element of document.querySelectorAll('*')) {
                // Check if the element has a src attribute and if it meets the criteria
                if (element.src && element.src.includes('assets.adobedtm.com') && element.src.includes('launch')) {
                    if (element.tagName.toLowerCase() !== 'script') {
                        this.warnings.push('dtm5');
                    }
                    if (!element.hasAttribute('async')) {
                        this.warnings.push('dtm4');
                    }
                }
            }
        } catch (e) { }
    }

    ,getMessages: function() {
        return ['v1'].concat(this.warnings).join('|');
    }
    ,addMessage: function(message) {
        this.warnings.push(message);
    }

    ,getPerformance: function() {
        var copy = {};
        for (var attr in this.measures) {
            if(this.measures.hasOwnProperty(attr)) {
                copy[attr] = this.measures[attr];
            }
        }

        this.measures = {};
        return copy;
    }

    ,dtmCodeDesc: {
        dtm1: 'satellite-lib must be placed in the <head> section',
        dtm2: 'trackPageLoad() must be placed and called before the closing </body> tag',
        dtm3: 'trackEvent() must be called at a stage where Document.readyState=complete (e.g. on the load event or a user event)',
        dtm4: 'Embed codes need to be loaded in async mode',
        dtm5: 'Embed codes not in type script',
        dv1: 'visitor.accessType not set but mandatory',
        dv2: 'visitor.accountName not set but mandatory',
        dv3: 'visitor.accountId not set but mandatory',
        dv4: 'page.productName not set but mandatory',
        dv5: 'page.businessUnit not set but mandatory',
        dv6: 'page.name not set but mandatory',
        dv7: 'page.loadTimestamp not set but mandatory',
        dv8: 'page.loadTime not set but mandatory',
        dv9: 'visitor.ipAddress not set but mandatory',
        dv10: 'page.type not set but mandatory',
        dv11: 'page.language not set but mandatory',
        dv12: 'page.environment must be set to \'prod\', \'cert\' or \'dev\'',
        dv13: 'content must be of type array of objects',
        dv14: 'account number must contain at least one \':\', e.g. \'ae:12345\''
    }

    ,debugMessage: function(event, data) {
        if(this.isDebugEnabled()) {
            console.log('[AA] --------- [' + (this.debugCounter++) + '] Web Analytics Data ---------');
            console.log('[AA] ' + event);
            console.groupCollapsed("[AA] AA Data: ");
            if(window.eventData) {
                console.log("[AA] eventData:\n" + JSON.stringify(window.eventData, true, 2));
            }
            if(window.pageData) {
                console.log("[AA] pageData:\n" + JSON.stringify(window.pageData, true, 2));
            }
            console.groupEnd();
            if(this.warnings.length > 0) {
                console.groupCollapsed("[AA] Warnings ("+this.warnings.length+"): ");
                for(var i=0; i<this.warnings.length; i++) {
                    var error = this.dtmCodeDesc[this.warnings[i]] ? this.dtmCodeDesc[this.warnings[i]] : 'Error Code: ' + this.warnings[i];
                    console.log('[AA] ' + error);
                }
                console.log('[AA] More can be found here: https://confluence.cbsels.com/display/AA/AA+Error+Catalog');
                console.groupEnd();
            }
            console.log("This mode can be disabled by calling 'pageDataTracker.disableDebug()'");
        }
    }

    ,getTrackingCode: function() {
      var campaign = _satellite.getVar('Campaign - ID');
      if(!campaign) {
        campaign = window.sessionStorage ? sessionStorage.getItem('dgcid') : '';
      }
      return campaign;
    }

    ,isDebugEnabled: function() {
        if(typeof this.debug === 'undefined') {
            this.debug = (document.cookie.indexOf(this.debugCookie) !== -1) || (window.pageData && pageData.page && pageData.page.environment && pageData.page.environment.toLowerCase() === 'dev');
            //this.debug = (document.cookie.indexOf(this.debugCookie) !== -1);
        }
        return this.debug;
    }

    ,enableDebug: function(expire) {
        if (typeof expire === 'undefined') {
            expire = 86400;
        }
        console.log('You just enabled debug mode for Adobe Analytics tracking. This mode will persist for 24h.');
        console.log("This mode can be disabled by calling 'pageDataTracker.disableDebug()'");
        this.setCookie(this.debugCookie, 'true', expire, document.location.hostname);
        this.debug = true;
    }

    ,disableDebug: function() {
        console.log('Debug mode is now disabled.');
        this.deleteCookie(this.debugCookie);
        this.debug = false;
    }

    ,setAnalyticsData: function() {
        if(!(window.pageData && pageData.page && pageData.page.productName && pageData.page.name)) {
            return;
        }
        pageData.page.analyticsPagename = pageData.page.productName + ':' + pageData.page.name;

        var pageEls = pageData.page.name.indexOf(':') > -1 ? pageData.page.name.split(':') : [pageData.page.name];
        pageData.page.sectionName = pageData.page.productName + ':' + pageEls[0];
    }

    ,getEvents: function() {
        pageData.savedEvents = {};
        pageData.eventList = [];

        var val = this.getCookie(this.eventCookieName);
        if (val) {
            pageData.savedEvents = val;
        }

        this.deleteCookie(this.eventCookieName);
    }

    ,updatePageData(data) {
        window.pageData = window.pageData || {};
        if (data && typeof(data) === 'object') {
            for (var x in data) {
                if(data.hasOwnProperty(x) && data[x] instanceof Array) {
                    pageData[x] = data[x];
                } else if(data.hasOwnProperty(x) && typeof(data[x]) === 'object') {
                    if(!pageData[x]) {
                        pageData[x] = {};
                    }
                    for (var y in data[x]) {
                        if(data[x].hasOwnProperty(y)) {
                            pageData[x][y] = data[x][y];
                        }
                    }
                }
            }
        }
    }

    ,handleEventData: function(event, data) {
        var val;
        switch(event) {
            case 'newPage':
                this.updatePageData(data);
                this.setAnalyticsData();
            case 'saveSearch':
            case 'searchResultsUpdated':
                if (data) {
                    // overwrite page-load object
                    if (data.search && typeof(data.search) == 'object') {
                        window.eventData.search.resultsPosition = '';
                        pageData.search = pageData.search || {};
                        var fields = ['advancedCriteria', 'criteria', 'currentPage', 'dataFormCriteria', 'facets', 'resultsByType', 'resultsPerPage', 'sortType', 'totalResults', 'type', 'database',
                        'suggestedClickPosition','suggestedLetterCount','suggestedResultCount', 'autoSuggestCategory', 'autoSuggestDetails','typedTerm','selectedTerm', 'channel',
                        'facetOperation', 'details'];
                        for (var i=0; i<fields.length; i++) {
                            if (data.search[fields[i]]) {
                                pageData.search[fields[i]] = data.search[fields[i]];
                            }
                        }
                    }
                }
                this.setAnalyticsData();
                break;
            case 'navigationClick':
                if (data && data.link) {
                    window.eventData.navigationLink = {
                        name: ((data.link.location || 'no location') + ':' + (data.link.name || 'no name'))
                    };
                }
                break;
            case 'autoSuggestClick':
                if (data && data.search) {
                    val = {
                        autoSuggestSearchData: (
                            'letterct:' + (data.search.suggestedLetterCount || 'none') +
                            '|resultct:' + (data.search.suggestedResultCount || 'none') +
                            '|clickpos:' + (data.search.suggestedClickPosition || 'none')
                        ).toLowerCase(),
                        autoSuggestSearchTerm: (data.search.typedTerm || ''),
                        autoSuggestTypedTerm: (data.search.typedTerm || ''),
                        autoSuggestSelectedTerm: (data.search.selectedTerm || ''),
                        autoSuggestCategory: (data.search.autoSuggestCategory || ''),
                        autoSuggestDetails: (data.search.autoSuggestDetails || '')
                    };
                }
                break;
            case 'linkOut':
                if (data && data.content && data.content.length > 0) {
                    window.eventData.linkOut = data.content[0].linkOut;
                    window.eventData.referringProduct = _satellite.getVar('Page - Product Name') + ':' + data.content[0].id;
                }
                break;
            case 'socialShare':
                if (data && data.social) {
                    window.eventData.sharePlatform = data.social.sharePlatform || '';
                }
                break;
            case 'contentInteraction':
                if (data && data.action) {
                    window.eventData.action.name = pageData.page.productName + ':' + data.action.name;
                }
                break;
            case 'searchWithinContent':
                if (data && data.search) {
                    window.pageData.search = window.pageData.search || {};
                    pageData.search.withinContentCriteria = data.search.withinContentCriteria;
                }
                break;
            case 'contentShare':
                if (data && data.content) {
                    window.eventData.sharePlatform = data.content[0].sharePlatform;
                }
                break;
            case 'contentLinkClick':
                if (data && data.link) {
                    window.eventData.action = { name: pageData.page.productName + ':' + (data.link.type || 'no link type') + ':' + (data.link.name || 'no link name') };
                }
                break;
            case 'contentWindowLoad':
            case 'contentTabClick':
                if (data && data.content) {
                    window.eventData.tabName = data.content[0].tabName || '';
                    window.eventData.windowName = data.content[0].windowName || '';
                }
                break;
            case 'userProfileUpdate':
                if (data && data.user) {
                    if (Object.prototype.toString.call(data.user) === "[object Array]") {
                        window.eventData.user = data.user[0];
                    }
                }
                break;
            case 'videoStart':
                if (data.video) {
                    data.video.length = parseFloat(data.video.length || '0');
                    data.video.position = parseFloat(data.video.position || '0');
                    s.Media.open(data.video.id, data.video.length, s.Media.playerName);
                    s.Media.play(data.video.id, data.video.position);
                }
                break;
            case 'videoPlay':
                if (data.video) {
                    data.video.position = parseFloat(data.video.position || '0');
                    s.Media.play(data.video.id, data.video.position);
                }
                break;
            case 'videoStop':
                if (data.video) {
                    data.video.position = parseFloat(data.video.position || '0');
                    s.Media.stop(data.video.id, data.video.position);
                }
                break;
            case 'videoComplete':
                if (data.video) {
                    data.video.position = parseFloat(data.video.position || '0');
                    s.Media.stop(data.video.id, data.video.position);
                    s.Media.close(data.video.id);
                }
                break;
            case 'addWebsiteExtension':
                if(data && data.page) {
                    val = {
                        wx: data.page.websiteExtension
                    }
                }
                break;
        }

        if (val) {
            this.setCookie(this.eventCookieName, val);
        }
    }

    ,registerCallbacks: function() {
        var self = this;
        if(window.usabilla_live) {
            window.usabilla_live('setEventCallback', function(category, action, label, value) {
                if(action == 'Campaign:Open') {
                    self.trackEvent('ctaImpression', {
                        cta: {
                            ids: ['usabillaid:' + label]
                        }
                    });
                } else if(action == 'Campaign:Success') {
                    self.trackEvent('ctaClick', {
                        cta: {
                            ids: ['usabillaid:' + label]
                        }
                    });
                }
            });
        }
    }

    ,getConsortiumAccountId: function() {
        var id = '';
        if (window.pageData && pageData.visitor && (pageData.visitor.consortiumId || pageData.visitor.accountId)) {
            id = (pageData.visitor.consortiumId || 'no consortium ID') + '|' + (pageData.visitor.accountId || 'no account ID');
        }

        return id;
    }

    ,getSearchClickPosition: function() {
        if (window.eventData && eventData.search && eventData.search.resultsPosition) {
            var pos = parseInt(eventData.search.resultsPosition), clickPos;
            if (!isNaN(pos)) {
                var page = pageData.search.currentPage ? parseInt(pageData.search.currentPage) : '', perPage = pageData.search.resultsPerPage ? parseInt(pageData.search.resultsPerPage) : '';
                if (!isNaN(page) && !isNaN(perPage)) {
                    clickPos = pos + ((page - 1) * perPage);
                }
            }
            return clickPos ? clickPos.toString() : eventData.search.resultsPosition;
        }
        return '';
    }

    ,getSearchFacets: function() {
        var facetList = '';
        if (window.pageData && pageData.search && pageData.search.facets) {
            if (typeof(pageData.search.facets) == 'object') {
                for (var i=0; i<pageData.search.facets.length; i++) {
                    var f = pageData.search.facets[i];
                    facetList += (facetList ? '|' : '') + f.name + '=' + f.values.join('^');
                }
            }
        }
        return facetList;
    }

    ,getSearchResultsByType: function() {
        var resultTypes = '';
        if (window.pageData && pageData.search && pageData.search.resultsByType) {
            for (var i=0; i<pageData.search.resultsByType.length; i++) {
                var r = pageData.search.resultsByType[i];
                resultTypes += (resultTypes ? '|' : '') + r.name + (r.results || r.values ? '=' + (r.results || r.values) : '');
            }
        }
        return resultTypes;
    }

    ,getJournalInfo: function() {
        var info = '';
        if (window.pageData && pageData.journal && (pageData.journal.name || pageData.journal.specialty || pageData.journal.section || pageData.journal.issn || pageData.journal.issueNumber || pageData.journal.volumeNumber || pageData.journal.family || pageData.journal.publisher)) {
            var journal = pageData.journal;
            info = (journal.name || 'no name') 
            + '|' + (journal.specialty || 'no specialty') 
            + '|' + (journal.section || 'no section') 
            + '|' + (journal.issn || 'no issn') 
            + '|' + (journal.issueNumber || 'no issue #') 
            + '|' + (journal.volumeNumber || 'no volume #')
            + '|' + (journal.family || 'no family')
            + '|' + (journal.publisher || 'no publisher');

        }
        return info;
    }

    ,getBibliographicInfo: function(doc) {
        if (!doc || !(doc.publisher || doc.indexTerms || doc.publicationType || doc.publicationRights || doc.volumeNumber || doc.issueNumber || doc.subjectAreas || doc.isbn)) {
            return '';
        }

        var terms = doc.indexTerms ? doc.indexTerms.split('+') : '';
        if (terms) {
            terms = terms.slice(0, 5).join('+');
            terms = terms.length > 100 ? terms.substring(0, 100) : terms;
        }

        var areas = doc.subjectAreas ? doc.subjectAreas.split('>') : '';
        if (areas) {
            areas = areas.slice(0, 5).join('>');
            areas = areas.length > 100 ? areas.substring(0, 100) : areas;
        }

        var biblio	= (doc.publisher || 'none')
            + '^' + (doc.publicationType || 'none')
            + '^' + (doc.publicationRights || 'none')
            + '^' + (terms || 'none')
            + '^' + (doc.volumeNumber || 'none')
            + '^' + (doc.issueNumber || 'none')
            + '^' + (areas || 'none')
            + '^' + (doc.isbn || 'none');

        return this.stripProductDelimiters(biblio).toLowerCase();
    }

    ,getContentItem: function() {
        var docs = window.eventData && eventData.content ? eventData.content : pageData.content;
        if (docs && docs.length > 0) {
            return docs[0];
        }
    }

    ,getFormattedDate: function(ts) {
        if (!ts) {
            return '';
        }

        var d = new Date(parseInt(ts) * 1000);

        // now do formatting
        var year = d.getFullYear()
            ,month = ((d.getMonth() + 1) < 10 ? '0' : '') + (d.getMonth() + 1)
            ,date = (d.getDate() < 10 ? '0' : '') + d.getDate()
            ,hours = d.getHours() > 12 ? d.getHours() - 12 : d.getHours()
            ,mins = (d.getMinutes() < 10 ? '0' : '') + d.getMinutes()
            ,ampm = d.getHours() > 12 ? 'pm' : 'am';

        hours = (hours < 10 ? '0' : '') + hours;
        return year + '-' + month + '-' + date;
    }

    ,getVisitorId: function() {
        var orgId = '4D6368F454EC41940A4C98A6@AdobeOrg';
        if(Visitor && Visitor.getInstance(orgId)) {
            return Visitor.getInstance(orgId).getMarketingCloudVisitorID();
        } else {
            return ''
        }
    }

    ,setProductsVariable: function() {
        var prodList = window.eventData && eventData.content ? eventData.content : pageData.content
            ,prods = [];
        if (prodList) {
            for (var i=0; i<prodList.length; i++) {
                if (prodList[i].id || prodList[i].type || prodList[i].publishDate || prodList[i].onlineDate) {
                    if (!prodList[i].id) {
                        prodList[i].id = 'no id';
                    }
                    var prodName = (pageData.page.productName || 'xx').toLowerCase();
                    if (prodList[i].id.indexOf(prodName + ':') != 0) {
                        prodList[i].id = prodName + ':' + prodList[i].id;
                    }
                    prodList[i].id = this.stripProductDelimiters(prodList[i].id);
                    var merch = [];
                    if (prodList[i].format) {
                        merch.push('evar17=' + this.stripProductDelimiters(prodList[i].format.toLowerCase()));
                    }
                    if (prodList[i].type) {
                        var type = prodList[i].type;
                        if (prodList[i].accessType) {
                            type += ':' + prodList[i].accessType;
                        }
                        merch.push('evar20=' + this.stripProductDelimiters(type.toLowerCase()));

                        if(type.indexOf(':manuscript') > 0) {
                            /*
                            var regex = /[a-z]+:manuscript:id:([a-z]+-[a-z]-[0-9]+-[0-9]+)/gmi;
                            var m = regex.exec(prodList[i].id);
                            if(m) {
                                merch.push('evar200=' + m[1]);
                            }
                            merch.push('evar200=' + prodList[i].id);
                            */
                            a = prodList[i].id.lastIndexOf(':');
                            if(a>0) {
                                merch.push('evar200=' + prodList[i].id.substring(a+1).toUpperCase());
                            }
                        } else if(type.indexOf(':submission') > 0) {
                            merch.push('evar200=' + prodList[i].id);
                        }
                    }
                    if(!prodList[i].title) {
                        prodList[i].title = prodList[i].name;
                    }
                    if (prodList[i].title) {
                        merch.push('evar75=' + this.stripProductDelimiters(prodList[i].title.toLowerCase()));
                    }
                    if (prodList[i].breadcrumb) {
                        merch.push('evar63=' + this.stripProductDelimiters(prodList[i].breadcrumb).toLowerCase());
                    }
                    var nowTs = new Date().getTime()/1000;
                    if (prodList[i].onlineDate && !isNaN(prodList[i].onlineDate)) {
                        if(prodList[i].onlineDate > 32503680000) {
                            prodList[i].onlineDate = prodList[i].onlineDate/1000;
                        }
                        merch.push('evar122=' + this.stripProductDelimiters(pageDataTracker.getFormattedDate(prodList[i].onlineDate)));
                        var onlineAge = Math.floor((nowTs - prodList[i].onlineDate) / 86400);
                        onlineAge = (onlineAge === 0) ? 'zero' : onlineAge;
                        merch.push('evar128=' + onlineAge);
                    }
                    if (prodList[i].publishDate && !isNaN(prodList[i].publishDate)) {
                        if(prodList[i].publishDate > 32503680000) {
                            prodList[i].publishDate = prodList[i].publishDate/1000;
                        }
                        merch.push('evar123=' + this.stripProductDelimiters(pageDataTracker.getFormattedDate(prodList[i].publishDate)));
                        var publishAge = Math.floor((nowTs - prodList[i].publishDate) / 86400);
                        publishAge = (publishAge === 0) ? 'zero' : publishAge;
                        merch.push('evar127=' + publishAge);
                    }
                    if (prodList[i].onlineDate && prodList[i].publishDate) {
                        merch.push('evar38=' + this.stripProductDelimiters(pageDataTracker.getFormattedDate(prodList[i].onlineDate) + '^' + pageDataTracker.getFormattedDate(prodList[i].publishDate)));
                    }
                    if (prodList[i].mapId) {
                        merch.push('evar70=' + this.stripProductDelimiters(prodList[i].mapId));
                    }
					if (prodList[i].relevancyScore) {
						merch.push('evar71=' + this.stripProductDelimiters(prodList[i].relevancyScore));
					}
                    if (prodList[i].status) {
                        merch.push('evar73=' + this.stripProductDelimiters(prodList[i].status));
                    }
                    if (prodList[i].previousStatus) {
                        merch.push('evar111=' + this.stripProductDelimiters(prodList[i].previousStatus));
                    }
                    if (prodList[i].entitlementType) {
                        merch.push('evar80=' + this.stripProductDelimiters(prodList[i].entitlementType));
                    }
                    if (prodList[i].recordType) {
                        merch.push('evar93=' + this.stripProductDelimiters(prodList[i].recordType));
                    }
                    if (prodList[i].exportType) {
                        merch.push('evar99=' + this.stripProductDelimiters(prodList[i].exportType));
                    }
                    if (prodList[i].importType) {
                        merch.push('evar142=' + this.stripProductDelimiters(prodList[i].importType));
                    }
                    if (prodList[i].section) {
                        merch.push('evar100=' + this.stripProductDelimiters(prodList[i].section));
                    }
                    if (prodList[i].detail) {
                        merch.push('evar104=' + this.stripProductDelimiters(prodList[i].detail.toLowerCase()));
                    } else if(prodList[i].details) {
                        merch.push('evar104=' + this.stripProductDelimiters(prodList[i].details.toLowerCase()));
                    }
                    if (prodList[i].position) {
                        merch.push('evar116=' + this.stripProductDelimiters(prodList[i].position));
                    }
                    if (prodList[i].publicationTitle) {
                        merch.push('evar129=' + this.stripProductDelimiters(prodList[i].publicationTitle));
                    }
                    if (prodList[i].specialIssueTitle) {
                        merch.push('evar130=' + this.stripProductDelimiters(prodList[i].specialIssueTitle));
                    }
                    if (prodList[i].specialIssueNumber) {
                        merch.push('evar131=' + this.stripProductDelimiters(prodList[i].specialIssueNumber));
                    }
                    if (prodList[i].referenceModuleTitle) {
                        merch.push('evar139=' + this.stripProductDelimiters(prodList[i].referenceModuleTitle));
                    }
                    if (prodList[i].referenceModuleISBN) {
                        merch.push('evar140=' + this.stripProductDelimiters(prodList[i].referenceModuleISBN));
                    }
                    if (prodList[i].volumeTitle) {
                        merch.push('evar132=' + this.stripProductDelimiters(prodList[i].volumeTitle));
                    }
                    if (prodList[i].publicationSection) {
                        merch.push('evar133=' + this.stripProductDelimiters(prodList[i].publicationSection));
                    }
                    if (prodList[i].publicationSpecialty) {
                        merch.push('evar134=' + this.stripProductDelimiters(prodList[i].publicationSpecialty));
                    }
                    if (prodList[i].issn) {
                        merch.push('evar135=' + this.stripProductDelimiters(prodList[i].issn));
                    }
                    if (prodList[i].id2) {
                        merch.push('evar159=' + this.stripProductDelimiters(prodList[i].id2));
                    }
                    if (prodList[i].id3) {
                        merch.push('evar160=' + this.stripProductDelimiters(prodList[i].id3));
                    }
                    if (prodList[i].provider) {
                        merch.push('evar164=' + this.stripProductDelimiters(prodList[i].provider));
                    }
                    if (prodList[i].citationStyle) {
                        merch.push('evar170=' + this.stripProductDelimiters(prodList[i].citationStyle));
                    }

                    var biblio = this.getBibliographicInfo(prodList[i]);
                    if (biblio) {
                        merch.push('evar28=' + biblio);
                    }

                    if (prodList[i].turnawayId) {
                        pageData.eventList.push('product turnaway');
                    }

                    var price = prodList[i].price || '', qty = prodList[i].quantity || '', evts = [];
                    if (price && qty) {
                        qty = parseInt(qty || '1');
                        price = parseFloat(price || '0');
                        price = (price * qty).toFixed(2);

                        if (window.eventData && eventData.eventName && eventData.eventName == 'cartAdd') {
                            evts.push('event20=' + price);
                        }
                    }

                    var type = window.pageData && pageData.page && pageData.page.type ? pageData.page.type : '', evt = window.eventData && eventData.eventName ? eventData.eventName : '';
                    if (type.match(/^CP\-/gi) !== null && (!evt || evt == 'newPage' || evt == 'contentView')) {
                        evts.push('event181=1');
                    }
                    if (evt == 'contentDownload' || type.match(/^CP\-DL/gi) !== null) {
                        evts.push('event182=1');
                    }
                    if (evt == 'contentDownloadRequest') {
                        evts.push('event319=1');
                    }
                    if (evt == 'contentExport') {
                        evts.push('event184=1');
                    }
                    if (this.eventFires('recommendationViews')) {
                        evts.push('event264=1');
                    }

                    if(prodList[i].datapoints) {
                        evts.push('event239=' + prodList[i].datapoints);
                    }
                    if(prodList[i].documents) {
                        evts.push('event240=' + prodList[i].documents);
                    }
                    if(prodList[i].size) {
                        evts.push('event335=' + prodList[i].size);
                        evts.push('event336=1')
                    }

                    if(evt == 'genAIContentUpdated') {
                        evts.push('event51=1');
                    }

                    prods.push([
                        ''					// empty category
                        ,prodList[i].id		// id
                        ,qty				// qty
                        ,price				// price
                        ,evts.join('|')		// events
                        ,merch.join('|')	// merchandising eVars
                    ].join(';'));
                }
            }
        }

        return prods.join(',');
    }
    ,eventFires: function(eventName) {
      var evt = window.eventData && eventData.eventName ? eventData.eventName : '';
      if(evt == eventName) {
        return true;
      }
      // initial pageload and new pages
      if((!window.eventData || evt == 'newPage') && window.pageData && window.pageData.trackEvents) {
        var tEvents = window.pageData.trackEvents;
        for(var i=0; i<tEvents.length; i++) {
          if(tEvents[i] == eventName) {
            return true;
          }
        }
      }
      return false;
    }

    ,md5: function(s){function L(k,d){return(k<<d)|(k>>>(32-d))}function K(G,k){var I,d,F,H,x;F=(G&2147483648);H=(k&2147483648);I=(G&1073741824);d=(k&1073741824);x=(G&1073741823)+(k&1073741823);if(I&d){return(x^2147483648^F^H)}if(I|d){if(x&1073741824){return(x^3221225472^F^H)}else{return(x^1073741824^F^H)}}else{return(x^F^H)}}function r(d,F,k){return(d&F)|((~d)&k)}function q(d,F,k){return(d&k)|(F&(~k))}function p(d,F,k){return(d^F^k)}function n(d,F,k){return(F^(d|(~k)))}function u(G,F,aa,Z,k,H,I){G=K(G,K(K(r(F,aa,Z),k),I));return K(L(G,H),F)}function f(G,F,aa,Z,k,H,I){G=K(G,K(K(q(F,aa,Z),k),I));return K(L(G,H),F)}function D(G,F,aa,Z,k,H,I){G=K(G,K(K(p(F,aa,Z),k),I));return K(L(G,H),F)}function t(G,F,aa,Z,k,H,I){G=K(G,K(K(n(F,aa,Z),k),I));return K(L(G,H),F)}function e(G){var Z;var F=G.length;var x=F+8;var k=(x-(x%64))/64;var I=(k+1)*16;var aa=Array(I-1);var d=0;var H=0;while(H<F){Z=(H-(H%4))/4;d=(H%4)*8;aa[Z]=(aa[Z]| (G.charCodeAt(H)<<d));H++}Z=(H-(H%4))/4;d=(H%4)*8;aa[Z]=aa[Z]|(128<<d);aa[I-2]=F<<3;aa[I-1]=F>>>29;return aa}function B(x){var k="",F="",G,d;for(d=0;d<=3;d++){G=(x>>>(d*8))&255;F="0"+G.toString(16);k=k+F.substr(F.length-2,2)}return k}function J(k){k=k.replace(/rn/g,"n");var d="";for(var F=0;F<k.length;F++){var x=k.charCodeAt(F);if(x<128){d+=String.fromCharCode(x)}else{if((x>127)&&(x<2048)){d+=String.fromCharCode((x>>6)|192);d+=String.fromCharCode((x&63)|128)}else{d+=String.fromCharCode((x>>12)|224);d+=String.fromCharCode(((x>>6)&63)|128);d+=String.fromCharCode((x&63)|128)}}}return d}var C=Array();var P,h,E,v,g,Y,X,W,V;var S=7,Q=12,N=17,M=22;var A=5,z=9,y=14,w=20;var o=4,m=11,l=16,j=23;var U=6,T=10,R=15,O=21;s=J(s);C=e(s);Y=1732584193;X=4023233417;W=2562383102;V=271733878;for(P=0;P<C.length;P+=16){h=Y;E=X;v=W;g=V;Y=u(Y,X,W,V,C[P+0],S,3614090360);V=u(V,Y,X,W,C[P+1],Q,3905402710);W=u(W,V,Y,X,C[P+2],N,606105819);X=u(X,W,V,Y,C[P+3],M,3250441966);Y=u(Y,X,W,V,C[P+4],S,4118548399);V=u(V,Y,X,W,C[P+5],Q,1200080426);W=u(W,V,Y,X,C[P+6],N,2821735955);X=u(X,W,V,Y,C[P+7],M,4249261313);Y=u(Y,X,W,V,C[P+8],S,1770035416);V=u(V,Y,X,W,C[P+9],Q,2336552879);W=u(W,V,Y,X,C[P+10],N,4294925233);X=u(X,W,V,Y,C[P+11],M,2304563134);Y=u(Y,X,W,V,C[P+12],S,1804603682);V=u(V,Y,X,W,C[P+13],Q,4254626195);W=u(W,V,Y,X,C[P+14],N,2792965006);X=u(X,W,V,Y,C[P+15],M,1236535329);Y=f(Y,X,W,V,C[P+1],A,4129170786);V=f(V,Y,X,W,C[P+6],z,3225465664);W=f(W,V,Y,X,C[P+11],y,643717713);X=f(X,W,V,Y,C[P+0],w,3921069994);Y=f(Y,X,W,V,C[P+5],A,3593408605);V=f(V,Y,X,W,C[P+10],z,38016083);W=f(W,V,Y,X,C[P+15],y,3634488961);X=f(X,W,V,Y,C[P+4],w,3889429448);Y=f(Y,X,W,V,C[P+9],A,568446438);V=f(V,Y,X,W,C[P+14],z,3275163606);W=f(W,V,Y,X,C[P+3],y,4107603335);X=f(X,W,V,Y,C[P+8],w,1163531501);Y=f(Y,X,W,V,C[P+13],A,2850285829);V=f(V,Y,X,W,C[P+2],z,4243563512);W=f(W,V,Y,X,C[P+7],y,1735328473);X=f(X,W,V,Y,C[P+12],w,2368359562);Y=D(Y,X,W,V,C[P+5],o,4294588738);V=D(V,Y,X,W,C[P+8],m,2272392833);W=D(W,V,Y,X,C[P+11],l,1839030562);X=D(X,W,V,Y,C[P+14],j,4259657740);Y=D(Y,X,W,V,C[P+1],o,2763975236);V=D(V,Y,X,W,C[P+4],m,1272893353);W=D(W,V,Y,X,C[P+7],l,4139469664);X=D(X,W,V,Y,C[P+10],j,3200236656);Y=D(Y,X,W,V,C[P+13],o,681279174);V=D(V,Y,X,W,C[P+0],m,3936430074);W=D(W,V,Y,X,C[P+3],l,3572445317);X=D(X,W,V,Y,C[P+6],j,76029189);Y=D(Y,X,W,V,C[P+9],o,3654602809);V=D(V,Y,X,W,C[P+12],m,3873151461);W=D(W,V,Y,X,C[P+15],l,530742520);X=D(X,W,V,Y,C[P+2],j,3299628645);Y=t(Y,X,W,V,C[P+0],U,4096336452);V=t(V,Y,X,W,C[P+7],T,1126891415);W=t(W,V,Y,X,C[P+14],R,2878612391);X=t(X,W,V,Y,C[P+5],O,4237533241);Y=t(Y,X,W,V,C[P+12],U,1700485571);V=t(V,Y,X,W,C[P+3],T,2399980690);W=t(W,V,Y,X,C[P+10],R,4293915773);X=t(X,W,V,Y,C[P+1],O,2240044497);Y=t(Y,X,W,V,C[P+8],U,1873313359);V=t(V,Y,X,W,C[P+15],T,4264355552);W=t(W,V,Y,X,C[P+6],R,2734768916);X=t(X,W,V,Y,C[P+13],O,1309151649);Y=t(Y,X,W,V,C[P+4],U,4149444226);V=t(V,Y,X,W,C[P+11],T,3174756917);W=t(W,V,Y,X,C[P+2],R,718787259);X=t(X,W,V,Y,C[P+9],O,3951481745);Y=K(Y,h);X=K(X,E);W=K(W,v);V=K(V,g)}var i=B(Y)+B(X)+B(W)+B(V);return i.toLowerCase()}
    ,stripProductDelimiters: function(val) {
        if (val) {
            return val.replace(/\;|\||\,/gi, '-');
        }
    }

    ,setCookie: function(name, value, seconds, domain) {
        domain = document.location.hostname;
        var expires = '';
        var expiresNow = '';
        var date = new Date();
        date.setTime(date.getTime() + (-1 * 1000));
        expiresNow = "; expires=" + date.toGMTString();

        if (typeof(seconds) != 'undefined') {
            date.setTime(date.getTime() + (seconds * 1000));
            expires = '; expires=' + date.toGMTString();
        }

        var type = typeof(value);
        type = type.toLowerCase();
        if (type != 'undefined' && type != 'string') {
            value = JSON.stringify(value);
        }

        // fix scoping issues
        // keep writing the old cookie, but make it expire
        document.cookie = name + '=' + value + expiresNow + '; path=/';

        // now just set the right one
        document.cookie = name + '=' + value + expires + '; path=/; domain=' + domain;
    }

    ,getCookie: function(name) {
        name = name + '=';
        var carray = document.cookie.split(';'), value;

        for (var i=0; i<carray.length; i++) {
            var c = carray[i];
            while (c.charAt(0) == ' ') {
                c = c.substring(1, c.length);
            }
            if (c.indexOf(name) == 0) {
                value = c.substring(name.length, c.length);
                try {
                    value = JSON.parse(value);
                } catch(ex) {}

                return value;
            }
        }

        return null;
    }

    ,deleteCookie: function(name) {
        this.setCookie(name, '', -1);
        this.setCookie(name, '', -1, document.location.hostname);
    }

    ,mapAdobeVars: function(s) {
        var vars = {
            pageName		: 'Page - Analytics Pagename'
            ,channel		: 'Page - Section Name'
            ,campaign		: 'Campaign - ID'
            ,currencyCode	: 'Page - Currency Code'
            ,purchaseID		: 'Order - ID'
            ,prop1			: 'Visitor - Account ID'
            ,prop2			: 'Page - Product Name'
            ,prop4			: 'Page - Type'
            ,prop6			: 'Search - Type'
            ,prop7			: 'Search - Facet List'
            ,prop8			: 'Search - Feature Used'
            ,prop12			: 'Visitor - User ID'
            ,prop13			: 'Search - Sort Type'
            ,prop14			: 'Page - Load Time'
            ,prop15         : 'Support - Topic Name'
            ,prop16			: 'Page - Business Unit'
            ,prop21			: 'Search - Criteria'
            ,prop24			: 'Page - Language'
            ,prop25			: 'Page - Product Feature'
            ,prop28         : 'Support - Search Criteria'
            ,prop30			: 'Visitor - IP Address'
            ,prop33         : 'Page - Product Application Version'
            ,prop34         : 'Page - Website Extensions'
            ,prop60			: 'Search - Data Form Criteria'
            ,prop63			: 'Page - Extended Page Name'
            ,prop65         : 'Page - Online State'
            ,prop67         : 'Research Networks'
            ,prop40: 'Page - UX Properties'

            ,eVar3			: 'Search - Total Results'
            ,eVar7			: 'Visitor - Account Name'
            ,eVar15			: 'Event - Search Results Click Position'
            ,eVar19			: 'Search - Advanced Criteria'
            ,eVar21			: 'Promo - Clicked ID'
            ,eVar22			: 'Page - Test ID'
            ,eVar47			: 'Page - Test Subject ID'
            ,eVar27			: 'Event - AutoSuggest Search Data'
            ,eVar157		: 'Event - AutoSuggest Search Typed Term'
            ,eVar156		: 'Event - AutoSuggest Search Selected Term'
            ,eVar162		: 'Event - AutoSuggest Search Category'
            ,eVar163		: 'Event - AutoSuggest Search Details'
            ,eVar33			: 'Visitor - Access Type'
            ,eVar34			: 'Order - Promo Code'
            ,eVar39			: 'Order - Payment Method'
            ,eVar41			: 'Visitor - Industry'
            ,eVar42			: 'Visitor - SIS ID'
            ,eVar43			: 'Page - Error Type'
            ,eVar44			: 'Event - Updated User Fields'
            ,eVar48			: 'Email - Recipient ID'
            ,eVar51			: 'Email - Message ID'
            ,eVar52			: 'Visitor - Department ID'
            ,eVar53			: 'Visitor - Department Name'
            ,eVar60			: 'Search - Within Content Criteria'
            ,eVar61			: 'Search - Within Results Criteria'
            ,eVar62			: 'Search - Result Types'
            ,eVar74			: 'Page - Journal Info'
            ,eVar59			: 'Page - Journal Publisher'
            ,eVar76			: 'Email - Broadlog ID'
            ,eVar78			: 'Visitor - Details'
            ,eVar80         : 'Visitor - Usage Path Info'
            ,eVar102		: 'Form - Name'
            ,eVar103        : 'Event - Conversion Driver'
            ,eVar105        : 'Search - Current Page'
            ,eVar106        : 'Visitor - App Session ID'
            ,eVar107        : 'Page - Secondary Product Name'
            ,eVar117        : 'Search - Database'
            ,eVar126        : 'Page - Environment'
            ,eVar141        : 'Search - Criteria Original'
            ,eVar143        : 'Page - Tabs'
            ,eVar161        : 'Search - Channel'
            ,eVar169        : 'Search - Facet Operation'
            ,eVar173        : 'Search - Details'
            ,eVar174        : 'Campaign - Spredfast ID'
            ,eVar175        : 'Visitor - TMX Device ID'
            ,eVar176        : 'Visitor - TMX Request ID'
            ,eVar148        : 'Visitor - Platform Name'
            ,eVar149        : 'Visitor - Platform ID'
            ,eVar152        : 'Visitor - Product ID'
            ,eVar153        : 'Visitor - Superaccount ID'
            ,eVar154        : 'Visitor - Superaccount Name'
            ,eVar177        : 'Page - Context Domain'
            ,eVar189    : 'Page - Experimentation User Id'
            ,eVar190    : 'Page - Identity User'
            ,eVar199    : 'Page - ID+ Parameters'

            ,list2			: 'Page - Widget Names'
            ,list3			: 'Promo - IDs'
        };

        for (var i in vars) {
            s[i] = s[i] ? s[i] : _satellite.getVar(vars[i]);
        }
    }
};

// async support fallback
(function(w) {
	var eventBuffer = [];
	if(w.appData) {
		if(Array.isArray(w.appData)) {
			eventBuffer = w.appData;
		} else {
			console.error('Elsevier DataLayer "window.appData" must be specified as array');
			return;
		}
    }

	w.appData = [];

	var oldPush = w.appData.push;

	var appDataPush = function() {
        oldPush.apply(w.appData, arguments);
        for(var i=0; i<arguments.length; i++) {
            var data = arguments[i];
            if(data.event) {
                if(data.event == 'pageLoad') {
                    w.pageDataTracker.trackPageLoad(data);
                } else {
                    w.pageDataTracker.trackEvent(data.event, data);
                }
            }
        }
	};

	w.appData.push = appDataPush;
	for(var i=0; i<eventBuffer.length; i++) {
	    var data = eventBuffer[i];
	    w.appData.push(data);
	}
})(window);

</script><iframe id="ps_yqbca" src="https://service.seamlessaccess.org/ps/" style="display: none; position: absolute; top: -999px; left: -999px;"></iframe><div class="js-react-modal"></div><div class="js-react-modal"></div><div class="js-react-modal"></div><div class="js-react-modal"></div><div class="js-react-modal"></div><div class="js-react-modal"></div><div id="onetrust-consent-sdk" data-nosnippet="true"><div class="onetrust-pc-dark-filter ot-hide ot-fade-in"></div><div id="onetrust-pc-sdk" class="otPcCenter ot-hide ot-fade-in" lang="en" aria-label="Preference center" role="region"><div role="dialog" aria-modal="true" style="height: 100%;" aria-label="Cookie Preference Center"><!-- Close Button --><div class="ot-pc-header"><!-- Logo Tag --><div class="ot-pc-logo" role="img" aria-label="Company Logo"><img alt="Company Logo" src="https://cdn.cookielaw.org/logos/static/ot_company_logo.png"></div></div><!-- Close Button --><div id="ot-pc-content" class="ot-pc-scrollbar"><div class="ot-optout-signal ot-hide"><div class="ot-optout-icon"><svg xmlns="http://www.w3.org/2000/svg"><path class="ot-floating-button__svg-fill" d="M14.588 0l.445.328c1.807 1.303 3.961 2.533 6.461 3.688 2.015.93 4.576 1.746 7.682 2.446 0 14.178-4.73 24.133-14.19 29.864l-.398.236C4.863 30.87 0 20.837 0 6.462c3.107-.7 5.668-1.516 7.682-2.446 2.709-1.251 5.01-2.59 6.906-4.016zm5.87 13.88a.75.75 0 00-.974.159l-5.475 6.625-3.005-2.997-.077-.067a.75.75 0 00-.983 1.13l4.172 4.16 6.525-7.895.06-.083a.75.75 0 00-.16-.973z" fill="#FFF" fill-rule="evenodd"></path></svg></div><span></span></div><h2 id="ot-pc-title">Cookie Preference Center</h2><div id="ot-pc-desc">We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our <a href="https://www.elsevier.com/legal/cookienotice/_nocache" target="_blank">Cookie Policy</a> and the list of <a href="https://support.google.com/admanager/answer/9012903" target="_blank">Google Ad-Tech Vendors</a>.
<br>
<br>
You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer. See the different category headings below to find out more or change your settings.
<br>
</div><button id="accept-recommended-btn-handler" ot-button-order="0">Allow all</button><section class="ot-sdk-row ot-cat-grp"><h3 id="ot-category-title"> Manage Consent Preferences</h3><div class="ot-accordion-layout ot-cat-item ot-vs-config" data-optanongroupid="1"><button aria-expanded="false" ot-accordion="true" aria-controls="ot-desc-id-1" aria-labelledby="ot-header-id-1 ot-status-id-1"></button><!-- Accordion header --><div class="ot-acc-hdr ot-always-active-group"><div class="ot-plus-minus"><span></span><span></span></div><h4 class="ot-cat-header" id="ot-header-id-1">Strictly Necessary Cookies</h4><div id="ot-status-id-1" class="ot-always-active">Always active</div></div><!-- accordion detail --><div class="ot-acc-grpcntr ot-acc-txt"><p class="ot-acc-grpdesc ot-category-desc" id="ot-desc-id-1">These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.
<br><br></p><div class="ot-hlst-cntr"><button class="ot-link-btn category-host-list-handler" aria-label="Strictly Necessary Cookies - Cookie Details List" data-parent-id="1">Cookie Details List?</button></div></div></div><div class="ot-accordion-layout ot-cat-item ot-vs-config" data-optanongroupid="2"><button aria-expanded="false" ot-accordion="true" aria-controls="ot-desc-id-2" aria-labelledby="ot-header-id-2"></button><!-- Accordion header --><div class="ot-acc-hdr"><div class="ot-plus-minus"><span></span><span></span></div><h4 class="ot-cat-header" id="ot-header-id-2">Performance Cookies</h4><div class="ot-tgl"><input type="checkbox" name="ot-group-id-2" id="ot-group-id-2" role="switch" class="category-switch-handler" data-optanongroupid="2" checked="" aria-labelledby="ot-header-id-2"> <label class="ot-switch" for="ot-group-id-2"><span class="ot-switch-nob"></span> <span class="ot-label-txt">Performance Cookies</span></label> </div></div><!-- accordion detail --><div class="ot-acc-grpcntr ot-acc-txt"><p class="ot-acc-grpdesc ot-category-desc" id="ot-desc-id-2">These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.</p><div class="ot-hlst-cntr"><button class="ot-link-btn category-host-list-handler" aria-label="Performance Cookies - Cookie Details List" data-parent-id="2">Cookie Details List?</button></div></div></div><div class="ot-accordion-layout ot-cat-item ot-vs-config" data-optanongroupid="8"><button aria-expanded="false" ot-accordion="true" aria-controls="ot-desc-id-8" aria-labelledby="ot-header-id-8"></button><!-- Accordion header --><div class="ot-acc-hdr"><div class="ot-plus-minus"><span></span><span></span></div><h4 class="ot-cat-header" id="ot-header-id-8">Contextual Advertising Cookies</h4><div class="ot-tgl"><input type="checkbox" name="ot-group-id-8" id="ot-group-id-8" role="switch" class="category-switch-handler" data-optanongroupid="8" checked="" aria-labelledby="ot-header-id-8"> <label class="ot-switch" for="ot-group-id-8"><span class="ot-switch-nob"></span> <span class="ot-label-txt">Contextual Advertising Cookies</span></label> </div></div><!-- accordion detail --><div class="ot-acc-grpcntr ot-acc-txt"><p class="ot-acc-grpdesc ot-category-desc" id="ot-desc-id-8">These cookies are used for properly showing banner advertisements on our site and associated functions such as limiting the number of times ads are shown to each user.</p><div class="ot-hlst-cntr"><button class="ot-link-btn category-host-list-handler" aria-label="Contextual Advertising Cookies - Cookie Details List" data-parent-id="8">Cookie Details List?</button></div></div></div><!-- Groups sections starts --><!-- Group section ends --><!-- Accordion Group section starts --><!-- Accordion Group section ends --></section></div><section id="ot-pc-lst" class="ot-hide ot-hosts-ui ot-pc-scrollbar"><div id="ot-pc-hdr"><div id="ot-lst-title"><button class="ot-link-btn back-btn-handler" aria-label="Back"><svg id="ot-back-arw" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 444.531 444.531" xml:space="preserve"><title>Back Button</title><g><path fill="#656565" d="M213.13,222.409L351.88,83.653c7.05-7.043,10.567-15.657,10.567-25.841c0-10.183-3.518-18.793-10.567-25.835
                    l-21.409-21.416C323.432,3.521,314.817,0,304.637,0s-18.791,3.521-25.841,10.561L92.649,196.425
                    c-7.044,7.043-10.566,15.656-10.566,25.841s3.521,18.791,10.566,25.837l186.146,185.864c7.05,7.043,15.66,10.564,25.841,10.564
                    s18.795-3.521,25.834-10.564l21.409-21.412c7.05-7.039,10.567-15.604,10.567-25.697c0-10.085-3.518-18.746-10.567-25.978
                    L213.13,222.409z"></path></g></svg></button><h3>Cookie List</h3></div><div class="ot-lst-subhdr"><div class="ot-search-cntr"><p role="status" class="ot-scrn-rdr"></p><input id="vendor-search-handler" type="text" name="vendor-search-handler" placeholder="Search¡­" aria-label="Cookie list search"> <svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 -30 110 110" aria-hidden="true"><title>Search Icon</title><path fill="#2e3644" d="M55.146,51.887L41.588,37.786c3.486-4.144,5.396-9.358,5.396-14.786c0-12.682-10.318-23-23-23s-23,10.318-23,23
            s10.318,23,23,23c4.761,0,9.298-1.436,13.177-4.162l13.661,14.208c0.571,0.593,1.339,0.92,2.162,0.92
            c0.779,0,1.518-0.297,2.079-0.837C56.255,54.982,56.293,53.08,55.146,51.887z M23.984,6c9.374,0,17,7.626,17,17s-7.626,17-17,17
            s-17-7.626-17-17S14.61,6,23.984,6z"></path></svg></div><div class="ot-fltr-cntr"><button id="filter-btn-handler" aria-label="Filter" aria-haspopup="true"><svg role="presentation" aria-hidden="true" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 402.577 402.577" xml:space="preserve"><title>Filter Icon</title><g><path fill="#fff" d="M400.858,11.427c-3.241-7.421-8.85-11.132-16.854-11.136H18.564c-7.993,0-13.61,3.715-16.846,11.136
      c-3.234,7.801-1.903,14.467,3.999,19.985l140.757,140.753v138.755c0,4.955,1.809,9.232,5.424,12.854l73.085,73.083
      c3.429,3.614,7.71,5.428,12.851,5.428c2.282,0,4.66-0.479,7.135-1.43c7.426-3.238,11.14-8.851,11.14-16.845V172.166L396.861,31.413
      C402.765,25.895,404.093,19.231,400.858,11.427z"></path></g></svg></button></div><div id="ot-anchor"></div><section id="ot-fltr-modal"><div id="ot-fltr-cnt"><div id="ot-filter-list-header"></div><button id="clear-filters-handler">Clear</button><div class="ot-fltr-scrlcnt ot-pc-scrollbar"><div class="ot-fltr-opts" role="list"><div class="ot-fltr-opt" role="listitem"><div class="ot-chkbox"><input id="chkbox-id" type="checkbox" class="category-filter-handler"> <label for="chkbox-id"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div></div></div><div class="ot-fltr-btns"><button id="filter-apply-handler">Apply</button> <button id="filter-cancel-handler">Cancel</button></div></div></div></section></div></div><section id="ot-lst-cnt" class="ot-host-cnt ot-pc-scrollbar"><div id="ot-sel-blk"><div class="ot-sel-all"><div class="ot-sel-all-hdr"><span class="ot-consent-hdr">Consent</span> <span class="ot-li-hdr">Leg.Interest</span></div><div class="ot-sel-all-chkbox"><div class="ot-chkbox" id="ot-selall-hostcntr"><input id="select-all-hosts-groups-handler" type="checkbox"> <label for="select-all-hosts-groups-handler"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div><div class="ot-chkbox" id="ot-selall-vencntr"><input id="select-all-vendor-groups-handler" type="checkbox"> <label for="select-all-vendor-groups-handler"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div><div class="ot-chkbox" id="ot-selall-licntr"><input id="select-all-vendor-leg-handler" type="checkbox"> <label for="select-all-vendor-leg-handler"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div></div></div></div><div class="ot-sdk-row"><div class="ot-sdk-column"><ul id="ot-host-lst"></ul></div></div></section></section><div class="ot-pc-footer ot-pc-scrollbar"><div class="ot-btn-container"> <button class="save-preference-btn-handler onetrust-close-btn-handler" ot-button-order="2">Confirm my choices</button></div><!-- Footer logo --><div class="ot-pc-footer-logo"><a href="https://www.onetrust.com/products/cookie-consent/" target="_blank" rel="noopener noreferrer" aria-label="Powered by OneTrust Opens in a new Tab"><img alt="Powered by Onetrust" src="https://cdn.cookielaw.org/logos/static/powered_by_logo.svg" title="Powered by OneTrust Opens in a new Tab"></a></div></div><!-- Cookie subgroup container --><!-- Vendor list link --><!-- Cookie lost link --><!-- Toggle HTML element --><!-- Checkbox HTML --><!-- plus minus--><!-- Arrow SVG element --><!-- Accordion basic element --><span class="ot-scrn-rdr" aria-atomic="true" aria-live="polite"></span><!-- Vendor Service container and item template --></div><iframe class="ot-text-resize" sandbox="allow-same-origin" title="onetrust-text-resize" style="position: absolute; top: -50000px; width: 100em;" aria-hidden="true"></iframe></div></div><button aria-label="Feedback" type="button" id="_pendo-badge_9BcFvkCLLiElWp6hocDK3ZG6Z4E" data-layout="badgeBlank" class="_pendo-badge _pendo-badge_" style="z-index: 19000; margin: 0px; height: 32px; width: 128px; font-size: 0px; background: rgba(255, 255, 255, 0); padding: 0px; line-height: 1; min-width: auto; box-shadow: rgb(136, 136, 136) 0px 0px 0px 0px; border: 0px; float: none; vertical-align: baseline; cursor: pointer; position: absolute; top: 38217px; left: 692px;"><img id="pendo-image-badge-19b66351" src="https://pendo-static-5661679399600128.storage.googleapis.com/D_T2uHq_M1r-XQq8htU6Z3GjHfE/guide-media-75af8ddc-3c43-49fd-8836-cfc7e2c3ea60" alt="Feedback" data-_pendo-image-1="" class="_pendo-image _pendo-badge-image" style="display: block; height: 32px; width: 128px; box-shadow: rgb(136, 136, 136) 0px 0px 0px 0px; float: none; vertical-align: baseline;"></button><script>_satellite["_runScript1"](function(event, target, Promise) {
_satellite.logger.log("eventDispatcher: clearing tracking state");try{s.events="",s.linkTrackVars="",s.linkTrackEvents=""}catch(e){_satellite.logger.log("eventDispatcher: s object - could not reset state.")}try{dispatcherData=JSON.parse(event.detail),window.ddqueue=window.ddqueue||[],window.ddqueue.push(dispatcherData),window.eventData=dispatcherData.eventData,window.pageData=dispatcherData.pageData,_satellite.track(dispatcherData.eventName)}catch(e){_satellite.logger.log("eventDispatcher: exception"),_satellite.logger.log(e)}
});</script></body><iframe name="goog_topics_frame" src="https://securepubads.g.doubleclick.net/static/topics/topics_frame.html" style="display: none;"></iframe></html>